The Synthesis and Evaluation of Heterocycles as Anti-Tuberculosis Agents

by

Kristiana Tika Santoso

A thesis

submitted to Victoria University of Wellington in fulfilment of the requirements for the degree of Doctor of Philosophy

Te Whare Wānanga o te Ūpoko o te Ika a Māui

2019



I hope that in this year to come, you make mistakes. Because if you are making mistakes, then you are making new things, trying new things, learning, living, pushing yourself, challenging yourself, changing your world. You're doing things you've never done before, and more importantly, you're doing something

Neil Gaiman

Abstract

Tuberculosis (TB) is the leading cause of death from a single infectious agent, *Mycobacterium tuberculosis* (*Mtb*), worldwide. Currently, the efficacy of TB treatment regimens has declined due to the rise in antibacterial resistance and the shortage of new TB drugs. Thus, much effort has been spent in anti-tuberculosis drug development and in identifying new therapeutic targets against *Mtb*. One such target is NADH dehydrogenase-II (NDH-II), an essential enzyme in the mycobacterial electron transport chain that is not present in mammalian cells. In this thesis, four classes of heterocyclic compounds that have the potential to target NDH-II and their evaluation as anti-tubercular agents, are described. An overview of TB drug development and NDH-II as a promising target for TB drugs are described in Chapter 1.

In Chapters 2 and 3, the potential of anti-tubercular drugs based on the quinolinequinone (QQ) scaffold is described. QQs have previously shown promise as TB drugs by activating NDH-II to overproduce harmful reactive oxygen species leading to bacterial cell death. Chapter 2 describes the total synthesis of the QQ natural products ascidiathiazone A and ascidiathiazone B, and derivatives thereof, using a synthetic route that allows for high divergency and the efficient synthesis of the natural products and their intermediates. To this end, the first total synthesis of ascidiathiazone B is reported, as is the identification of ascidiathiazone A as a promising anti-tuberculosis drug with an MIC of 1.6 μ M against *Mtb*. Insight into the ability of a representative quinone, 7-chloro-6-chloroethylamino-2-methyl-QQ, to increase NDH-II activity is also described. In Chapter 3, the syntheses of thirtytwo simplified QQs with different functional groups at the 6- and 7-positions of the QQ scaffold are described. These compounds were screened against Mtb, with the lead compound from this library, 7-chloro-6-propargylamino-QQ, exhibiting an MIC of 8 µM against Mtb. Structure-activity data revealed diminished biological activity for QQs bearing tertiary amines, as compared to those with secondary amines, suggesting that the presence of a hydrogen bond donor at the 6- and 7-positions of QQs may play a critical role in antimycobacterial activity.

In Chapter 4, the synthesis and anti-mycobacterial activity of chromonyl-pyrimidines is presented. Chromonyl-pyrimidines have a structural resemblance to quinolinyl pyrimidines, a class of known NDH-II inhibitors and anti-TB agents. Chromones have shown promise as TB drugs, though they have not yet been reported to bind NDH-II. Despite this, chromonyl-pyrimidines contain a ketone functionality that may be able to bind the quinone binding site. For the first eleven-member library of chromonyl pyrimidines synthesised, all but two of the compounds exhibited inhibitory activity against *Mtb*, however, the growth inhibition was modest (MIC = 36-684 μ M). Accordingly, a second generation of chromonyl pyrimidines was synthesised, which included six compounds with improved potency against *Mtb* – all with an MIC value of 12.5 μ M. The activity of these chromonyl pyrimidines was attributed to the presence of aromatic rings both on the pyrimidine and the chromone scaffolds, though changes to the electronic properties of the aryl groups, *i.e.* the incorporations of electron-withdrawing and electron-donating groups, did not affect inhibitory activity.

Finally, in Chapter 5, a library of phthalazinones and pyrimidinyl-phthalazinones with antitubercular activity is described. While phthalazinones have not yet been extensively explored as anti-mycobacterial agents, the phthalazinone scaffold has the potential to act as an uncoupler. Uncouplers are typically weak acids or bases that act on the electron transport chain by dissipating the proton motive force and ultimately preventing the generation of ATP. In *Mtb*, this uncoupling process is detrimental and leads to cell death. Phthalazinones are weakly basic and, due to their bicyclic ketone-bearing motif, has the potential to bind NDH-II at the proposed Q-site. Accordingly, a series of phthalazinones was synthesised to investigate their anti-tubercular activity and uncoupling activity. From the library of phthalazinones, N-tert-butyl- and nitro-substituted phthalazinones elicited high inhibitory activity, both with an MIC value of 3 µM. Of particular note among the pyrimidinylphthalazinones was the 4-fluorophenyl-pyrimidinyl-N-heptyl phthalazinone, which showed high potency against Mtb with an MIC of 1.6 µM. Further biological studies showed that some phthalazinones increased the rate of NADH oxidation in mycobacteria, which could be a result of uncoupling activity, while a number of pyrimidinyl-phthalazinones decreased NADH oxidation rates. These mechanistic results indicated that the two classes of compounds may have different modes of inhibition.

Acknowledgements

"If I have seen further it is by standing on ye shoulders of Giants"

Isaac Newton

This PhD would not have existed if it weren't for the amazing giants whose shoulders I stood on. The first giants I'd like to thank are Mattie Timmer and Bridget Stocker, from whom I have learned almost everything I know about organic chemistry. Thank you for your dedication and patience in guiding me through this project. Your passion and enthusiasm for research are inspirational and I am grateful to have had the privilege to learn how to be a researcher from such accomplished scientists. Many thanks also to Greg Cook and his team for hosting me in their lab and helping me with the biology side of my project.

The second giants in my life are my beautiful whānau. Mum and dad, you've sacrificed so much to do the best by us and for that I'm eternally grateful. Yohanes, you're the wisest and most intelligent big brother a girl could have and Tania, thank you for being my best friend, my number one supporter, and my biggest inspiration. I'm so incredibly proud to be a Santoso.

Special thanks to Ian Vorster, to whom no request is unimportant, Patricia Stein, whose super power is to solve seemingly impossible problems, Martyn Coles and Mat Anker for their help with XRD experiments, Rohan Borah for his expertise in redox chemistry and all members of the immunoglycomics group, especially Stefan Munneke and Amy Foster for all their help. Special mention to Matthias Lein, who has cheered me on since my second-year, thank you for always having time for me no matter where you are in the world. Finally, thank you to my funding provider, the Maurice Wilkins Centre, for making this journey possible.

Huge hugs to those I'm honoured to call friends, who have been there for me at the beginning, and will now be there at the end: Stevie Jamieson, Claire Turner, Siobhan Bradley, Ethan Woolly, Lynne Gledstone-Brown. We can finally talk about something else now.

Finally, to my favourite Swiss family, the Lassueurs, thank you for the many care packages and kind words. In particular, to the most caring, beautiful and loyal person I could ever imagine to share my life with, Loïc Lassueur, thank you for coming along on this, at times, tumultuous journey without complaint. You've made the past three and a half years much easier by filling every spare moment with memorable adventures. Now let's celebrate with more adventures.

Table of Contents

Absti	iii			
Ackn	owledgements	v		
List o	vii			
CHAPT	1			
1.1.	Tuberculosis (TB)	1		
1.2.	The electron transport chain as a new TB drug target			
1.3.	NDH-II as an attractive TB drug target	16		
1.4.	NDH-II substrates have antimycobacterial activity	21		
1.5.	Thesis outline			
CHAPT				
2.1.	Introduction			
2.2.	Results and Discussion			
2.3.	Conclusion	55		
2.4.	Experimental			
CHAPT				
3.1.	Introduction			
3.2.	Results and Discussion	76		
3.3.	Conclusion			
3.4.	Experimental			
CHAPTER FOUR				
4.1.	Introduction			
4.2.	Results and discussion			
4.3.	Conclusion			
4.4.	Experimental			
CHAPT	TER FIVE			
5.1.	Introduction			
5.2.	Results and Discussion			
5.3.	Conclusion			
5.4.	Experimental			
CHAPTER SIX				
References				

List of abbreviations		FAD	flavin adenine dinucleotide	
		FCCP	carbonyl cyanide <i>p</i> -	
Ac	acetate		trifluoromethoxyphenyl hydrazone	
ADP	adenosine diphosphate	GC	glassy carbon	
AIBN	azobisisobutyronitrile	HEPES (4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid)		
aq.	aqueous			
ATP	adenosine triphosphate			
ATPase	adenosinetriphosphatase	HMBC	heteronuclear multiple	
BDQ	bedaquiline	HONO	2-heptyl-4-	
Boc	tert-butyloxycarbonyl	hydroxyquinoline-N-		
br.	broad		oxide	
calcd.	calculated	HRMS	high resolution mass spectrometry	
СССР	<i>m</i> - chlorophenylhydrazone	HSQC	heteronuclear single quantum coherence	
COSY	homonuclear correlation spectroscopy	HTS	high-throughput screen	
CV	cyclic voltammetry	IC ₅₀	half maximal inhibitory concentration	
d	doublet	IL	interleukin	
DC	dendritic cells	IMV	inverted membrane	
DMAP	4-dimethylaminopyridine		vesicle	
DMF	dimethylformamide	INF-y	interferon-y	
DMSO	dimethylsulfoxide	INH	isoniazid	
DNA	deoxyribonucleid acid	IR	infra-red	
E. coli	Escherischia coli	LAM	lipoarabinomannan	
EDCI	N-(3- dimethylaminopropyl)- N'-ethylcarbodiimide- hydrochloride	m/z	mass/charge	
		MBC	minimum bactericidal concentration	
EMB	ethambutol	Me	methyl	
ESI	electrospray ionisation	m-CPBA	<i>meta-</i> chloroperoxybenzoic acid	
Et	ethyl	MIC	minimum inhibition	
ETC	electron transport chain		concentration	

MDR	multidrug-resistant	ROS	reactive oxygen species
MHz	mega Hertz	RR	rifampicin-resistant
MK	menaquinone	S	singlet
Mtb	Mycobacterium tuberculosis	SAR	structure-activity relationship
NADH	nicotinamide adenine dinucleotide	t	triplet
NBS	N-bromosuccinimide	ТВ	tuberculosis
NDH-I	type I NADH dehydrogenase I	THF	tetrahydrofuran
NDH-II	type II NADH dehydrogenase	TLC	chromatography
NK	natural killer	TLR	toll-like receptor
NMR	nuclear magnetic	TNF-α	tumour necrosis factor-α
	resonance	UV	ultra-violet
obsd.	observed	XDR	extensively drug-resistant
OD	optical density	XRD	X-ray diffraction
PAS	para-amino salicylic acid	WHO	World Health Organisation
PMF	proton motive force		
ppm	parts per million		
PRR	pattern recognition receptors		
PZA	pyrazinamide		
q	quartet		
Q	quinone		
\mathbf{QH}_2	hydroquinone		
QQ	quinolinequinone		
Q-site	quinone binding site		
Q-TOF	quadrupole time of flight		
\mathbf{R}_{f}	retention factor		
RIF	rifampicin		
RNAP	RNA polymerase		
RNI	reactive nitrogen intermediates		

CHAPTER ONE Introduction

1.1. Tuberculosis (TB)

Tuberculosis (TB) is an infectious disease caused by the bacterium complex *Mycobacterium tuberculosis* (*Mtb*), whereby *M. tuberculosis*, *M. africanum*, and *M. bovis* are human pathogens.^{1,2} Currently, an estimated 1.7 billion people, a quarter of the world's population, are infected with the bacteria.³ In the most recent global TB report, the World Health Organisation (WHO) recorded nearly 1.6 million TB deaths and 6.4 million new TB cases in 2017,³ making TB the leading cause of death from a single infectious agent worldwide. Given the long history of TB, the fact that it remains a global threat today is alarming as almost all TB cases can be cured with timely diagnosis and prompt treatment.² One reason for the continuous TB epidemic is

the high rate of patient non-compliance due to the lengthy duration and financial burden of the treatment.⁴ As a consequence, countries with the highest incidence of TB are developing countries. In 2017, TB cases in just seven countries – India, Indonesia, China, the Philippines, Nigeria, Bangladesh and Pakistan – accounted for 63% of the total global incidence of the disease.³ Additionally, the rise of drug resistant *Mtb* strains continues to threaten the success of current treatment regimens and consequently, the need for new anti-tubercular agents has become an urgent global priority. However, the development of TB drugs is difficult due to the manner by which *Mtb* resides within the host. This is evidenced by the current treatment regime, which involves a combination therapy of four different antibiotics, and which has remained the same since it was introduced in the 1970s.^{2,5}

1.1.1. The immune response to TB

The most common form of TB is pulmonary TB, where the bacteria reside in the lungs. Typical symptoms of this form of the disease include a chronic cough with blood-tinged sputum, fever and weight loss. These symptoms are present only in the active form of the disease. The bacteria are spread from the saliva of active pulmonary TB sufferers through aerosolised droplet nuclei of about 1-5 μ m in diameter.⁶ The small size of the particles allows them to easily travel into the lungs where they are engulfed by alveolar macrophages. *Mtb* can also reside in other organs such as the brain and the kidneys (termed extrapulmonary TB).⁶⁻⁸ Most individuals infected by *Mtb* have a latent form of the disease, which is asymptomatic and non-infectious. Approximately 5-15% of latent TB cases will develop into active TB, and this typically occurs when the immune system becomes compromised.⁷

The immunological responses to the invasion of the lungs by *Mtb* are triggered by alveolar macrophages engulfing the bacteria. Here, the highly conserved mycobacterial cell wall structure allows pattern recognition receptors (PRRs) such as C-type lectins⁹ and toll-like receptors (TLRs) on the surface of macrophages to recognise specific cell wall components of the bacteria.¹⁰ As a defensive response, macrophages then induce the immediate killing of *Mtb* through cidal mechanisms such as the production of reactive nitrogen intermediates (RNI) and reactive oxygen species (ROS).¹¹ However, the bacteria also have defence mechanisms that allow them to survive and replicate within the compartments of the macrophage.⁷ Although these defence mechanisms are not yet well understood, it has been reported that *Mtb* can prevent phagosome maturation and acidification, which inhibits fusion of the phagosome with the lysozome.¹² Furthermore, *Mtb* can also reduce antigen expression by downregulating major

histocompatibility complex (MHC) class II molecules on macrophages that are required for recognition of the internalised bacteria by T cells.¹¹

The extraordinary ability of *Mtb* to remain viable within macrophages leads to the recruitment of other immune cells, such as dendritic cells (DCs), to the site of infection. The activation of macrophages and DCs then initiates further proliferation of immune cells, ultimately leading to granuloma formation (Figure 1.1).¹¹ First, cytokines are produced, such as tumour necrosis factor- α (TNF- α) and the interleukins (ILs), including IL-6, IL-12, IL-1 α , IL-1 β . Cytokines are an important part of the body's defence mechanisms as they can further activate macrophages (*i.e.* IL-12), control mycobacterial growth through granuloma formation (*i.e.* TNF- α), or activate other immune cells such as T cells and natural killer (NK) cells that can produce other pro-inflammatory cytokines such as interferon- γ (INF- γ).¹³ The resulting aggregation of mononuclear immune cells marks the early stages of granuloma formation and the end of exponential bacterial growth.¹⁴ Chapter One



Figure 1.1: The immunological activities that occur during the invasion of *Mtb*. The mycobacteria is introduced into the body via small droplet nuclei before typically residing in the lungs, its primary site of infection. Here, the bacteria are recognised through their highly conserved cell wall structures by PRRs of macrophages and are engulfed. This activates a string of immunological events including the production of cytokines by macrophages, which can in turn activate T cells. The recruitment of immune cells leads to the formation of giant foam cells that continue to recruit more cytokines and chemokines until a granuloma is formed. Inside the granuloma, the mycobacteria are able to exist in their non-replicating, dormant form. This is the latent form of TB, which can be reactivated when the immune system is weakened or compromised. The reactivation of the bacteria is marked by the disintegration of the granuloma and the release of *Mtb* into the body.^{13,14}

Granuloma formation is an important immunological event resulting in the containment of the infection by preventing the mycobacteria from proliferating. This bacterial growth arrest is achieved as the granulomas mature, where fibrous capsules are formed surrounding the macrophages while more pro-inflammatory cytokines⁶ and chemokines¹⁵ are produced. Simultaneously, infected macrophages differentiate into foamy macrophages, macrophages laden with lipid droplets, which are collectively known as giant foam cells. The conversion of infected macrophages into foamy macrophages occurs due to the high lipid content of the TB bacterial cell wall¹⁴ and is hypothesised to assist in the bacilli's persistence by providing a potential nutrient source.¹⁶ Thus, granulomas provide a suitable environment for the

mycobacteria to survive the bombardment of immune cells, allowing for infection localisation as the bacteria enter their dormant state. This dormant non-replicating form of mycobacteria can be reactivated when the immune system is compromised,^{11,13} for example during coinfection with HIV.^{6,17} With the immune system weakened, the granulomas can no longer contain the bacteria and the bacteria spread and infect other organs, which can lead to death of the host if the disease is left untreated.⁷

1.1.2. Current treatment for TB

The current therapeutic regimen for drug-susceptible TB has a high success rate $(>95\%)^2$, however, it involves at least six months of directly observed therapy to ensure that patients remain compliant despite becoming asymptomatic before treatment is complete.² The six months is comprised of two stages: the intensive phase, and the short-course chemotherapy phase. The intensive phase involves a combination therapy of all four first-line antibiotics, rifampicin (RIF, **1**), isoniazid (INH, **2**), pyrazinamide (PZA, **3**), and ethambutol (EBM, **4**) (Figure 1.2), for two months. The remaining four months are spent in the chemotherapy phase with INH and RIF.^{2,5} The lengthy treatment and requirement of DOT workers is often unachievable in areas with limited resources and this can lead to non-compliance on the patients' part, which can result in the exposure of the bacteria to sub-lethal concentrations of the antibiotics. This, in turn, can trigger the development of antibiotic resistance,¹⁸⁻²⁰ which is evidenced by the rise of rifampicin-resistant (RR), multidrug-resistant (MDR), and extensively drug-resistant (XDR) strains of *Mtb*.



Figure 1.2: Current first-line TB drugs RIF (1), INH (2), PZA (3), EMB (4).²

MDR-TB are defined as TB strains that are resistant to at least RIF (1) and INH (2), while, in addition to these drugs, XDR-TB are also resistant to any fluoroquinolones (broad-spectrum antibiotics) and at least one of the three injectable second-line drugs kanamycin (5), capreomycin (6), and amikacin (7) (Figure 1.3).^{2,18} In 2017, about 20% of known TB cases were MDR-TB and RR-TB, a percentage that has been continuously increasing since 2009.³ Of these resistant strains, 8.5% were categorised as XDR-TB, an increase from 6.2% in 2016.³ To treat resistant strains of *Mtb*, second-line drugs including para-amino salicylic acid (PAS) (8), ethionamide (9), ofloxacin (10), cycloserine (11) and streptomycin (12), are required. In contrast to first-line antibiotics, which provide the standard treatment for TB, second-line drugs have more unpleasant side effects.²¹ Patients with MDR-TB require a combination therapy of five or more drugs for at least 9 months.²¹ This therapy involves second-line injectable drugs during the intensive phase, where the duration of each phase varies among different individuals. Typically, the first round of treatment has a success rate of just 50% and patients are required to have repeat regimens, often with different drugs. XDR-TB cases require substantially longer treatment durations of up to three years, the involvement of third-line drugs, such as clofazimine (13),² and have a low (26%) treatment success rate.²¹

Second-line drugs



Third-line drug



Figure 1.3: Current second-line and third-line drugs for TB treatment.²

1.1.3. The mechanisms of action of current TB drugs

The first drug for TB, a protein synthesis inhibitor named streptomycin (**12**), was discovered in the mid-1940s by Albert Schatz and Selman Waksman.²² The immediate hope of eradication of TB, however, was short-lived when the first clinical trials saw patients relapsing and the bacteria quickly developing resistance to the drug.^{2,19} Fortunately, the revolutionary idea of treating TB with antibiotics soon led to the development of a second drug PAS (**8**) in 1944.²³ Although each antibiotic alone was unsuccessful in eradicating the disease from patients, together they were effective and resulted in little evidence of bacterial resistance. This marked the beginning of combination therapy for TB.¹⁹

The next few decades saw the emergence of a number of antibiotics that are still important for the control of the disease today; namely RIF (1),²⁴ INH (2),²⁵ PZA (3),²⁶ and EMB (4).²⁷ RIF (1) can effectively inhibit the DNA-dependent RNA polymerase (RNAP), an enzyme essential in the chain elongation process of transcription,¹⁸ while INH (2) and PZA (3) are fatty acid biosynthesis inhibitors.¹⁷ EMB (4) disrupts the integrity of the mycobacterial cell wall by inhibiting the arabinosyl transferase enzyme that is required for the synthesis of the arabinogalactans found in the outer cell wall.²⁷

With the increasing occurrence of drug-resistant *Mtb* strains, much effort has been spent identifying the molecular mechanisms adopted by the bacteria to aid their survival. Although TB treatment involves many different antibiotics targeting different essential cell processes, each bacterial strain may only be exposed to one of these drugs at a time due to their compartmentalisation in the body.¹⁹ The compartmentalisation of the bacterial population in the body means *Mtb* can survive in different areas of the body; for example in pulmonary cavities, empyema pus (solid caseous material of dead tissue), or macrophages. This gives rise to different populations of bacteria that need to be targeted, each with their own unique environments.¹⁹

In pulmonary cavities, the bacteria have access to oxygen and are often in their replicating states. These bacteria typically exist in the early stages of acute TB and are readily targeted by INH (2), which is cidal to bacteria in aerobic environments.²⁸ However, this is not the case for bacteria living in low pH environments such as empyema pus where antibiotics like INH (2) are not stable. In this case, PZA (3) is a more effective antibiotic as its active form, pyrazinoic acid, is stable under acidic conditions.^{20,29} In macrophages, bacteria exist in microaerophilic conditions, where they have occasional bursts of metabolic activity, but otherwise are in an ideal condition to resume their dormant state. Under these conditions, drugs are often

tolerated by the bacteria due to their relatively low metabolic activities. This non-replicating form of bacteria are extremely difficult to target, with RIF (1) being one of the few antibiotics that is effective.¹⁸

As bacterial populations live in a variety of conditions, *Mtb* typically develop drug-resistance through chromosomal mutations rather than through transduction or transformation processes in which antibiotic-resistance is transferred through genetic materials.¹⁸⁻²⁰ This type of acquired antibiotic resistance develops due to high survival pressures imposed by the drug the bacteria are exposed to. For example, EMB-resistance is established by chromosomal mutations in the gene encoding arabinosyl transferase, an enzyme inhibited by EMB,³⁰ while RR-mutants induce reduced binding affinity of RIF (1) to RNAP. This was evident in the mutations found in 11 out of the 12 amino acids associated with RIF's binding pocket, usually into amino acids with longer side chains to prevent RIF binding. In addition, other RR-mutants also have a single nucleotide mutation involving a substitution in the *rpoB* gene, which is the gene encoding the β -subunit of RNAP.¹⁸

PZA (**3**) is a prodrug that is activated by the bacterial enzyme pyrazinamidase to the active form, pyrazinoic acid. Accordingly, in mutants that are highly resistant to PZA (**3**), mutations associated with the *pncA* gene were found. *PncA* is the gene responsible for coding the pyrazinamidase enzyme and this mutation is observed in 70% of PZA-resistant strains.^{29.32} The development of PZA-resistance in strains without the *pncA* mutation is yet to be explained and this portrays the complexity of the molecular mechanisms that are modified as the bacteria evolve.¹⁹ The resistance to INH (**1**) is also complicated as it is associated with mutations in five different loci: *katG*, *inhA*, *ahpC*, *kasA*, and *ndh*. Some of the mutations are linked. For example, the loss of catalase activity due to *katG* mutations result in the overexpression of *ahpC*, the alkyl hydroperoxide reductase enzyme, though the reason for this association is unknown.¹⁹ Despite extensive research around *Mtb*'s drug resistance, the mycobacteria's ability to quickly develop sophisticated resistance mechanisms, especially given their slow-replicating nature, remains poorly understood.

As well as acquired antibiotic resistance, *Mtb* also have intrinsic antibiotic resistance mechanisms, such as the highly complex cell wall (Figure 1.4). The cell wall is very thick, comprising of many layers of different components such as lipoarabinomannan glycolipids (LAM), arabinogalactans and peptidoglycans. LAM is a polymer made of phosphoryl-inositol-mannose monomers on a polysaccharide backbone, whereas arabinogalactans are long polysaccharides comprised of linear galactan and branched arabinose chains, and

peptidoglycans are polymers of amino acids and aminosugars. Arabinogalactans are also covalently bound to trehalose-dimycolates, which are highly hydrophobic long chain fatty acids, giving the outer bacterial membrane a waxy and non-fluid barrier. Accordingly, the highly lipophilic cell wall of *Mtb* makes it difficult for drugs to enter the cell, which in turn, imparts another level of complexity for effective anti-TB drug development.^{7,20}



Figure 1.4: Cartoon depicting the complex structures making up the TB cell wall. The cell wall is comprised of structural layers of lipophilic mycolic acids, namely trehalose-dimycolates, and hydrophilic carbohydrates comprising of arabinogalactans and peptidoglycan. This makes the cell wall a difficult barrier for drugs to pass through and enter the cell. Image taken from Dangerfield E., et al., *Chemistry in Australia*, May 2010, with permission.⁷

1.2. The electron transport chain as a new TB drug target

1.2.1. The electron transport chain (ETC) of Mtb

One way to develop new TB drugs is to target unexplored receptors in the bacteria, as evidenced by the recent development of bedaquiline (BDQ, **14**, Figure 1.5), which targets the respiratory system of *Mtb* and is the first FDA-approved drug to treat TB in over forty years.³³ Specifically, BDQ (**14**) inhibits F_1F_0 -ATP synthase, an enzyme found in the ETC that is responsible for the production of adenosine triphosphate (ATP) through oxidative phosphorylation.³³ This exciting discovery has since triggered a number of studies into the essentiality of the ETC in *Mtb* and other ways in which the transport chain can be targeted.³⁴



Figure 1.5: F₁F₀-ATP synthase inhibitor bedaquiline (BDQ).

All living organisms generate energy in the form of ATP through phosphorylation reactions, which convert adenosine diphosphate (ADP) to ATP. ATP can be generated through substrate-level phosphorylation, where substrates are metabolised to generate ATP as seen in the citric acid cycle in human mitrochondria.³⁹ This type of phosphorylation occurs within the bacterial cytoplasm and involves soluble enzymes. Alternatively, bacteria can synthesise ATP through oxidative phosphorylation.⁴⁰ Oxidative phosphorylation couples oxygen intake with ATP synthesis and is a form of respiration used by obligate aerobes such as *Mtb*. Specifically, the oxidative phosphorylation process generates ATP through the ETC, which involves a number of redox reactions ultimately leading to the reduction of O_2 .³⁴ This process has been shown to be crucial in both the replicating and non-replicating states of mycobacteria.⁴¹

The ETC is comprised of a group of membrane-bound enzymes that facilitate the downstream flow of electrons and the transport of protons out of the cell membrane.³⁴ The protons remain outside the cell membrane because the membrane is impermeable to protons, resulting in the establishment of a transmembrane proton gradient that conserves energy. Consequently, two gradients, the electrical potential ($\Delta \varphi$) and the chemical potential (ΔpH), are created, which together make up the proton motive force (PMF).^{40,41} The $\Delta \varphi$ is generated due to charge separation that results when protons are moved out of the cell. Similarly, ΔpH occurs due to the decrease in pH outside the membrane when the protons move outside. The maintenance of the PMF is of paramount importance for bacteria as its aberration can lead to the loss of cell viability.⁴¹ For example, when the pH is neutral, the PMF will exist predominantly in the form of $\Delta \varphi$. As protons are removed from inside the bacterial membrane, the pH outside the membrane will decrease and ΔpH will increase.⁴¹ This can be neutralised by the decrease in $\Delta \phi$ through the influx of other cations such as Mg²⁺.⁴²

In Mtb, the PMF is generated by the oxidation of electron donors, such as NADH and succinate, by NADH dehydrogenases (type 1: NDH-I, type 2: NDH-II), and succinate dehydrogenase (SDH), respectively (Figure 1.6). These enzymatic processes release protons that are then translocated out of the cell membrane by proton-pumping enzymes (i.e. NDH-I and SDH) to generate a transmembrane proton gradient. Such oxidation reactions are coupled to the reduction of menaquinone (MK, 15), an electron acceptor found in the ETC of Mtb, to menaquinol (MKH₂, **16**).³⁴ The redox reactions then continue down the ETC, so that electrons flow from substrates with low reduction potentials, such as NADH ($E^{\circ} = -0.32$ V), to those with higher reduction potentials, such as O_2 (E° = +0.816 V).³⁹ Hence, the direction of the electron flow can be determined by the position of each enzyme on the ETC. For example, NDH-I and NDH-II, which bind and oxidise NADH to NAD⁺, are found at the beginning of the ETC due to the low reduction potential of NADH. On the other hand, oxygen, with a much more positive reduction potential, is the substrate of the cytochrome be complex, an enzyme found toward the end of the chain. Accordingly, substrates between these two enzymes have reduction potentials between the two extremes.³⁹ After the reduction of O₂ to H₂O, the next enzyme in the ETC is the F₁F₀-ATP synthase. However, at this stage, the proton concentration is much higher outside the membrane than inside, and the ATP synthase catalyses proton translocation back into the membrane. Thus, protons move down the concentration gradient and generate energy that is captured in ATP through the phosphorylation of ADP.⁴⁰



Figure 1.6: A schematic representation of the *Mtb* ETC showing the positions of oxidoreductase enzymes. The chain components are: NDH-I, NDH-II, SDH, cytochrome *bc* complex, and F_1F_0 ATP synthase. Each enzyme catalyses redox reactions of different substrates, and the resulting protons and electrons are moved outside the membrane as well as down the ETC. The movement of electrons down the ETC is aided by the reduction of MK (15) to MKH₂ (16), which is then reoxidised to form MK (15).⁴¹

1.2.2. The oxidative phosphorylation process is essential to Mtb

Both types of ATP generation mechanisms, substrate-level phosphorylation and oxidative phosphorylation, are present in *Mtb*, though oxidative phosphorylation produces a substantially greater amount of ATP.³⁹ Although oxidative phosphorylation is much more efficient, it was hypothesised that the inhibition of F_1F_0 -ATP synthase would not be detrimental to *Mtb* given the bacteria's ability to produce ATP through substrate-level phosphorylation. In fact, this compensatory relationship between the two types of phosphorylation is seen in other aerobic bacteria such as *Escherichia colt*⁴³ and *Bacillus subtilis*.⁴⁴ However, the inhibition of ATP synthase by BDQ (**14**) was proven to be cidal to *Mtb*.³³ This served as evidence that oxidative phosphorylation is a vital process for the survival of *Mtb*.

The F_1F_0 -ATP synthase facilitates the bacteria's ability to survive inside phagocytic vacuoles.⁴² Given the mildly acidic nature of these vacuoles with a pH range of 6.1-6.4⁴⁵ and the sensitivity of all living cells to large deviations from the preferred neutral pH of 7, F_1F_0 -ATP synthase was found to have a role in the maintenance of a neutral internal pH despite the low external pH.⁴² This was demonstrated in experiments where *M. smegmatis* and *M. bovine* maintained a near neutral internal pH in highly acidic environments (pH=4). However, cell viability and survival quickly deteriorated when a protonophore, carbonyl cyanide *m*-chlorophenyl-hydrazone (CCCP), was added to the growth medium, which allowed protons to enter the cells. The fact that cell viability was lost only when CCCP was added also portrayed the extraordinarily high impermeability of the cell wall to protons.^{45,46}

As well as aiding in the survival of latent bacteria, F_1F_0 -ATP synthase is also reported to be essential in active forms of *Mtb*, as evidenced by the loss of cell viability when the enzyme is inhibited. This was demonstrated in a 2005 study which showed that a lack of intact F_1F_0 -ATP synthase led to the inhibition of cell growth under both active and dormant stages of mycobacteria. Unlike *E. coli* and *B. subtilis* where the reduced ATP production is compensated by substrate-level phosphorylation, F_1F_0 -ATP synthase was required in mycobacteria. The speculative reasons for this essentiality are that the amount of ATP generated by glycolysis is not sufficient for the high demands required to build the complex cell wall of mycobacteria and/or that F_1F_0 -ATP synthase was needed as a translocation proton sink.⁴⁷ Given the established impermeability of the mycobacterial cell wall,⁴⁵ *Mtb* may not support uncoupled respiration or allow uncontrolled proton entry through the adjustment of membrane permeability.⁴⁷ To this end, the inhibition of oxidative phosphorylation in mycobacteria provides a new and exciting prospect for anti-tubercular drug design and has subsequently been the target of many recent drug developments.

1.2.3. BDQ: The first TB drug to inhibit oxidative phosphorylation

As mentioned above, BDQ (14) was the first drug that allowed researchers to determine the necessity of oxidative phosphorylation in mycobacteria.^{33,48} As an inhibitor of the F_1F_0 -ATP synthase, BDQ (14) binds to the F_0 c-subunit of the enzyme^{49,50} and disconnects the mycobacterial respiration from ATP synthesis (Figure 1.7). Inhibitors with this mechanism of action are known as uncouplers. The uncoupling of respiration and ATP synthesis is detrimental to mycobacteria as they cannot use substrate-level phosphorylation as a compensatory mechanism. Moreover, the administration of BDQ (14) to *Mtb* leads to the

downregulation of glycolysis, which occurs in the absence of fermentable carbon sources, such as succinate. Accordingly, the mycobacteria do not attempt to compensate for ATP depletion, suggesting that there is a more immediate threat introduced by the drug.



Figure 1.7: A cartoon representation of the uncoupler-like mechanism of BDQ (14). **A**). A simplified representation of the unimpaired ETC establishing a transmembrane proton gradient through successive redox reactions down the chain. The proton gradient is created through a number of membrane-bound enzymes catalysing redox reactions of different substrates such as NADH, and O₂. The protons and electrons produced from these reactions are either pumped out of the membrane or transferred down the chain, respectively. In addition, the redox reaction between MK (15) and MKH₂ (16) aids in the downward movement of electrons. **B**). BDQ (14) binds to ATP synthase, thereby allowing protons to enter the cell freely. This results in a reduction of the pH gradient and, ultimately the dissipation of the PMF.³³

Within the ETC, the uncoupling also results in the upregulation of non-proton pumps such as NDH-II and the downregulation of the majority of other proton translocating pumps.

Additionally, processes that result in the production of reducing equivalents, such as NADH, are bypassed. Taken together, this suggests that the bacteria implements these modifications in order to avoid the hyperpolarisation of the PMF caused by the increased NADH/NAD⁺ ratio induced by BDQ (14).³³ This is necessary because PMF homeostasis is important in all living things, as shown in a study where a hyperpolarised mitochondrial membrane resulted in ROS production and increased $\Delta \varphi$ in eukaryotes.⁵¹ Indeed, BDQ (14) elicits a transcriptional response indicative of ROS-production in *Mtb*, though a change in $\Delta \varphi$ was not observed. Additionally, the binding of BDQ (14) to F₁F₀-ATP synthase also resulted in increased O₂ consumption and the reduction of Δ pH. On the whole, these responses suggest an uncoupler-like mode of action for BDQ (14), where the uncoupling of respiration from ATP synthesis is achieved via the free and uncontrolled movement of protons through the cell membrane.³³ This leads to the dissipation of the PMF, which has been reported to be lethal in mycobacteria.⁵² The neutrality of $\Delta \varphi$ is likely to be maintained through the efflux of other neutral cations such as K⁺.³³

1.3. NDH-II as an attractive TB drug target

Of particular relevance to this thesis is the NDH-II enzyme in *Mtb*, which has shown promise as an antitubercular drug target. NDH-II is a small, monotopic membrane protein, weighing between 40-60 kDa.⁵³ While it is absent in mammalian mitochondria, there are two copies of the enzyme in *Mtb*: *ndh* and its single subunit homologue *ndh*. Along with NDH-I, NDH-II catalyses the oxidation of NADH that is fed into the ETC (Figure 1.6).⁵⁴ NDH-I then translocates the released protons to the outside of the membrane,⁵⁴ while NDH-II, being a non-proton pumping enzyme, uses the protons and electrons produced to drive the reduction of MK (**15**) to MKH₂ (**16**) via a flavin co-factor (FAD).^{53,55}

Mutagenesis studies have shown that NDH-I and NdhA are dispensable to *Mtb*, however a lack of the *ndb* gene leads to growth arrest and multiple amino acid auxotrophy which leads to the loss of cell viability.⁴⁷ Furthermore, Ndh inhibition leads to a 25-fold reduction in NADH oxidation, which indicates that NDH-II is the main enzyme responsible for this essential process.^{35,38,47} The preference of a non-proton pump to oxidise NADH over a proton pump is of interest, as NDH-II is less efficient in PMF and ATP generation than NDH-I.⁴¹ However, this may be beneficial under non-replicating conditions to avoid the accumulation of protons during low ATP synthase activity.⁵⁶ Moreover, the use of NDH-II rather than NDH-I will allow for high metabolic flux,⁴¹ where NADH continues to get oxidised to NAD⁺ and the

PMF is maintained. PMF homeostasis is essential for mycobacterial persistence under hypoxic conditions.⁵² Furthermore, NDH-I activity in aerobes such as *Mtb* may lead to undesired production of ROS.^{41,57} Due to the essentiality of NDH-II for the growth and survival of *Mtb* and its absence in mammalian mitochondria, it is an attractive target for the development of new TB drugs.^{35,58}

1.3.1. Structure of NDH-II

Crystal structures of NDH-II have been solved in the yeast strain *Saccharomyces cerevisiae*,⁵⁹ as well as in bacterial species *Caldalkalibacillus thermarum*,^{53,58} *Staphylococcus aureus*,⁶⁰ and *Pseudomonas falciparum*.⁶¹ In all cases, the enzyme was crystallised as a homodimer comprising of three domains (Figure 1.8). The first and second domains are situated in the aqueous environment of the cytoplasm, binding NADH and FAD, respectively. The last domain is a hydrophobic membrane-anchoring domain in which the quinone binding site (Q-site) is found.^{58,62} The distinct binding sites are arranged such that both NADH and quinone are close in proximity to FAD, suggesting that the NADH oxidation and quinone reduction occurs via the reduction and oxidation of FAD, respectively (Scheme 1.1). ⁵³



Figure 1.8: The homodimeric structure of bacterial NDH-II is comprised of three domains. The first domain binds NADH (blue), while the second domain binds the flavin co-factor FAD (gold) and the last domain is the membrane-anchoring domain (pink) where the quinone binding site (Q-site) is found. Image taken from Heikal, A., *et al. Mol. Microbiol.* © 2014 John Wiley & Sons Ltd. with permission.⁵³



Scheme 1.1: The oxidation and reduction reactions involving NADH, FAD and a quinone species proposed to occur within the NDH-II enzyme. Here, NADH oxidation to NAD⁺ is coupled to the reduction of the FAD co-factor to FADH₂. The reoxidation of FADH₂ to FAD in turn occurs as the quinone is reduced to the quinol species.

Unfortunately, the co-crystallisation of the enzyme with its natural quinone substrate is challenging and has only been achieved with the yeast equivalent of the enzyme, Ndi1, and its substrate ubiquinone (17) (Figure 1.9).⁶³ To gain insight into the Q-site of the bacterial NDH-II, Cook and co-workers conducted a docking study based on the crystal structure of the Ndi1-ubiquinone complex using a high resolution *C. thermarum* NDH-II crystal structure.⁵⁸ For this experiment, both physiologically irrelevant and relevant quinones, ubiquinone (17) and menadione (18), respectively, were chosen to be modelled at the Q-site. In addition, the co-factor FAD was included in the docking study.⁵⁸



Figure 1.9: Structures of ubiquinone (17) and menadione (18).

The studies showed that both quinones **17** and **18** fit well into the Q-site, with the hydrophobic moieties of amino acids glutamine (Q317) and isoleucine (I379) accommodating the planar quinone ring (Figure 1.10).^{58,62} There is also a hydrogen bond between one of the carbonyl oxygens of quinones **17** and **18** and an amine proton on the FAD isoalloxazine ring. In the case of menadione (**18**), another hydrogen bond is observed between the second carbonyl oxygen of quinone **18** with a proton of an arginine group (R382) (Figure 1.10B),⁵⁸ though it is unclear whether this interaction is physiologically plausible as this residue is suspected to be well within the membrane.⁵³ In fact, it was speculated that this carbonyl would be interacting with a phosphate group in the phospholipid bilayer.⁵⁸ Finally, a distant edge-to-face π - π interaction could contribute to the higher affinity of menadione (**18**) to NDH-II compared to ubiquinone (**17**) and, in turn, could explain why menadione (**18**) is the only quinone substrate found in *C. thermarum.*⁵⁸

Chapter One



Figure 1.10: The docking of A). ubiquinone (**17**) and B). menadione (**18**) in the Q-site of NDH-II, showing the hydrophobic interactions between the quinone head group with Q317 and I379, as well as favourable interactions with the FAD isoalloxazine ring.⁵⁸

Following the investigations into the predicted Q-site, the co-crystallisation of *C. thermarum* NDH-II with a known inhibitor 2-heptyl-4-hydroxyquinoline-*N*-oxide (HQNO) (**19**) was undertaken (Figure 1.11).⁶² Here, similar interactions were observed between NDH-II and HQNO (**19**) in the crystal structure as was also noted in the docking studies involving NDH-II and menadione (**18**).⁵⁸ Specifically, the pyridone group in HQNO (**19**) was sandwiched between hydrophobic side chains of Q317 and I379, while the ketone oxygen participates in hydrogen bonding with the FAD isoalloxazine ring. These interactions were previously observed in docking studies with menadione (**18**) in the NDH-II Q-site.⁵⁸ Also, a lack of NDH-II inhibition resulted when HQNO (**19**) was added to an I379-mutant, verifying the importance of this amino acid for binding.⁶² Further stabilisation of the compound was evident in the weak

hydrophobic interactions to accommodate the alkyl chain in HQNO (**19**). Comparisons between this crystal structure and that of the yeast Ndi1-ubiquinone complex showed the same interactions with the quinone group, suggesting that these are conserved binding mechanisms between NDH-II and their substrates.⁶² Moreover, it also indicates that HQNO (**19**) inhibits NDH-II by a competitive inhibition mechanism.



Figure 1.11: A). The crystal structure of NDH-II-HQNO complex showing interactions between the ketone head group with Q317, I379 and the FAD isoalloxazine ring.⁶² B). The structure of HQNO (**19**).

1.4. NDH-II substrates have antimycobacterial activity

In the search for new TB drugs, NDH-II has become a prominent target for drug discovery and development. To this end, several classes of compounds have been reported to bind NDH-II and through enzyme activation⁶⁴ or inhibition,⁵⁶ and cause TB cell death. These classes of compounds will be discussed in the following overview.

1.4.1. Quinolinequinones (QQs) activate NDH-II

Quinones are nature's electron acceptors and, consequently, are vital for the biological redox processes that occur in the ETC. When quinolinequinones (QQs), a class of heterocyclic quinones, were reported to elicit anti-tubercular activity by Stocker and co-workers,⁶⁵ it was hypothesised that NDH-II could be the target enzyme of these compounds. Accordingly,

Chapter One

studies into the mode of action by which a representative QQ, 7-chloro-6-(2-chloroethylamino)-5,8-QQ (QQ8c, **20**, Figure 1.12), inhibited *Mtb* growth was undertaken.⁶⁴



QQ8c (20)

Figure 1.12: The structure of QQ8c (20).

First, the minimum inhibition concentration (MIC) and minimum bactericidal concentration (MBC) against *Mtb* were determined for QQ8c (20) and found to both be 8.1 μ M (isoniazid = 0.72 µM in the same assay).⁶⁴ Here, the MIC is defined as the minimum concentration of the drug required to completely inhibit the growth of the bacteria, whereas the MBC is the minimum concentration required to kill the bacteria. When compared to the first-line TB drug INH (2), QQ8c (20) reduced *Mtb* cell viability to the same extent. Moreover, drug resistance, as is observed with INH (2), was not detected upon treatment of Mtb with QQ8c (20), which suggests a novel mode of action.⁶⁴ Next, QQ8c (20) was shown to increase the rate of NADH oxidation both in aerobic and anaerobic environments. As NADH oxidation is coupled to quinone reduction, the concentration of the reduced quinol species was also measured. Here, the presence of the quinol was only observed in the absence of O2 and not under aerobic conditions. This hints to a redox cycling mechanism, whereby the quinol is re-oxidised by O₂ to produce ROS in aerobic environments. Indeed, QQ8c (20)-induced O2 consumption was significantly reduced in the presence of ROS-scavenging enzymes. Moreover, in the presence of QQ8c (20), the rate of NADH oxidation was significantly increased in inverted membrane vesicles (IMVs) that overexpress NDH-II compared to wild type IMVs. Taken together, these results showed that QQ8c (20) specifically stimulates Mtb NDH-II to produce cidal levels of ROS.64

1.4.2. Phenothiazines are NDH-II inhibitors

Phenothiazines are known to exhibit anti-mycobacterial activity,⁶⁶ with some reported to be active against resistant strains of Mtb.⁶⁷⁻⁶⁹ Although this anti-tubercular activity has been attributed to different drug targets within the bacteria,^{70,71} there is strong evidence supporting the hypothesis that phenothiazines specifically inhibit NDH-II.³⁵ Trifluoperazine (**21**, Figure 1.13), with a reported MIC value of 10 μ M against Mtb,⁶⁸ exhibits a synergistic antitubercular activity with RIF (**1**) and INH (**2**).⁶⁹ Mode of action studies have shown that trifluoperazine (**21**) inhibits O₂ consumption in Mtb. In such cases, O₂ consumption can be resumed by the addition of electron donors specific to cytochrome c,³⁵ which is found in the cytochrome bc complex, indicating that inhibition occurs downstream from this complex in the ETC (Figure 1.6).³⁵ Indeed, the inhibition of purified Mtb NDH-II by trifluoperazine (**21**) was demonstrated in later experiments.³⁸



Figure 1.13: Structures of phenothiazines 21 and 22.

Also exhibiting synergistic effects with first-line TB drugs is thioridazine (22),^{72,73} an anti-psychotic drug that elicits anti-tubercular activity *in vitro*^{74,75} as well as in murine models of MDR-TB infections.⁷³ Although the exact mechanism of this compound is unknown, thioridazine (22) causes a reduction in ATP synthesis through the dissipation of the mycobacterial $\Delta \varphi$.⁵⁶ Furthermore, phenothiazines were found to have a strong correlation between the inhibition of NDH-II and their antitubercular activities, suggesting NDH-II to be the target of these compounds.^{38,56} That said, other modes of action have also been described, whereby phenothiazines inhibit the bacterial efflux system and allow the lysosome to decrease its pH to a level lethal to *Mth*.^{67,76,77} Unfortunately, phenothiazines are highly toxic⁷⁸ and can induce mitochondrial toxicities in the human brain.⁷⁹

1.4.3. Thioquinazolinones disrupt NDH-II

In 2013, thioquinazolinone **23** (Figure 1.14) was identified as an NDH-II inhibitor in a wholecell high throughput screen (HTS) against resistant *Mtb* strains.⁸⁰ Since then, two separate medicinal chemistry studies have been undertaken to obtain thioquinazolinones with low micromolar MIC values against *Mtb*.^{81,82}



Figure 1.14: The structure of thioquinazolinone 23 and the optimised compound 24.⁸¹

In the thioquinazolinones SAR studies, the replacement of the thioether group with other heteroatoms, such as oxygen and nitrogen, as well as a methylene group led to a loss of inhibitory activity.82 The substitution of the phenyl ring with saturated, smaller or heterocyclic rings also reduced antitubercular activity, giving the fluoro-phenyl analogue 23 as the most potent derivative. Similarly, the instalment of a gem-difluoro group on the cyclohexyl ring also increased the anti-tubercular properties of the drug.⁸¹ The efficacy of thioquinazolinones 23 and 24 against Mtb was attributed to NDH-II disruption as treatment of the bacteria with these compounds gave rise to mutations in the NdhA gene, the non-essential gene for NDH-II.⁸⁰ Although the mutations in the essential NDH-II gene, Ndh, were not observed, quinazoline 24 was shown to elicit similar inhibitory activities against both Ndh and NdhA.⁸¹ This suggests that both isoforms of NDH-II were affected by thioquinazoline 24 and the lack of Ndh mutation may be due to deleterious effects that a single mutation could exert on the enzyme function.⁸² Mechanistic studies showed that quinazolinone **24** had very little effect on the rate of O₂ consumption in *Mtb*, indicating a different mode of inhibition to QQ8 (20). Kinetic studies also showed a noncompetitive mode of inhibition against NADH and a representative quinone, suggesting an allosteric inhibition mechanism.⁸²

1.4.4. Other anti-tubercular agents that bind NDH-II

An important class of NDH-II inhibitors is the quinolinyl pyrimidines, of which the lead compound (**25**, Figure 1.15) exhibited a micromolar MIC value.⁷⁹ These inhibitors were identified via a HTS against mycobacterial NDH-II. Through SAR studies, some information has been obtained regarding the binding pocket for this class of compounds, though the compounds' mode of action is yet to be determined. Here, primary amines on the quinoline and pyrimidine moieties of the quinolinyl pyrimidines were important for potential hydrogen bonding interactions within the NDH-II binding site. In addition, removing the aryl substituent on the quinoline ring also led to loss of antitubercular activity, while installing aromatic groups, rather than alkyl chains, on the pyrimidine ring increased the potency of the drug.⁷⁹ Unfortunately, the mechanism by which quinolinyl pyrimidines inhibit *Mth* growth has not been fully explored.



Figure 1.15: The structure of the lead quinolinyl pyrimidine 25 against Mtb.

The final class of NDH-II inhibitors are the quinolones. Quinolones are known anti-bacterial compounds and, in particular, fluoroquinolones are the current second-line TB drugs.⁸³ Although quinolones are generally known to exert their anti-microbial activity by inhibiting DNA gyrase,⁸⁴ several compounds of this class, such as HQNO (**19**),⁶² have the potential to bind bacterial NDH-II.^{85,86} Recently, an anti-tubercular quinolone (**26**, Figure 1.16) with nanomolar IC₅₀ values (concentration of drug required to inhibit bacterial growth by half) was discovered from a HTS against *Mtb* NDH-II and subsequent lead compound optimisation.⁸⁷ SAR studies of this class of compounds showed that the ketone moiety was essential for anti-tubercular activity, as was the C ring. The instalment of fluoro-groups at C5 and C7 was important for inhibitory activity, though substitutions at other positions of the phenyl group

led to a loss of growth inhibition. At the 3-position, different groups including CH₃, Br, and Cl were tolerated and the lack of subsitution at this position led to a loss in anti-tubercular activity.⁸⁷ Despite their high potency against many bacterial species, quinolones have long been used as broad-spectrum antibiotics and, as a result, are becoming increasingly tolerated by many species of bacteria.⁸⁴



Figure 1.16: Lead anti-tubercular drug, quinolone 26.

1.5. Thesis outline

With insights into the structure of NDH-II and TB drugs that are reported to bind this enzyme, the overall objective of this thesis was to develop new heterocyclic compounds as TB drug candidates. To this end, the potential anti-tubercular activity of the natural products ascidiathiazone A (27) and ascidiathiazone B (28, Chapter 2), QQs (29, Chapter 3), chromonyl-pyrimidines (30, Chapter 4), and phthalazinones (31, 32, Chapter 5) were investigated (Figure 1.17). Here, I conducted the biological screening of ascidiathiazones A (27) and B (28), and derivatives thereof, chromonyl-pyrimidines (30), and phthalazinones (31, 32) under the supervision of Professor Gregory Cook, while the QQs (29) and several chromonyl-pyrimidines (30) were sent to the Cook laboratory at the University of Otago for testing.



Figure 1.17: Synthetic target molecules 27 and 28 as well as general structures 29-32 to be explored for anti-tubercular activity.

CHAPTER TWO Total synthesis and anti-tubercular activity of Ascidiathiazones A and B

2.1. Introduction

Ascidians, a class of sea squirts or tunicates,⁸⁸ are marine invertebrates that produce a vast array of bioactive secondary metabolites.^{89,90} Within ascidians, the polyclinidiae family is one of the most diverse families, of which the *Aplidium* genus is comprised of 320 distinct species.⁸⁹ Metabolites from ascidians of this genus are of interest due to their high toxicity and favourable pharmacological properties.⁸⁹⁻⁹¹ For example, aplidine (**33**, Figure 2.1), which is extracted from *Aplidium albicans*, is currently undergoing clinical trials for its anti-cancer potential,^{92,93} while the meridinianins (**34**), a group of brominated indoles isolated from *Aplidium meridianum*, act as protein kinase⁹⁴ and tyrosine kinase inhibitors.⁹⁵ The caelestines (**35**), a class of brominated
quinolines that were isolated from the Australian ascidian *Aplidium caelestis*, exhibit modest antimicrobial activity against various bacterial strains including *Staphylococcus aureus*, *Escherischia coli*, and *Pseudomonas aeruginosa*.⁹⁶



Figure 2.1: Natural products aplidine (33), meridinianins (34) and caelestines (35).^{92,94,96}

Ascidians of the *Aplidium* genus are a particularly rich source of meroterpenes that include prenylated quinones and hydroquinones.^{89,97} Meroterpenes exhibit significant biological activities that are often attributed to their ability to undergo redox reactions and produce ROS. Examples of bioactive prenylated hydroquinones from *Aplidium* tunicates include geranylhydroquinone (**36**) and rossinone A (**37**, Figure 2.2).^{97,98} Geranylhydroquinone (**36**) exhibited anti-proliferative activity against Rous sarcoma and mammary carcinoma,⁹⁸⁻¹⁰⁰ while rossinone A (**37**) was reported to suppress superoxide production in human peripheral blood neutrophils during respiratory burst activity and thus, shows promise as an anti-inflammatory agent.⁹⁷



Figure 2.2: Examples of prenylated hydroquinones: geranylhydroquinone (**36**) and rossinone A (**37**).⁹⁷⁻⁹⁹

Quinone meroterpenes have also been extracted from *Aplidium* ascidians, such as the Mediterranean *Aplidium conicum*, from which structurally unique quinones bearing a 1,1-dioxo-1,4-thiazine ring were discovered.¹⁰¹ Four distinct families of dioxo-thiazinoquinones have been identified from this particular ascidian species: the conicaquinones (**38**, **39**, Figure 2.3),¹⁰² the aplidinones (**40**-**42**),⁹¹ the thiaplidiaquinones (**43**, **44**),⁹⁰ and more recently, the conithiaquinones (**45**, **46**).¹⁰³ These dioxo-thiaziquinones were found to exhibit anti-cancer properties, with conicaquinones A (**38**) and B (**39**) inhibiting the growth of rat glioma cells,¹⁰² aplidinone A (**40**) showing modest growth inhibition of a human leukaemia T cell line,¹⁰¹ thiaplidiaquinones A (**43**) and B (**44**) causing apoptosis of Jurkat cells,⁹⁰ and the conithiaquinones A (**45**) and B (**46**) showing cytotoxicity against breast cancer cells.¹⁰³ Despite the potential of this family of compounds as new pharmaceuticals, their modes of action are largely unexplored. Thiaplidiaquinones **43** and **44** however, have been shown to exhibit anti-cancer cancer activity by the induction of ROS overproduction.⁹⁰

Chapter Two



Figure 2.3: Conicaquinones A (**38**) and B (**39**),¹⁰² aplidinones A (**40**), B (**41**), and C (**42**),⁹¹ thiaplidiaquinones A (**43**), and B (**44**),⁹¹ and conithiaquinones A (**45**) and B (**46**).¹⁰³

2.1.1. Ascidian natural products ascidiathiazones A and B

The relatively unusual scaffold of a 1,1-dioxo-1,4-thiazine ring fused to a quinone ring has also been reported in ascidiathiazone A (**27**, Figure 2.4) and its structurally related analogue ascidiathiazone B (**28**).¹⁰⁴ These ascidiathiazones were extracted from a New Zealand ascidian *Aplidium* sp. and have been reported to exhibit anti-inflammatory activity by inhibiting the production of superoxides by human neutrophils.^{104,105}



Figure 2.4: Ascidiathiazone A (27) and ascidiathiazone B (28).¹⁰⁴

In addition to the isolation and structural elucidation of natural products **27** and **28**, the total synthesis of ascidiathiazone A (**27**) was also achieved (Scheme 2.1).¹⁰⁴ Here, quinolinic acid (**47**) was esterified to give methyl ester **48**, which was then oxidised to the corresponding quinone (**49**) with Fremy's salt (potassium nitrosodisulfonate). Next, the thiazine ring was installed by treating QQ **49** with hypotaurine in the presence of cerium chloride to give tricyclic quinone **50**, along with its regioisomer **51** as a minor product. Finally, thiazine **50** was hydrolysed to give ascidiathiazone A (**27**). Following the synthesis of ascidiathiazone A (**27**), a library of structural analogues were prepared,¹⁰⁵ though the synthesis of ascidiathiazone B (**28**) has not been reported.



Scheme 2.1: Total synthesis of ascidiathiazone A (27) by Copp and co-workers.¹⁰⁴

To explore the SAR between ascidiathiazones **27** and **28** and their associated anti-inflammatory activity, the natural products and their synthetic analogues were screened for their ability to suppress superoxide production.¹⁰⁵ Here, it was noted that both the carboxylic acid moiety and the pyridinyl ring were required to retain the biological activity of the compounds. The absence of the thiazine ring however, resulted in good anti-inflammatory activity, though the inclusion of methylsulfone and methylamine substituents in place of the thiazine group led to a loss of anti-inflammatory activity. Furthermore, compounds with the [2,3-g] regiochemistry (*i.e.* **27**) exhibited greater anti-inflammatory activity compared to the corresponding [3,2-g] regioisomers (*i.e.* **28**).¹⁰⁵

2.1.2. Project aim and retrosynthesis

Natural products bearing the tricyclic thiazino-quinone scaffold exhibit a number of pharmacological properties,^{90,101,102} however their anti-tubercular activity has not been explored. Given the tuberculostatic activity of QQs⁶⁵ as well as their ability to bind and activate

mycobacterial NDH-II (Chapter 1, Section 1.4.1.),⁶⁵ it was proposed that the dioxo-thiazinebearing QQs ascidiathiazone A (**27**) and ascidiathiazone B (**28**) may also show promise as TB drugs. Accordingly, methodology to allow for the efficient synthesis of ascidiathiazones A (**27**) and B (**28**), and derivatives thereof, was sought, with investigations into the anti-tubercular activity of these compounds subsequently being undertaken.

To this end, a retrosynthetic strategy was proposed whereby target ascidiathiazones **27** and **28** could be prepared through the treatment of primary chlorides **52-55** with sodium sulfide to give the desired thiazine ring (Scheme 2.2).⁶⁵ Having obtained the tricyclic scaffold, oxidation of the sulfide moiety was then envisioned to give the corresponding sulfones (**27** and **28**). Here, direct oxidation of the [2,3-g] sulfide will provide ascidiathiazone A (**27**), while an additional base-catalysed air oxidation of the [3,2-g] sulfone derivative will give ascidiathiazone B (**28**). The primary chlorides **52-55** could, in turn, be synthesised from common intermediates dichloroquinone **56** or **57**, which are oxidation products of the commercially available 8-hydroxyquinaldine (**58**). Oxidation of methylpyridines to their corresponding carboxylic acids can be performed under the agency of SeO₂¹⁰⁶⁻¹⁰⁸ and other oxidants such as KMnO4¹⁰⁹ and NaIO4¹¹⁰ and, as such, it was proposed that this transformation could be conducted at any stage of the synthesis. Accordingly, both methyl-substituted (**52**, **54**, and **56**) and carboxylic acid-substituted (**53**, **55**, and **57**) quinones were included in the retrosynthesis.



Scheme 2.2: Retrosynthesis of ascidiathiazones A (27) and ascidiathiazone B (28).

In contrast to the published synthesis of ascidiathiazone A (27),¹⁰⁴ the described synthetic strategy has the advantage of accessing both the [2,3-g] and [3,2-g] regioisomers of thiazino-QQs from common intermediate dichloroquinones (*i.e.* 56 or 57).⁶⁵ Moreover, through the early introduction of the sulfide moiety, which could subsequently be oxidised to the sulfoxide or the sulfone,⁶⁵ investigations into the effect of the sulfur oxidation state on the anti-tubercular activity of ascidithiazone analogues could be explored. As such, studies on the biological activity of QQs have indicated that the oxidation state of the thiol moiety may influence the anti-tubercular and anti-proliferative activity of the QQs,⁶⁵ thus suggesting that SARs concerning the sulfur oxidation state in the ascidiathiazone scaffold is an important avenue to investigate.

2.2. Results and Discussion

2.2.1. The synthesis of thiazinoquinones

Having established a synthetic plan for the preparation of ascidiathiazone A (27) and ascidiathiazone B (28), 8-hydroxyquinaldine (58) was treated with SeO₂ to give 8-hydroxyquinolinic acid 47 in a modest yield (Scheme 2.3).¹⁰⁶ Isolation of acid 47 from the reaction mixture proceeded by extracting from the crude material through a Soxhlet apparatus using EtOAc, as described in literature.¹⁰⁶ A second oxidation reaction under the agency of sodium chlorate in concentrated HCl65 was then performed in an attempt to convert carboxylic acid 47 to carboxy-dichloroquinone 57. Unfortunately, the reaction yielded a complex mixture of products, as observed by TLC analysis, and there was no evidence for quinone formation by NMR spectroscopy or HRMS analysis. Accordingly, an alternative route was explored whereby quinoline 58 was first oxidised to dichloroquinone 56 using sodium chlorate under acidic conditions.⁶⁵ Although this reaction was low-yielding, it was readily performed on a multigram scale and required inexpensive reagents. Crystallisation of dichloride 56 from MeOH gave yellow crystals that were then subjected to a benzylic oxidation promoted by SeO₂. The reaction progress was monitored by TLC analysis, which suggested that dichloroquinone 56 was fully consumed, but unfortunately, many products were formed during the course of the reaction. Despite formation of the desired dichloroquinone (57), as indicated by HRMS, (calcd. for [C₁₀H₃Cl₂NO₄+H]⁺: 271.9512, obsd.: 271.9525; calcd. for [C₁₀H₃Cl₂NO₄+Na]⁺: 293.9331, obsd.: 293.9331; calcd. for [C10H3Cl2NO4-H]-: 269.9366, obsd.: 269.9366), attempts to isolate and purify carboxy-dichloroquinone 57 by filtration over Celite and various column chromatography methods (silica gel, reverse phase with C₁₈, and ion exchange) proved futile, with futher product degradation being observed after each attempted purification.



Scheme 2.3: Synthetic strategies to form 2-carboxy-dichloroquinone 57.

Due to the instability of quinone 57, it was proposed that the carboxylic acid moiety could be introduced during the final stages of the synthesis. Indeed, in literature procedures involving quinolinic acids, the carboxylic acid functionality is often protected as a methyl ester while synthetic manipulations take place, with hydrolysis occurring at the end of the synthesis.^{104,105,111-113} Given the selectivity of SeO₂ for the oxidation of allylic and benzylic methyl groups,^{106,114} it was thus envisioned that this oxidation step could occur once the thiazine ring had been installed on the QQ scaffold. Accordingly, dichloroquinone 56 was subjected to a substitution reaction with 2-chloroethylamine hydrochloride to give regioisomers 59 and 60 in a 3:2 ratio, respectively (Scheme 2.4). Here, isomers 59 and 60 could be differentiated using 1D and 2D NMR spectroscopy. Specifically, carbons involved in tautomerisation are more broad and less visible65 and accordingly, peak broadening was observed in the ¹³C NMR spectra for carbons 5, 6, and 7 of the 7-isomer (59), and carbons 6, 7, and 8 in the 6-isomer (60). Furthermore, an HMBC between H4 and C5 allowed for assignment of the regioisomers (Figure 2.5). Here, silica gel flash column chromatography was utilised to separate the two regioisomers, with the 7-isomer 59 being obtained as orange-red crystals, while the 6-isomer 60 was isolated as dark red crystals. Both regioisomers were then treated with sodium sulfide⁶⁵ to form highly reactive primary thiols that underwent subsequent intramolecular cyclisation *in situ* to give tricyclic quinones **61** and **62** as purple crystals.



Scheme 2.4: The syntheses of tricyclic QQs 61 and 62 from dichloroquinone 56.



Figure 2.5: HMBC (500 MHz, CDCl₃) spectrum of chloroethylamino-QQ 59.

2.2.2. The synthesis of ascidiathiazone A

To prepare ascidiathiazone A (27), thiazine **61** was subjected to consecutive oxidation reactions of the sulfide and methyl groups to produce the desired sulfone and carboxylic acid moieties, respectively (Scheme 2.5). The oxidation of a sulfide to a sulfone is well-precedented and can be completed utilising either *m*-CPBA⁶⁵ or H₂O₂.^{115,116} For compounds containing thiazine rings, the amine group is often protected, typically with a *tert*-butyloxycarbonyl (Boc) group, before the oxidation is undertaken,^{117,119} presumably to prevent oxidation of the nitrogen atom to a hydroxylamine. Notwithstanding, in other examples concerning thiazines, the desired sulfone was prepared without the need to first protect the amine moiety.^{120,121} As the oxidation of secondary amines to hydroxylamines is typically low-yielding¹²² and requires harsh conditions,¹²³ the oxidation of thiazine **61** was thus performed without prior protection of the secondary amine. Here, *m*-CPBA was chosen as the oxidising agent as it allowed for the controlled oxidation of the sulfide moiety in a stepwise fashion via the sulfoxide intermediate, with *m*-CPBA being added stoichiometrically while H₂O₂ is typically added in excess. In this way, sulfoxide **63** was readily isolated from the chlorobenzoic acid by-product by an aqueous extraction and further oxidised using an additional equivalent of *m*-CPBA to give sulfone **64**.

Alternatively, sulfone **64** could be prepared in one step and in higher yield (92%) from thiazine **61** by adding 2 equivalents of *m*-CPBA.



Scheme 2.5: The synthesis of ascidiathiazone A (27) via sulfone 64.

The formation of sulfoxide **63** was corroborated by ¹H NMR spectroscopy, whereby the four methylene protons at the 2- and 3-positions were observed at 2.52, 3.31, 4.00, and 4.13 ppm (Figure 2.6A). This is due to the orientation of the thiazine ring in sulfoxide **63**, whereby the S=O group is likely to adopt an axial conformation (**I**, Figure 2.7). The preferred axial position of a sulfoxide oxygen atom in a saturated thiazine ring is unconventional and has been a topic of controversy, however, the formation of a favoured pseudo-axial sulfoxide conformer has been realised in many experiments,^{121,124} with evidence to support this assignment including XRD data from crystal structures.¹²⁵⁻¹²⁹ The orientation of the sulfoxide substituent has been attributed to favourable axial SO/H interactions within the ring,¹²¹ which in turn results in the diastereopicity of the methylene protons at the 2- and 3-positions. Confirmation that sulfoxide **63** was formed was also obtained from HRMS data ([C₁₂H₁₀N₂O₃S+H]⁺ calcd.: 293.0227, obsd.: 293.0198), as well as IR data showing a typical S=O stretch at 1059 cm^{-1,130} In contrast, the ¹H NMR spectrum for the corresponding sulfone **64** revealed only two distinct resonances (3.72, and 4.27 ppm) for the 2- and 3-position as each pair of geminal protons occupies very similar proton environments (Figure 2.6B).



Figure 2.6: ¹H NMR spectra of A). sulfoxide **63** (500 MHz, CDCl₃), and B). sulfone **64** (500 MHz, pyridine-d₅).



Figure 2.7: Structure of the thiazine ring, showing the S=O substituent in the axial position.

With sulfone **64** in hand, a final oxidation step employing SeO₂ was applied to synthesise ascidiathiazone A (**27**) (Scheme 2.6). The oxidation reaction was sluggish and required stirring at 90 °C for three days, as further increases in temperature led to quinone degradation. Nonetheless, the desired carboxylic acid **27** was isolated successfully as a bright yellow solid, albeit in a modest (12%) yield, with the spectral data matching those reported in literature.¹⁰⁴

2.2.3. An alternative synthetic route to ascidiathiazone A

In an attempt to increase the overall yield for the ascidiathiazone A (27) synthesis, an alternative approach involving the benzylic oxidation of thiazine 61 prior to sulfur oxidation was attempted (Scheme 2.6). Gratifyingly, the benzylic oxidation occurred selectively without any evidence of sulfur oxidation, giving carboxylic acid 65 in 83% yield following filtration through Celite, acidification, and aqueous extraction.



Scheme 2.6: The synthesis of ascidiathiazone A (27) through carboxylic acid 65.

Evidence for the formation of carboxylic acid **65** was obtained through ¹H and ¹³C NMR analysis. The disappearance of the resonances attributed to the methyl group for methylpyrimidine **61**, which were noted at $\delta_H = 2.69$ ppm and $\delta_C = 25$ ppm, in combination with the appearance of a resonance at $\delta_C = 165.7$ ppm in the ¹³C NMR spectrum of **65** were indicative of the presence of a carboxylic acid carbonyl carbon. This carbon was also found to correlate to protons at the 8- and 9- positions, as determined by HMBC (Figure 2.8). Moreover, the mass of the desired compound was observed by HRMS (calcd. for [C₁₂H₈N₂O₄S+H]⁺: 277.0278, obsd.: 277.0277; calcd. for [C₁₂H₈N₂O₄S-H]⁻.: 275.0132, obsd.: 275.0135), thereby corroborating the presence of acid **65**.



Figure 2.8: HMBC spectrum (500 MHz, DMSO-d₆) of thiazine-quinolinic acid 65.

With the carboxy-quinone 65 in hand, the final oxidation reactions were undertaken to install the sulfone functionality present in ascidiathiazone A (27). Again, an initial oxidation step was employed in order to isolate sulfoxide 66 in an excellent (93%) yield. Due to its highly polar nature, sulfoxide 66 precipitated from the reaction mixture and was readily collected through filtration. However, when sulfoxide 66 was subjected to a second oxidation reaction, the reaction was sluggish and did not reach completion, which was presumably due to the low solubility of sulfoxide 66 in organic solvents (CH₂Cl₂ and acetone). To circumvent this issue, a two-step oxidation reaction of 65 was conducted using two equivalents of m-CPBA in acetone. Although product formation was evidenced by TLC and HRMS analysis (calcd. for $[C_{12}H_8N_2O_6S+H]^+$: 309.0176, obsd.: 309.0175), the oxidation reaction did not reach completion and resulted in the recovery of sulfide 65 and sulfoxide 66. Additional equivalents of *m*-CPBA did not assist in the consumption of sulfide **65** and sulfoxide intermediate **66** and instead further complicated the purification procedure. Thus, in an alternative approach, sulfide 65 was treated with a 28% H₂O₂ solution for two hours, followed by the addition of a second equivalent of 28% H_2O_2 , this time in AcOH.¹¹⁵ Gratifyingly, the desired sulfone 27 precipitated from the solution after one hour of stirring at 70 °C to give ascidiathiazone A (27)

as a bright yellow solid in a moderate yield (52%). In addition, crystallisation of ascidiathiazone A (27) from H_2O resulted in small yellow crystals that were of sufficient quality for X-ray crystallography. The structure of ascidiathiazone A (27) was confirmed by XRD data, which revealed the sulfone and carboxylic acid functionalities (Figure 2.9).



Figure 2.9: XRD crystal structure of ascidiathiazone A (27).

Compared to the literature synthesis of ascidiathiazone A (27), which was achieved in 32% yield over 4 steps,¹⁰⁴ the presented synthetic route had a lower overall yield of 6% over 5 steps due to the low-yielding oxidation step of hydroxyquinoline **58** to afford dichloroquinone **56**. That said, the presented synthetic routes allowed for a variety of ascidiathiazone A (27) analogues to be prepared for SAR studies of their anti-tubercular activity.

2.2.4. The synthesis of ascidiathiazone B

Having successfully prepared ascidiathiazone A (27), similar synthetic strategies were adopted to synthesise ascidiathiazone B (28) (Scheme 2.7). Accordingly, thiazine 62 was treated with *m*-

CPBA to form sulfoxide 67 and, subsequently, sulfone 68. Gratifyingly, improved yields were achieved upon the oxidation of thiazine 62 compared to the oxidation of its regioisomer 61, giving sulfone **68** in 98% yield or 30% yield over two steps from the corresponding sulfide (62). Next, sulfone 68 was subjected to base-catalysed air oxidation with potassium hydroxide^{105,131} to give the unsaturated sulfone **69** in a high yield. The formation of the alkene moiety was evident by the loss of the resonances for the methyelene protons at 3.41 and 3.94 ppm in the ¹H NMR spectrum of sulfone 39 (Figure 2.10A), and the appearance of two doublets correlating to protons 2 and 3 at 7.24 and 6.45 ppm, respectively, in the ¹H NMR spectrum of thiazine 69 (Figure 2.10B). The observed $J_{\rm H2,H3}$ value of 8.9 Hz is typical of $J_{\rm H,H}$ values of *cis* alkene protons,¹³⁰ while also matching literature data for proton resonances in unsaturated 1,1-dioxo-thiazino-quinones.^{105,131} Having prepared sulfone **68**, oxidation of the methyl group to the corresponding carboxylic acid was then performed under the agency of SeO2. The oxidation was complete after 24 hours, whereby TLC analysis showed the appearance of a slower running product $[R_f = 0.09 \text{ (EtOAc/MeOH/AcOH, 4/1/0.1, v/v/v)}].$ Due to the polar nature of ascidiathiazone B (28), purification was difficult and required both standard and reverse phase column chromatography, as well as size exclusion chromatography. Nonetheless, ascidiathiazone B (28) was successfully isolated in a 33% yield, with data matching those reported for natural product 28.¹⁰⁴ In this way, I confirmed the structural assignment of ascidiathiazone B (28) as this is the first reported total synthesis of this natural product. Here, ascidiathiazone B (28) was synthesised in 6 steps from commercially available starting materials (8-hydroxyquinoline 58) and in 2% overall yield.



Scheme 2.7: The synthesis of ascidiathiazone B (28) from thiazine 62 in 3 steps.



8.6 8.4 8.2 8.0 7.8 7.6 7.4 7.2 7.0 6.8 6.6 6.4 6.2 6.0 5.8 5.6 5.4 5.2 5.0 4.8 4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 filorm

Figure 2.10: ¹H NMR spectrum (500 MHz, D_2O) of A). saturated sulfone 68 and B). unsaturated sulfone 69.

Next, the alternative synthetic route was applied to thiazine **62** in order to prepare additional derivatives of ascidiathiazone B (**28**) for assessment of their anti-tubercular activity. To this end, thiazine **62** was treated with SeO₂ to give carboxy-quinone **70** in 72% yield (Scheme 2.8). Next, sulfide oxidation reactions with *m*-CPBA and H₂O₂ gave the corresponding sulfoxide **71** and sulfone **72**, respectively, in moderate to good yields. Both sulfoxide **71** and sulfone **72** precipitated from CH₂Cl₂ and H₂O, respectively, and were collected by filtration. The formation of sulfone **72** was corroborated by HRMS (calcd. for [C₁₂H₈N₂O₆S+H]⁺: 309.0176, obsd.: 309.0170, calcd. for [C₁₂H₈N₂O₆S-H]⁻: 307.0030, obsd.: 307.0051), as well as by NMR analysis. NMR data for thiazine **72** was similar to its regioisomer, ascidiathiazone A (**27**), with the most notable difference being the slightly larger Δ H9-H8 value for sulfone **72** (8.48 ppm-8.27 ppm = 0.21 ppm), compared to that for ascidiathiazone A (**27**, 8.40 ppm-8.22 ppm = 0.18 ppm) (Figure 2.11). Finally, sulfone **72** was subjected to base-catalysed air oxidation to give ascidiathiazone B (**28**) in 80% yield, giving ascidiathiazone B (**28**) in an improved overall yield of 2.5% over six steps, compared to the previous synthetic route.



Scheme 2.8: Synthesis of ascidiathiazone B (28) via carboxyquinone 72.



9.8 9.6 9.4 9.2 9.0 8.8 8.6 8.4 8.2 8.0 7.8 7.6 7.4 7.2 7.0 6.8 6.6 6.4 6.2 6.0 5.8 5.6 5.4 5.2 5.0 4.8 4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 [100m]

Figure 2.11: ¹H NMR spectra (500 MHz, DMSO-d₆) of A). ascidiathiazone A (**27**), and its regioisomer B). carboxy-quinone **72**.

2.2.5. MIC values

To investigate the anti-tubercular activity of ascidiathiazone A (27) and ascidiathiazone B (28) along with synthetic derivatives 47, 59-72, two strains of mycobacteria, *M. smegmatis* mc²155 and *Mtb* mc²6230 were employed, as measured by the MIC (Table 2.1). Here, the MIC values were determined as the minimal concentration of the compound required to inhibit bacterial growth. Both *M. smegmatis* mc²155 and *Mtb* mc²6230 are commonly used for mycobacterial studies as they are non-pathogenic,¹³² and, in the case of *M. smegmatis*, fast-growing.^{133,134} These studies were undertaken under the supervision of Professor Gregory Cook at the University of Otago.

Table 2.1: The MIC values (μ M) of ascidiathiazones **27**, **28**, and analogues **47**, **59**–**72** against *M. smegmatis* and *Mtb*

Entry	Compound	MIC against	MIC against
		M. smegmatis (µM)	M. tuberculosis (µM)
1	$HO \longrightarrow N \longrightarrow O \\ N \longrightarrow O \\ O \\ O \\ O \\ O \\ H \\ O \\$	>100	100
2	$HO \xrightarrow{N} \xrightarrow{N} \xrightarrow{N} \xrightarrow{N} \xrightarrow{N} \xrightarrow{N} \xrightarrow{N} \xrightarrow{N}$	>100	100
3	$HO \xrightarrow{V} O \xrightarrow{O} O \xrightarrow{O} S \xrightarrow{V} O \xrightarrow{V}$	>100	100

>100

>100



100

50



67

0

 \int

64

Ν

0_0 _\\// _S_

> Ν́ Η



>100 50

>100 25

20

>100 25

50 12.5

8

7

4

5

6



9







100

25



>100 100

12

13



0

∬ O

59

CI

`N´ H CI

>100 1.6

12.5

3

3

14



>100

50

15



50



From the MIC values, it was noted that the anti-mycobacterial activity of the ascidiathiazone analogues varied greatly between the two species of bacteria. Indeed, this is a common phenomenon,¹³⁵ despite extensive literature precedence on the use of *M. smegmatis* as a bacterial model for *Mtb* in drug discovery.^{136,137} Herein, a lack of growth inhibition against *M. smegmatis* was observed for almost all of the compounds, with the exceptions of compounds **61**, **62**, **59**, **47**, and **69**, which showed modest inhibitory activity (50 – 100 μ M, Entries 9, 10, 13, 15, 16). Notwithstanding, the anti-tubercular activity of thiazino-QQs **61**, **62**, **59**, **47**, **69** against *M. smegmatis* correlated to low MIC values against *Mtb* (3 – 12 μ M).

In contrast, all compounds exhibited inhibitory activity against *Mtb*, with MIC values ranging from 100 μ M to 1.6 μ M. In most cases, [2,3-g] and [3,2-g] regioisomers similar potency. This can be seen in sulfides **65** and **70** (100 μ M), sulfoxides **66** and **71** (100 μ M) and **63** and **67** (50 μ M), and sulfones **64** and **68** (25 μ M) (Entries 1-8). When different MIC values were observed between regioisomers, the [2,3-g] isomers tended to have higher inhibitory activity than the corresponding [3,2-g] isomers, as in thiazines **61** and **62** (12.5 μ M and 25 μ M, Entries 9 and 10, respectively), and in sulfone **72**, which was a considerably weaker inhibitor than its [2,3-g] regioisomer, ascidiathiazone A (**27**) (100 μ M and 1.6 μ M, respectively, Entries 11 and 12). In chloroethylaminoQQs **59** and **60** however, the [3,2-g] isomer gave better anti-tubercular activity (12.5 μ M vs. 3 μ M, Entries 13 and 14, respectively).

Previous studies on the biological activity of QQs have identified tuberculostatic QQs that bear sulfone and sulfoxide functionalities⁶⁵ and, accordingly, the effect of different sulfur oxidation states on the anti-tubercular activity of QQs was analysed. Here, the sulfone moiety

tended to increase growth inhibition compared to the corresponding sulfides and sulfoxides. For example, sulfones **64** and **68** had lower MIC values (25μ M) than sulfoxides **63** and **67** (50 μ M, Entries 5-8), while ascidiathiazone A (**27**) was exceptionally potent against *Mtb* compared to the corresponding sulfide (**61**) and sulfoxide (**66**) (Entries 12, 1, and 3, respectively). In the case of the [3,2-g] isomers, unsaturation at carbons 2 and 3 correlated to a remarkable decrease in MIC, with unsaturated thiazine **69** being much more potent than the saturated form **68** (6 μ M compared to 25 μ M, Entries 16 and 8, respectively), as well as ascidiathiazone B (**28**) with an MIC of 3 μ M compared to acid **72** at 100 μ M (Entries 17, 11, respectively).

As mentioned above, the carboxy-functionality was previously deemed important for the antiinflammatory activity of ascidiathiazone analogues¹⁰⁵ and this structural feature was thus also explored for anti-tubercular activity. Here, compounds bearing a carboxylic acid group gave wide ranging MIC values. In particular, acids **65**, **70**, **66**, **71**, and **72** all have modest inhibitory activity at 100 μ M (Entries 1-4, 11), while acid **47**, along with natural products **27** and **28** have the lowest MIC values of the library at 3, 1.6, and 3 μ M, respectively (Entries 15, 12, and 17, respectively). These results suggest that the presence of both sulfone and carboxyfunctionalities are important for anti-tubercular activity of the tricylic ascidiathiazone analogues.

Overall, this *in vitro* assay demonstrated the potent anti-tubercular activity of natural products ascidiathiazone A (27) and ascidiathiazone B (28), with ascidiathiazone A (27) being twice as potent than ascidiathiazone B (28). Moreover, ascidiathiazone A (27) has previously been reported to exhibit low cytotoxicity in mammalian cell line L6 (IC₅₀: 170 μ M),¹³⁸ making it a promising lead compound as an anti-tubercular agent. That said, the mechanism by which ascidiathiazone A (27) exerts anti-mycobacterial activity is yet to be determined.

2.2.6. NADH oxidation

To investigate whether the ascidiathiazone analogues perturb NDH-II function, the effects of each compound on the rate of NADH oxidation in mycobacterial inverted membrane vesicles (IMVs) were measured. IMVs have intact ETCs that oxidise NADH, which provides an excellent model for mycobacterial NADH oxidation. As NADH absorbs light at 340 nm,^{33,64} NADH oxidation by IMVs was monitored by measuring the absorbance at 340 nm over time. The rate of NADH oxidation in the presence of each ascidiathiazone analogue, alongside the negative control, *i.e.* IMV only, and the basal rate of oxidation, *i.e.* IMV and NADH only, are





Figure 2.12: Rates of NADH oxidation after treating IMVs with compounds **27**, **28**, **47** and **59-74**. The basal rate was determined by measuring the rate of NADH oxidation by IMVs without the addition of any drug, while the negative control contained only IMVs.

As shown in Figure 2.12, chloroethylamino-QQs **59** and **60** exerted an appreciable effect on NADH oxidation by increasing the reaction rate. This observation is consistent with previous studies whereby the closely related QQ8c (**20**, Figure 2.13) stimulated NADH oxidation and oxygen consumption in IMVs.⁶⁴ Next, the NADH oxidation and O₂ consumption induced by QQ **60** were determined by monitoring the fluorescence of the pH-sensitive dye acridine orange (**73**) and the O₂ concentration in the IMVs, respectively (Figure 2.14). Here, upon the addition of NADH (t = 5 s), a reduction in O₂ concentration and the fluorescence quenching of acridine orange (**73**) were observed as NADH undergoes oxidation and releases protons. When QQ **60** was added (t = 6 s), the rate of O₂ consumption increased drastically, which supported the hypothesis that QQ **60** stimulates NADH oxidation. However, the fluorescence of acridine orange (**73**) continued to decrease after QQ **60** was added, indicating that the IMV cell membrane remained impermeable to protons (the drop in fluorescence seen here is due to the inherent fluorescence of QQ **60**). As uncouplers of respiration allow protons to move

Chapter Two

in and out of cell membranes, this observation indicated that QQ **60** does not uncouple respiration in *Mtb*. This observation is consistent with the mode of action of QQ8c (**20**).⁶⁴ As the oxygen concentration is depleted, ion diffusion through the membrane takes place and fluorescence increases as the pH increases (at t = 7 s).



Figure 2.13: QQ8c (20) and acridine orange (73).



Figure 2.14: QQ 60 increased oxygen consumption in IMVs and did not act as an uncoupler. Oxygen concentration (blue line) decreases significantly faster after 60 was added to the solution (at t = 6 seconds), while the fluorescence of acridine orange (73) (red line) continued to decrease.

In the case of QQ8c (20), similar assays were conducted with IMVs that overexpress the NDH-2 enzyme, thereby confirming that QQ8c (20) activates NDH-2 specifically.⁶⁴ Herein,

wild type IMVs were used, though due to the structural resemblance of quinone **60** to QQ8c (**20**), as well as the widely accepted view that *Mtb* utilise NDH-II exclusively to oxidise NADH,⁴¹ it was postulated that compound **60** inhibits *Mtb* growth through NDH-II activation. Notwithstanding, studies of the modes of action of lead compounds ascidiathiazone A (**27**) and ascidiathiazone B (**28**) are underway.

2.3. Conclusion

In summary, the total synthesis of the natural product ascidiathiazone A (27) and, for the first time, the total synthesis of ascidiathiazone B (28) were achieved. Although the synthesis of ascidiathiazone A (27) has been previously reported (4 steps and 32% overall yield from quinolinic acid 47),¹⁰⁴ the present divergent synthetic strategy allowed for both natural products 27 and 28 to be synthesised from a common intermediate. Herein, ascidiathiazone A (27) was synthesised in 6% overall yield over five steps, while ascidiathiazone B (28) in 2.5% overall yield over six steps, both from the commercially available 8-hydroxyquinoline (58). In addition, this synthetic route allowed for the preparation of a number of related structures for SAR analysis. In paricular, the effect of a carboxylic acid functionality as well as different sulfur oxidation states on the anti-tubercular activity of the compounds was investigated.

Next, the library of ascidiathiazone analogues was screened against *M. smegmatis* and *Mtb*, from which MIC values for each compound were obtained. While the compounds did not show inhibitory activity against *M. smegmatis*, they did inhibit *Mtb* growth at low concentrations. The lead compound from this library was ascidiathiazone A (**27**), with a remarkably low MIC of 1.6 μ M, and, moreover, low toxicity against mammalian cell line L6.¹³⁸ Other potent inhibitors identified were ascidiathiazone B (**28**), quinolinic acid **47**, and quinone **60** – all with MIC values of 3 μ M.

To gain some insight into the mode of action of the ascidiathiazone analogues, IMVs were treated with each compound, and the resulting NADH oxidation rates measured. In this assay, quinone **60** stimulated NADH oxidation, an observation that was further supported in assays that saw QQ **60** increase O₂ consumption in IMVs without acting as an uncoupler. Taken together, compound **60** thus has a mode of action similar to the structurally related QQ8c (**20**), although QQ **60** is a more potent *Mtb* inhibitor than QQ8c (**20**) (MIC = 3 μ M vs. 8.1 μ M,⁶⁴ respectively).

2.4. Experimental

2.4.1. Chemistry

General procedure. Unless otherwise stated, all reactions were performed under atmospheric air. Prior to use, CH₂Cl₂ (Fisher) was distilled from P₂O₅, pyridine (BDH) was distilled over CaH₂, SeO₂ (Aldrich) was sublimed, and EtOAc, petroleum ether, acetone, MeOH (Pure Science) and H₂O were distilled. 8-hydroxy-2-methyl-quinoline (Aldrich), NaOH (Pure Science), 37% HCl (Merck), sodium chlorate (Sigma Aldrich), EtOH (absolute, Pure Science), 2-chloroethylamine hydrochloride (Aldrich), NaHCO₃ (Pure Science), MgSO₄ (Pure Science), sodium sulfide (Pure Science), *m*-CPBA (Aldrich), AcOH (Panreac), 28% H₂O₂ (Riedel-de Haen), KOH (Pure Science) were used as received.

All solvents were removed by evaporation under reduced pressure. Reactions were monitored by TLC-analysis on Macherey-Nagel silica gel coated plastic sheets (0.20 mm, with fluorescent indicator UV₂₅₄) with detection by UV-absorption (short wave UV – 254 nm; long wave UV – 366 nm) by dipping in KMnO₄ in H₂O. Column chromatography was performed on Pure Science silica gel (40 – 63 micron). Infrared spectra were recorded as thin films using a Bruker Tensor 27 FTIR spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling accessory and are reported in wavenumbers (cm⁻¹). Melting points (m.p.) were obtained on a DigiMelt MPA160 melting point appartus. UV data were obtained on an Agilent 8453 spectrometer. Nuclear magnetic resonance spectra were recorded at 20 °C in D₂O, CDCl₃, pyridine-d₅, or DMSO-d₆ using either a Varian INOVA operating at 500 MHz or Varian VNMRS operating at 600 MHz. Chemical shifts are given in ppm (δ) relative to solvent residues. NMR peak assignments were made using COSY, HSQC, and HMBC 2D experiments. High-resolution (ESI) mass spectrometric data were obtained with an Agilent 6530 Accurate-Mass Q-TOF LC-MS equipped with a 1260 Infinity binary pump.



8-Hydroxy-2-quinolinic acid (47). In a round-bottomed flask was stirred 8-hydroxy-2-methyl-quinoline (225 mg, 1.4 mmol) and selenium dioxide (782 mg, 7.05 mmol, 5 equiv.) in pyridine (10 mL). The reaction was stirred at 90 °C for 20 h, after which time the disappearance of the

starting material was observed via TLC. The reaction was cooled and filtered over Celite and the solvent evaporated *in vacuo*. A solution of NaOH (2 M in H₂O) was then added to the brown residue, the resulting precipitate filtered, then the solution acidified with 2 M aq. HCl

to pH=4. The product was then obtained by filtration as a brown solid (51 mg, 20%). The data obtained for this compound matched those reported in literature.¹⁰⁶

6,7-Dichloro-2-methyl-5,8-quinolinequinone (56). In a round-bottomed flask, 8-hydroxy-2-methyl-quinoline (14.5 g, 0.09 mol) was dissolved in conc. HCl (600 mL) and the reaction warmed to 40 °C. Sodium chlorate (48.5 g, 0.45 mol, 5 equiv.) was then slowly added to the reaction mixture over a period of 1 h, after which time the reaction was

stirred at room temperature for an additional 2 h. The solution was then diluted to 1 L with H_2O and the white precipitate filtered, the filtrate extracted with CH_2Cl_2 (6 x 250 mL) and the organic layers combined and concentrated *in vacuo*. The resulting bright orange solid was recrystallised in ethanol to provide the title compound as bright yellow crystals (6.20 g, 29%). The data obtained for this compound matched those reported in the literature.⁶⁵

ö

56



Dichloroquinolinequinone **56** (2.5 g, 10 mmol) was dissolved in ethanol (95 mL) and water (48 mL) before 2-chloroethylamine hydrochloride (1.7 g, 15 mmol, 1.5 equiv.) and 2 M aq. NaOH (9 mL, 18 mmol, 1.8 equiv.) were added. The red solution was warmed to reflux and stirred for 1 h, after which time TLC analysis indicated complete disappearance of the starting material. The solvent was removed *in vacuo* and the resulting red solid redissolved in CH₂Cl₂ (100 mL) and washed with sat. aq. NaHCO₃ (100 mL), followed by brine (100 mL) before being dried with anhydrous MgSO₄, filtered and the filtrate concentrated *in vacuo*. Purification by silica gel column chromatography (CH₂Cl₂/EtOAc, $1/0 \rightarrow 3/1$, v/v) allowed for the separatation of the two regioisomers giving **59** as red-orange crystals (1.6 g, 56%) and **60** as dark red crystals (1.1 g, 38%). Data for **59**: R_f = 0.43 (EtOAc/petroleum ether, 1/1, v/v); m.p. = 230.9 °C; UV-Vis (MeOH) λ_{max} (log ε): 465 (3.51) nm; IR (ν_{max}): 3310, 1694, 1598, 1575, 1557, 1505, 1450, 1323, 1248, 1192, 1147, 1111, 1092, 850, 818, 737, 566, 466, 423 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.35 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.52 (d, $J_{3,4} = 8.0$ Hz, 1H,

H3), 6.36 (br. s, 1H, NH), 4.21 (q, $J_{2',3'} = 6.1$ Hz, 2H, H2'), 3.79 (t, $J_{2',3'} = 5.7$ Hz, 2H, H3'), 2.74 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.0 (C8), 176.1 (C5), 164.0 (C2), 145.6 (C8a), 144.3 (C7), 135.0 (C4), 128.6 (C3), 127.5 (C4a), 46.2 (C2'), 44.2 (C3'), 25.1 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₂H₁₀Cl₂N₂O₂+H]⁺: 285.0192, obsd.: 285.0192. Data for **60**: R_f = 0.31 (1/1, EtOAc/petroleum ether, v/v); m.p. = 154.9 °C; IR (ν_{max}): 3337, 1666, 1600.2, 1581, 1518, 1451, 1313, 1227, 1143, 1074, 931, 841, 752, 701, 643, 565, 471, 436 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.19 (d, $J_{3,4}$ = 8.2 Hz, 1H, H4), 7.42 (d, $J_{3,4}$ = 7.9 Hz, 1H, H3), 6.31 (br. s, 1H, NH), 4.18 (q, $J_{2',3'}$ = 6.0 Hz, 2H, H2'), 3.77 (t, $J_{2',3'}$ = 5.7 Hz, 2H, H3'), 2.72 (CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.8 (C5), 175.6 (C8), 166.1 (C2), 147.8 (C8a), 143.3 (C6), 135.0 (C4), 126.7 (C3), 124.7 (C4a), 46.0 (C2'), 44.2 (C3'), 25.5 (CH₃): HRMS-ESI (m/z) calcd. for [C₁₂H₁₀Cl₂N₂O₂+H]⁺: 285.0192.

7-Methyl-2,3-dihydro-4H-[1,4]thiazino[2,3-g]quinoline-5,10-



dione (61). To a solution of QQ 59 (115 mg, 0.40 mmol) in EtOH (30 mL) was added dropwise a solution of sodium sulfide (159 mg, 1.22 mmol, 3 equiv.) in H_2O (15 mL). The solution was stirred for 30 min at room temperature, after which time TLC analysis showed the

disappearance of starting materials. The dark purple liquid was then diluted with water (100 mL) and extracted with CH₂Cl₂ (2 x 100 mL) before being dried with anhydrous MgSO₄, filtered and the filtrate concentrated *in vacuo*. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $3/1 \rightarrow 1/3$, v/v) yielded the title compound as purple crystals (86 mg, 86%). R_f = 0.38 (EtOAc); m.p. = 259 °C; UV-vis (MeOH) λ_{max} (log ε): 553 nm (3.42); IR (ν_{maz}): 3358, 1676, 1620, 1592, 1574, 1547, 1488, 1204, 1153, 1119, 816, 733, 538, 468, 413 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.22 (d, $J_{8,9} = 7.7$ Hz, 1H, H9), 7.41 (d, $J_{8,9} = 7.9$ Hz, 1H, H8), 6.17 (br. s, 1H, NH), 3.79 (t, $J_{2,3} = 4.3$ Hz, 2H, H3), 3.01 (q, $J_{2,3} = 4.1$ Hz, 2H, H2), 2.69 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 178.6 (C5), 176.6 (C10), 163.1 (C7), 146.3 (C5a), 141.3 (C4a), 134.3 (C9), 128.4 (C9a), 127.8 (C8), 111.1 (C10a), 42.0 (C3), 25.0 (CH₃), 23.9 (C2); HRMS-ESI (*m*/*z*) calcd. for [C₁₂H₁₀N₂O₂S+H]⁺: 247.0536, obsd.: 247.0524.



1-Oxo-7-methyl-2,3-dihydro-4*H*-[1,4]thiazino[2,3-g]quinoline-5,10-dione (63). Thiazine 61 (95 mg, 0.39 mmol) was dissolved in freshly distilled CH_2Cl_2 (3.9 mL) and cooled to 0 °C before *m*-CPBA (67 mg, 0.39 mmol) was added. The reaction was allowed to warm to room temperature and stirred for 30 min before TLC analysis indicated

the consumption of starting materials and the presence of sulfoxide **63**. The bright yellow solution was then concentrated *in vacuo* and purified by silica gel flash column chromatography (CH₂Cl₂/MeOH, $1/0 \rightarrow 4/1$, v/v) to give the title compound as a yellow amorphous solid (45 mg, 44%). R_f = 0.10 (EtOAc/MeOH, 4/1, v/v); IR (v_{max}): 2931, 2830, 1677, 1603, 1577, 1508, 1307, 1251, 1220, 1177, 1143, 1110, 1061, 1024, 842, 748, 701, 644, 554, 420 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.45 (d, $J_{8,9} = 8.7$ Hz, 1H, H9), 7.60 (d, $J_{8,9} = 8.9$ Hz, 1H, H8), 7.28 (br. s, 1H, NH), 4.11 (t, $J_{3a,3b} = 15.3$ Hz, 1H, H3a), 3.97 (d, $J_{3a,3b} = 15.0$ Hz, 1H, H3b), 3.28 (d, $J_{2a,2b} = 14.2$ Hz, 1H, H2a), 2.76 (s, 3H, CH₃), 2.50 (t, $J_{2a,2b} = 14.5$ Hz, 1H, H2b); ¹³C NMR (125 MHz, CDCl₃) δ ppm 178.7 (C5), 177.6 (C10), 164.4 (C7), 145.7 (C5a), 135.5 (C9), 129.5 (C8), 128.5 (C9a), 112.4 (C10a), 41.3 (C2), 31.2 (C3), 25.22 (CH₃); HRMS-ESI (*m/z*) calcd. for [C₁₂H₁₀N₂O₃S+H]⁺: 263.0485, obsd.: 263.0482.



1,1-Dioxo-7-methyl-2,3-dihydro-*4H***-[1,4]thiazino**[*2,3-g*]**quinoline-5,10-dione (64).** To a solution of thiazine **61** (52 mg, 0.21 mmol) in CH₂Cl₂ (12 mL) was added *m*-CPBA (80 mg, 0.46 mmol). The reaction was stirred at room temperature for 20 h, after which time TLC analysis indicated the disappearance of starting materials and the

formation of sulfone **64**. The bright yellow solution was then concentrated *in vacuo* and purified by silica gel flash column chromatography (CH₂Cl₂/MeOH, $1/0 \rightarrow 4/1$, v/v) to give the title compound as a yellow amorphous solid (50 mg, 86%). R_f = 0.20 (EtOAc/MeOH, 4/1, v/v); IR (v_{max}): 2918, 2853, 1689, 1635, 1590, 1578, 1370, 1329, 1297, 1242, 1197, 1130, 1069, 954, 742, cm⁻¹; ¹H NMR (500 MHz, pyridine-d₆) δ ppm 10.47 (br. s, 1H, NH), 8.42 (d, $J_{8,9} = 8.1$ Hz, 1H, H9), 7.40 (d, $J_{8,9} = 8.1$ Hz, 1H, H8), 4.27 (m, 2H, H2), 3.73-3.71 (m, 2H, H3), 2.58 (s, 3H, CH₃); ¹³C NMR (125 MHz, pyridine-d₅) δ ppm 178.3 (C5), 175.5 (C10), 163.6 (C7), 148.(C4a), 146.7 (C5a), 135.0 (C9), 129.0 (C8), 112.6 (C10a), 49.8 (C2), 40.4 (C3), 24.9 (CH₃); HRMS-ESI (*m*/*z*) calcd. for [C₁₂H₁₀N₂O₄S+H]⁺: 279.0434, obsd.: 279.0433.



2,3-Dihydro-*4H***-[1,4]thiazino**[*2,3-g*]**quinoline-5,10-dione-7-carboxylic acid (65).** Thiazine **61** (20 mg, 0.080 mmol) was dissolved in freshly distilled pyridine (0.76 mL) to which SeO₂ (40 mg, 0.37 mmol, 4.5 equiv.) was then added. The reaction was warmed to 90 °C and stirred overnight before TLC analysis

showed the disappearance of starting materials. The solution was then filtered through a pad of Celite and washed with EtOH (5 mL). The resulting filtrate was then concentrated *in vacuo* to give a dark purple residue that was re-dissolved in H₂O. The pH of the solution was then increased to 10 by the addition of 2 M aq. NaOH and the reaction was washed with CH₂Cl₂ (3 x 10 mL). The aqueous layer was then collected and acidified to pH 1 with 2 M aq. HCl before the product was extracted with EtOAc (3 x 10 mL). The organic layers were collected, dried with anhydrous MgSO₄, filtered, and the filtrate concentrated *in vacuo* to give the title compound as a dark purple amorphous solid (19 mg, 83%). R_f = 0.02 (EtOAc); IR (v_{max}): 3369, 2921, 1732, 1694, 1582, 1544, 1495, 1450, 1337, 1261, 1220, 1161, 982, 835, 721, 553, 440 cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.34 (d, $J_{8,9}$ = 8.0 Hz, 1H, H9), 8.27 (d, $J_{8,9}$ = 8.0 Hz, 1H, H8), 8.15 (br. s, 1H, NH), 3.66-3.63 (m, 2H, H3), 2.99-2.97 (m, 2H, H2); ¹³C NMR (125 MHz, DMSO-d₆) δ ppm 176.7 (C5), 175.8 (C10), 165.8 (CO₂H), 151.0 (C7), 147.0 (C5a), 143.7 (C4a), 134.9 (C9), 132.3 (C9a), 129.0 (C8), 109.2 (C10a), 42.2 (C3), 23.1 (C2); HRMS-ESI (*m*/*z*) calcd. for [C₁₂H₈N₂O₄S+H]⁺: 277.0278, obsd.: 277.0277, and for [C₁₂H₈N₂O₄S-H]⁻: 275.0132, obsd.: 275.0135.



1-Oxo-2,3-dihydro-4H-[1,4]thiazino[2,3-g]quinoline-5,10dione-7-carboxylic acid (66). Acid 65 (9 mg, 0.03 mmol) was dissolved in acetone (0.09 mL) and cooled to 0 °C before *m*-CPBA (5.2 mg, 0.03 mmol) was added. The bright yellow solution was allowed to warm to room temperature and stirred for 30 min

before TLC analysis showed the complete disappearance of starting materials. The solution was then concentrated *in vacuo*, re-dissolved in H₂O (1 mL) and washed with EtOAc (3 x 1mL). The aqueous solution was then concentrated to give the title compound as a yellow solid (9.2 mg, 94% yield). R_f = 0.18 (MeOH/EtOAc, 4/1, v/v); IR (υ_{max}): 3375, 2933, 1603, 1578, 1379, 1330, 1252, 1184, 1110, 1023, 950, 844, 640, 618, 570 cm⁻¹; ¹H NMR (600 MHz, D₂O) δ ppm 8.65 (d, $J_{8,9}$ = 8.1 Hz, 1H, H9), 8.31 (d, $J_{8,9}$ = 8.1 Hz, 1H, H8), 4.17 (dt, $J_{3a,3b}$ = 15.1 Hz, $J_{2a,3a}$ =3.3 Hz, 1H, H3a), 3.81 (td, $J_{3a,3b}$ = 14.9 Hz, $J_{2b,3b}$ = 2.9 Hz, 1H, 3b), 3.47 (dt, $J_{2a,2b}$ = 14.7 Hz, $J_{2b,3b}$ = 2.6 Hz, 1H, H2b), 2.78 (td, $J_{2a,2b}$ = 14.6 Hz, $J_{2a,3a}$ = 3.9 Hz, 1H, H2a); ¹³C NMR (150 MHz,

D₂O) δ ppm 178.5 (C10), 177.8 (C5), 157.5 (CO₂H), 147.2 (C7 or C5a), 145.8 (C7 or C5a), 136.6 (C9), 130.1 (C9a), 128.6 (C8), 107.7 (C10a), 39.6 (C2), 30.7 (C3); HRMS-ESI (*m/z*) calcd. for: [C₁₂H₈N₂O₅S-H]⁻: 291.0081, found: 291.0092.



Ascidiathiazone A (27). <u>Procedure A:</u> To a solution of tricyclic acid 65 (15 mg, 0.05 mmol) in H₂O (0.25 mL) was added H₂O₂ (28%, 0.025 mL). The reaction was stirred for 2 h before H₂O₂ (28%, 0.0125 mL) and AcOH (0.25 mL) were added. The yellow solution was then warmed to 70 °C for 3 h. The resulting yellow

solid was collected by filtration and dried in a dessicator to give the title compound (8.0 mg, 52%) as a yellow amorphous solid. Procedure B: Selenium dioxide (110 mg, 0.99 mmol, 4.5 equiv.) was added to a solution of sulfone 64 (60 mg, 0.22 mmol) pyridine (2.1 mL). The reaction was warmed to 90 °C and stirred for 24 h, after which time TLC analysis indicated the consumption of the starting materials and the formation of the 27. The yellow solution was filtered through Celite and concentrated in vacuo to give a yellow solid, which was then redissolved in H₂O and carefully neutralised with glacial AcOH before being concentrated in *vacuo*. Purification by silica gel flash column chromatography (CH₂Cl₂/MeOH, 99/1 \rightarrow 4/1, v/v) yielded the title compound as a yellow amorphous solid (8 mg, 12%). $R_f = 0.62$ (MeOH); IR (thin film): 2997, 1728, 1595, 1557, 1349, 1301, 1270, 1210, 1168, 1106, 958, 827, 726, 640, 563, 478, 429 cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆): δ ppm 9.44 (br. s, 1H, NH), 8.51 (d, J_{8,9} = 8.0 Hz, 1H, H9), 8.38 (d, $J_{8,9}$ = 8.0 Hz, 1H, H9), 3.89-3.41 (m, 2H, H3), 3.40-3.39 (m, 2H, H2); ¹³C NMR (150 MHz, DMSO-d₆) δ ppm 176.4 (C5), 173.4 (C10), 165.3 (CO₂H), 151.7 (C7), 147.8 (C4a), 146.3 (C5a), 135.7 (C9), 131.5 (C9a), 129.0 (C8), 110.8 (C10a), 48.2 (C2), 40.1 (C3); HRMS-ESI (m/z): $[C_{12}H_8N_2O_6S-H]^-$ calcd.: 307.0030, obsd.: 307.0034. The data obtained for this compound matched those reported in literature.¹⁰⁴



8-Methyl-2,3-dihydro-4H-[1,4]thiazino[3,2-g]quinoline-5,10-

dione (62). To a solution of QQ 60 (112.5 mg, 0.39 mmol) in EtOH (28 mL) was added a solution of sodium sulfide (153 mg, 1.17 mmol, 3 equiv.) in H_2O (14 mL) dropwise. The solution was stirred for 30 min at room temperature, after which time TLC analysis showed the

disappearance of starting materials. The dark purple liquid was then diluted with water (100

mL) and extracted with CH₂Cl₂ (2 x 100 mL) before being dried with anhydrous MgSO₄, filtered and the filtrate concentrated *in vacuo*. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $3/1 \rightarrow 1/3$, v/v) yielded the title compound as purple crystals (81 mg, 82%). R_f = 0.38 (EtOAc); m.p. = 268 °C; UV-vis (MeOH) λ_{max} (log ε): 550 nm (3.40); IR (υ_{maz}): 1672, 1594, 1574, 1550, 1478, 1200, 1152, 1119, 812, 730, 538, 485 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.22 (d, $J_{6,7}$ = 7.7 Hz, 1H, H6), 7.41 (d, $J_{6,7}$ = 7.9 Hz, 1H, H7), 6.17 (br. s, 1H, NH), 3.79 (t, $J_{2,3}$ = 4.3 Hz, 2H, H3), 3.01 (q, $J_{2,3}$ = 4.1 Hz, 2H, H2), 2.69 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 178.6 (C5), 176.6 (C10), 163.1 (C8), 146.3 (C9a), 141.3 (C4a), 134.3 (C6), 128.4 (C5a), 127.8 (C7), 111.1 (C10a), 42.0 (C3), 25.0 (CH₃), 23.9 (C2); HRMS-ESI (*m/x*) calcd. for [C₁₂H₁₀N₂O₂S+H]⁺: 247.0536, obsd.: 247.0524.



1-Oxo-8-methyl-2,3-dihydro-4H-[1,4]thiazino[3,2-g]quinoline-

5,10-dione (67). Thiazine **62** (60 mg, 0.24 mmol) was dissolved in freshly distilled CH_2Cl_2 (2.4 mL) and cooled to 0 °C in an ice-bath before *m*-CPBA (41 mg, 0.24 mmol) was added. The reaction was allowed to warm to room temperature and then stirred for 30 min

before TLC analysis deemed the reaction complete. The bright yellow solution was then concentrated *in vacuo*, re-dissolved in H₂O (5 mL), and washed with EtOAc (2 x 10 mL) to give the title compound as a yellow solid (38 mg, 60%). $R_f = 0.4$ (CH₂Cl₂/MeOH, 4/1, v/v); IR (ν_{max}): 3060, 2855, 1654, 1577, 1328, 1151, 1078, 965 cm⁻¹; ¹H NMR (500 MHz, D₂O) δ ppm 8.01 (d, $J_{6,7} = 8.0$ Hz, 1H, H6), 7.49 (d, $J_{6,7} = 8.0$ Hz, 1H, H7), 4.06 (dt, $J_{3a,3b} = 15.2$ Hz, $J_{2a,3a} = 3.2$ Hz, 1H, H3a), 3.65 (td, $J_{3a,3b} = 14.9$ Hz, $J_{2b,3b} = 2.5$ Hz, 1H, H3b), 3.40 (dt, $J_{2a,2b} = 14.7$ Hz, $J_{2b,3b} = 2.6$ Hz, 1H, H2b), 2.74 (td, $J_{2a,2b} = 14.6$ Hz, $J_{2a,3a} = 3.9$ Hz, 1H, H2a), 2.56 (s, 3H, CH₃); ¹³C NMR (150 MHz, D₂O): δ ppm 178.2 (C5), 177.0 (C10), 166.6 (C3), 146.7 C9a), 145.9 (C4a), 135.4 (C6), 128.1 (C7), 125.0 (C5a), 108.3 (C10a), 39.7 (C2), 30.6 (C3), 23.8 (CH₃); HRMS-ESI (m/x) calcd. for [C₁₂H₁₀N₂O₃S+H]⁺: 263.0485, obsd.: 263.0486.



1,1-Dioxo-8-methyl-2,3-dihydro-4H-[1,4]thiazino[3,2-

g]quinoline-5,10-dione (68). To a solution of thiazine 62 (128 mg, 0.52 mmol) in CH_2Cl_2 (7.8 mL) was added *m*-CPBA (189 mg, 1.1 mmol). The reaction was stirred for 20 h at room temperature after which time TLC analysis showed the disappearance of starting

materials. The bright yellow solution was the concentrated *in vacuo* to give a yellow solid, which was subsequently purified by silica gel column chromatography (CH₂Cl₂/MeOH, $1/0 \rightarrow 19/1$,

v/v) to yield the title compound as a bright yellow amorphous solid (141 mg, 98%). $R_f = 0.5$ (CH₂Cl₂/MeOH, 4/1, v/v); IR (v_{max}): 2915, 2850, 1690, 1635, 1592, 1565, 1382, 1329, 1290, 1240, 1195, 1136, 960, 752, 705 cm⁻¹; ¹H NMR (500 MHz, D₂O/CD₃OD): δ ppm 8.37 (d, $J_{6,7} = 8.1$ Hz, 1H, H6), 7.64 (d, $J_{6,7} = 8.2$ Hz, 1H, H7), 4.08-4.05 (m, 2H, H3), 3.56-3.52 (m, 2H, H2), 2.64 (s, 3H, CH₃); ¹³C NMR (125 MHz, D₂O/CD₃OD): δ ppm 177.8 (C5 or C10), 175.10 (C5 or C10), 166.4 (C8), 147.9 (C4a), 146.8 (C9a), 135.5 (C6), 127.9 (C7), 125.1 (C5a), 47.9 (C2), 39.1 (C3), 23.7 (CH₃); HRMS-ESI (m/x) calcd. for [C₁₂H₁₀N₂O₄S+H]⁺: 279.0434, obsd.: 279.0433.



1,1-Dioxo-8-methyl-*4H***-[1,4]thiazino**[*3,2-g*]quinoline-5,10-dione (69). Sulfone 68 (96 mg, 0.34 mmol) was dissolved in 1 M aq. KOH (10 mL) and stirred for 3 h before being passed through a cationic ion exchange resin (BIO-REX 70, 200-400 mesh). The resulting yellow solution was concentrated *in vacuo* then freeze-dried to give the title

compound as a bright yellow amorphous solid (75 mg, 80%). $R_f = 0.25$ (CH₂Cl₂/EtOAc, 4/1, v/v); IR (ν_{max}): 3464, 3054, 2853, 1689, 1664, 1636, 1594, 1570, 1508, 1437, 1374, 1329, 1285, 1242, 1197, 1135, 1081, 964, 850, 751, 705, 603, 556 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 8.36 (d, $J_{6,7} = 8.0$ Hz, 1H, H6), 7.51 (d, $J_{2,3} = 8.9$ Hz, 1H, H3), 7.43 (d, $J_{6,7} = 8.0$ Hz, 1H, H7), 6.98 (d, $J_{2,3} = 8.9$ Hz, 1H, H2), 2.6 (s, 3H, CH₃); ¹³C NMR (150 MHz, pyridine-d₅) δ ppm 179.5 (C5), 178.0 (C10), 166.8 (C8), 148.0 (C9a), 141.5 (C4a), 135.2 (C6), 131.2 (C3), 128.1 (C7), 126.5 (C5a), 119.1 (C10a), 113.5 (C2), 25.6 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₂H₈N₂O₄S+H]⁺: 277.0278, obsd.: 277.0277.



2,3-dihydro-4H-[1,4]thiazino[3,2-g]quinoline-5,10-dione-8carboxylic acid (72). To a solution of methyl-quinolinequinone 62 (83.4 mg, 0.3 mmol) in freshly distilled pyridine (3.23 mL) was added SeO₂ (170 mg, 1.5 mmol, 4.5 equiv.). The mixture was stirred at 90 °C overnight, after which time TLC analysis showed

the disappearance of starting materials and the presence of a carboxy-QQ **72**. The dark purple solution was then filtered over Celite and concentrated *in vacuo* before being redissolved in H_2O (5 mL). The pH of the solution was then increased to 10 by the addition of 2 M aq. NaOH and the reaction then washed with CH₂Cl₂ (3 x 10 mL). The aqueous layer was collected

and acidified to pH 1 with 2 M HCl before the product was extracted with EtOAc (3 x 10 mL). The organic layers were collected and dried with anhydrous MgSO₄, filtered, and the filtrate concentrated *in vacuo* to give the title compound as a dark purple amorphous solid (48 mg, 58%). $R_f = 0.04$ (EtOAc); IR (ν_{max}): 3369, 2922, 1732, 1694, 1582, 1544, 1495, 1450, 1337, 1261, 1221, 1161, 982, 835, 721, 553, 440 cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.39 (d, $J_{6,7} = 7.9$ Hz, 1H, H6), 8.21 (d, $J_{6,7} = 7.9$ Hz, 1H, H7), 7.98 (t, $J_{NH,3} = 3.3$ Hz, 1H, NH), 3.63-3.61 (m, 2H, H3), 3.00-2.98 (m, 2H, H2); ¹³C NMR (125 MHz, DMSO-d₆) δ ppm 177.3 (C5 or C10), 176.3 (C5 or C10), 165.8 (CO₂H), 152.2 (C8), 148.8 (C9a), 142.3 (C4a), 135.8 (C6), 129.6 (C5a), 127.5 (C7), 111.8 (C10a), 41.8 (C3), 23.3 (C2); HRMS-ESI (m/x) calcd. for [C₁₂H₈N₂O₄S+H]⁺: 277.0278, obsd.: 277.0277, and for [C₁₂H₈N₂O₄S-H]⁻: 275.0132, obsd.: 275.0135.



1-Oxo-2,3-dihydro-4H-[1,4]thiazino[3,2-g]quinoline-5,10dione-8-carboxylic acid (73). Acid 72 (19 mg, 0.07 mmol) was dissolved in acetone (0.2 mL) and cooled to 0 °C before *m*-CPBA (12 mg, 0.07 mmol) was added. The ice bath was then removed and the reaction was stirred for 30 min before TLC analysis

showed the complete disappearance of starting materials. The solution was concentrated *in vacuo*, re-dissolved in H₂O (1 mL) and washed with EtOAc (3 x 1 mL). The aqueous solution was then concentrated to give the title compound as a yellow amorphous solid (19 mg, 94% yield). R_f = 0.18 (MeOH/EtOAc, 4/1, v/v); IR (ν_{max}): 3375, 2923, 1593, 1560, 1381, 1333, 1232, 1189, 1110, 1020, 953, 641, 618, 570 cm⁻¹; ¹H NMR (600 MHz, DMSO-d₆): δ ppm 9.45 (br. s, 1H, NH), 8.51 (d, $J_{6,7}$ = 8.1 Hz, 1H, H6), 8.28 (d, $J_{6,7}$ = 8.2 Hz, 1H, H7), 3.86-3.83 (m, 1H, H3a), 3.57 (t, $J_{3a,3b}$ =14.5 Hz, 1H, H3b), 3.15 (t, $J_{2z,3b}$ = 14.0 Hz. 1H, H2a), 2.44 (td, $J_{2a,2b}$ = 14.1 Hz, $J_{2b,3b}$ = 3.6 Hz, 1H, H2b); ¹³C NMR (125 MHz, DMSO-d₆): δ ppm 179.7 (C5), 176.2 (C10), 165.8 (CO₂H), 153.5 (C8), 148.4 (C9a), 145.9 (C4a), 136.4 (C6), 130.1 (C5a), 127.6 (C7), 113.2 (C10a), 40.9 (C2), 31.6 (C3); HRMS-ESI (*m*/*z*) calcd. for: [C₁₂H₈N₂O₅S-H]⁻: 291.0081, found: 291.0092.


mL). The yellow solution was then warmed to 70 °C and stirred for 3 h. The resulting yellow solid was then collected by filtration and dried in a dessicator to give the title compound as a yellow solid (35.5 mg, 33%). $R_f = 0.62$ (MeOH); IR (v_{max}): 3461, 1660, 1562, 1452, 1275, 1117, 989, 950, 795, 708, 685, 549, 499, 459 cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆): δ ppm 9.31 (br. s, 1H, NH), 8.50 (d, $J_{6,7} = 8.0$ Hz, 1H, H6), 8.28 (d, $J_{6,7} = 8.0$ Hz, 1H, H7), 3.89-3.87 (m, 2H, H3), 3.42-3.40 (m, 2H, H2); ¹³C NMR (125 MHz, DMSO-d₆): δ ppm 178.8 (C5), 165.7 (CO₂H), 153.9 (C8),148.1 (C9a), 147.3 (C4a), 136.4 (C6), 129.5 (C5a), 127.5 (C7),48.7 (C2), 39.9 (C3); HRMS-ESI (m/s) calcd. for [C₁₂H₈N₂O₆S+H]⁺: 309.0176, obsd.: 309.0170, calcd. for [M-H]⁻: 307.0030, obsd.: 307.0034.



Ascidiathiazone B (28). <u>Procedure A:</u> Selenium dioxide (44 mg, 0.4 mmol, 4.5 equiv.) was added to a solution of thiazine **70** (14.6 mg, 0.09 mmol) in dry pyridine (0.86 mL). The reaction was stirred at 80 °C for 3 d, after which time TLC analysis showed the disappearance of starting materials. The yellow solution was then

filtered through a pad of celite, concentrated *in vacuo*, and re-dissolved in H₂O (1 mL) and 0.1 mL of 2 M aq. NaOH. After stirring at reflux for 10 min, the reaction was allowed to cool to room temperature and neutralised with 2 M aq. HCl. The resulting orange mixture was then passed through a short C18 reverse chromatography column, concentrated *in vacuo*, and the residue purified by silica gel flash column chromatography (CH₂Cl₂/MeOH, $1/0 \rightarrow 1/1$, v/v). The residue was then passed through a short reversed-phase C18 column and freeze dried to give the title compound as an orange-red amorphous solid (9.0 mg, 33%). Procedure B: Sulfone **74** (5 mg, 0.02 mmol) was dissolved in 1 M aq. KOH (3 mL) and stirred for 3 h before being passed through a cationic ion exchange resin (BIO-REX 70, 200-400 mesh). The resulting orange-red solution was concentrated *in vacuo* then freeze-dried to give the title compound as an orange-red amorphous solid (4.1 mg, 80%). R_f = 0.10 (EtOAc/MeOH/AcOH, 4/1/0.1, v/v/v); IR (v_{max}): 3429, 1624, 1571, 1560, 1453, 1293, 1112 cm⁻¹; ¹H NMR (600 MHz, DMSO-d₆): δ ppm 8.40 (d, $J_{6,7}$ =8.0 Hz, 1H, H6), 8.24 (d, $J_{6,7}$ =8.0

Hz, 1H, H7), 7.27 (d, $J_{2,3}$ =8.0 Hz, 1H, H3), 6.23 (d, $J_{2,3}$ =8.0 Hz, 1H, H2); ¹³C NMR (125 MHz, DMSO-d₆): δ ppm 181.2 (C5), 176.7 (C10), 166.1 (<u>C</u>O₂H), 160.7 (C8), 148.2 (C4a), 147.2 (C9a), 139.2 (C3), 136.0 (C7), 128.1 (C5a), 126.7 (C7), 115.5 (C10a), 113.3 (C2); HRMS-ESI (*m/x*) calcd. for [C₁₂H₆N₂O₆S-H]⁻: 304.9874, obsd.: 304.9875. The data for this compound matched those reported in the literature.¹⁰⁴

2.4.2. Biology

Samples. Each compound was dissolved in sterile DMSO to make 10 mM stock solutions.

Obtaining MIC values. In clear-bottomed 96-well plates (Nunc), two-fold serial dilutions of each compound were added to volumes of 7H9 medium for *Mtb* and HdB minimal medium for *M. smegmatis*. The last column of each plate did not contain any compound and served as a negative control. Previously prepared M. *smegmatis* mc²6533 and *Mtb* mc²6230 (Howard Hughes Medical Institute, Albert Einstein College of Medicine) inocula were diluted with their respective media to achieve 0.05 OD_{600} . The inocula were then added to each well and the plates incubated at 37 °C for two and five days for those containing M. *smegmatis* and *Mtb*, respectively. After incubation, 20 µL of resazurin was added to the wells, and the plates incubated at 37 °C for one hour or 24 hours for *M. smegmatis* and *Mtb*, respectively. The wells that remained blue were deemed to contain non-replicating bacteria, while those that underwent a colour change to purple or pink were deemed to contain replicating bacteria. MIC values were ascertained by visual judgment of colour.

Measuring rates of NADH oxidation. *M. smegmatis* IMVs were prepared prior to testing as previously described.³³ To make a stock solution of *M. smegmatis* IMVs, 1 μ L of IMV solution (20 mg/mL protein) was added to 1 mL of HEPES-NaOH buffer (pH 7.5). The HEPES-NaOH was composed of 10 mM HEPES-NaOH, 5 mM MgCl₂, 100 mM KCl. In clear-bottomed 96-well plates, 20 μ L of the IMV/buffer solution was added to each well, followed by 2 μ L of 10 mM (in DMSO) solutions of each compound. NADH (10 μ L, 400 μ M) was then added to each well. The solution in the well was mixed with a pipette and put into a Thermo Scientific Varioskan Flash plate reader. Each plate had two wells without any drug, to serve as negative controls. The vehicle control contained IMV/buffer solution (20 μ L) and NADH (10 μ L) to obtain the basal rate of NADH oxidation. Absorbance values were recorded every minute for twenty minutes at 340 nm to allow for calculations of the NADH consumption rate, using an

extinction coefficient $\varepsilon_{340} = 6.22 \text{ mM}^{-1} \text{cm}^{-1}$. The experiments were undertaken three times, and the average rate of reaction was taken for each compound.

Measuring O_2 consumption and fluorescence of acridine orange. In a respiratory chamber, IMVs (20 µL, 20 mg/mL) were incubated with 5 µM acridine orange (75) in 1 mL HEPES-NaOH buffer (pH 7.5) for 5 seconds before 1 mM NADH was added. After one second, QQ 61 was added into the chamber until all of the O₂ was consumed and the chamber enters anoxia. The change in O₂ concentration and fluorescence over time was recorded.

CHAPTER THREE The anti-tubercular and redox activity of quinolinequinones

3.1. Introduction

Quinones are vital to redox processes in living organisms due to their propensity to undergo reversible redox reactions. For example, ubiquinones (**17**, Figure 3.1) are electron acceptors that are essential for respiration in nearly all aerobic organisms.¹³⁹⁻¹⁴¹ Within biological systems, the reduction of quinones occurs enzymatically as part of the oxidative phosphorylation process to generate ATP.¹⁴² Quinone species (Q) are reduced to their respective hydroquinones (QH₂) through a carefully regulated two-electron reduction that occurs with the concomitant oxidation of NADH (equation 1).^{143,144} Subsequently, QH₂ is re-oxidised to the original quinone by molecular oxygen by two one-electron steps (equations 2-4).^{145,146} Here, radicals

QH' and HO₂' are generated from the first one-electron redox reaction (equation 2). The hydroperoxy radical HO₂' can then undergo deprotonation reactions to form superoxide O₂'- (equation 3), which triggers the formation of peroxides (H₂O₂) and the regeneration of the quinone (Q, equation 4-5). Finally, peroxides (H₂O₂) then react with superoxides (O₂') to produce hydroxyl radicals HO' (equation 6).¹⁴⁷ While the formation of ROS is important for cell signalling, unregulated production of superoxides can be detrimental to the cell.¹⁴⁶ Indeed, many quinone-based drugs exhibit their therapeutic activity by accepting electrons from NADH and generating harmful levels of ROS.^{144,148-151}

$$Q + NADH + H^+ \to QH_2 + NAD^+ \tag{1}$$

$$QH_2 + O_2 \to QH^{\bullet} + HO_2^{\bullet} \tag{2}$$

$$HO_2^{\bullet} \rightleftharpoons O_2^{\bullet-} + H^+ \tag{3}$$

$$QH^{\bullet} + O_2 \to Q + HO_2^{\bullet} \tag{4}$$

$$2O_2^{\bullet-} + 2H^+ \to H_2O_2 + O_2 \tag{5}$$

$$O_2^{\bullet-} + H_2 O_2 \to H O^{\bullet} + H O^- + O_2$$
 (6)



Figure 3.1: Ubiquinones (17), a class of quinones found in mammalian mitochondria.¹³⁹⁻¹⁴¹

3.1.1. Pharmacological properties of quinolinequinone-containing drugs

Streptonigrin (74, Figure 3.2) is a QQ-bearing metabolite isolated from *Streptomyces flocculus* that exhibits anti-tumour properties.^{152,153} The QQ scaffold in streptonigrin (74) is essential for its anti-proliferative activity, which is attributed to the generation of radical species and peroxides during the redox cycling of quinone 74.^{144,151,153} These radical species can cleave DNA in tumour cells. The reduction of the quinone moiety was thought to be catalysed by the NQO1 enzyme, a two-electron reductase that is overexpressed in many cancer cells including lung, breast and colon.^{154,155} To improve the anti-cancer activity of streptonigrin (74), structurally refined QQs were synthesised and their rates of DNA cleavage measured. Here, methoxy-QQ 75 was as equally potent as streptonigrin (74) in its ability to cleave DNA, while QQs 76 and

Chapter Three

77 surpassed the activity induced by the natural product by almost two-fold.¹⁴⁴ Another QQ with anti-tumour properties is LY83583 (78),¹⁵⁶ a commercially available drug known to competitively inhibit guanylate cyclase.^{156,157} Again, the mode of action of LY83583 (78) was reportedly due to the formation of ROS and hydroxyl radical species¹⁵⁶ through the redox cycling of the QQ motif.¹⁵⁷



Figure 3.2: The structure of streptonigrin (74), a QQ-containing secondary metabolite, and biologically active QQ derivatives **75-78**.¹⁴⁴

In addition to their anti-cancer properties, QQs are also known to exhibit anti-bacterial activity. Recently, a library of aryl- and aniline-substituted QQs were tested for their ability to inhibit the growth of both the Gram positive and Gram negative bacteria, *S. aureus* and *E. coli*, respectively.¹⁵⁰ For both bacterial species, aniline-substituted QQs exhibited higher inhibitory activity compared to QQs functionalised with aryl substituents. Of particular relevance to this project is the anti-mycobacterial activity of quinones.^{149,158-160} In seminal studies, 6-cyclo-octyl-QQ (**79**, Figure 3.3) was found to inhibit the growth of *Mtb* at low concentrations (MIC = 3.5 μ M).^{149,158} Since this work, others have demonstrated the anti-tubercular activity of isobenzoquinones, such as isoquinoline **80** (IC₅₀ = 1.3 μ M),¹⁵⁹ while enamine-benzoquinone **81** was found to be potent against resistant strains of *Mtb* (MIC = 1.2 μ M).¹⁶⁰ In the latter study, SAR analysis of enamine-quinone analogues indicated that the quinone ring was essential for anti-tubercular activity as its removal led to reduced drug potency against *Mtb*.¹⁶⁰



Figure 3.3: Examples of quinone-containing compounds 79-81 that exhibit anti-tubercular activity.^{149,158-160}

In 2010, Stocker and co-workers synthesised a library of QQs that exhibited bacteriostatic activity against *M. bovis* BCG.⁶⁵ Here, the most active compounds, QQs **82** and **83** (Figure 3.4), were found to possess anti-tubercular activity (MIC = $7.5-45 \mu$ M) that was comparable to the current first-line drug EMB (**4**, MIC = $15-30.9 \mu$ M) in the same assay.⁶⁵ Following this discovery, mechanistic studies of a representative QQ, QQ8c (**20**), revealed that QQ8c (**20**) specifically targeted mycobacterial NDH-II, which led to the production of lethal levels of ROS (Chapter 1, Section 1.4.1.).⁶⁴ Similarly, an analogue of QQ8c, methyl-QQ **60**, increased NADH oxidation rates and O₂ consumption in mycobacterial ETC (Chapter 2, Section 2.2.6).



Figure 3.4: Amino-QQs 82, 83, QQ8c (20) and QQ 60 are potent bacteriostatic agents.^{64,65}

3.1.2. Redox potential of quinones

The ability of quinones to interact with oxidoreductases, both as natural substrates and as pharmaceutical agents, has been attributed to their propensity to undergo redox reactions.

Chapter Three

Redox reactions of organic materials typically involve the generation of highly reactive radical species that need to be adequately stabilised for the redox active compound to undergo redox cycling.¹⁶¹ If the radical species is too reactive, it can self-react, while a persistent radical may not readily undergo subsequent reduction or oxidation reactions.¹⁶² In quinones (II), a one-electron reduction forms a semiquinone radical (III), which can then be reduced to form a quinol (IV, Scheme 3.1). Here, the negative charge of the semiquinone radical (III) is stabilised by resonance due to the extensive conjugation present in the benzene ring. Consequently, the two-step reduction of quinones (II) is reversible, thereby allowing for redox cycling.^{141,163} The tendency for a quinone to undergo reduction can be measured by its redox potential, whereby a high redox potential indicates that the quinone will readily accept electrons.^{163,164}



Scheme 3.1: The reversible reduction of quinones (II) to semiquinones (III) and quinols (IV).

The capacity of a given quinone to accept electrons can be fine-tuned through the installation of different functionalities on the ring.¹⁶⁵ Generally, the addition of electron-donating groups on the quinone scaffold increases the electron density of the molecule, thereby reducing the ability of the quinone to accept electrons. Accordingly, quinones bearing electron-donating groups usually have lower redox potentials than those with electron-withdrawing groups.^{163,165} This trend was illustrated effectively in the study of substituted phenothiazines, whereby cyano- (**84**) and trifluoromethyl-substituted (**85**) phenothiazines had higher redox potentials compared to unsubstituted ethyl-phenothiazine **86**, while dimethyl phenothiazine **87** had the lowest redox potential of the group (Figure 3.5).¹⁶⁶ That said, exceptions to this trend have been noted, such as the lower reduction potential of sulfonic acid **88** compared to unsubstituted quinone **89**.¹⁶⁷ Moreover, as quinones behave differently in different media,¹⁶⁸ their oxidising strength is likely to be affected by pH, intermolecular interactions and entropy in physiological systems.¹⁶⁹

Chapter Three



Figure 3.5: Electron-withdrawing functional groups on the phenothiazine scaffold, as in phenothiazines 84 and 85, leads to an increase in reduction potential compared to unsubstituted phenothiazine 86. Conversely, methylphenothiazine 89 has a relatively low reduction potential. That said, quinone 88, which bears an electron withdrawing sulfonic acid functionality, has a lower reduction potential than unfunctionalised benzoquinone (89).

The redox potentials of quinones have been reported to correlate with their therapeutic effects.^{170,171} For example, Livertoux *et al.* described a linear relationship between the redox potentials of a range of quinones ($E^{\circ} = -0.23$ V to -0.72 V vs. Hg/Hg⁺) and the rate of superoxide production in rat microsomes.¹⁶⁷ More recently, Ohayon *et al.* reported on the anticancer activity of an *ortho*-quinone-containing natural product, β -lapachone (**90**, Figure 3.6). β -Lapachone (**90**) inhibits deubiquitinases in tumour cells by generating ROS and irreversibly oxidising cysteine residues within the enzyme binding site.¹⁷² A study of several β -lapachone analogues demonstrated that the most potent deubiquitinase inhibitors had redox potentials between -0.20 V and -0.24 V (vs. Ag/Ag⁺).¹⁷¹ Compounds that had redox potentials outside this optimal range exhibited minimal or no anti-cancer properties.¹⁷¹ However, the authors also reported that *ortho*-quinone **90** displayed a higher degree of enzyme inhibition than *para*-

quinone **91** (100% at 0.5 μ M vs. 11% inhibition at 1 μ M, respectively), despite both having a reduction potential of -0.24 V (vs. Ag/Ag⁺). This difference in activity was attributed to the enhanced stability of *ortho*-quinol (**V**) due to the formation of a hydrogen bond between the two quinol oxygens.¹⁷¹ This study simultaneously highlights both the value and the limitations of predicting the potency of redox active drugs through the measurement of redox potentials. While the reduction potentials of a compound can provide insight into the relative reactivities of different drug candidates, the ability of a compound to undergo redox reactions in a physiological setting cannot always be predicted.^{168,169}



Figure 3.6: The reduction of *ortho*-quinone β -lapachone (90) to quinol V, and the *para*-quinone analogue 91.¹⁷¹

3.1.3. Project aims and retrosynthetic analysis of QQs

As discussed in Chapter 1 (Section 1.2), redox reactions facilitated by NDH-II are crucial for the viability of *Mtb*. Given the capacity of QQs to activate NDH-II⁶⁴ and exhibit tuberculostatic activity,⁶⁵ investigations into how changes to the QQ scaffold influence antitubercular activity could lead to the discovery of a more potent QQ TB drug. To this end, it was proposed that a library of QQs bearing different amine substituents would be synthesised and subsequently screened against *Mtb* for their bacteriostatic effects. Herein, particular focus was given to the installation of tertiary amines on the QQ scaffold, which will allow investigations into potential hydrogen bonding interactions involving the amine proton to be made. Similarly, the installation of amines with quaternary carbons, *i.e.* tert-butylamine and aniline, on the QQ scaffold may reduce the availability of the amine proton to participate in hydrogen bonding due to increased steric bulk. Next, QQs bearing aliphatic chains were included in the library as the NDH-II Q-site is reportedly surrounded by hydrophobic grooves^{53,58,62} and, moreover, the natural substrate of NDH-II, MK (**15**),¹⁷³ possesses a long hydrophobic tail. Finally, aryl-substituted QQs could enhance the binding affinity of the QQs to the target enzyme due to potential π -stacking interactions with the FAD isoalloxazine ring or other aromatic side chains in the NDH-II Q-site (*i.e.* Y13 and Y383).⁵³

The synthesis of QQs is well-precedented and there are several synthetic routes available to access the QQ motif. Typically, the quinone moiety is prepared through employment of the Teuber reaction,¹⁷⁴ whereby phenols or anilines are treated with Fremy's salt,^{105,139,175} though other oxidants such as ceric(IV) ammonium nitrate,^{176,177} (diacetoxyiodo)benzene,¹⁷⁸ or potassium dichromate¹⁷⁹ can also be used. Once the quinone ring is formed however, the installation of substituents on the quinone scaffold can be challenging and is often circumvented by the introduction of functional groups prior to quinone formation.¹³⁹ Accordingly, to prepare a library of amine-substituted QQs, it was envisioned that the 6,7dichloroquinone backbone would first be prepared to allow for subsequent functionalisation. Here, the presence of chloride leaving groups would enable nucleophilic substitution reactions to take place, which would otherwise be sluggish and low-yielding.¹⁷⁷ To this end, it was envisaged that the QQ analogues VI-IX could be synthesised by the substitution of dichloro-QQs 92 and 56 by various alkyl- and aryl-amines (Scheme 3.2). For the purpose of this research, it was proposed that both the 6- (VI, VII) and 7-regioisomers (VIII, IX) would be prepared in the same synthetic step, though it should be noted that the 6-isomer (VI, VII) can be preferentially formed by the addition of a metal catalyst to the reaction mixture.65,180 DichloroQQs 92 and 56 could, in turn, be prepared by the oxidation of commercially available reagents, 8-hydroxyquinoline (93) and 8-hydroxyquinaldine (58), respectively.⁶⁵



IX, $R^1 = CH_3$, $R^2 = alkyl, aryl$

Scheme 3.2: Retrosynthetic analysis of QQs VI-IX.

3.2. Results and Discussion

3.2.1. The synthesis of QQs

Having established a retrosynthetic plan for the synthesis of 6- and 7-amino-substituted QQs (VI-IX), 8-hydroxyquinoline (93) and 8-hydroxyquinaldine (58) were first oxidised with sodium chlorate to afford dichloroquinones 92 and 56, respectively (Scheme 3.3).^{65,181} After recrystallisation from ethanol, QQs 92 and 56 were then treated with a variety of amines to give the 6- and 7-isomers (94-111) in good combined yields and in an approximately 1:1 ratio.⁶⁵ Derivatives prepared included those designed to probe the effect of bulky amines (*i.e.* QQs 94-97, QQs 104-105), aliphatic chains (*i.e.* QQs 98-101, and 108-109) and aromatic groups (*i.e.* QQs 106-107 and 110-111) on anti-tubercular activity.



Scheme 3.3: Synthesis of QQs 94-111.

The amine-substitution conditions of dichloroQQs **92** and **56** were chosen to give a mixture of regioisomers as there is no suitable methodology available for the regioselective synthesis of both isomers.⁶⁵ Notwithstanding, the two regioisomers were separable by silica gel flash column chromatography, with the 7-isomer being eluted first, which is consistent with literature precedent.^{178,182} Generally, the substitution of dichlorides **92** and **56** with different amines proceeded smoothly, giving close to a quantitative yield for the combined regioisomers. However, a number of QQ analogues required numerous purification steps to separate the regioisomers, which resulted in decreased yields. In particular, multiple attempts at purification by column chromatography were required for QQ analogues bearing long alkyl chains, such as octylamine-substituted QQs (**102** and **103**), heptylanilino-QQs **108** and tetradecylanilino-

QQs **109**. Here, the use of toluene as the mobile phase in silica gel column chromatography assisted in the separation.

As with the synthesis of 2-chloroethylamino-QQs **59** and **60** (Chapter 2, Section 2.2.1.), NMR spectroscopy was used to elucidate the structure of each isomer.⁶⁵ Specifically, in the ¹³C NMR spectrum, carbons involved in tautomerisation were observed as broad resonances that were less visible than typical quaternary carbon resonances.⁶⁵ The carbonyl carbons involved in tautomerisation were then assigned via an HMBC between H4 and C5. In addition, the ¹H NMR revealed a smaller Δ H2-H4 value for the 7-isomer compared to the 6-isomer in all QQs that were unfunctionalised at the 2-position,⁶⁵ as illustrated in Figure 3.7 with QQs **98a** and **98b**.



Figure 3.7: ¹H NMR (500 MHz, CDCl₃) spectra of A). 6-chloro-7-propylaminoQQ **98a** and B). its regioisomer **98b**.

In addition to NMR spectroscopy, the structural assignment of some analogues, such as the aniline-substituted QQ **104b**, was confirmed by XRD (Figure 3.8). Here, the crystal structure confirmed the aromaticity of the pyridine ring, with an average C-C bond length close to 1.40 Å (Appendix 3, Table A.3.1.), typical for aromatic C-C bond lengths,¹⁸³ and N-C lengths of 1.34 Å, typical for aromatic C-N bonds.¹⁸⁴ On the other hand, the quinone ring contained

bonds of different length, whereby typical aromatic C-C bonds were observed,¹⁸⁴ as well as longer bonds suggestive of single bond character (1.46 Å-1.50 Å).¹⁸³ The different bond lengths observed within the quinone ring indicated that the quinone moiety is not aromatic, despite its planar orientation.¹⁸⁵



Figure 3.8: Crystal structure of 6-anilino-2-methylquinolinequinone (104b).

Intermolecular hydrogen bonds were also observed in the QQ **104b** crystal structure, which showed the secondary amine as the hydrogen bond donor (H2n, Figure 3.9). Here, a bifurcated hydrogen bond was present between H2n and the ring nitrogen N1, as well as the carbonyl O1 (for bond lengths, see Appendix 3, Table A.3.2.). Similar interactions have previously been reported in literature^{186,187} and provide the possibility for hydrogen bonding in a biological setting.



Figure 3.9: Intermolecular hydrogen bond interactions observed in anilino-QQ 104b.

3.2.2. The anti-tubercular activity of QQs

The QQs **94-111** were screened for their ability to inhibit *Mtb* growth by Professor Gregory Cook and co-workers at the University of Otago. Accordingly, the MIC value of each QQ was obtained (Table 3.1). Analysis of the QQ library highlighted the importance of several structural features for anti-tubercular activity. For example, QQs bearing tertiary amines, such as dimethylamino-QQs **94a** and **94b** (Entries 1 and 2, respectively) and piperidine-substituted QQs **95a** and **96b** (Entries 3 and 4), exhibited only low levels of *Mtb* growth inhibition. As tertiary amines are unable to act as hydrogen bond donors, this suggests that the ability of the QQ to form a hydrogen bond with the target enzyme may be important for anti-tubercular activity.

Table 3.1: MIC values in μ M and redox values (E₁ and E₂ in acetonitrile and E' in microemulsions) of synthesised QQ analogues **94-111**, as well as literature MIC values of streptomycin (**12**)¹⁸⁸ and QQ8c (**20**)⁶⁴ and measured E₁ and E₂ values for QQ8c (**20**) in DMF.

Entry	Compound	MIC	E_1 (V)	$E_2(V)$	$E'(V)^{b}$
		(µM)			
1		>512	-0.60	-1.13	n.d.
	94a				
2		512	-0.62	-1.11	n.d.
	94b				
3	O CI N O 95a	256	-0.61	-1.17	-0.49
4	96b	128	-0.57	-1.13	-0.47
5	CI N O H	512	-0.42	-1.00	n.d.
	104a				





16

0 .CI Ν́ Η ∬ 0 Ρh 106a

16 -0.64 -1.21 -0.59

17



128	-0.60	-1.15	n.d.

106b

16 -0.70 -1.30 -0.60

18



128

Chapter Three



102a

0

84

25	$ \begin{array}{c} $	16	-0.67	-1.26	-0.62
26	$ \begin{array}{c} 0 \\ H \\ N \\ CI \\ 0 \\ 103b \end{array} $	128	-0.72	-1.27	n.d.
27	O CI N O H 97a	>512	-0.59	-1.10	-0.68
28	О Н N С С И 97b	256	-0.69	-1.25	-0.68
29	O N O H 100a	128	-0.49	-1.07	n.d.
30	O H IN	8	-0.50	-1.10	n.d.

85



^a ACN/toluene (2/1, v/v) was used;^b in microemulsions;^c in DMF; n.d. not determined

The effect of aniline-substituents on the *Mtb* growth inhibition of QQs was then analysed. Here, aniline-substituted QQs **104a**, **105a**, **105b** were moderate to poor inhibitors of *Mtb* growth, with MIC values between 256 and 512 μ M, while QQ **104b** exerted no inhibitory activity (MIC >512 μ M, Entries 5-8). Next, the inhibitory activity of anilino-QQs bearing aliphatic chains of different length were investigated. In comparison to unsubstituted anilino-QQs **104-105**, heptylanilino-QQs **108a** and **108b** resulted in lower MIC values of 32 μ M (Entry 9) and 64 μ M (Entry 10), respectively. That said, the addition of a longer lipid chain, as in tetradecylanilino QQs **109a** and **109b**, led to a complete loss of anti-mycobacterial activity (Entries 11-12). These findings suggest that there could be an optimal carbon chain length on the QQ scaffold that confers higher inhibitory activity. Indeed, a similar observation was found by Bohne and co-workers,¹⁸⁹ whereby quinolones with a 12-carbon alkyl chain exerted higher inhibitory activity against *Toxoplasma gandii* NDH-II than a shorter 7-carbon chain.¹⁸⁹ Moreover, when HQNO (**19**), a heptyl-substituted quinolone, was co-crystallised with *C. thermarum* NDH-II, the authors suggested a hydrophobic groove in the crystal structure comprising of V350, V362, L375 and A372 that could accommodate a longer alkyl chain.⁶²

Next, the effect of the position of a phenyl group on the QQ scaffold was investigated by screening the Mtb growth inhibition of methoxybenzylamino- (110-111, Entries 13-15) and phenylethylamino-QQs 106-107 (Entries 16-19). Gratifyingly, these QQs, in particular the 7isomers 110a, 111a, 106a, 107a (Entries 13, 15, 16, 18, respectively), all with an MIC value of 16 μ M, inhibited mycobacterial growth much more effectively than the anilino-QQs. The biological activity of QQs bearing aliphatic chains was then investigated (Entries 20-32). Here, propylamine-substituted QQs 98-99 displayed a modest growth inhibition of Mtb, with MIC values between 128 µM and 512 µM (Entries 20-23). The longer alkyl chain lengths, as in octylamino-QQs 102a and 102b (Entries 24 and 25, respectively), led to increased antitubercular activity, though this increase was not observed in methyl-quinoline **103b** (Entry 26). As with heptylanilino-QQs **108-109**, the higher inhibition exerted by longer lipid tails in QQs 102a and 102b confirms the importance of enhanced hydrophobicity at this position. Finally, tert-butylamino-QQs 97a and 97b showed poor anti-mycobacterial activity (Entries 27 and 28, respectively), while propargylamino-QQs 100a, 100b, 101a, and 101b (Entries 29-32) showed a range of inhibitory activities (MIC = $8 - 256 \,\mu$ M), with 7-chloro-6-propargylamino QQ 100b having the lowest MIC value of the library (8 µM, Entry 30).

Another important SAR was the position at which the amine substituent was installed on the QQ scaffold. For QQs bearing aryl groups, the 7-isomers exhibited better anti-tubercular activity compared to the 6-isomer in all cases aside from tetradecylanilino-QQs **109a** and **109b**, which were both inactive against *Mtb* (Entries 11 and 12). This trend was evidenced by the difference in MIC values between regioisomers **104a** and **104b** (MIC = 512 μ M vs. >512 μ M, Entries 5 and 6, respectively), **105a** and **105b** (256 μ M vs. 512 μ M, Entries 7 and 8, respectively), **110** and **110b** (MIC = 16 μ M vs. 32 μ M, Entries13 and 14, respectively), **106a** and **106b** (MIC = 16 μ M vs. 128 μ M, Entries 16 and 17, respectively) and **107a/107b** (16 μ M vs. 128 μ M, Entries 18 and 19, respectively). Conversely, the 6-isomers tended to exhibit higher

inhibitory activity than the corresponding 7-isomers in QQs bearing aliphatic chains, with the exceptions of propylamino-QQs **98a/98b** (MIC = 128 μ M for both, Entries 20 and 21), and **99a/99b** (MIC = 128 μ M vs. 512 μ M, Entries 22 and 23, respectively). Notable examples of this trend include the enhanced inhibitory activity of 6-isomers **97b**, **100b**, **101b** and **102b** (MIC = 256 μ M, 8 μ M, 64 μ M and 16 μ M, Entries 28, 30, 32 and 25, respectively) compared to their corresponding 7-isomers **97a**, **100a**, **101a**, **102a** (MIC = >512 μ M, 128 μ M, 256 μ M and 64 μ M, Entries 27, 29, 32 and 24, respectively).

In summary, the QQ analogues exhibited good to modest anti-tubercular activity, with only five compounds (94a, 104b, 109a, 109b, 97a) failing to inhibit bacterial growth (Entries 1, 6, 11, 12, and 27). Propargylamine-substituted QQ 100b (MIC = 9 μ M, Entry 30) was the most active compound of the series, exhibiting an MIC value comparable to first-line drug streptomycin (12, MIC = 8.6 μ M, Entry 33)¹⁸⁸ and NDH-II activator QQ8c (20, MIC = 8.1 μM, Entry 34).⁶⁴ QQs bearing aryl groups, *i.e.* heptylanilino-QQs **108**, benzylamino-QQs **110**, 111, and phenylethylamino-QQs 106, 107, were effective *Mtb* growth inhibitors. Here, the lack of inhibitory activity of QQs bearing longer lipid chains (QQs 108) suggests that an optimal alkyl chain length is important for anti-tubercular activity. Similarly, QQs bearing short aliphatic chains, *i.e.* propylamino-QQs 98, 99 were less potent than those with longer alkyl groups, *i.e.* octylamino-QQs 102 and 103, though the addition of an acetylene group *i.e.* in propargylamines 100 and 101, led to increased growth inhibition. In addition, QQs bearing tertiary amines, *i.e.* dimethylamino-QQs 94 and piperidino-QQs 95, or amines adjacent to a quaternary carbon, i.e. tert-butylamino-QQs 97 and anilino-QQs 104-105, are poor growth inhibitors of *Mtb*. Along with these new insights into the SAR between QQs and *Mtb* growth inhibition, trends from previous findings were also confirmed,⁶⁵ such as the negligible effect of the methyl substituent on the 2-position of QQs on the biological activity of the compounds. Furthermore, this set of QQs allowed for the identification of a new lead antimycobacterial compound, propargylamino-QQ 100b. Given the stimulatory effects exerted by QQs 20⁶⁴ and 60 (Chapter 2) on NADH oxidation, it's likely that QQ 100b could have a similar inhibition mechanism, though this is yet to be confirmed.

3.2.3. Reduction potentials of QQs

Given the ability of quinones to undergo reduction and aid in ROS generation,^{64,149,150} redox potentials of QQs **94-111** were determined by cyclic voltammetry (CV). To serve as a reference, the redox potentials of menadione (**18**), a methyl analogue of the NDH-II substrate MK (**15**),

Chapter Three

was also measured. The CV experiments were conducted in acetonitrile, whereby two consecutive one-electron redox events occured, as reported for quinones in aprotic solvents (Scheme 3.1, page 81).^{168,190} For example, the voltammogram of QQ **111a** (Figure 3.10) revealed two reduction or cathodic peaks as the voltage is scanned at negative potentials. When the switching potential of -1.5 V was reached, the scan direction was reversed, resulting in the stepwise oxidation of the reduced species.¹⁹¹ The redox potentials for the first and second electron transfers, E_1 and E_2 , respectively, are determined as the midpoint potential of the corresponding reduction and oxidation peaks. All potentials reported in this section are referenced against Ag/Ag⁺.



Figure 3.10: Voltammogram of 1.4 mM QQ **111a** in a 50 mM $(C_2H_5)_4N^+(PF_6)^-$ solution of acetonitrile at 100 mV/s on a glassy carbon (GC) electrode, in the presence of N₂.

The redox potentials of QQs **94-111** were comparable to that of menadione (**18**, $E_1 = -0.70$ V, $E_2 = -1.27$ V, Entry 35, Table 3.1), whereby E_1 ranged from -0.42 V to -0.78 V and E_2 occurred between -0.90 V and -1.30 V (Entries 1-32). In addition, the difference in potential between the two redox events (ΔE_1 - E_2) was consistent among the QQs, at approximately 0.55 V, indicating that the QQ semiquinone radicals had a similar stability to menadione (**18**, ΔE_1 - E_2 = 0.58 V). The similarity in redox behaviour between synthesised QQs **94-111** and menadione (**18**) indicated that the QQs may be able to participate in redox reactions in NDH-II. Moreover,

a CV conducted when the solution was not purged with N₂ revealed additional reduction peaks at -0.6 V and -1.3 V and the absence of QQ dianion formation (Figure 3.11). The discrepancy between the two voltammograms (Figure 3.10 and Figure 3.11) is likely to be caused by the presence of O_2 in the solvent that was not previously degassed prior to obtaining the CV. Here, O_2 can undergo reduction at -0.6 V to form superoxide anion radicals, which can react with the semiquinone radicals generated at -0.85 V. The by-product of the reaction between reduced oxygen species and semiquinone radicals can then undergo an irreversible reduction, observed at -1.3 V, while the remaining semiquinone species in the bulk solution are oxidised to the parent quinone at -0.7 V. The reaction between semiquinones and superoxide radicals is wellprecedented for quinones with low one-electron reduction potentials,¹⁶³ and provide the possibility for QQs to undergo redox cycling to form ROS in *Mtb*.



Figure 3.11: Cyclic voltammogram of 1.4 mM QQ **111a** in a 50 mM $(C_2H_5)_4N^+(PF_6)^-$ solution of acetonitrile at 100 mV/s on a GC electrode, without purging with N₂.

The relationship between the different functionalities on the quinone scaffold and the redox potentials of QQs **94-111** was analysed. In general, QQs bearing anilines, in particular aniline-substituted QQs **104-105** ($E_1 = -0.42$ V to -0.47 V, $E_2 = -1.00$ V to -1.06 V, Entries 5-8) and tetradecylanilino-QQs **109** ($E_1 = -0.45$ V/-0.53 V, $E_2 = -1.02$ V for both, Entries 11-12), as well as propargylamine (QQs **100-101**, $E_1 = -0.49$ V to -0.55 V, $E_2 = -1.05$ V to -1.10 V, Entries

29-32) had the highest redox potentials of the library. Conversely, QQs bearing hydrocarbons, *i.e.* octylamino-QQs **102-103** (E₁ = -0.67 V to -0.72 V, E₂ = -1.26 V to -1.27 V, Entries 24-26) and *tert*-butylamino-QQ **97** (E₁ =-0.59 V to -0.68 V, E₂ = -1.10 V to -1.25 V, Entry 28), had relatively low reduction potentials. It was also noted that QQs with aromatic groups positioned further away from the QQ scaffold, *i.e.* phenylethylamino-QQs **106-107** (E₁ = -0.60 V to -0.73 V, E₂ = -1.15 to -1.30, Entries 16-19) and benzylamines **110** (E₁ = -0.61 V to -0.63 V, E₂ = -1.18 to -1.24, Entries 13-14), were weaker oxidising agents compared to the anilino-QQs. This trend highlights the marked effect that functional groups have on the QQs' ability to accept electrons. In comparison to hydrocarbons, QQs bearing unsaturated substituents, *i.e.* phenyl-and propargyl groups, are higher in electronegativity,¹⁹²⁻¹⁹⁴ and thus result in weak electron-withdrawing properties. Hence, QQs bearing anilines and propargylamines underwent reduction more readily than those with hydrocarbon substituents, which is in agreement with literature.¹⁶⁵

In many cases, there was negligible difference in redox potentials between regioisomers (*i.e.* $E_1 = -0.59$ V and -0.60 V, $E_2 = -1.16$ V and -1.16 V for QQs **98a** and **98b**, Entries 20 and 21, respectively, and $E_1 = -0.68$ V and -0.67 V, $E_2 = -1.27$ V and -1.26 V for QQs **102a** and **102b**, Entries 24 and 25, respectively). However, when the regioisomers possessed different reduction potentials, the 7-isomer tended to accept electrons more readily than the corresponding 6-isomer, particularly for the first electron transfer. For example, QQ **97a** ($E_1 = -0.59$ V, Entry 27) had higher redox potentials than its regioisomer QQ **97b** ($E_1 = -0.69$ V, Entry 28), and, similarly, QQ **99a** was more readily reduced than its regioisomer **99b** ($E_1 = -0.56V/-0.60$ V, Entries 22 and 23, respectively). The greater susceptibility for the 7-isomers (**X**) to undergo reduction compared to the 6-isomers (**XI**) could be reasoned by intramolecular hydrogen bonds within the QQ (Figure 3.12). As well as the hydrogen bond between the amine proton and the carbonyl oxygen, the ring nitrogen in the 7-isomer, when protonated, could form an additional hydrogen bond with the C8 oxygen. The hydrogen bonds in the 7-isomer may lead to enhanced electrophilicity of the compound, thereby increasing its propensity to undergo reduction reactions.¹⁶³



Figure 3.12: Intramolecular hydrogen bonding interactions present in QQs X and XI.

In addition to the CV experiments in acetonitrile, experiments using H₂O as the solvent were undertaken in order to better emulate physiological conditions. However, due to the poor solubility of QQs **94-111** in H₂O, a novel CV methodology involving microemulsions, as designed by Professor Thomas Nann and co-workers at Victoria University of Wellington, was applied (patent pending).¹⁹⁵ A microemulsion is a thermodynamically stable mixture of immiscible liquids, typically oil and water, in combination with amphiphilic materials known as surfactants. This technique allows for the QQs to be solubilised in organic solvents in the microemulsion, while the redox reactions occur in an aqueous environment, whereby the quinones (**II**) undergo a two-electron step reaction to form quinols (**IV**) (Figure 3.13).¹⁹⁰



Figure 3.13: A). Two-electron reduction process from quinones (II) to quinols (IV) in aqueous solvents. B). Voltammogram of 50 mM of QQ 97b in a microemulsion against GC electrode.

CV experiments of QQs **94-111** were undertaken in water with the employment of microemulsions by Prof. Thomas Nann and co-workers. Here, the compounds were dissolved in toluene and mixed with H₂O to generate microemulsions, which were stabilised with sodium dodecylsulfate and 1-butanol as surfactant and co-surfactant, respectively. Unfortunately, many of the QQs did not show reversible redox reactions and, accordingly, their reduction potentials, E', could not be determined. Notwithstanding, E' values were obtained for QQs **95-97, 102, 106a, 107a, 108,** and **110b** (Entries 3, 4, 9, 10, 14, 16, 18, 24, 25, 27 and 28, Table 3.1). Here, the redox potentials of the QQs obtained from the CVs involving microemulsions differed from those obtained from the CVs conducted in acetonitrile. For example, in the microemulsion, piperidino-QQs **95a** and **96b** gave high redox potentials at -0.49 V and -0.47 V, respectively (Entries 3 and 4), while in acetonitrile, QQs **95a** and **96b** were weakly reducing relative to other QQs in the library. The inconsistency in redox activity of the QQs in the different solvents is perhaps not surprising, as the electrochemical behaviour of quinones has been reported to change in various media.¹⁶⁸ Indeed, different redox values were also obtained when dimethylformamide (DMF) was used as solvent (see Appendix 3, Table A.3.3.)

3.2.4. Relationship between redox potentials and anti-tubercular activity of QQs

Next, the relationship between the tuberculostatic activity and redox potentials of QQs **94-111** was analysed. Unfortunately, no trend was observed between the redox activity of the QQs in acetonitrile (E_1 and E_2) and their MIC values (Figure 3.14). Moreover, a lack of correlation was also observed with E_1/E_2 values obtained from CV experiments conducted in DMF (Appendix 3, Figure A.3.1.).



Figure 3.14: No relationship was found between the redox potential of QQs 94-111 determined by CV in acetonitrile and their anti-tubercular activity.

That said, when the MIC values were plotted against the redox potentials obtained from microemulsion CVs, an optimal redox potential window was observed, whereby QQs with redox potentials between -0.50 V to -0.62 V tended to exhibit the highest inhibitory activity (Figure 3.15). For QQs with redox potentials higher than -0.62 V, there was a near linear relationship between the redox potential and MIC values, suggesting that QQs with lower reduction potentials were more effective growth inhibitors of *Mtb*.

Chapter Three



Figure 3.15: The relationship between the redox potential of selected QQs in microemulsions and their anti-tubercular activity as measured in MIC.

The optimal redox potential of -0.6 V for the observed anti-tubercular activity of the QQs is comparable to that of *Mtb* NDH-II's natural substrate, MK (**15**), which has a redox potential of -0.66 V in water (vs. Fc/Fc⁺).¹⁹⁶ Thus, it was hypothesised that QQs with redox potential much higher than -0.66 V are likely to be reduced too quickly and are therefore less effective in interacting with NDH-II. Conversely, QQs with low redox potentials are less likely to undergo reduction and may not be involved in the enzymatic reduction by NDH-II. Taken together, these results suggest that an optimal redox potential of approximately -0.6 V, as determined when microemulsions of the QQs were measured appears to be required for the quinones to exert anti-tubercular activity. That said, the redox potentials of the remaining QQs need to be determined to ascertain the relationship between redox and anti-tubercular activity of the compounds.

3.2.5. Proposed mechanism of anti-tubercular activity of lead propargylamino-QQ

The acetylene motif is a common moiety in many biologically active compounds, particularly in anti-cancer^{186,197,198} and anti-mycobacterial agents,^{199,200} and accordingly, a redox-independent mechanism of lead propargylamine-substituted QQ **100b** was postulated. Here, the acetylene group could covalently bind nucleophilic amino acid residues, resulting in irreversible inhibition (**XII**, Scheme 3.4A).²⁰¹ Potential nucleophilic residues in the NDH-II Q-site that could form covalent bonds with an electrophilic group such as allene include two highly conserved glutamine residues, Q317 and Q321.⁵³ Glutamines are nucleophilic amino acids²⁰² that have previously been reported to be involved in covalent inhibition, *i.e.* with 2-deoxy-2-fluoro- β -D-glucopyranoside.^{203,204} In addition, Q317 and Q321 play an important role in quinone binding, as evidenced by the decrease in quinone binding affinity when the glutamine residues were mutated to alanines.⁵³

The above hypothesis could also explain the difference in biological activity between the structurally related QQs **20** (MIC = 8.1μ M) and **98b** (MIC = 128μ M), where QQ8c **20** bears a chloroethylamine substituent on the 6-position and QQ **98b** is substituted with a propylamine group (Figure 3.11). Thus, it is possible that nucleophilic residues, such as glutamine, can displace the chloride atom in QQ8c (**20**) to give the covalent adduct **XIII** (Scheme 3.4B). Alternatively, the chloride atom could be ejected via an intramolecular attack by the amine nitrogen to yield aziridinium **XIV**, which can then undergo ring-opening by a nucleophilic amino acid residue to give **XIII** (Scheme 3.4C).



Scheme 3.4: Possible mechanisms of covalent bond formation between QQ 100b and QQ8c (20) with nucleophilic amino acid residues within the binding site. A). The acetylene group in QQ 100b is subject to nucleophilic attack to form the enol XII, while QQ8c (20) can undergo B). a substitution reaction with the nucleophile to afford covalent adduct XIII or C). an intramolecular substitution reaction to form aziridinium XIV before undergoing nucleophilic attack.

3.3. Conclusion

In this chapter a library of QQs containing different functional groups were synthesised to establish SAR for the growth inhibition of *Mtb*. Herein, 32 compounds were successfully prepared, giving the desired QQs in two steps from commercially available materials in high yields (64-99%). The synthesised QQs were then screened against *Mtb* to obtain MIC values for SAR analysis. The SAR study showed that QQs functionalised with phenylethylamine and benzylamine exhibited high anti-tubercular activity, while those with aniline substituents were poor *Mtb* growth inhibitors. QQ analogues with alkyl chains tended to have a mixed range of anti-tubercular activity, while those with tertiary amines did not exhibit growth inhibition. Notably, the most biologically active compound was propargylamino-substituted QQ **98b**, with an MIC comparable to streptomycin (**12**) and QQ8c (**20**) (8 μ mol, 8.6 μ mol,¹⁸⁸ and 8.1 μ mol,⁶⁴ respectively). In addition to MIC values, the redox potentials of a selection of QQs

were also determined, and while no correlation between the redox potential and tuberculostatic activity in acetonitrile, an optimal redox potential of approximately -0.60 V for biological activity against *Mtb* was observed for QQs compatible with the microemulsion system.

While the mode of action of the lead QQ analogue **98b** is unknown, acetylene groups are known to enhance biological potential of a variety of anti-tumour agents.¹⁹⁷ A potential explanation for this observation is that the acetylene moiety could undergo nucleophilic attack by amino acid residues in the binding site, such as glutamine, which could result in a covalent bond and irreversible binding. To confirm this hypothesis, further biological analyses are warranted and should include co-crystallisation of the quinone with NDH-II to examine the binding site more closely. Furthermore, future work could focus on the specificity of the QQs for bacterial NDH-II over other potential enzyme targets, such as NQO1, whereby the latter is overexpressed in many cancer cells.¹³⁹

3.4. Experimental

3.4.1. Chemistry - synthesis

General procedure. Unless otherwise stated, all reactions were performed under atmospheric air. Prior to use, dioxane (Sigma Aldrich) was distilled over CaCl₂, toluene (drum), EtOAc (drum), and petroleum ether (drum) were distilled. CH₂Cl₂ (LabServ), sodium chlorate (BDH), 8-hydroxyquinoline (BDH), 37% HCl (Merck), EtOH (absolute, Pure Science), 8hydroxyquinaldine (Aldrich), NaHCO₃ (Pure Science), MgSO₄ (Pure Science), pyridine (Roth), dimethylamine (BDH), piperidine (BDH), tertbutylamine (Aldrich), propylamine (Aldrich), propargylamine (AKSci), octylamine (Aldrich), aniline (BDH), 4-heptylaniline (Aldrich), 4tetradecylaniline (Aldrich), methoxybenzylamine (Aldrich), and phenylethylamine (HW) were used as received.

All solvents were removed by evaporation under reduced pressure. Reactions were monitored by TLC-analysis on Macherey-Nagel silica gel coated plastic sheets (0.20 mm) with either visual detection, or detection by UV-absorption (254 nm) and by dipping in KMnO₄ in H₂O. Column chromatography was performed using Pure Science silica gel (40–63 micron) as the stationary phase and the solvent systems indicated. High-resolution (ESI) mass spectra were recorded on an Agilent 6530 Accurate-Mass Q-TOF LC-MS equipped with a 1260 Infinity binary pump. Infrared spectra were recorded as thin films using a Bruker Alpha II FTIR spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling accessory, and are reported in wavenumbers (cm⁻¹). Melting points (m.p.) were obtained on a DigiMelt MPA160 melting point apparatus and UV data obtained on an Cary 150 spectrophotometer. Nuclear magnetic resonance (NMR) spectra were acquired at 20 C in CDCl₃, as indicated using a Varian Unity-INOVA 500 MHz spectrometer, where ¹H and ¹³C were measured at 500 and 125 MHz, respectively. ¹H NMR spectral data are presented as illustrated: chemical shift (δ) in ppm, multiplicity [s (singlet), d (doublet), t (triplet), m (multiplet over the range specified)], number of protons, (nH), coupling constants (J) in Hertz, assignment of protons). ¹H NMR spectra are referenced to the CHCl₃ (δ 7.26 ppm), residual solvent peaks. ¹³C NMR spectra were proton decoupled and referenced to TMS (δ 0 ppm). NMR peak assignments were made using COSY, HSQC, and HMBC experiments.



6,7-Dichloro-5,8-quinolinequinone (92). In a round-bottomed flask fitted with a condenser, 8-hydroxyquinoline (14.5 g, 0.1 mol) was dissolved in conc. HCl (600 mL). The reaction was then warmed to 40 °C before sodium chlorate (53 g, 0.5 mol, 5 equiv.) was added in batches over a period of 1 h, where each batch was added after the yellow gas produced had receded. The

reaction was then left to stir for 2 h before it was diluted with H₂O (1400 mL). The white precipitate was filtered off, and the filtrate extracted with CH₂Cl₂ (6 x 250 mL) before the organic layer was collected and concentrated *in vacuo*. The bright orange solid was then recrystallised from ethanol to yield the dichloroquinolinequinone **92** as bright yellow crystals (6.6 g, 29%). R_f = 0.50 (EtOAc); m.p.: 221.7 °C (lit.⁶⁵ 219.4 – 221.0 °C); IR (thin film): 2971, 1694, 1677, 1573, 1558, 1290, 1275, 1194, 1137, 895, 824, 724, 693, 636 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.10 (d, $J_{2,3}$ = 4.6 Hz, 1H, H2), 8.53 (d, $J_{3,4}$ = 7.9 Hz, 1H, H4), 7.76 (dd, $J_{3,4}$ = 7.8 Hz, $J_{2,3}$ = 4.6 Hz, 1H, H3); ¹³C NMR (125 MHz, CDCl₃): δ 175.6 (C5), 174.4 (C8), 155.4 (C2), 146.8 (C8a), 144.4 (C6 or C7), 143.2 (C6 or C7), 135.7 (C4), 128.3 (C4a and C3); HRMS(ESI) *m*/ χ calcd. for [C₉H₃Cl₂NO₂+H]⁺: 227.9614, obsd.: 227.9618. The data obtained for this compound matched those reported in literature.⁶⁵

General procedure for the synthesis of substituted QQs. To a solution of dichloroquinolinequinones **92** or **56** (1 equiv.) in dioxane (5 mL/mmol) was added the desired amine (1.2 equiv.). The coloured solution was stirred at room temperature before pyridine (2.1 equiv.) was added and the reaction stirred for 4 h, after which TLC analysis showed the disappearance of starting materials. The reaction was then concentrated *in vacuo*, redissolved in EtOAc and washed with sat. aq. NaHCO₃, followed by brine. The organic layers were collected and dried using anhydrous MgSO₄, which was filtered and the filtrate concentrated *in vacuo*. The resulting solid was then purified using silica gel flash column chromatography (CH₂Cl₂/EtOAc or toluene/EtOAc) to give each regioisomer.



6-Chloro-7-dimethylamino-2-methyl-5,8quinolinequinone (94a) and 7-chloro-6dimethylamino-2-methyl-5,8-quinolinequinone (94b). By subjecting dichloroQQ 56 (227.3 mg, 1.0 mmol) and dimethylamine (33% aq., 0.33 mL, 1.5

mmol) to the general procedure for the synthesis of substituted QQs, 94a (125.3 mg, 50%)
and **94b** (100 mg, 41%) were isolated as red crystals. Data for **94a**: $R_f = 0.53$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 233.5 °C; IR (ν_{max}): 2961, 2922, 2852, 1690, 1570, 1508, 1449, 1412, 1309, 1259, 1090, 1067, 1015, 796, 775, 751, 706, 645, 567 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 500 (3.32) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.18 (d, $J_{3,4} = 7.9$ Hz, 1H, H4), 7.42 (d, $J_{3,4} = 7.9$ Hz, 1H, H3), 3.25 (s, 6H, -N(CH₃)₂), 2.73 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 181.6 (C5), 176.6 (C8), 165.2 (C2), 150.1 (C7), 147.0 (C8a), 135.0 (C4), 126.8 (C3), 125.8 (C4a), 120.8 (C6), 44.5 (-N(CH₃)₂), 25.3 (CH₃); HRMS(ESI) *m*/ χ calcd. for [C₁₂H₁₁ClN₂O₂+H]⁺: 251.0582, obsd.: 251.0587. Data for **94b**: $R_f = 0.46$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 152.9 °C; UV–vis (toluene) λ_{max} (log ε): 485 (2.32) nm; IR (ν_{max}): 2945, 1671, 1639, 1553, 1435, 1372, 1286, 1202, 1158, 1138, 1098, 1064, 1010, 933, 869, 859, 830, 809, 772, 746, 700, 650, 565 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.20 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.43 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 3.26 (s, 6H, -N(CH₃)₂), 2.75 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 181.8 (C5), 176.8 (C8), 165.3 (C2), 150.3 (C6), 147.2 (C8a), 135.1 (C4), 126.9 (C3), 126.0 (C4a), 120.9 (C7), 44.7 (*N*(CH₃)₂), 25.44 (CH₃); HRMS(ESI) *m*/ χ calcd. for [C₁₂H₁₁ClN₂O₂+H]⁺: 251.0582, obsd.: 251.0587.



6-Chloro-7-piperidinyl-5,8-quinolinequinone (95a). By subjecting dichloroQQ **92** (139.1 mg, 0.61 mmol) and piperidine (0.07 mL, 0.73 mmol) to the general procedure for the synthesis of substituted QQs, the title compound was isolated as purple crystals (67.5 mg, 40%); $R_f = 0.59$ (4/1, CH₂Cl₂/EtOAc, v/v); m.p.: 95.2 °C; IR (ν_{max}): 2934, 2849,

1689, 1641, 1587, 1555, 1450, 1397, 1314, 1293, 1244, 1218, 1187, 1141, 1118, 1073, 1035, 987, 852, 834, 809, 784, 722, 644, 509, 562, 444, 420 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 465 (2.32) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.90 (dd, $J_{2,3} = 4.6$ Hz, $J_{2,4} = 1.7$ Hz, 1H, H2), 8.40 (dd, $J_{3,4} = 7.9$ Hz, $J_{2,4} = 1.7$ Hz, 1H, H4), 7.61 (dd, $J_{3,4} = 7.9$ Hz, $J_{2,3} = 4.7$ Hz, 1H, H3), 3.58-3.56 (m, 4H, H1'), 3.45, 1.79-1.75 (m, 4H, H2'), 1.72-1.68 (m, 2H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 180.3 (C8), 176.9 (C5), 153.8 (C2), 151.20 (C7), 147.2 (C8a), 134.5 (C4), 128.5 (C4a), 127.8 (C3), 120.8 (C6), 53.2 (C1'), 26.9 (C2'), 24.0 (C3'); HRMS(ESI) *m*/ χ calcd. for $[C_{14}H_{13}CIN_2O_2+H]^+$: 277.0738, obsd.: 277.0736.



7-Chloro-6-piperidinyl-2-methyl-5,8-quinolinequinone (96b). By subjecting dichloroQQ 56 (202.5 mg, 0.84 mmol) and piperidine (0.1 mL, 1.0 mmol) to the general procedure for the synthesis of substituted QQs, the title compound was isolated as purple crystals (80.6 mg, 33%); $R_f = 0.32$ (CH₂Cl₂/EtOAc, 24/1, v/v); m.p.: 153.2

°C; IR (υ_{max}): 2922, 1672, 1648, 1548, 1443, 1293, 1242, 1206, 1101, 985, 859, 745, 702, 568, 448, 420 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 515 (2.90) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.19 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.43 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 3.54 (m, 4H, H1'), 2.74 (s, 3H, CH₃), 1.77 (m, 4H, H2'), 1.71 (m, 2H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 181.6 (C5), 176.8 (C8), 165.2 (C2), 150.1 (C6), 147.1 (C8a), 135.1 (C4), 127.0 (C3), 126.2 (C4a), 123.0 (C7), 53.2 (C1'), 27.0 (C2'), 25.3 (CH₃), 24.2 (C3'); HRMS(ESI) *m*/*z* calcd. for [C₁₅H₁₅ClN₂O₂+H]⁺: 291.0895, obsd.: 291.0899.



6-Chloro-2-methyl-7-tertbutylamino-5,8-quinolinequinone (97a) and 7chloro-2-methyl-7-tertbutylamino-5,8-

quinolinequinone (97b). By subjecting dichloroQQ 56 (195 mg, 0.81 mmol) and

tert-butylamine (0.13 mL, 1.2 mmol) to the general procedure for the synthesis of substituted QQs, **97a** (88.1 mg, 39%) and **97b** (56.4 mg, 25%) were isolated as red crystals. Data for **97a**: $R_f = 0.70$ (CH₂Cl₂/EtOAc, 9/1, v/v); m.p.: 113.2 °C; IR (ν_{max}): 3371, 1670, 1594, 1560, 1534, 1369, 1314, 1201, 1163, 1092, 848, 678, 422 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 485 (2.39) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.31 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.48 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 6.04 (br. s, 1H, NH), 2.73 (s, 3H, CH₃), 1.57 (s, 9H, 'Bu-CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 179.4 (C8), 175.8 (C5), 163.7 (C2), 146.6 (C7), 146.1 (C8a), 134.8 (C4), 128.2 (C3), 127.2 (C4a), 55.8 ('Bu-C_q), 31.6 ('Bu-CH₃), 25.1 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₄H₁₅ClN₂O₂+H]⁺: 279.0895, obsd.: 279.0896. Data for **97b**: $R_f = 0.35$ (CH₂Cl₂/EtOAc, 9/1, v/v); m.p.: 177.2 °C; IR (ν_{max}): 3376, 1670, 1594, 1535, 1369, 1314, 1201, 1163, 1092, 849, 749, 678, 414 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 485 (1.48) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.22 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.42 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 6.04 (br s., 1H, NH), 2.76 (s, 3H, CH₃), 1.57 (s, 9H, 'Bu-CH₃); ^{1.5}C (C2), 147.6 (C8a), 145.4 (C6), 135.1 (C4), 126.6 (C3), 125.2 (C4a), 55.4 ('Bu-C_q), 31.6 ('Bu-CH₃), 25.4 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₄H₁₅ClN₂O₂+H]⁺: 279.0895, obsd.: (C4), 126.6 (C3), 125.2 (C4a), 55.4 ('Bu-C_q), 31.6 ('Bu-CH₃), 25.4 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₄H₁₅ClN₂O₂+H]⁺: 279.0895, obsd.: (C4), 126.6 (C3), 125.2 (C4a), 55.4 ('Bu-C_q), 31.6 ('Bu-CH₃), 25.4 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₄H₁₅ClN₂O₂+H]⁺: 279.0895, obsd.: (Bu-CH₃), 25.4 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₄H₁₅ClN₂O₂+H]⁺: 279.0895, obsd.:



6-Chloro-7-propylamino-5,8quinolinequinone (98a) and 7-chloro-6-propylamino-5,8-quinolinequinone (98b). By subjecting dichloroQQ 92 (44.2 mg, 0.5 mmol) and propylamine (0.05

mL, 0.6 mmol) to the general procedure for the synthesis of substituted QQs, 98a (75.2 mg, 60%) and 98b (47.6 mg, 39%) were isolated as red crystals. Data for 98a: $R_f = 0.43$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 145.7 °C (lit.¹⁸⁷ 135-136 °C); IR (u_{max}): 3284, 2929, 1693, 1576, 1553, 1506, 1464, 1431, 1375, 1284, 1259, 1236, 1195, 1165, 1151, 1137, 1093, 1036, 1026, 1006, 984, 871, 834, 818, 726, 611, 551, 493, 455, 439, 418 cm⁻¹; UV-vis (toluene) λ_{max} (log ε): 480 (2.64) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.92 (d, *J*_{2,3} = 4.7 Hz, 1H, H2), 8.47 (d, $J_{3,4} = 7.9$ Hz, 1H, H4), 7.65 (dd, $J_{3,4} = 7.9$ Hz, $J_{2,3} = 4.7$ Hz, 1H, H3), 6.28 (br. s, 1H, NH), 3.85 (q, $J_{1'2'} = 6.9$ Hz, 2H, H1'), 1.75 (sext., $J_{1'2'} = J_{2'3'} = 7.2$ Hz, 2H, H2'), 1.03 (t, $J_{2'3'} = 7.3$ Hz, 2H, H3'); ¹³C NMR (125 MHz, CDCl₃): δ 179.0 (C8), 175.7 (C5), 153.4 (C2), 146.0 (C8a), 134.8 (C4), 130.1 (C4a), 128.5 (C3), 123.8 (C6), 46.9 (C1'), 24.4 (C2'), 11.2 (C3'); HRMS-ESI (m/z) calcd. for [C₁₂H₁₁ClN₂O₂+H]⁺: 251.0582, obsd.: 251.0588. The spectral data obtained for this compound were consistent with those reported in literature.¹⁸⁷ Data for **98b**: $R_f = 0.26$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 154.4 °C (lit.¹⁸⁷ 134-135 °C); IR (u_{max}): 3227, 2956, 2919, 1676, 1560, 1551, 1458, 1330, 1304, 1266, 1207, 1134, 1110, 1071, 1040, 1023, 831, 821, 803, 746, 732, 710, 677, 656, 649, 563, 492 cm⁻¹; UV-vis (toluene) λ_{max} (log ε): 480 (3.48) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.02 (dd, $J_{2,3}$ = 4.7 Hz, $J_{2,4}$ = 1.4 Hz, 1H, H2), 8.35 (dd, $J_{3,4}$ = 8.1 Hz, $J_{2,4} = 1.4$ Hz, 1H, H4), 7.59 (dd, $J_{3,4} = 7.9$ Hz, $J_{2,3} = 4.7$ Hz, 1H, H3), 6.06 (br. s, 1H, NH), 3.85 (q, $J_{1',2'} = 7.0$ Hz, 2H, H1'), 1.74 (sext., $J_{1',2'} = J_{2',3'} = 7.0$ Hz, 2H, H2'), 1.03 (t, $J_{2',3'} =$ 7.5 Hz, 2H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 180.3 (C5), 155.4 (C2), 148.7 (C8a), 134.8 (C4), 126.8 (C4a), 126.6 (C3), 46.9 (C1'), 24.4 (C2'), 11.2 (C3'); HRMS-ESI (m/z) calcd. for [C12H11CIN2O2+H]+: 251.0582, obsd.: 251.0588. The spectral data obtained for this compound were consistent with those reported in literature.¹⁸⁷



quinolinequinone (99b). By subjecting dichloroQQ 56 (49.0 mg, 0.20 mmol) and propylamine (0.02 mL, 0.24 mmol) to the general procedure for the synthesis of substituted QQs, **99a** (27 mg, 51%) and **99b** (24.9 mg, 47%) were isolated as red crystals. Data for **99a**: R₁ = 0.40 (CH₂Cl₂/EtOAc, 9/1, v/v); m.p.: 150.7 °C; IR (ν_{max}): 3296, 1696, 1600, 1577, 1513, 1460, 1443, 1320, 1258, 1200, 1165, 1140, 1105, 1089, 851, 819, 738, 707, 595, 565, 525, 501, 474, 418 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 480 (2.28), 310 (2.89) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.35 (d, $J_{3,4}$ = 7.9 Hz, 1H, H4), 7.49 (d, $J_{3,4}$ = 8.0 Hz, 1H, H3), 6.18 (br. s, 1H, NH), 3.83 (q, $J_{1',2'} = J_{2',3'} = 7.3$ Hz, 2H, H1'), 2.73 (s, 3H, CH₃), 1.73 (sext., $J_{1',2'} = J_{2',3'} = 7.1$ Hz, 2H, H2'), 1.01 (t, *J*_{2',3'} = 7.4 Hz, 2H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.2 (C8), 176.0 (C5), 163.5 (C2), 145.5 (C8a), 144.4 (C7), 134.0 (C4), 128.4 (C3), 127.9 (C4a), 46.8 (C1'), 25.0 (CH₃), 24.3 (C2'), 11.06 (C3'); HRMS-ESI (m/z) calcd. for $[C_{13}H_{13}CIN_2O_2+H]^+$: 265.0738, obsd.: 265.0740. Data for **99b**: $R_f = 0.3$ (CH₂Cl₂/EtOAc, 9/1, v/v), m.p.: 114.1 °C; IR (v_{max}): 2958, 1673, 1571, 1509, 1453, 1310, 1225, 1111, 1067, 839, 776, 748, 701, 649, 574, 419 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 475 (2.30) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.21 (d, $J_{3,4}$ = 8.0 Hz, 1H, H4), 7.41 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 6.04 (br. s, 1H, NH), 3.82 (q, $J_{1',2'} = J_{2',3'} = 6.9$ Hz, 2H, H1'), 2.75 (s, 3H, CH₃), 1.72 (sext., $J_{1',2'} = J_{2',3'} = 7.2$ Hz, 2H, H2'), 1.01 (t, $J_{2',3'} = 7.4$ Hz, 2H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 180.2 (C5), 175.5 (C8), 166.0 (C2), 148.3 (C8a), 143.6 (C7), 134.9 (C4), 126.5 (C3), 124.6 (C4a), 46.8 (C1'), 25.6 (CH₃), 24.4 (C2'), 11.2 (C3'); HRMS-ESI (m/z) calcd. for $[C_{13}H_{13}CIN_2O_2+H]^+$: 265.0738, obsd.: 265.0740.



6-Chloro-7-propargylamino-5,8quinolinequinone (100a) and 7chloro-6-propargylamino-5,8-(100b). quinolinequinone By

0.83 mmol) and propargylamine (0.06 mL, 1.0 mmol) to the general procedure for the synthesis of substituted QQs, 100a (63.5 mg, 31%) and (57.3 mg, 28%) were isolated as red crystals. Data for **100a**: $R_f = 0.27$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 199.8 °C (lit.¹⁸⁶ 140-142 °C); IR (v_{max}): 3189, 1697, 1599, 1565, 1507, 1422, 1348, 1322, 1196, 1152, 1093, 817, 724, 575 cm⁻¹;

UV-vis (CH₂Cl₂) λ_{max} (log ε): 455 (1.71) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.96 (dd, $J_{2,3}$ = 4.6 Hz, $J_{2,4}$ = 1.5 Hz, 1H, H2), 8.49 (dd, $J_{3,4}$ = 7.9 Hz, $J_{2,4}$ = 1.5 Hz, 1H, H4), 7.69 (dd, $J_{3,4}$ = 7.9 Hz, $J_{2,3} = 4.6$ Hz, 1H, H3), 6.21 (br. s, 1H, NH), 4.69 (dd, $J_{1',\text{NH}} = 6.0$ Hz, $J_{1',3'} = 2.5$ Hz, 2H, H1'), 2.43 (t, $J_{1',3'}$ = 2.5 Hz, 1H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 178.6 (C8), 176.0 (C5), 153.9 (C2), 146.1 (C8a), 144.1 (C7), 134.9 (C4), 129.7 (C4a), 128.6 (C3), 79.0 (C2'), 74.0 (C3'), 35.3 (C1'); HRMS-ESI (m/z) calcd. for $[C_{12}H_7CIN_2O_2+H]^+$: 247.0269, obsd.: 247.0260. The spectral data obtained for this compound were consistent with those reported in literature.¹⁸⁶ Data for **100b**: $R_f = 0.16$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 137.1 °C (lit.¹⁸⁶ 140-142 °C); IR (u_{max}): 3248, 1691, 1595, 1570, 1513, 1345, 1308, 1267, 1207, 1147, 1117, 1075, 832, 806, 759, 731, 680, 656, 595, 451, 411 cm⁻¹; UV-vis (toluene) λ_{max} (log ε): 460 (3.72), 300 (1.23) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 9.03 (dd, $J_{2,3} = 4.7$ Hz, $J_{2,4} = 1.7$ Hz, 1H, H2), 8.38 (dd, $J_{3,4} = 7.9$ Hz, $J_{2,4} = 1.8$ Hz, 1H, H4), 7.62 (dd, $J_{3,4} = 7.8$ Hz, $J_{2,3} = 4.7$ Hz, 1H, H3), 6.02 (br. s, 1H, NH), 4.66 (dd, $J_{1',NH} = 6.0$ Hz, $J_{1',3'} = 2.6$ Hz, 2H, H1'), 2.42 (t, $J_{1',3'} = 2.5$ Hz, 1H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.7 (C5), 155.3 (C2), 148.1 (C8a), 143.1 (C6), 134.8 (C4), 126.8 (C3), 78.9 (C2'), 73.7 (C3'), 35.2 (C1'); HRMS-ESI (m/z) calcd. for $[C_{12}H_7CIN_2O_2+H]^+$: 247.0269, obsd.: 247.0260. The data obtained for this compound were consistent with those reported in literature.¹⁸⁶



quinolinequinone (101b). By subjecting dichloroQQ **56** (77 mg, 0.32 mmol) and propargylamine (0.03 mL, 0.48 mmol) to the general procedure for the synthesis of substituted QQs, **101a** (37.5 mg, 45%) was isolated as red crystals and **101b** (33.4 mg, 40%) was isolated as orange crystals. Data for **101a**: $R_f = 0.32$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 213.7 °C; IR (ν_{max}): 3310, 3216, 1691, 1603, 1580, 1497, 1352, 1320, 1279, 1250, 1202, 1154, 1114, 830, 740, 706, 683, 600, 558, 473, 435, 421 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 475 (2.22) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.34 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.51 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 6.12 (br. s, 1H, NH), 4.66 (dd, $J_{1',NH} = 4.7$ Hz, $J_{1',3'} = 2.5$ Hz, 2H, H1'), 2.74 (s, 3H, CH₃), 2.41 (t, $J_{1',3'} = 2.5$ Hz, 1H, H3'); ¹³C NMR (125 MHz, CDCl₃): δ ppm 178.9 (C8), 176.1 (C5), 164.1 (C2), 145.6 (C8a), 143.9 (C7), 135.1 (C4), 128.6 (C3), 127.5 (C6), 79.1 (C2'), 73.8 (C3'), 35.2 (C1'), 25.2 (CH₃); HRMS-ESI (m/s) calcd. for [C₁₃H₂ClN₂O₂+H]⁺: 261.0425, obsd.: 261.0426. Data

for **101b**: $R_f = 0.19$ (CH₂Cl₂/EtOAc, 4/1, v/v); m.p.: 163.2 °C; IR (ν_{max}): 3180, 2924, 1611, 1574, 1558, 1504, 1454, 1357, 1312, 1294, 1257, 1145, 1068, 1025, 930, 750, 734, 702, 612, 553, 509 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 455 (2.17) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.25 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.45 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 6.00 (br. s, 1H, NH), 4.65 (dd, $J_{1',NH} = 4.7$ Hz, $J_{1',3'} = 2.5$ Hz, 2H, H1'), 2.77 (s, 3H, CH₃), 2.41 (t, $J_{1',3'} = 2.5$ Hz, 1H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.8 (C8), 175.9 (C5), 166.2 (C2), 147.8 (C8a), 143.1 (C6), 135.1 (C4), 126.8 (C3), 79.2 (C2'), 73.8 (C3'), 35.2 (C1'), 25.6 (CH₃); HRMS-ESI (m/x) calcd. for [C₁₃H₉ClN₂O₂+H]⁺: 261.0425, obsd.: 261.0426.



dichloroQQ 92 (176 mg, 0.77 mmol) and octylamine (0.15 mL, 0.93 mmol) to the general procedure for the synthesis of substituted QQs, 102a (69.2 mg, 28%) and 102b (88.9 mg, 36%) were isolated as red crystals. Data for **102a**: $R_f = 0.69$ (EtOAc); m.p.: 148.9 °C; IR (ν_{max}): 2922, 2851, 1691, 1592, 1559, 1508, 1428, 1325, 1306, 1252, 1196, 1138, 1098, 820, 728 cm⁻¹; UVvis (toluene) λ_{max} (log ε): 485 (2.46) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.88 (d, $J_{2,4} = 4.6$ Hz, 1H, H2), 8.44 (d, $J_{3,4} = 7.8$ Hz, 1H, H4), 7.63 (dd, $J_{3,4} = 7.8$ Hz, $J_{2,3} = 4.5$ Hz, 1H, H3), 6.24 (br. s, 1H, NH), 3.84 (q, $J_{1',2'} = J_{1',NH} = 7.2$ Hz, 2H, H1'), 1.68 (pent., $J_{1',2'} = J_{2',3'} = 7.6$ Hz, 2H, H2'), 1.39- 1.25 (m, 8H, H3'-H7'), 0.85 (t, $J_{7,8'} = 7.0$ Hz, 2H, H8'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.0 (C8), 175.7 (C5), 153.4 (C2), 144.6 (C7), 134.8 (C4), 130.1 (C4a), 128.5 (C3), 45.2 (C1'), 31.8 (C6'), 31.1 (C2'), 29.3 (C4'), 29.2 (C3'), 26.7 (C5'), 22.7 (C7'), 14.15 (C8'); HRMS-ESI (m/z) calcd. for $[C_{17}H_{21}CIN_2O_2+H]^+$: 321.1364, obsd.: 321.1364. Data for **102b**: R_f = 0.33 (EtOAc); m.p.: 116.2 °C; IR (u_{max}): 3237, 2921, 1675, 1589, 1560, 1513, 1443, 1373, 1305, 1264, 1206, 1113, 1073, 827, 803, 748, 714, 654, 572, 411 cm⁻¹; UV-vis (toluene) λ_{max} $(\log \epsilon)$: 485 (2.67) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.00 (d, $J_{2,4}$ = 4.5 Hz, 1H, H2), 8.34 $(d, J_{3,4} = 7.9 \text{ Hz}, 1\text{H}, \text{H4}), 7.57 (dd, J_{3,4} = 7.8 \text{ Hz}, J_{2,3} = 4.7 \text{ Hz}, 1\text{H}, \text{H3}), 6.05 (br. s, 1\text{H}, \text{NH}),$ 3.85 (q, $J_{1',2'} = J_{1',NH} = 7.2$ Hz, 2H, H1'), 1.69 (pent., $J_{1',2'} = J_{2',3'} = 7.2$ Hz, 2H, H2'), 1.39-1.24 (m, 8H, H3'- H7'), 0.87 (t, $J_{7',8'} = 7.0$ Hz, 2H, H8'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 180.1(C8), 175.2(C5), 155.4 (C2), 148.5 (C8a), 143.8 (C6), 134.8 (C4), 134.7 (C4a), 126.7 (C3), 45.2 (C1'), 31.8 (C6'), 31.0 (C2'), 29.20 (C4'), 29.16 (C3'), 26.6 (C5'), 22.6 (C7'), 14.05 (C8'); calcd. for [C₁₇H₂₁ClN₂O₂+H]⁺: 321.1364, obsd.: 321.1361.



5,8-quinolinequinone (103b). By subjecting dichloroQQ 56 (113.9 mg, 0.47 mmol) and octylamine (0.09 mL, 0.56 mmol) to the general procedure for the synthesis of substituted QQs, 103a (58.2 mg, 37%) and 103b (53.5 mg, 34%) were isolated as red crystals. Data for **103a**: $R_f = 0.52$ (CH₂Cl₂/EtOAc, 9/1, v/v); m.p.: 118 °C; IR (ν_{max}): 3304, 2923, 1694, 1598, 1574, 1553, 1509, 1443, 1318, 1258, 1202, 1162, 1143, 1109, 1090, 819, 739, 707, 587, 537, 479, 448, 417 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 485 (2.84) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.32 (d, $J_{3,4}$ = 7.9 Hz, 1H, H4), 7.48 (d, $J_{3,4}$ = 8.0 Hz, 1H, H3), 6.19 (br. s, 1H, NH), 3.84 (q, J_{1',2'} = 6.8 Hz, 2H, H1'), 2.71 (s, 3H, CH₃), 1.71-1.66 (m, 2H, H2'), 1.41-1.25 (m, 10H, H2'- H7'), 0.86 (t, $J_{7',8'}$ = 6.4 Hz, 2H, H8'); ¹³C NMR (125 MHz, CDCl₃): δ ppm 179.2 (C8), 174.2 (C5), 163.5 (C2), 145.4 (C8a), 134.9 (C4), 128.4 (C3), 127.8 (C4a), 45.2 (C1'), 31.7 (C6'), 31.1 (C2'), 29.2 (C4'), 29.28 (C3'), 26.6 (C5'), 22.6 (C7'), 14.1 (C8'); HRMS-ESI (m/z) calcd. for $[C_{18}H_{23}CIN_2O_2+H]^+$: 335.1521, obsd.: 335.1525. Data for **103b**: $R_f = 0.49$ (CH₂Cl₂/EtOAc, 9/1, v/v); m.p.: 111.7 °C; IR (v_{max}): 2918, 2853, 1675, 1563, 1519, 1313, 1286, 1224, 1115, 839, 776, 750, 704, 645, 572 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 485 (2.19) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.21 (d, $J_{3,4}$ = 8.0 Hz, 1H, H4), 7.41 (d, $J_{3,4}$ = 8.0 Hz, 1H, H3), 6.03 (br. s, 1H, NH), $3.85 (q, J_{1',2'} = 6.5 Hz, 2H, H1')$, $2.76 (s, 3H, CH_3)$, 1.72-1.66 (m, 2H, H2'), 1.43-1.37 (m, 2H, H2'), 2H, H2'), 1.35-1.25 (m, 8H, H3'- H7'), 0.88 (t, $J_{7,8'} = 6.8$ Hz, 2H, H8'); ¹³C NMR (125 MHz, CDCl₃): δ ppm 180.2 (C8), 166.1 (C2), 148.1 (C8a), 135.0 (C4), 126.5 (C3), 124.6 (C4a), 45.2 (C1'), 31.9 (C6'), 31.1 (C2'), 29.33 (C4'), 29.28 (C3'), 25.6 (C5'), 22.8 (C7'), 14.22 (C8'); HRMS-ESI (m/z) calcd. for $[C_{18}H_{23}CIN_2O_2+H]^+$: 335.1521, obsd.: 335.1525.



6-Chloro-7-phenylamino-5,8quinolinequinone (104a) and 7-chloro-6-phenylamino-5,8-quinolinequinone (104b). By subjecting dichloroQQ 92 (120.9 mg, 0.53 mmol) and aniline (0.06

mL, 0.62 mmol) to the general procedure for the synthesis of substituted QQs, 104a (51.3 mg,

24%) and 104b (54.3 mg, 36%) were isolated as red crystals. Data for 104a: $R_f = 0.33$ (CH₂Cl₂/EtOAc, 24/1, v/v); m.p.: 235.7 °C; IR (u_{max}): 2955, 2922, 2852, 1692, 1558, 1462, 1447, 1378, 1315, 1245, 1152, 1066, 852, 758, 723, 691, 629, 579, 550, 540, 452, 418 cm⁻¹; UVvis (CH₂Cl₂) λ_{max} (log ε): 490 (2.48) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 9.00 (d, $J_{2,4} = 4.5$ Hz, 1H, H2), 8.52 (d, J_{3,4} = 7.2 Hz, 1H, H4), 7.86 (br. s, 1H, NH), 7.71 (dd, J_{3,4} = 7.8 Hz, J_{2,3} = 4.7 Hz, 1H, H3), 7.37 (t, $J_{\rho-CH2,m-CH2} = J_{m-CH2,p-CH2} = 7.6$ Hz, 2H, m-PhCH), 7.25 (t, $J_{m-CH2,p-CH2}$ = 7.3 Hz, 2H, p-PhCH), 7.12 (d, $J_{o-CH2,m-CH2}$ = 7.8 Hz, 2H, o-PhCH); ¹³C NMR (125 MHz, CDCl₃): δ ppm 179.0 (C8), 176.5 (C5), 153.9 (C2), 146.1 (C8a), 141.9 (C7), 136.9 (Ph-Cq), 135.0 (C4), 130.0 (C4a), 128.53 (C3), 128.5 (m-PhCH), 126.1 (p-PhCH), 124.6 (o-PhCH); HRMS-ESI (m/z) calcd. for $[C_{15}H_9ClN_2O_2+H]^+$: 285.0245, obsd.: 285.0426. Data for **104b**: R_f = 0.26 (CH₂Cl₂/EtOAc, 24/1, v/v); m.p. 205.8 °C; IR (ν_{max}): 2923, 1674, 1646, 1588, 1559, 1484, 1444, 926, 858, 800, 757, 731, 685, 577, 549, 510, 449, 415 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 485 (2.54) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 9.06 (d, *J*_{2,4} = 4.8 Hz, 1H, H2), 8.44 $(dd, J_{3,4} = 8.0 \text{ Hz}, J_{2,4} = 1.6 \text{ Hz}, 1\text{H}, \text{H4}), 7.71 (br. s, 1\text{H}, \text{NH}), 7.68 (dd, J_{3,4} = 8.0 \text{ Hz}, J_{2,3} = 4.7 \text{ Hz})$ Hz, 1H, H3), 7.37 (t, $J_{o-CH2,m-CH2} = J_{m-CH2,p-CH2} = 7.6$ Hz, 2H, m-PhCH), 7.25 (t, $J_{m-CH2,p-CH2} = 7.3$ Hz, 2H, *p*-PhCH), 7.10 (d, $J_{o-CH2,m-CH2} = 7.8$ Hz, 2H, *o*-PhCH); ¹³C NMR (125 MHz, CDCl₃) δ ppm 180.3 (C5), 176.0 (C8), 155.6 (C2), 148.5 (C8a), 141.2 (C6), 137.2 (Ph-C_q), 135.0 (C4), 128.69 (C3), 128.64 (m-PhCH), 127.1 (C4a), 126.2 (p-PhCH), 124.7 (o-PhCH); HRMS-ESI (m/z) calcd. for $[C_{15}H_9ClN_2O_2+H]^+$: 285.0245, obsd.: 285.0426.





subjecting dichloroQQ **56** (115 mg, 0.48 mmol) and aniline (0.05 mL, 0.57 mmol) to the general procedure for the synthesis of substituted QQs, **105a** (34.4 mg, 24%) and **105b** (94.6 mg, 24%) were isolated as red crystals. Data for **105a**: $R_f = 0.32$ (CH₂Cl₂/EtOAc, 24/1, v/v); m.p.: 226.2 °C; IR (ν_{max}): 3236, 1688, 1634, 1552, 1485, 1443, 1284, 1225, 1151, 1073, 986, 910, 872, 848, 815, 768, 736, 693, 574, 562, 501, 472, 448, 419 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 490 (2.68) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.38 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.81 (br. s, 1H, NH), 7.54 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 7.36 (t, $J_{o-CH,m-CH} = J_{m-CH,p-CH3} = 7.9$ Hz, 2H, *m*-PhCH), 7.24 (t, $J_{m-CH,p-CH3} = 7.6$ Hz, 1H, *p*-PhCH), 7.11 (d, $J_{o-CH,m-CH} = 7.8$ Hz, 2H, *o*-PhCH), 2.77 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.4 (C8), 176.9 (C5), 164.3 (C2), 145.8 (C8a),

141.9 (C6 or C7), 137.2 (Ph-C_q), 135.3 (C4), 128.64 (C3), 128.62 (*m*-PhCH), 128.0 (C4a), 126.1 (*p*-PhCH), 124.6 (*o*-PhCH), 25.2 (CH₃); HRMS-ESI (*m/s*) calcd. for [C₁₆H₁₁ClN₂O₂+H]⁺: 299.0582, obsd.: 299.0586. Data for **105b**: $R_f = 0.22$ (CH₂Cl₂/EtOAc, 24/1, v/v); m.p: 226.7 °C; IR (v_{max}): 2955, 2918, 1678, 1646, 1546, 1420, 1375, 1287, 1222, 1199, 1144, 1033, 905, 888, 849, 707, 707, 698, 586, 560, 509 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 485 (2.18) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.31 (d, $J_{3,4} = 8.0$ Hz, 1H, H4), 7.66 (br. s, 1H, NH), 7.48 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 7.37 (t, $J_{o-CH,m-CH} = 7.8$ Hz, 2H, *m*-PhCH), 7.24 (t, $J_{m-CH_3p-CH3} = 7.8$ Hz, 1H, *p*-PhCH), 7.09 (d, $J_{o-CH,m-CH} = 7.8$ Hz, 2H, *o*-PhCH), 2.79 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 184.5 (C8), 180.1 (C5), 166.1 (C2), 148.1 (C8a), 140.8 (C7), 137.1 (Ph-C_q), 135.0 (C4), 128.5 (*m*-PhCH), 126.8 (C3), 125.9 (*p*-PhCH), 124.7 (C4a), 124.4 (*o*-PhCH), 25.5 (CH₃); HRMS-ESI (*m*/*x*) calcd. for [C₁₆H₁₁ClN₂O₂+H]⁺: 299.0582, obsd.: 299.0586.



quinolinequinone (106b). By subjecting dichloroQQ 92 (168.5 mg, 0.74 mmol) and 2phenylethylamine (0.11 mL, 0.89 mmol) to the general procedure for the synthesis of substituted QQs, **106a** (39.3 mg, 17%) and **106b** (127.3 mg, 55%) were isolated as red crystals. Data for **106a**: $R_f = 0.31$ (EtOAc/petroleum ether, 2/1, v/v); m.p.: 170.7 °C; IR (v_{max}): 3286, 2164, 1638, 1639, 1591, 1583, 1520, 1356, 1307, 1253, 1189, 1142, 1096, 830, 817, 756, 732, 724, 699, 667, 647, 613, 530, 498, 482, 419 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 485 (3.69) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.92 (d, $J_{2,3}$ = 4.5 Hz, 1H, H2), 8.47 (d, $J_{3,4}$ = 7.8 Hz, 1H, H4), 7.65 (dd, *J*_{3,4} = 7.7 Hz, *J*_{2,3} = 4.7 Hz, 1H, H3), 7.34-7.31 (m, 2H, *m*-PhCH), 7.26-7.24 (m, 3H, *o*-PhCH, *p*-PhCH), 6.25 (br. s, 1H, NH), 4.14 (q, $J_{1',2'} = J_{1',NH} = 6.8$ Hz, 2H, H1'), 3.01 (t, *J*_{1',2'} = 6.9 Hz, 2H, H2'), 3.00; ¹³C NMR (125 MHz, CDCl₃) δ ppm 178.8 (C8), 175.6 (C5), 153.4 (C2), 146.0 (C8a), 137.5 (Ph-Cq), 134.7 (C4), 128.9 (m-PhCH), 128.8 (o-PhCH), 128.4 (C3), 127.0 (*p*-PhCH), 46.2 (C1'), 37.3 (C2'); HRMS-ESI (m/z) calcd. for $[C_{17}H_{13}CIN_2O_2+H]^+$: 313.0738, obsd.: 313.0738. Data for **106b**: $R_f = 0.18$ (EtOAc/petroleum ether, 2/1, v/v); m.p.: 165.2 °C; IR (umax): 3183, 2953, 2922, 2853, 1688, 1596, 1563, 1497, 1356, 1327, 1260, 1215, 1111, 1075, 744, 731, 680, 554, 498, 463, 410 cm⁻¹; UV-vis (toluene) λ_{max} (log ε): 485 (2.72) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 9.01 (d, $J_{2,3} = 5.1$ Hz, 1H, H2), 8.32 (d, $J_{3,4} = 7.8$ Hz, 1H, H4), 7.57 (dd, $J_{3,4} = 7.9$ Hz, $J_{2,3} = 4.6$ Hz, 1H, H3), 7.35-7.32 (m, 2H, *m*-PhCH), 7.27-7.23 (m, 3H, *o*-PhCH, *p*-PhCH), 6.07 (br. s, 1H, NH), 4.14 (q, $J_{1',2'} = J_{1',NH} = 6.8$ Hz, 2H, H1'), 3.00 (t, $J_{1',2'} = 7.1$ Hz, 2H, H2'); ¹³C NMR (125 MHz, CDCl₃): δ ppm 180.0 (C5), 155.2 (C2), 148.4 (C8), 143.6 (C6), 137.4 (Ph-Cq), 134.7 (C4), 128.9 (*m*-PhCH), 128.81 (*o*-PhCH), 127.7 (C4a), 127.0 (*p*-PhCH), 126.5 (C3), 46.1 (C1'), 37.2 (C2'); HRMS-ESI (*m*/*z*) calcd. for [C₁₇H₁₃ClN₂O₂+H]⁺: 313.0738, obsd.: 313.0738.



quinolinequinone (107b). By subjecting dichloroQQ 56 (185.6 mg, 0.77 mmol) and 2phenylethylamine (0.12 mL, 0.92 mmol) to the general procedure for the synthesis of substituted QQs, 107a (70.5 mg, 28%) and 107b (93.1 mg, 37%) were isolated as red crystals. Data for **107a**: $R_f = 0.42$ (EtOAc/petroleum ether, 2/1, v/v); m.p.: 165.9 °C; IR (v_{max}): 3302, 1695, 1633, 1571, 1493, 1464, 1305, 1230, 1147, 1107, 851, 817, 735, 694, 665, 595, 579, 517, 492, 476, 449, 419, 404 cm⁻¹; UV-vis (toluene) λ_{max} (log ε): 490 (2.83) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.32 (d, $J_{3,4}$ = 8.0 Hz, 1H, H4), 7.48 (d, $J_{3,4}$ = 8.0 Hz, 1H, H3), 7.33-7.30 (m, 2H, *m*-PhCH), 7.25-7.22 (m, 3H, ρ -PhCH), ρ -PhCH), 6.21 (br. s, 1H, NH), 4.12 (q, $J_{\text{HI'}\text{H2'}}$ = $J_{\rm H1',NH} = 6.9$ Hz, 2H, H1'), 2.99 (t, $J_{1',2'} = 7.2$ Hz, 2H, H2'), 2.72 (s, 3H, CH₃); ¹³C NMR (125) MHz, CDCl₃) δ ppm 179.1 (C8), 175.9 (C5), 163.6 (C2), 145.5 (C8a), 144.4 (C7). 137.7 (Ph-Cq), 134.9 (C4), 129.0 (m-PhCH), 128.9 (o-PhCH), 128.5 (C3), 128.3 (C4a), 127.0 (p-PhCH), 46.1 (C1'), 37.4 (C2'), 25.1 (CH₃); HRMS-ESI (m/z) calcd. for $[C_{18}H_{15}CIN_2O_2+H]^+$: 327.0895, obsd.: 327.0895. Data for **107b**: $R_f = 0.27$ (EtOAc/petroleum ether, 2/1, v/v); m.p.: 143.0 °C; IR (umax): 3210, 1682, 1567, 1507, 1440, 1362, 1306, 1230, 1114, 1069, 844, 770, 749, 697, 645, 566, 506, 489, 460, 421 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 475 (2.78) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.20 (d, $J_{3,4}$ = 8.0 Hz, 1H, H4), 7.41 (d, $J_{3,4}$ = 8.0 Hz, 1H, H3), 7.33-7.32 (m, 2H, m-PhCH), 7.26-7.24 (m, 3H, o-PhCH, p-PhCH), 6.06 (br. s, 1H, NH), 4.12 (q, J_{H1',H2'} = $J_{\text{H1',NH}} = 6.9 \text{ Hz}, 2\text{H}, \text{H1'}, 2.99 \text{ (t, } J_{1',2'} = 7.2 \text{ Hz}, 2\text{H}, \text{H2'}, 2.75 \text{ (s, 3H, CH_3); }^{13}\text{C NMR} (125)$ MHz, CDCl₃) δ ppm 179.9 (C5), 175.5 (C8), 165.9 (C2), 148.0 (C8a), 143.5 (C6), 137.5 (Ph-Cq), 134.8 (C4), 128.9 (o-PhCH), 128.8 (m-PhCH), 127.0 (p-PhCH), 126.4 (C3), 124.5 (C4a), 46.1 (C1'), 37.2 (C2'), 25.5 (CH₃); HRMS-ESI (m/z) calcd. for $[C_{18}H_{15}ClN_2O_2+H]^+$: 327.0895, obsd.: 327.0895.



5,8-quinolinequinone (108a) and 7-chloro-6-(4-heptyl)anilino-5,8-quinolinequinone (108b). By subjecting dichloroQQ 92 (136.3 mg, 0.60 mmol) and 4-heptylaniline (0.15 mL, 0.72 mmol) to the general procedure for the synthesis of substituted QQs, 108a (91.9 mg, 40%) and 108b (66.6 mg, 29%) were isolated as red crystals. Data for 108a: R: = 0.23 (petroleum ether/EtOAc, 1/1, v/v); m.p.: 150.5 °C; IR (v_{max}): 2915, 2849, 1690, 1636, 1589, 1577, 1559, 1555, 1513, 1481, 1470, 1452, 1322, 1311, 1302, 1277, 1248, 1217, 1180, 1152, 1067, 856, 844, 725, 623, 567 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 505 (2.69) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.98 (d, $J_{2,3}$ = 4.7 Hz, 1H, H2), 8.51 (d, $J_{3,4}$ = 7.9 Hz, 1H, H4), 7.84 (br. s, 1H, NH), 7.70 (dd, J_{3,4} = 7.7 Hz, J_{2,3} = 4.7 Hz, 1H, H3), 7.16, (d, J_{2',3'} = 7.6 Hz, 2H, H3'), 7.02 (d, J_{2',3'} = 7.6 Hz, 2H, H2'), 2.62 (t, J_{5',6'} = 7.7 Hz, 2H, H5'), 1.65-1.59 (m, 2H, H6'), 1.32-1.27 (m, 8H, H7'- H10'), 0.88 (t, $J_{10',11'} = 6.1$ Hz, 3H, H11'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.2 (C8), 176.5 (C5), 153.9 (C2), 146.3 (C8a), 142.2 (C6), 141.4 (C4'), 135.1 (C4), 134.6 (C1'), 130.2 (C4a), 128.6 (C3), 128.5 (C3'), 124.7 (C2'), 113.5 (C7), 35.6 (C5'), 31.9 (C9'), 31.5 (C6'), 29.3 (C7'), 29.3 (C8'), 22.8 (C10'), 14.2 (C11'); HRMS(ESI) m/z calcd. for $[C_{22}H_{23}CIN_2O_2+H]^+$: 383.1521, obsd.: 358.1520. Data for **108b**: R_i = 0.11 (petroleum ether/EtOAc, 1/1, v/v); m.p: 174.4 °C; IR (v_{max}): 3340, 2920, 1670, 1606, 1578, 1518, 1492, 1309, 1213, 1144, 863, 839, 813, 746, 687, 638. 525, 458 cm⁻¹; UV-vis (toluene) λ_{max} (log ε): 495 (2.72) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.04 (dd, $J_{3,4}$ = 4.7 Hz, $J_{2,4}$ = 1.4 Hz, 1H, H4), 8.42 (dd, *J*_{2,3} = 7.8 Hz, *J*_{2,4} = 1.3 Hz, 1H, H2), 7.66 (br. s, 1H, NH), 7.63 (dd, *J*_{3,4} = 4.7 Hz, $J_{2,3} = 7.8$ Hz, 1H, H3), 7.16, (d, $J_{2',3'} = 8.3$ Hz, 2H, H3'), 7.01 (d, $J_{2',3'} = 8.2$ Hz, 2H, H2'), 2.61 (t, $J_{5',6'} = 7.9$ Hz, 2H, H5'), 1.61 (pent., $J_{5',6',7'} = 7.6$ Hz, 2H, H6'), 1.32-1.27 (m, 8H, H7'- H10'), 0.87 (t, $J_{10',11'} = 6.9$ Hz, 3H, H11'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 180.2 (C5), 176.0 (C8), 155.5 (C2), 148.4 (C8a), 141.1 (C4'), 134.5 (C1'), 134.9 (C4), 128.6 (C3'), 127.0 (C3), 124.6 (C2'), 115.6 (C6), 35.6 (C5'), 31.9 (C9'), 31.5 (C6'), 29.3 (C7'), 29.3 (C8'), 22.8 (C10'), 14.2 (C11'); HRMS-ESI (m/2) calcd. for $[C_{22}H_{23}CIN_2O_2+H]^+$: 383.1521, obsd.: 358.1520.



6-Chloro-7-(4-tetradecyl)anilino-5,8-quinolinequinone (109a) and 7-chloro-6-(4tetradecyl)anilino-5,8-quinolinequinone (109b). By subjecting dichloroQQ 92 (129.7 mg, 0.57 mmol) and 4-tetradecylaniline (196.2 mg, 0.68 mmol) to the general procedure for the synthesis of substituted QQs, 109a (90.5 mg, 33%) and 109b (79.5 mg, 29%) were isolated as red crystals. Data for **109a**: $R_f = 0.67$ (CH₂Cl₂/EtOAc, 5/1, v/v); m.p.: 152.3 °C; IR (ν_{max}): 3236, 2913, 2848, 1691, 1637, 1588, 1556, 1513, 1467, 1322, 1303, 1217, 1151, 1067, 1018, 857, 834, 817, 725, 623, 571, 551, 825, 510, 469, 450, 417 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 495 (2.39) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.99 (d, $J_{2,3}$ = 4.7 Hz, 1H, H2), 8.52 (d, $J_{3,4}$ = 7.9 Hz, 1H, H4), 7.83 (br. s, 1H, NH), 7.71 (dd, $J_{3,4}$ = 7.8 Hz, $J_{2,3}$ = 4.7 Hz, 1H, H3), 7.17 (d, $J_{2',3'} = 8.2$ Hz, 2H, H3'), 7.02 (d, $J_{2',3'} = 8.2$ Hz, 2H, H2'), 2.62 (t, $J_{5',6'} = 7.4$ Hz, 2H, H5'), 1.62-1.55 (m, H6'), 1.31-1.26 (m, 22H, H7'-H17'), 0.88 (t, $J_{17',18'} = 7.0$ Hz, 2H, H18'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.1 (C8), 176.4 (C5), 153.8 (C2), 146.1 (C8a), 141.3 (C1'), 134.9 (C4), 134.5 (C4'), 130.0 (C4a), 128.5 (C3), 128.4 (C3'), 124.6 (C2'), 113.5 (C6), 35.5 (C5'), 31.9 (C6'), 31.4, 29.69, 29.68, 29.67, 29.65, 29.6, 29.5, 29.4, 29.3, 22.7 (C7'-C17'), 14.12 (C18'); HRMS-ESI (m/z) calcd. for $[C_{29}H_{37}CIN_2O_2+H]^+$: 481.2616, obsd.: 481.2618. Data for **109b**: R_f $= 0.5 (CH_2Cl_2/EtOAc, 5/1, v/v); m.p.: 160.7 °C; IR (v_{max}): 3339, 2916, 2848, 1670, 1616, 1608,$ 1578, 1471, 1313, 1215, 1144, 863, 837, 818, 623, 453 cm⁻¹; UV-vis (CH₂Cl₂) λ_{max} (log ε): 495 (2.29) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.05 (d, $J_{2,3}$ = 4.8 Hz, 1H, H2), 8.43 (d, $J_{3,4}$ = 7.9 Hz, 1H, H4), 7.65-7.62 (m, 2H, NH, H3), 7.17 (d, $J_{2',3'} = 7.5$ Hz, 2H, H3'), 7.01 (d, $J_{2',3'} =$ 7.5 Hz, 2H, H2'), 2.62 (t, J_{5',6'} = 7.1 Hz, 2H, H5'), 1.69-1.59 (m, H6'), 1.31-1.26 (m, 22H, H7'-H17'), 0.88 (t, *J*_{17',18'} = 7.2 Hz, 2H, H18'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 180.3 (C5), 176.0 (C8), 155.5 (C2), 148.6 (C8a), 141.4 (C4'), 134.9 (C4), 134.7 (C1'), 128.6 (C3'), 127.0 (C3), 126.9 (C4a), 124.6 (C2'), 35.6 (C5'), 32.1 (C6'), 31.5, 29.9, 29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 22.8 (C7'-C17'), 14.3 (C18'); HRMS-ESI (m/z) calcd. for $[C_{29}H_{37}CIN_2O_2+H]^+$: 481.2616, obsd.: 481.2616.



5,8-quinolinequinone (110b). By subjecting dichloroQQ 92 (143.6 mg, 0.63 mmol) and methoxybenzylamine (0.10 mL, 0.76 mmol) to the general procedure for the synthesis of substituted QQs, 110a (167.4 mg, 67%) and 110b (52.5 mg, 21%) were isolated as red crystals. Data for **110a**: $R_f = 0.29$ (CH₂Cl₂/EtOAc, 5/1, v/v); m.p.: 179.3 °C; IR (ν_{max}): 3308, 1698, 1595, 1560, 1509, 1447, 1359, 1302, 1246, 1181, 1149, 1089, 1036, 809, 724, 580, 545, 517, 445, 410 cm⁻¹; UV-vis (DMF) λ_{max} (log ε): 465 (3.53) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.91 (d, $J_{2,3} = 4.8$ Hz, 1H, H2), 8.46 (d, $J_{3,4} = 7.8$ Hz, 1H, H4), 7.64 (dd, $J_{3,4} = 7.9$ Hz $J_{2,3} = 4.6$ Hz, 1H, H3), 7.25 (d, J_{o-CH,m-CH} = 8.1 Hz, 2H, o-PhCH), 6.90 (d, J_{o-CH,m-CH} = 8.1 Hz, 2H, m-PhCH), 6.30 (br s, 1H, NH), 5.00 (d, $J_{CH2,NH} = 5.1$ Hz, 2H, CH₂) 3.79 (s, 3H, O-CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 179.0 (C8), 175.6 (C5), 159.7 (C_q-OCH₃), 153.6 (C2), 146.1 (C8a), 144.4 (C7), 134.9 (C4), 129.9 (C4a), 128.6 (C3), 129.3 (*o*-PhCH), 114.5 (*m*-PhCH), 55.5 (OCH₃); HRMS-ESI (m/z) calcd. for $[C_{17}H_{13}CIN_2O_2+H]^+$: 329.0887, obsd.: 328.0688. Data for **110b**: R_f $= 0.20 (CH_2Cl_2/EtOAc, 5/1, v/v); IR (v_{max}): 3310, 1699, 1603, 1576, 1516, 1350, 1235, 1100,$ 1024, 800, 725, 678, 511 cm⁻¹; UV-vis (DMF) λ_{max} (log ε): 460 (2.03) nm; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.92 (d, $J_{2,3}$ = 4.6 Hz, 1H, H2), 8.43 (d, $J_{3,4}$ = 7.8 Hz, 1H, H4), 7.68 – 7.62 (m, 1H, H3), 7.24 (d, *J*_{o-CH,m-CH} = 8.7 Hz, 2H, o-PhCH), 6.91 (d, *J*_{o-CH,m-CH} = 8.1 Hz, 2H, m-PhCH), 5.86 (br s, 1H, NH), 4.33 (d, $J_{CH2,NH} = 5.5$ Hz, 2H, CH₂) 3.81 (s, 3H, O-CH₃); ¹³C NMR (125) MHz, CDCl₃) δ ppm 181.6 (C8), 175.5 (C5), 159.5 (C_q-OCH₃), 153.4 (C2), 146.0 (C8a), 144.5 (C6), 134.7 (C4), 129.9 (C4a), 128.4 (C3), 129.3 (o-PhCH), 114.4 (m-PhCH), 55.3 (OCH₃); HRMS-ESI (m/z) calcd. for $[C_{17}H_{13}CIN_2O_2+H]^+: 329.0887$, obsd.: 328.0688.



6-Chloro-7-(4-methoxybenzyl)amino-2-methyl-5,8quinolinequinone (111a). By subjecting dichloroQQ 56 (211.8 mg, 0.88 mmol) and methoxybenzylamine (0.14 mL, 1.05 mmol) to the general procedure for the synthesis of substituted QQs, the title compound was isolated as

orange crystals (147.8 mg, 49%); $R_f = 0.39$ (CH₂Cl₂/EtOAc, 9/1, v/v); m.p.: 169.3 °C; IR (ν_{max}): 3315, 1699, 1600, 1576, 1557, 1506, 1436, 1357, 1323, 1239, 1177, 1153, 1106, 1094, 1034, 818, 801, 738, 678, 599, 562, 518, 472, 417 cm⁻¹; UV–vis (toluene) λ_{max} (log ε): 485 (2.20),

320 (2.51) nm; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.29 (d, $J_{3,4} = 8.1$ Hz, 1H, H4), 7.47 (d, $J_{3,4} = 8.0$ Hz, 1H, H3), 7.24 (d, $J_{o-CH,m-CH} = 8.1$ Hz, 2H, o-PhCH), 6.87 (d, $J_{o-CH,m-CH} = 8.1$ Hz, 2H, m-PhCH), 6.23 (br s, 1H, NH), 4.97 (d, $J_{NH,CH2} = 6.0$ Hz, 2H, CH₂-Ph), 3.77 (s, 3H, O-CH₃), 2.69 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 179.1 (C8), 176.0 (C5), 163.6 (C2), 159.5 (C_q-OCH₃), 145.5 (C8a), 144.3 (C7), 134.9 (C4), 129.6 (C_q-CH₂), 129.2 (o-PhCH), 128.4 (C3), 127.7 (C4a), 114.4 (m-PhCH), 55.3 (O-CH₃), 50.53, 48.7 (CH₂), 25.0 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₈H₁₅ClN₂O₂+H]⁺: 343.0844, obsd.: 343.0846.

3.4.2. Cyclic voltammetry (acetonitrile)

The electrochemical measurements were conducted at ambient room temperature (~20 °C) using a PGSTAT128N potentiostat-galvanostat (Metrohm Autolab Instruments, Switzerland), equipped with a three-electrode cell. Glassy carbon electrode and platinum wire were used for the working and counter electrodes, respectively, and a silver wire was used for a reference electrode. For all samples the QQ concentration was approximately 1 mM and the electrolyte concentration (C_2H_5)₄N(PF₆) was 50 mM in a 30 mL solution of acetonitrile. All the CVs were recorded at 100 mV/s.

CHAPTER FOUR The synthesis of chromonylpyrimidines and their potential as antitubercular agents

4.1. Introduction

Recently, a high-throughput screen of 100,000 compounds identified amino-quinolinyl pyrimidines (*i.e.* **XV**, Figure 4.1) as a promising class of *Mtb* NDH-II inhibitor.⁷⁹ In particular, the incorporation of primary amines at the 2'- and 4-positions on the quinolinyl pyrimidine scaffold were found to be essential for enzyme inhibition and were thus postulated to participate in hydrogen bonding interactions within the enzyme binding site. Quinolinyl pyrimidines (**XV**) bearing monosubstituted phenyl substituents at the 2- and 6'-positions were excellent NDH-II inhibitors, with lead compound **25** exhibiting an IC₅₀ value of 0.043 μ M.⁷⁹ SAR studies of monosubstituted phenyl quinolinyl pyrimidines revealed that alterations to the

phenyl substituents did not greatly affect the anti-tubercular activity of the compounds. For example, the potency of *para*-chlorophenyl quinolinyl pyrimidine **25** against NDH-II (measured in IC₅₀) and *Mtb* (measured in MIC) was comparable to derivatives **112-114**, despite differences in substituents on the phenyl ring. Here, quinolinyl pyrimidine **112** featured a chloride at the *meta*-position of the phenyl group on the pyrimidine ring, while this chloride was absent in quinolinyl pyrimidine **113**. In quinolinyl pyrimidine **114**, the strongly electron-withdrawing fluoro-substituent on the phenyl substituent in quinolinyl pyrimidine **25** was replaced with an electron-donating methoxy group. These observations suggest that small structural changes to aryl-substituted quinolinyl pyrimidines **XV** may be well-tolerated and, moreover, the correlation between NDH-II inhibition and MIC values against *Mtb* indicated that NDH-II may be the target of growth inhibition by quinolinyl pyrimidines (**XV**).⁷⁹ Since this study, little work has been reported on the development of quinolinyl pyrimidines as anti-tubercular agents and their mode of action is yet to be confirmed.²⁰⁵



Figure 4.1: Quinolinyl pyrimidine general structure (**XV**) and derivatives **25**, **112-114**, with enzyme inhibition activity (IC_{50}) and anti-tubercular activity (MIC).⁷⁹

Given the anti-tubercular activity of quinolinyl pyrimidines (**XV**), it was envisioned that a structurally related class of compounds, chromonyl-pyrimidines (**XVI**, Figure 4.2A), could be promising new TB drug candidates. The bicylic 1,4-chromone scaffold in chromonyl-pyrimidines (**XVI**) mimics the quinone motif and is anticipated to bind NDH-II at the proposed Q-site. Moreover, the replacement of the quinoline group with a less polar group, such as a chromone, might enhance interactions with the hydrophobic NDH-II active site. Here, the primary amine in the quinoline moiety of quinolinyl pyrimidines is replaced by a ketone, which could act as a hydrogen acceptor, for example with the amine proton of the FAD isoalloxazine ring. In addition, both quinolinyl pyrimidines **XVI** can stabilise a positive charge through resonance (Figure 4.2B), allowing them to remain stable under acidic environments, such as empysema pus, in which *Mtb* can reside (Chapter 1, Section 1.1.3).²⁰⁶



Figure 4.2: A).Proposed anti-tubercular drug scaffold, chromonyl-pyrimidines (XVI). B). Both quinolinyl pyrimidines XV and chromonyl-pyrimidines XVI can stabilise a positive charge through resonance.

4.1.1. The role of chromones in drug discovery

Chromones are oxygen-containing heterocyclic compounds known for their wide range of pharmacological properties.²⁰⁷ In particular, the therapeutic potential of chromone-based drugs for the treatment of cancer,²⁰⁸⁻²¹³ neurodegenerative diseases,²¹⁴ and infections^{210,215,216} have been extensively investigated. Accordingly, many chromone-containing drugs have advanced to clinical trials,²¹⁷⁻²²⁰ though none hitherto as anti-mycobacterial agents. That said, the anti-

tubercular activity of chromones has been demonstrated with tricyclic chromones **115** and **116** (Figure 4.3),^{221,222} which inhibited *Mtb* cell growth by 99% at 62.5 μ g/mL.²²² In addition, pyridinyl tricyclic chromones **117** and **118** showed promise as anti-tubercular agents against MDR-TB, with MIC values of 0.07 μ M and 0.61 μ M, respectively.²²³



Figure 4.3: Examples of anti-tubercular chromones 115-118.^{222,223}

The biological activity of chromones has been attributed to their redox properties and their role as antioxidants.^{224,225} For example, flavone (**119**, Figure 4.4) inhibited the NADH : oxidoreductase enzyme in *Saccharomyces cerevisiae*,²²⁶ while glycosyl-chromones **120** and **121** showed radical scavenging activity against ROS 1,1-diphenyl 2-picryl hydrazyl (DPPH),^{227,228} and 2-(*cis*-1,2-dihydroxy-4-oxo-cyclohex-5-enyl)-5,7-dihydroxy-chromone (DEDC, **122**) elevated ROS generation in human neuroblastoma SH-SY5Y cells.²²⁹ Chromones are also involved in kinase²³⁰ and tubulin polymerisation inhibition²³¹ in tumour cells, adenylyl cyclase type 1 inhibition for chronic pain,²³² DNA polymerase inhibition in HIV-1,²³³ and cyclooxygenase inhibition in inflammatory diseases.²³⁴ Hence, the diverse pharmaceutical properties and low cytotoxicity against mammalian cells²³⁵ of chromones make them an attractive scaffold in the search for new NDH-II inhibitors.



Figure 4.4: Chromone-based drugs, flavone (**119**),²²⁶ glycosylated chromones **120**²²⁷ and **121**,²²⁸ and DEDC (**122**),²²⁸ that exert their pharmacological properties through their redox and antioxidant activities.

4.1.2. The synthesis of chromones

Typically, 2-substituted 1,4-chromones are prepared through the esterification of 2'hydroxyacetophenone (123) to give ester 124,^{225,236} which can undergo a Baker-Venkatamaran rearrangement (\rightarrow 125)^{237,238} and subsequent acid-catalysed annulation to yield 2-substituted chromones, *i.e.* 126 (Scheme 4.1).^{207,239,240} Other methodologies for preparing chromones include the Simonis reaction of phenols (127),^{241,242} a Kostanecki reaction to afford cayboxychromones (128),^{243,244} and an intramolecular Wittig reaction of silylated ester 129, which can be prepared from salicylic acid (130).²⁴⁵



Scheme 4.1: Common strategies for the synthesis of chromones **126** and carboxy-chromones **128**.^{207,225,236-245}

4.1.3. The role of pyrimidines in drug discovery

The pyrimidine scaffold is a well-cited structural motif in drug discovery²⁴⁶ and is one of the most common nitrogen-containing heterocycles present in the current repertoire of FDA-approved dugs.²⁴⁷ Pyrimidine-containing pharmaceuticals have primarily been used to treat cancer,²⁴⁸⁻²⁵⁰ cardiovascular,^{251,252} and infectious diseases.²⁵³⁻²⁵⁶ Of particular interest for this project is a study on the anti-tubercular activity of a series of aniline-substituted-pyrimidines, which resulted in the identification of a lead pyrimidine candidate, derivative **131** (MIC = 8.9 μ M against *Mtb*, Figure 4.5).²⁵⁷ In other studies, 2-hydroxypyrimidine **132** demonstrated 96% inhibition of *Mtb* growth at 6.25 μ g/mL,²⁵⁸ and thiophene-substituted pyrimidine **133** gave a low MIC value of 0.4 μ M against *Mtb*, comparable to that of INH (**2**).²⁵⁹



Figure 4.5: Examples of pyrimidine-containing anti-tubercular agents 131-133.257-259

Although many pyrimidine-containing anti-tubercular agents have been identified,^{258,260-266} the mechanisms by which the heterocycles inhibit mycobacterial growth have only been investigated in a few cases. For example, some pyrimidines are known to inhibit bacterial dihydrofolate reductases, an enzyme responsible for the reduction of folates to tetrahydrofolate, which in turn is important for nucleic and amino acid biosynthesis.²⁶⁷ Accordingly, their anti-mycobacterial activity is typically attributed to their antifolate activity, as in epiroprim (**134**, Figure 4.6) and azapteridine **135**, which exhibited antifolate activity against *M. leprae* and *M. avium*, respectively.²⁶⁸⁻²⁷⁰ Unfortunately, however, pyrimidines **134** and **135** were less efficaciouis against *Mtb*. Another notable enzyme target of pyrimidines is the acetohydroxacid synthase, which is inhibited by pyrimidine **136** in RR-TB and MDR-TB.²⁶⁰ Acetohydroxyacid synthase is involved in the biosynthesis of amino acids leucine, isoleucine and valine.



Figure 4.6: Epiroprim $(134)^{268}$ and azapteridine 135^{270} inhibit dihydrofolate reductase in bacteria, while sulfonamide 136 inhibits acetohydroxacid synthase.²⁶⁰

4.1.4. Pyrimidine synthesis

To synthesise 2-amino-substituted pyrimidines (**XVII**) guanidinium salts (*i.e.* **137**) are often used (Scheme 4.2). Key in the pyrimidine synthesis is the carbon-nitrogen bond formation to provide the 6-membered heterocycle, and accordingly, several methodologies involving different substrates have been developed. For example, treatment of guanidines **137** with malonitrile (**138**) or 1,3-diesters **139** affords tri-aminopyrimidines **140**²⁷¹ or di-hydroxypyrimidines **141**,²⁷²⁻²⁷⁴ respectively. To synthesise alkyl- or aryl-substituted pyrimidines, guanidines **137** can be reacted with 1,3-diketones **142** to give pyrimidines **143**,²⁷⁵⁻²⁷⁷ or chlorovinyl aldehydes **144**, which can be prepared by applying Vilsmeier-Haack conditions to ketones **145**, to give dialkyl pyrimidines **146**.²⁷⁸



Scheme 4.2: Synthetic approaches to form functionalised pyrimidines from guanidinium salts **137**.²⁷¹⁻²⁷⁴

4.1.5. Project aims and retrosynthesis

The aim of the research in this chapter is to investigate the potential of chromonyl-pyrimidines (**XVI**) as anti-tubercular agents. Accordingly, the preparation of a library of chromonyl-pyrimidines (**XVI**) with various functionalisations at the 6'- and 2-positions was proposed (Scheme 4.3). Here, the synthesis of pyrimidines installed with methyl, chloromethyl, and

methoxymethyl groups was proposed so as to provide insight into how the electronic properties of the pyrimidine ring influences the anti-tubercular activity of the compounds. Similarly, substituents at the 2-position were chosen to probe the pharmacophore of chromonyl-pyrimidines, whereby an ester and cyclopropyl group provide an electrophilic centre for the chromone to interact with nucleophilic residues in NDH-II. In addition, cyclopropyl and phenyl groups are apolar and are thus anticipated to enhance the binding affinity of chromonyl-pyrimidines to the hydrophobic Q-site.

Retrosynthetically, it was envisioned that chromonyl-pyrimidines **XVI** would be synthesised by a nucleophilic substitution of chloropyrimidines **XVII** by amino-chromones **XVIII**. Chloropyrimidines **XVII** could, in turn, be prepared by the condensation of functionalised beta-ketoesters **147** with guanidine, followed by a chlorination reaction.²⁷⁹ Substituted chromones **XVIII** could be constructed from the condensation of 2'-hydroxyacetophenone (**123**) with functionalised acid chlorides or carboxylic acids to form an ester, which would then undergo an acid-catalysed cyclisation reaction.²⁸⁰ The library of functionalised chromonylpyrimidines (**XVI**) will then be screened for their ability to inhibit *Mtb*.



Scheme 4.3: The retrosynthetic analysis of chromonyl-pyrimidines (XVI).

4.2. Results and discussion

4.2.1. Docking studies

To understand how chromonyl-pyrimidines (XVI) could bind NDH-II,²⁸¹ docking studies of 6-((2-amino-6-methylpyrimidin-4-yl)amino)-2-methyl-4*H*-chromen-4-one (**148**, Figure 4.7A) in the C. thermarum NDH-II crystal structure (PDB: 6BDO)⁶² were undertaken using the UCSF Chimera/DOCK6 programme suite.^{282,283} In the docking studies, chromonyl-pyrimidine 148 was well-placed in the proposed Q-site of NDH-II (Figure 4.7B-D). Specifically, chromonylpyrimidine 148 is sandwiched between hydrophobic residues Q317 and I379, with the pyrimidine moiety occupying a site surrounded by more polar groups, R382 and E324 (Figure 4.7B). The methyl substituent of the pyrimidine ring, however, interacts with hydrophobic side chains I320 and Q321, indicating that less polar substituents at this position may be wellaccommodated. The hydrophobic interactions of the bicyclic chromone moiety with Q317 and I379, as shown in Figure 4.7C, are consistent with those of quinone and quinolone scaffolds in menadione (18)⁵⁸ and HQNO (19),⁶² respectively (Chapter 1, Section 1.3.1). Unfortunately, the ketone oxygen of chromone 148, which was anticipated to form a hydrogen bond with the isoalloxazine ring nitrogen is not well-positioned to interact with FAD. Notwithstanding, a hydrogen bond measured at 2.09 Å was observed between an amine proton of the pyrimidine ring and the oxygen in glutamic acid E324 (Figure 4.7D). Taken together, these results demonstrated that chromonyl-pyrimidines **XVII** could be accommodated in the putative NDH-II Q-site in a similar manner to other substrates, *i.e.* menadione (18)⁵⁸ and HQNO (19).62



Figure 4.7: Docking studies of chromonyl-pyrimidine **148** in *C. thermarum* NDH-II (PDB: 6BDO).⁶² A). Structure of 6-((2-amino-6-methylpyrimidin-4-yl)amino)-2-methyl-4*H*-chromen-4-one (**148**). B). Several binding modes of chromonyl-pyrimidine **148** (light blue) in the putative NDH-II Q-site are in close proximity to FAD (gold). C). The bicyclic chromone is sandwiched between amino acids Q317 and I379, which are important residues for quinone binding. D). There is a hydrogen bond (black line) between an amine proton of the pyrimidine ring and the oxygen of glutamic acid E324. Molecular graphics and analyses were performed with USCF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco.

4.2.2. The synthesis of functionalised pyrimidines

The synthesis of functionalised chloropyrimidines commenced with the condensation of guanidine hydrochloride (137) and ethyl acetoacetate in the presence of sodium hydride to give pyrimidine 149 as an off-white solid in 63% yield (lit. 54%)²⁸⁴ (Scheme 4.4). Pyrimidinol 149 was then chlorinated under the agency of POCl₃ to give 4-chloro-6-methylpyrimidine (150). Similarly, guanidine 137 was treated with ethyl 4-chloroacetoacetate to give both the

hydroxymethyl- as well as the methoxymethyl-substituted pyrimidines 151^{285} and 152, respectively, in an approximately 2:1 ratio and a high combined yield of 83% (53% for 151, lit.: 46° ²⁸⁵). Hydroxypyrimidines 151 and 152 were readily separated by silica gel flash chromatography (R_f = 0.37 and 0.53, CH₂Cl₂/MeOH/EtOH/NH₃ (25%), 5/2/2/1 v/v/v/v, respectively) before they were treated with POCl₃ to give the desired chloropyrimidines, 153 and 154, respectively. The spectral data obtained for pyrimidines 150^{279} and 153^{285} matched those reported in the literature, while the formation of chloride 154 was evidenced by NMR spectroscopy and HRMS data (calcd. for [C₆H₈ClN₃O+H]⁺: 174.0429, obsd.: 174.0429).



Scheme 4.4: The synthesis of chloropyrimidines 150,²⁷⁹ 153²⁸⁵ and 154.

4.2.3. The synthesis of functionalised chromones

To synthesise 2-substituted amino-chromones, 2'-hydroxyacetophenone (**123**) was first subjected to Kostanecki conditions to give ethyl ester **155**,^{243,244} which was then nitrated to give 6-nitro chromone **156** in 90% yield over the two steps (Scheme 4.5).²⁸⁶ Next, a Claisen

condensation between acetophenone **123** and ethyl cyclopropanecarboxylate afforded chromone **157**,²⁸⁷ which was isolated in 74% yield. A subsequent nitration reaction then successfully gave cyclopropyl-substituted nitrochromone **158** in high yield.



Scheme 4.5: The synthesis of nitro-chromones 156 and 158.^{286,287}

Finally, in an attempt to synthesise 2-phenyl-chromone (**159**), 2'-hydroxyacetophenone (**123**) was first reacted with ethyl benzoate under basic conditions (Scheme 4.6). However, this reaction was unsuccessful, as evidenced by the recovery of starting material **123** and the isolation of benzoic acid as a by-product. Accordingly, it was decided that the ester carbonyl carbon was not sufficiently electrophilic to undergo nucleophilic attack with acetophenone **123** and, instead, benzaldehyde would react more readily with phenol **123** as the carbonyl carbon in an aldehyde group is more electron-deficient than that of an ester. Gratifyingly, the condensation of acetophenone **123** with benzaldehyde proceeded smoothly to yield chalcone **160**, which underwent iodine-promoted oxidation to provide the desired phenylchromone **159** in good yield.²⁸⁸ Next, chromone **159** was subjected to nitration conditions. Unfortunately, mono-nitration was not possible as an inseparable 1:1 mixture of di-nitrochromones **161** and **162** was obtained even when milder conditions, such as lower temperatures and the use of weaker acids, were applied.



Scheme 4.6: The synthesis of phenylchromone 159 from acetophenone 123 and the subsequent nitration reaction to give structural isomers 161 and 162.

Structural isomers **161** and **162** were characterised using NMR spectroscopy, whereby the ¹H NMR spectrum showed multiciplity patterns corresponding to both *meta-* and *para-*substituted nitrophenyl groups (Figure 4.8). Specifically for *p*-nitrophenyl **161**, proton resonances at 8.45 ppm and 8.15 ppm (d, $J_{1',2'} = 8.5$ Hz) correlated to protons at *ortho-* (H1') and *meta-* (H2') positions with respect to the chromone scaffold, respectively. The proton resonances correlating to *m*-phenylchromone **162** were more complicated as each nitrophenyl proton occupied different chemical environments. Here, the proton resonances corresponding to H3' and H4' revealed ⁴ $J_{3',4'}$ and ⁴ $J_{3',6'}$ coupling constants of 2.1 Hz and 2.0 Hz, respectively, which are typical of a long range W coupling.¹³⁰ Moreover, coupling constants ³ $J_{4',5'}$ and ³ $J_{5',6'}$ for geminal protons H4'/H5' and H5'/H6' were observed at 8.2 Hz and 7.9 Hz, respectively.¹³⁰ Further evidence of the presence of the di-nitro chromones was observed by HRMS data (calcd. for $[C_{15}H_8N_2O_6+H]^+$: 313.0455, obsd.: 313.0453).



Figure 4.8: ¹H NMR (500 MHz, CDCl₃) of a 1:1 mixture of structural isomers 161 and 162.

Consequently, it was decided that 2-phenyl-6-nitro chromone could be synthesised by first installing the nitro-substituent on 2'-hydroxyacetophenone (123, Scheme 4.7). Here, acetophenone 123 was treated with HNO3 and AcOH to give nitro-acetophenone 163 in 25% yield (lit. 30%),²⁸⁹ with 3'-nitro-acetophenone (164) as a minor (5% yield) by-product. The structures of acetophenones 163 and 164 were confirmed through XRD data (Figure 4.9A and Figure 4.9B, respectively). The formation of structural isomers 163 and 164 occurred due to the meta-directing properties of the carbonyl functionality combined with the ortho- and paradirecting hydroxyl group, giving C3' and C5' as the most favoured positions for electrophilic aromatic substitution.²⁹⁰ However, the lack of steric hindrance at the 5'-position relative to the 3'-position led to 5'-nitro acetophenone 163 being the major product. Fortuitously, the regioisomers were readily separated using silica gel flash column chromatography, with the desired nitro-acetophenone 163 being eluted first (R_f for 163 = 0.54 in toluene/EtOAc, 95/5, v/v; R_f for 164 = 0.24 in toluene/EtOAc, 95/5, v/v). Next, nitro-acetophenone 163 was reacted with benzoyl chloride in the presence of KOH and then treated with acid under reflux to give phenylchromone **165** as the major product,²⁹¹ along with diketone **166** as a minor byproduct. Both compounds were isolated and included in the final library of chromones. The

spectral data obtained for phenylchromone **165** matched those reported in literature,²⁹¹ while evidence for the formation of diketone **166** included the presence of two carbonyl carbon resonances at 194 and 175 ppm in the ¹³C NMR spectra, as well as HRMS data (calcd. for $[C_{22}H_{13}NO_5+H]^+$: 372.0867, obsd.: 372.0865).



Scheme 4.7: The synthesis of phenyl chromone 165.



Figure 4.9: XRD crystal structures of nitro-acetophenones 163 (A) and 164 (B).

Initially, it was speculated that the formation of the diketone by-product **166** occurred due to the presence of excess benzoyl chloride from the previous step. Accordingly, ester **167** (Scheme 4.8) was purified using silica gel flash column chromatography prior to acid treatment. Notwithstanding, the formation of by-product **166** occurred even in the absence of benzoyl chloride, albeit in a lower yield, along with the recovery of acetophenone **163**. Thus, it was postulated that upon the treatment of ester **167** with H₂SO₄ and AcOH, some ester hydrolysis occurred *in situ* and this allowed for the addition of the phenyl carbonyl group at the α -carbon of enolate **XIX** (Scheme 4.8). Next, elimination of water from ketone **XX** leading to the formation of diketone **XXI** and, subsequently, enol **XXII** was proposed, with enol **XXII** undergoing an intramolecular aldol-Claisen to give chalcone **XXIII**. E1 reaction would then

yield by-product **166**. To corroborate this mechanism, the second step of this reaction was undertaken in the absence of H_2O to yield phenyl-chromone **165** selectively in 65% yield.



Scheme 4.8: The mechanism of by-product 166 formation.

Finally, the iron-mediated reduction of nitrochromones **156**, **158**, **165**, and **166** was undertaken²⁹² to give amines **168–171** in good yields (49% - 93%) from their respective nitrosubstituted precursors (Scheme 4.9). Evidence for the successful reduction of the nitro group was obtained by IR spectroscopy, whereby N-H stretching frequencies at approximately 3400 cm⁻¹,¹³⁰ and the loss of NO₂ stretches (asymmetric stretches: 1550-1500 cm⁻¹ and symmetric stretches: 1360-1290 cm⁻¹) were observed.¹³⁰ Moreover, broad singlets at appoximately 4.0 ppm in CDCl₃ that were associated with amine protons were observed by ¹H NMR spectroscopy.



Scheme 4.9: Reduction of nitrochromones 156, 158, 165 and 166 with iron to give amines 168-171.

4.2.4. The synthesis of chromonyl-pyrimidines

Having prepared functionalised chloropyrimidines **150**, **153**, and **154** and aminochromones **168-171**, the assembly of the chromonyl-pyrimidines was undertaken. Accordingly, chloropyrimidines **150**, **153** and **154** were subjected to nucleophilic substitution by aminochromones **168-171** under acidic conditions to give chromonyl-pyrimidines **172-181** in good yields (Scheme 4.10). Here, the substitution reactions were performed in anhydrous conditions under an argon atmosphere to avoid acid-catalysed hydrolysis of chloropyrimidines **150**, **153**, and **154** to their respective pyrimidinols (**149**, **151**, **152**, respectively). Subsequently, ethyl ester **179** was subjected to hydrolysis to afford carboxylic acid **182** in 90% yield (Scheme 4.11).



Scheme 4.10: Synthesis of chromonyl-pyrimidines 172-181



Scheme 4.11: The hydrolysis of 179 to give acid 182.

The successful synthesis of chromonyl-pyrimidines **172-182** was demonstrated by NMR analysis, whereby the ¹H NMR spectra revealed a broad singlet at approximately 10 ppm, corresponding to a secondary amine proton. Moreover, HMBCs between the secondary amine

proton and carbons at the 4"-, 5- and 7-positions were observed, as illustrated in Figure 4.10 with chromonyl-pyrimidine **172**, thereby demonstrating that successful coupling between the chloropyrimidine and the amino-chromone has taken place.



Figure 4.10: HMBC (500 MHz, pyridine-d₅) of chromonyl pyrimidine 172.

In the synthesis of cyclopropyl-substituted chromonyl-pyrimidines **173**, **177**, **180**, HBF₄ was used instead of HCl to avoid nucleophilic cyclopropyl ring-opening by chloride ions. This side reaction was observed during the HCl-mediated synthesis of methyl-substituted chromonyl pyrimidine **173**, which resulted in the isolation of chloropropylchromone **183** (Scheme 4.12) and the observation of the coupled product between chromone **183** and methylpyrimidine **150** by HRMS (m/χ calcd. for [C₁₇H₁₇ClN₄O₂+H]⁺: 345.1113, obsd.: 345.1112). Here, different regioisomers of chloropropyl **183** could be produced by nucleophilic attack at either the 1'- or 2'-positions, however, attack at the 2'-position was more likely to occur as C2' is less sterically hindered compared to C1'. Moreover, conjugate addition of the chloride anion was favoured due to the stabilisation of the resulting negative charge through resonance structures of the

α,β-unsaturated ketone (*i.e.* **XXV**), giving primary chloride **183** as the addition product. Evidence for the formation of primary chloride **183** was observed in the ¹H NMR and COSY spectra, whereby three methylene protons at 3.63 ppm (t, $J_{1',2'} = 6.3$ Hz, H1'), 2.80 ppm (t, $J_{2',3'} = 7.7$ Hz, H3'), and 2.22 ppm (m, H2') were shown to correlate to each other.



Scheme 4.12: The side-reaction of amino-chromone 169 with HCl to give by-product 183 via intermediate XXV.

4.2.5. Anti-tubercular activity of chromonyl-pyrimidines

To investigate the anti-tubercular activity of chromonyl-pyrimidines **172-182**, the compounds were screened for their ability to inhibit *Mtb* by the Cook laboratory at the University of Otago (Table 4.1). Here, all chromonyl-pyrimidines apart from methoxy-methyl-substituted compounds **179** and **182** (Entries 1 and 2) inhibited *Mtb* growth. Notably, chromonyl-pyrimidines bearing a methoxymethyl group at the 6"-position had relatively high MIC values (Entries 1-3), though cyclopropyl **180** exhibited better inhibitory activity (MIC = 95 μ M, Entry 4). The instalment of a chloromethyl group, as in chromonyl-pyrimidines **176** and **178**, generally resulted in greater inhibition of *Mtb* (MIC = 171 μ M and 337 μ M, Entries 5 and 6, respectively) compared to their corresponding methoxymethyl-substituted chromonyl-pyrimidines **179**, **181** (MIC >1382 μ M and 684 μ M, Entries 1 and 3, respectively), though this trend was not observed with the cyclopropyl derivatives (MIC for **177** = 186 μ M, Entry 7, vs. MIC for **180** = 95 μ M, Entry 4). Overall however, the methyl-substituted pyrimidines **172-175** were the most effective inhibitors of mycobacterial growth (Entries 8-11), with
phenylchromones 174 and 175 giving the lowest MIC values of the library (MIC = 46 μ M and 36 μ M, Entries 10 and 11, respectively).

Entry	Compound	MIC (µg/mL)	MIC (µM)
1	$\begin{array}{c} OMe & H & O \\ 6'' & N & V \\ N & N & O \\ NH_2 & 179 & O \end{array} OEt$	>512	>1382
2	$ \begin{array}{c} OMe \\ H \\ N \\ N \\ NH_2 \end{array} \begin{array}{c} O \\ O \\$	>512	>1496
3	$ \begin{array}{c} OMe \\ H \\ N \\ N \\ NH_2 \end{array} $ $ \begin{array}{c} O \\ O $	256	684
4	$ \begin{array}{c} $	32	95
5	$ \begin{array}{c} CI \\ H \\ N \\ N \\ NH_2 \end{array} \begin{array}{c} O \\ OEt \\ OEt \end{array} $	64	171
6	$ \begin{array}{c} CI & H & O \\ N & N \\ N & N \\ NH_2 & 178 \\ \end{array} $	128	337
7	$ \begin{array}{c} CI \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	64	186

Table 4.1: MIC values (μ g/mL and μ M) of chromonylpyrimidines 172-182 against *Mtb*.



Next, the effect of different substituents at the 2-position of chromonyl-pyrimidines on their ability to inhibit *Mtb* growth was analysed. Here, the addition of carbonyl groups, as in esters **179**, **176**, **172** and acid **182** (Entries 1, 5, 8 and 2, respectively), resulted in reduced potency against *Mtb* compared to the corresponding cyclopropyl- and phenyl-substituted compounds across all derivatives. It was postulated that the esters may undergo hydrolysis to form carboxylic acids. Indeed, both ester **179** and its hydrolysed derivative **182**, were inactive against *Mtb* (Entries 1 and 2). Although only speculation, a carboxylic acid group could perhaps participate in acid-base interactions away from the putative Q-site, *i.e.* Q321 in NDH-II.

Compared to the respective ester- and phenyl-substituted derivatives, chromonyl-pyrimidines bearing a cyclopropyl group (**180**, **177**, **173**, Entries 4, 7, and 9, respectively) elicited good inhibitory activity against *Mtb*, with methoxymethyl-pyrimidine **180** leading to a particularly low MIC of 95 μ M. Finally, the instalment of phenyl substituents at the 2-position led to contrasting results, where reduced potency was exhibited by chloromethyl- (**181**) and methoxymethyl-substituted (**178**) analogues (MIC = 684 μ M and 337 μ M, Entries 3 and 7, respectively), while methyl-substituted chromonyl-pyrimidines **174** and **175** were the lead compounds of the library. Taken together, chromonyl-pyrimidines with a methyl substituent at the 6"-position led to the lowest MIC values compared to those bearing a chloromethyl or methoxymethyl group at this position. This anti-tubercular activity could potentially be attributed to the hydrophobic methyl substituent, which, in docking studies of methyl-pyrimidine **148**, could be accommodated in a hydrophobic groove in the NDH-II Q-site. In addition, installing a phenyl group at the 2-position of chromonyl-pyrimidines resulted in high anti-tubercular activity. The presence of an aromatic substituent at this position could lead to favourable π - π interactions with the FAD isoalloxazine ring within NDH-II. These results provided information for the development of a second generation of chromonyl pyrimidines.

4.2.6. The synthesis of a second generation of chromonyl pyrimidines

Having established the SAR of chromonyl-pyrimidines **172-182**, a second library of chromonyl-pyrimidines was prepared to further explore the pharmacophore of this class of compound. In light of the high anti-tubercular activity of methyl-pyrimidinyl phenyl-chromones **174** and **175**, it was proposed that methyl, phenyl and *p*-fluorophenyl groups would be installed at the 6"-position so as to probe potential π - π interactions within the target enzyme active site. Moreover, the electron-withdrawing chloromethyl group in the initial library of chromonyl pyrimidines showed modest anti-tubercular activity and the instalment of a fluorophenyl substituent on the pyrimidine ring could be used to investigate the effect of a less polar electron-withdrawing group on anti-tubercular activity. The effect of a phenyl substituent at the 2-position will be explored by the introduction of strong electron-withdrawing and electron-donating groups at the *para*-position of the phenyl substituent.

To this end, chromonyl pyrimidines bearing a methyl, phenyl, and *p*-fluorophenyl groups at the 6"-position and a nitrophenyl, aminophenyl and phenyl substituents at the 2-position were synthesised. First, guanidine carbonate (**137**) was treated with ethyl benzoylacetate (**183**)²⁹³ and ethyl 4-fluorobenzoylacetate (**184**) to give hydroxypyrimidines **185** and **186**, respectively, which were readily converted to chloropyrimidines **187**²⁹⁴ and **188**, respectively (Scheme 4.13).

Chapter Four



Scheme 4.13: The synthesis of phenyl- (187)²⁹⁴ and fluorophenyl pyrimidines (188).

With chloropyrimidines **187** and **188** in hand, the synthesis of the aryl chromone **192** was undertaken starting with nitro-acetophenone **163** (Scheme 4.14). As target chromone **192** bears a nitrophenyl group, it was envisaged that the amine functionality would be introduced at the beginning of the synthesis. In addition, the electron-donating properties of the amine substituent in acetophenone **189** would increase the nucleophilicity of the phenolic oxygen and expedite subsequent esterification reactions. Accordingly, nitro-acetophenone **163** was reduced under the agency of iron powder to form amino-acetophenone **189**, which was then *N*-protected as Boc-amidoacetophenone **190** in 35% yield over two steps. Next, acetophenone **190** was esterified with 4-nitro benzoic acid in the presence of coupling reagents EDCI and DMAP²⁹⁵ to afford ester **191**, which readily underwent a Baker-Venkataraman rearrangement²⁹⁵⁻²⁹⁷ to give the desired chromone **192**.



Scheme 4.14: The synthesis of nitro-phenyl chromone 192 from acetophenone 163.

Having synthesised the necessary building blocks, the assembly of the second library of chromonyl-pyrimidines was undertaken. As with the first library of chromonyl pyrimidines, the substitution reactions between chloropyrimidines **150**, **188**, and **189** and aminochromones **170** and **192** were performed under acidic conditions to give the final compounds in good yields (43%-73%, Scheme 4.15). Again, evidence for the successful synthesis of chromonyl-pyrimidines was provided by NMR spectroscopy, including an HMBC of the bridging amine proton with protons at the 5"-, 5- and 7-positions. In addition to these chromonyl-pyrimidines, nitro-phenylchromones **193** and **198** were reduced to give aminophenyl-substituted chromonyl-pyrimidines **194** and **199** as yellow solids. Here, the presence of an amine group was confirmed by IR spectroscopy (3349 cm⁻¹ and 3310 cm⁻¹ for chromonyl-pyrimidines **194** and **199**, respectively) and HRMS (calcd. for [C₂₀H₁₇N₅O₂+H]⁺: 360.1455, obsd.: 360.1455, and calcd. for [C₂₅H₁₈FN₅O₂+H]⁺: 440.1517, obsd.: 440.1519).



Scheme 4.15: The synthesis of chromonyl pyrimidines 193-199.

4.2.7. Anti-tubercular activity of a second library of chromonyl-pyrimidines

Having successfully prepared chromonyl-pyrimidines **193-199**, biological screening of the synthesised compounds for inhibitory activity against *Mtb* was undertaken under the supervision of Professor Greg Cook at the University of Otago. The MIC values of each chromonyl-pyrimidine against *Mtb* are reported in Table 4.2.



Table 4.2: MIC values (µM) of chromonyl-pyrimidines 193-199.



In comparison to the first library of chromonyl pyrimidines (172-182, Table 4.1), the second generation of chromonyl pyrimidines (193-199, Table 4.2) generally exhibited higher anti-tubercular activity. While methyl-substituted nitrophenyl 193 (MIC = 100 μ M, Entry 1) was less potent against *Mtb* compared to the previous lead compound 174 (MIC = 46 μ M), the aminophenyl-substituted chromonyl-pyrimidine 194 elicited higher anti-tubercular activity at MIC = 12.5 μ M (Entry 2). Surprisingly, chromonyl-pyrimidines 195-199 with aromatic

substituents at the 6"-position inhibited *Mtb* growth to the same extent (MIC = 12.5 μ M, Entries 3-7) as aminophenyl-substituted chromonyl-pyrimidine **194**, despite the varied electronic properties among the compounds. The lack of SAR among the chromonyl-pyrimidines with different phenyl substituents was unexpected, though a similar observation was noted with phenyl-substituted quinolinyl pyrimidines, as discussed in Section 4.1.⁷⁹ In light of these results, diphenyl-substituted chromonyl-pyrimidine **196** and the corresponding diphenyl quinolinyl-pyrimidine were docked into the NDH-II Q-site, which showed distant edge-to-face π - π interactions with the FAD isoalloxazine ring (Appendix 4, Figure A.4.1). In both cases, no hydrogen bonds were observed between the residues in the Q-site and the aryl-substituted scaffolds, which provides a possibility that these class of compounds could bind NDH-II at a different site or the two scaffolds have different target proteins. Notwithstanding, the incorporation of aromatic substituents to the chromonyl-pyrimidine scaffold improved their anti-tubercular activity compared to the first generation of chromonyl-pyrimidines.

4.3. Conclusion

In summary, this chapter describes the investigation of chromonyl-pyrimidines as potential anti-tubercular agents. Here, a convergent synthesis was utilised, whereby functionalised amino-chromones and chloro-pyrimidines were first prepared prior to the chromonyl-pyrimidine assembly. Screening of the first library of chromonyl-pyrimidines resulted in the identification of two lead chromonyl pyrimidines, **174** and **175**, with MIC values of 46 μ M and 36 μ M, respectively. The SAR from this set of compounds facilitated the design and synthesis of a second generation of chromonyl pyrimidines. Specifically, nitro-phenyl, phenyl, and aminophenyl groups were installed at the 2-position of the chromonyl scaffold while methyl, phenyl, and fluoro-phenyl substituents were incorporated at the 6"-position. Gratifyingly, the second library of chromonyl-pyrimidines **194-199** all exhibiting the same MIC of 12.5 μ M, despite the wide range of electronic properties among the compounds. From these studies, it is postulated that chromonyl pyrimidines bind NDH-II at a site that tolerates minor structural variations to the aromatic substituents of the compounds.

Key pharmacophores were obtained from the two libraries of chromonyl-pyrimidines, whereby chromonyl-pyrimidines with aromatic substituents at both 6"- and 2-positions were the most potent anti-tubercular agents (Figure 4.11). At the 6"-position, electrophilic carbons

gave good anti-tubercular activity, while aliphatic groups on the 2-position elicited higher antimycobacterial activity than electron-withdrawing groups.



Figure 4.11: Overall SAR of chromonyl-pyrimidines from this study.

4.4. Experimental

4.4.1. Docking

Chromonyl-pyrimidine **148** was prepared for docking using the *DockPrep* tool in USCF Chimera (version 13.1).²⁸² The quinone binding site of chain B of the *C. thermarum* NDH-II crystal structure (PDB: 6BDO)⁶² was used for docking. The NDH-II crystal structure was prepared by removing the co-crystallised ligand HQNO (**19**) and applying the *DockPrep* tool in USCF Chimera (version 13.1). A 5Å grid was generated whereby the centre was defined as residues 46, 47, 316, 317, 318, 347, 348, 349, 376, 379, 380, and 383. Chromonyl-pyrimidine **148** was then modelled into the NDH-II quinone binding site using the *anchor and grow* algorithm in DOCK 6 (version 6.9).²⁹⁸ The conformers with the top 50 binding scores were analysed.

4.4.2. Chemistry

General procedure. Unless otherwise stated, all reactions were performed under atmospheric air. Prior to use, DMF (Acros) was distilled from BaO, THF (Pancreac) was distilled over sodium wire and benzophenone, toluene (Roth) was dried with sodium wire, pyridine (BDH) was distilled over CaH₂, CH₂Cl₂ (Fisher) was distilled from P₂O₅, and EtOAc (drum), petroleum ether (drum), acetone (drum), MeOH (Pure Science) and H₂O was distilled. AcOH (Panreac), diethyl oxalate (BDH), 1,4-dioxane (Aldrich), EtOH (absolute, Pure Science), 2-ethoxyethanol (Unilab), ethyl cyclopropane carboxylate (Alfa Aesar), guanidine carbonate (Sigma Aldrich), guanidine hydrochloride (Sigma Aldrich), 37% HCl (Merck), HNO₃ (Labserv), H₂SO₄ (Panreac), 2'-hydroxyacetophenone (Merck), iron (Scientific Supplies), KOH (Pure Science), MgSO₄ (Pure Science), 60% NaH in oil (Sigma Aldrich), NaHCO₃ (Pure Science), 28% NH₃ (aq) (UNIVAR), phosphoryl chloride (PS), silver triflate (Sigma Aldrich), sodium (Aldrich) were used as received.

All solvents were removed by evaporation under reduced pressure. Reactions were monitored by TLC-analysis on Macherey-Nagel silica gel coated plastic sheets (0.20 mm, with fluorescent indicator UV_{254}) with detection by UV-absorption (short wave UV - 254 nm; long wave UV - 366 nm) and by dipping in KMnO₄ in H₂O. Column chromatography was performed on Pure Science silica gel (40 – 63 micron). Infrared spectra were recorded as thin films using a Bruker Alpha II FTIR spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling accessory and are reported in wavenumbers (cm⁻¹). Melting points (m.p.) were obtained on a DigiMelt MPA160 melting point apparatus. UV data were obtained on an Agilent 8453

Chapter Four

spectrometer. Nuclear magnetic resonance spectra were recorded at 20 °C in D₂O, CDCl₃, pyridine-d₅, or DMSO-d₆ using either a Varian INOVA operating at 500 MHz or Varian VNMRS operating at 600 MHz. Chemical shifts are given in ppm (δ) relative to solvent residues. NMR peak assignments were made using COSY, HSQC, and HMBC 2D experiments. High-resolution (ESI) mass spectrometric data were obtained with an Agilent 6530 Accurate-Mass Q-TOF LC-MS equipped with a 1260 Infinity binary pump.

2-Amino-6-methyl-pyrimidin-4-ol (149). In a two-necked roundbottomed flask was added 4Å mol sieves, followed by dry DMF (50 mL) and NaH (60% in oil, 4.0 g, 0.1 mol, 2 equiv.). The solution was stirred under argon at room temperature for 30 min before a solution of guanidine hydrochloride (5 g, 52.3 mmol) in dry DMF (50 mL) was added dropwise

into the solution over 30 min. The white suspension was then stirred at room temperature for a further 30 min before a solution of ethylacetoacetate (6.6 mL, 52.3 mmol, 1 equiv.) in dry DMF (50 mL) was added dropwise into the reaction flask, after which time the orange solution was heated to reflux. After 15 h, TLC analysis showed the disappearance of starting materials and the reaction was filtered, washed with hot dioxane and concentrated *in vacuo*. The resulting brown solid was then purified by silica gel flash column chromatography [CH₂Cl₂/MeOH/EtOH/NH₃ (25%), 35/2/2/1 \rightarrow 10/2/2/1, v/v/v/v] to yield the title compound as a white solid (4.1 g, 63% yield). R_f = 0.24 (EtOAc); IR (u_{max}): 3145, 1660, 1454, 846, 557 cm⁻¹; ¹H NMR (500 MHz, D₂O): δ ppm 5.73 (s, 1H, H5), 2.17 (s, 3H, CH₃); ¹³C NMR (125 MHz, D₂O): δ ppm 155.7 (C6), 101.3 (C5), 19.9 (CH₃); HRMS-ESI (*m/x*) calcd. for [C₅H₇N₃O+H]⁺: 126.0662, obsd.: 126.0664. The data obtained for this compound were consistent with those reported in literature.²⁹⁹



NH₂

149

2-Amino-6-hydroxymethylpyrimidin-4-ol (151)²⁸⁵ and **2-amino-6-methoxymethylpyrimidin-4-ol** (152). Guanidine hydrochloride (5 g, 52.3 mmol, 1.2 equiv.) and KO'Bu (26.3 g, 0.23 mol, 5.4 equiv.) were dissolved in MeOH (78 mL) and the solution was stirred at room

temperature before ethyl 4-chloroacetoacetate (6 mL, 43.4 mmol) was added dropwise over 1 h. The reaction was warmed to 60 °C and stirred for 2 h before it was cooled to room temperature. After 12 h of stirring, TLC analysis showed the disappearance of starting materials and the reaction was quenched by the addition of HCl until pH 5 was reached. The resulting brown precipitate was filtered and separated by silica gel flash column chromatography [CH₂Cl₂/MeOH/EtOH/NH₃ (25%), 95/2/2/1 \rightarrow 5/2/2/1, v/v/v/v] to give hydroxymethylpyrimidine **151** (4.2 g, 57%) and methoxymethylpyrimidine **152** (2 g, 24%) both as white solids. Data for **151**: R_f = 0.37 [CH₂Cl₂/MeOH/EtOH/NH₃ (25%), 5/2/2/1, v/v/v/v]; IR (ν_{max}): 3097, 3010, 2924, 2806, 2272, 1645. 1613, 1389, 1337, 1243, 1193, 1135, 959, 697, 597 cm⁻¹; ¹H NMR (500 MHz, D₂O): δ ppm 5.91 (s, 1H, H-5), 4.37 (s, 2H, CH₂); ¹³C NMR (150 MHz, D₂O): δ ppm 97.92 (C5), 61.7 (CH₂); HRMS-ESI (*m/x*) calcd. for [C₃H₇N₃O₂+H]⁺: 142.0611, obsd.: 142.0618. Data for **152**: R_f = 0.53 (CH₂Cl₂/MeOH/EtOH/NH₃ (25%), 5/2/2/1, v/v/v/v); IR (ν_{max}): 3325, 3118, 2995, 2878, 2826, 2753, 1601, 1380, 1349, 1120, 958, 902, 589 cm⁻¹; ¹H NMR (500 MHz, D₂O): δ ppm 5.84 (s, 1H, H5), 4.22 (s, 2H, CH₂), 3.40 (s, 3H, CH₃); ¹³C NMR (150 MHz, D₂O): δ ppm 157.0 (C4), 100.5 (C5), 73.3 (CH₂), 59.4 (CH₃); HRMS-ESI (*m/x*) calcd. for [C₆H₉N₃O₂+H]⁺: 156.0768, obsd.: 156.0768.



2-Amino-6-phenyl-pyrimidin-4-ol (185). Ethyl benzoylacetate (1 mL, 5.8 mmol) and guanidine carbonate (1.05 g, 5.8 mmol, 1 equiv.) were dissolved in EtOH (10 mL) and warmed to 100 °C. After 24 h of stirring, the precipitate was collected by filtration to give the title compound as a white solid (912 mg, 84%). $R_f = 0.3$ (EtOAc); IR (ν_{max}): 3165, 1561, 1517,

1396, 1232, 979, 888, 773, 669 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.89 (br. s, 1H, OH), 8.45 (d, $J_{2',3'} = 7.1$ Hz, 2H, H2'), 7.55 (t, $J_{2',3'} = J_{3',4'} = 7.3$ Hz, 2H, H3'), 7.49 (t, $J_{3',4'} = 7.2$ Hz, 1H, H4'), 6.94 (s, 1H, H5); HRMS-ESI (m/2) calcd. for $[C_{10}H_9N_3O+H]^+$: 188.0818, obsd.: 188.0819. The data obtained for this compound were consistent with those reported in literature.³⁰⁰



2-Amino-6-(4'-fluorophenyl)-pyrimidin-4-ol (186). Ethyl 3-(4-fluorophenyl)-3-oxopropanoate (0.5 mL, 2.78 mmol) and guanidine carbonate (500 mg, 2.78 mmol, 1 equiv.) were dissolved in EtOH (5 mL) and warmed to 100 °C. After 24 h of stirring, the precipitate was collected by filtration to give the title compound as a white solid (427

mg, 75%). $R_f = 0.36$ (EtOAc); IR (v_{max}): 3070, 1654, 1600, 1566, 1506, 1465, 1406, 1388, 1225, 1155, 826 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 8.26 – 8.23 (m, 2H, H2'), 7.73 (br. s,

2H, NH₂), 7.19 (m, 2H, H3'), 6.74 (s, 1H, H5); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 165.4 (d, $J_{4',F}$ = 280 Hz, C4'), 163.9 (C6), 161.4 (C4), 130.7 (C2'), 116.8 (d, $J_{3',F}$ = 22 Hz, C3'), 100.2 (C5); HRMS-ESI (*m*/*z*) calcd. for [C₁₀H₈FN₃O+H]⁺: 206.0724, obsd.: 206.0725. The data obtained for this compound were consistent with those reported in literature.⁷⁹

General procedure for the synthesis of chloropyrimidines. 4-Hydroxypyrimidine (1 equiv.) was evaporated three times in dry toluene (0.5 mL/mmol) under argon before it was dissolved in POCl₃ (0.5 mL/mmol). The reaction was heated to reflux for 2 h, after which time the POCl₃ was removed *in vacuo*. The solid was dissolved in a mixture of aqueous NH₃ (28%) and ice, and the crude product extracted with CH₂Cl₂ three times. The organic layers were then dried using anhydrous MgSO₄, filtered and the filtrate concentrated to give the crude product, which could then be recrystallised from hot ethanol.

6 N N NH₂ 150

2-Amino-4-chloro-6-methyl-pyrimidine (150). By subjecting pyrimidinol **149** (3 g, 26.3 mmol) and POCl₃ (15 mL) to the general procedure for the synthesis of chloropyrimidines, the title compound was isolated as white crystals (2.0 g, 53%); $R_f = 0.6$ (EtOAc); m.p.: 182 °C (lit.²⁷⁹ 182-183 °C); IR (ν_{max}): 3309, 3192, 2925, 1637, 1548, 1476, 1288, 872, 782, 490 cm⁻¹; ¹H NMR

(500 MHz, CDCl₃): δ ppm 6.55 (s, 1H, H-5), 5.15 (br. s, 2H, NH₂), 2.32 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 170.2 (C6), 162.7 (C2), 161.5 (C4), 110.6 (C5), 23.9 (CH₃); HRMS-ESI (*m*/*z*) calcd. for [C₅H₆³⁵ClN₃+H]⁺: 144.0323, obsd.: 144.0324.



2-Amino-4-chloro-6-chloromethyl-pyrimidine (153).²⁸⁵ By subjecting pyrimidinol 151 (235.6 mg, 1.67 mmol) and POCl₃ (2 mL) to the general procedure for the synthesis of chloropyrimidines, the title compound was isolated as a white amorphous solid (184.3 mg, 62%); R_f = 0.48 (EtOAc); IR (ν_{max}): 2948, 2855, 1625, 1550, 1466, 1413, 1377,

1313, 1292, 1222, 1164, 1010, 925, 887, 805, 779, 769, 629, 505 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 6.83 (C5), 5.60 (br. s, 2H, NH₂), 4.37 (s, 2H, CH₂); ¹³C NMR (125 MHz, CDCl₃) δ ppm 167.7 (C6), 162.8 (C4), 162.7 (C2), 109.2 (C5), 44.8 (CH₂); HRMS-ESI (*m*/ \approx) calcd. for [C₅H₅³⁵Cl₂N₃+H]⁺: 177.9933, obsd.: 177.9933.



2-Amino-4-chloro-6-methoxymethyl-pyrimidine (154). By subjecting pyrimidinol 152 (48 mg, 0.3 mmol) and POCl₃ (0.18 mL) to the general procedure for the synthesis of chloropyrimidines, the title compound was isolated as a white amorphous solid (25 mg, 48%); R_f = 0.35 (EtOAc); IR (ν_{max}): 3398, 3316, 1637, 1553, 1475, 1421, 1291,

1125, 889, 781, 524 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 6.76 (s, 1H, H5), 5.57 (br. s., 2H, NH₂), 4.32 (s, 2H, CH₂), 3.45 (s, 1H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ ppm 170.5 (C6), 162.7 (C4), 162.3 (C3), 107.8 (C5), 73.9 (CH₂), 59.2 (CH₃); HRMS-ESI (*m*/ \Re) calcd. for [C₆H₈ClN₃O+H]⁺: 174.0429, obsd.: 174.0429.

2-Amino-4-chloro-6-phenyl-pyrimidine (187). By subjecting pyrimidinol 185 (238.5 mg, 1.31 mmol) and POCl₃ (4.89 mL) to the general procedure for the synthesis of chloropyrimidines, the title compound was isolated as a white amorphous solid (148.2 mg, 55%); R_f 187 = 0.32 (CH₂Cl₂/EtOAc, 1/1, v/v); IR (v_{max}): 3173, 1651, 1625, 1589, 1557, 1538, 1496, 1480, 1462, 1447, 1418, 1319, 1295, 1228, 1193, 1171, 995, 947, 818, 813, 761, 687, 651, 562 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 7.92 – 7.90 (m, 2H, H2'), 7.44 – 7.40 (m, 3H, H3', H4'), 7.00 (s, 1H, H5); HRMS-ESI (*m/x*) calcd. for [C₁₀H₈³⁵ClN₃+H]⁺: 246.0480, obsd.: 246.0481. The data obtained for this compound were consistent with those reported in

literature.²⁹⁴



2-Amino-4-chloro-6-(4-fluorophenyl)-pyrimidine (188). By subjecting pyrimidinol 186 (183.5 mg, 0.90 mmol) and POCl₃ (3.34 mL) to the general procedure for the synthesis of chloropyrimidines, the title compound was isolated as a white amorphous solid (124.8 mg, 62%); $R_f = 0.29$ (CH₂Cl₂/EtOAc, 1/1,

v/v); IR (ν_{max}): 2747, 1664, 1606, 1570, 1541, 1510, 1468, 1234, 1161, 995, 942, 827, 550, 482 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.00 – 7.97 (m, 2H, H2'), 7.18 – 7.14 (m, 2H, H3'), 7.03 (s, 1H, H5); ¹³C NMR (500 MHz, CDCl₃): δ ppm 166.6 (C6), 162.1 (C4), 164.8 (d, $_{J^4,F}$ = 266.9 Hz, C4'), 129.3 (d, $J_{2,F}$ = 9.0 Hz, C2'), 115.9 (d, $J_{3',F}$ = 21.6 Hz, C3'), 106.8 (C5); HRMS-ESI (m/z) calcd. for [C₁₀H₇³⁵ClFN₃+H]⁺: 224.0385, obsd.: 224.0386.



Ethyl 4-oxo-4H-chromene-2-carboxylate (155). To a solution of sodium (2 g, 87 mmol, 5 equiv.) in EtOH (120 mL), was added dropwise a solution of 2'-hydroxyacetophenone (2.1 mL, 17.4 mmol) and diethyl oxalate (6 mL, 43.5 mmol, 2.5 equiv.) in EtOH (10 mL).

The solution turned cloudy yellow and was stirred at room temperature for 12 h, followed by 1 h at reflux, at which time TLC analysis showed the disappearance of starting materials. The reaction was quenched by the addition of 2 M HCl until pH 1 was reached. The resulting precipitate was filtered and the filtrate concentrated to get the crude product, which was purified by silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 3/1$, v/v) to give the title compound as a white solid (3.4 g, 91% yield). R_f = 0.41 (EtOAc/petroleum ether, 1/1, v/v); IR (υ_{max}): 1638, 1609, 1564, 1362, 1249, 1073, 1023, 999, 829, 768, 653, 550, 481, 464 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.06 (d, $J_{5.6} = 8.1$ Hz, 1H, H5), 7.63 (t, $J_{6.7} = J_{7.8} = 7.8$ Hz, 1H, H7), 7.48 (d, $J_{7.8} = 8.4$ Hz, 1H, H8), 7.33 (t, $J_{5.6} = J_{6.7} = 7.5$ Hz, 1H, H6), 6.99 (s, 1H, H3), 4.64 (q, $J_{CH2-CH3} = 7.1$ Hz, 2H, CH₂), 1.62 (t, $J_{CH2-CH3} = 7.1$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 178.2 (C4), 160.4 (C1¹), 155.8 (8a), 152.1 (C2), 134.6 (C7), 125.8 (C6), 125.6 (C5), 124.3 (C4a), 118.7 (C8), 114.6 (C3), 62.9 (CH₂), 14.0 (CH₃); HRMS-ESI (m/x) calcd. for [C₁₂H₁₀O₄+H]⁺: 219.0652, obsd.: 219.0656. The data obtained for this compound were consistent with those reported in literature.²⁸⁰</sup>



Ethyl 6-nitro-4-oxo-4*H*-chromene-2-carboxylate (156). Concentrated HNO₃ (70%, 0.1 mL) was added to chromone 155 (200 mg, 0.92 mmol) and cooled to 0 °C before concentrated H₂SO₄ (1.5 mL) was added to the reaction flask.

The solution was stirred at room temperature for 8 h, after which time the reaction was poured into an ice-water mixture. The resulting white precipitate was filtered and dried to obtain the crude compound, which was recrystallised in MeOH/CH₂Cl₂ (3/1, v/v) to yield white crystals (240 mg, 99% yield). $R_f = 0.54$ (petroleum ether/EtOAc, 1/1, v/v); IR (υ_{max}): 2954, 2925, 2853, 1737, 1667, 1530, 1494, 1363, 1346, 1271, 1081, 967 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 9.07 (d, $J_{5,7} = 2.6$ Hz, 1H, H5), 8.58 (dd, $J_{5,7} = 9.2$, $J_{6,7} = 2.8$ Hz, 1H, H7), 7.78 (d, $J_{7,8} = 9.2$ Hz, 1H, H8), 7.19 (s, 1H, H3), 4.50 (q, $J_{CH2-CH3} = 7.1$ Hz, 2H, CH₂), 1.46 (t, $J_{CH2-CH3} = 7.1$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 176.97 (C4), 159.90 (C1'), 158.8 (C8a), 152.9 (C2), 145.0 (C6), 129.1 (C7), 124.6 (C4a), 122.7 (C5), 120.78

(C8), 115.2 (C3), 63.6 (CH₂), 14.3 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₂H₉NO₆+H]⁺: 264.0503, obsd.: 264.0502. The data obtained for this compound matched those reported in literature.²⁸⁶

5 4 0 1' 157 **2-Cyclopropyl-***4H***-chromen-4-one (157).** NaH (1.2 g, 30 mmol, 4 equiv.) was washed in hexanes before it was suspended in freshly distilled THF (3 mL). A solution of 2'-hydroxyacetophenone (0.9 mL, 7.5 mmol) and ethyl cyclopropane carboxylate (2.2 mL, 18.7 mmol, 2

equiv.) in THF (1 mL) was then added into the NaH suspension dropwise. The reaction was stirred under reflux for 15 min before it was poured into an ice-water mixture and acidified to pH 6 with 2 M HCl. The product was then extracted using EtOAc, washed with brine, and dried with anhydrous MgSO4. After filtration, the filtrate was then concentrated in vacuo into a yellow-orange oil, to which MeOH (20 mL) and conc. HCl (37%, 1 mL) were added. The resulting orange solution was stirred at room temperature for 5 h, after which time TLC analysis showed the appearance of the product and the disappearance of starting materials. The reaction was concentrated in vacuo and the product extracted with EtOAc. After washing with NaHCO3 and brine, the organic solution was dried with anhydrous MgSO₄, filtered, and the resulting filtrate concentrated. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $10/1 \rightarrow 3/1$, v/v) gave the title compound as a white solid (1.03 g, 74% yield). $R_f = 0.29$ (petroleum ether/EtOAc, 3/1, v/v); IR (v_{max}): 1640, 1570, 1461, 1384, 1124, 1035, 956, 842, 775 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.17 (d, $J_{5,6}$ =8.2 Hz, 1H, H5), 7.61 (t, $J_{6,7}$ = $J_{7,8}$ = 7.8 Hz, 1H, H7), 7.37-7.34 (m, 2H, H8, H6), 6.21 (s, 1H, H3), 1.90 (m, 1H, C1'), 1.19-1.14 (m, 2H, C2'a), 1.13-1.08 (m, 2H, C2'b); ¹³C NMR (125 MHz, CDCl₃): δ ppm 177.9 (C4), 170.4 (C2), 156.2 (C8a), 133.3 (C7), 125.8 (C5), 125.0 (C8), 124.1 (C4a), 117.7 (C6), 108.0 (C3), 14.7 (C1'), 8.70 (C2'); HRMS-ESI (m/z) calcd. for $[C_{12}H_{10}O_2+H]^+$: 187.0754, obsd.: 187.0755. The data obtained for this compound were consistent with those reported in literature.³⁰¹



2-Cyclopropyl-6-nitro-4H-chromen-4-one (158). HNO_3 (70%, 0.16 mL) was added to cyclopropyl chromene 157 (294 mg, 1.58 mmol) and the mixture was cooled to 0 °C before conc. H_2SO_4 (2.4 mL) was added. The reaction was allowed to warm to

room temperature over 30 min before it was poured into an ice-water mixture and extracted

using EtOAc. The organic solution was collected, dried with anhydrous MgSO₄ and filtered. The filtrate was concentrated *in vacuo* to give the crude product as a yellow oil. Purification via silica gel flash column chromatography (petroleum ether/EtOAc, $20/1 \rightarrow 10/1$, v/v) gave the title compound as a white solid (322 mg, 88% yield). $R_f = 0.40$ (CH₂Cl₂/EtOAc, 9/1, v/v); IR (v_{max}): 2921, 2851, 1649, 1641, 1606, 1528, 1465, 1443, 1368, 1340, 1275, 1206, 1056, 1026, 953, 838, 743, 677 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.98 (d, $J_{5,7}$ =2.4 Hz, 1H, H5), 8.42 (dd, $J_{7,8}$ =9.1 Hz, $J_{5,7}$ =2.6 Hz, 1H, H7), 7.50 (d, $J_{7,8}$ =9.1 Hz, 1H, H8), 6.25 (s, 1H, H3), 1.96-1.91 (m, 1H, C1'), 1.23-1.15 (m, 4H, C2'); ¹³C NMR (125 MHz, CDCl₃): δ 175.7 (C4), 171.3 (C2), 158.9 (C8a), 144.5 (C6), 127.6 (C7), 124.0 (C4a), 122.2 (C5), 119.4 (C8), 108.1 (C3), 9.49 (C1'), 9.19 (C2'); HRMS-ESI (m/z) calcd. for [C₁₂H₉NO₄+H]⁺: 232.0604, obsd.: 232.0603.



h, the reaction was poured into an ice-H₂O mixture, and was stirred for a further 30 min at room temperature. The resulting white precipitate was collected and recrystallised in hot MeOH to give the title compound as white crystals (4.5 g, 30%). R_f = 0.54 (toluene/EtOAc, 95/5, v/v); m.p: 105.5 °C (lit.³⁰² 102 °C); IR (ν_{max}): 3089, 1644, 1519, 1337, 1295, 1248, 1212, 1116, 964, 903, 807, 746, 729, 644 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 12.87 (s, 1H, OH), 8.71 (d, $J_{4',6'}$ = 2.6 Hz, 1H, H6'), 8.35 (dd, $J_{3',4'}$ = 9.2 Hz $J_{4',6'}$ = 2.7 Hz, H4'), 7.09 (d, $J_{3',4'}$ = 9.2 Hz, 1H, H3'), 2.75 (s, 3H, H2); ¹³C NMR (125 MHz, CDCl₃): δ ppm 204.1 (C1), 167.2 (C2'), 139.6 (C5'), 131.2 (C4'), 127.3 (C6'), 119.6 (C3'), 118.6 (C1'), 26.8 (C2); HRMS-ESI (*m/z*) calcd. for [C₈H₇NO₄-H]⁻: 180.0302, obsd.: 180.0306. The data obtained for this compound matched those reported in literature.³⁰²



solution of benzoyl chloride (0.4 mL, 3.36 mmol, 12 equiv.) in freshly distilled pyridine (6 mL) was cooled to 0 °C before acetophenone **163** (50 mg, 0.28 mmol) was added. The ice

bath was then removed and the solution was allowed to warm to room temperature and stirred for 12 h, after which time TLC analysis showed the disappearance of starting materials and the appearance of new products. The reaction was then poured into an ice-HCl (2 M) mixture and extracted with EtOAc. The organic layers were collected, washed with brine, dried with anhydrous MgSO4 and filtered. The filtrate was then concentrated in vacuo before it was re-dissolved in pyridine (4.5 mL). KOH (424 mg, 7.5 mmol, 2.25 equiv.) was added to the solution before it was warmed to reflux. After 2 h, the reaction was diluted with H₂O and extracted with EtOAc (3 x 5 mL). The organic layers were then collected, washed with 0.1 M HCl and brine before it was dried with anhydrous MgSO₄ and filtered. After concentration in vacuo, the resulting solid was re-dissolved in AcOH (4 mL) and conc. H₂SO₄ (0.2 mL) and the solution warmed to reflux for 2 h. The reaction was then quenched by the addition of 0.1 M HCl, extracted with EtOAc, and washed with aqueous NaHCO₃ and brine. The organic layer was then dried with anhydrous MgSO4, filtered, and the filtrate concentrated in vacuo to give the crude product as a brown solid. Purification by silica gel column chromatography (petroleum ether/toluene, $1/0 \rightarrow 1/1$, v/v) gave the title compound 165 as a white solid (52 mg, 70%) with diketone 166 as a minor by-product (5 mg, 5%). Data for **165**: $R_f = 0.40$ (toluene/EtOAc, 95/5, v/v); IR (ν_{max}): 3329, 3067, 1656, 1493, 1387, 1176, 768, 663, 560 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 9.08-9.07 (m, 1H, H5), 8.53 (dd, $J_{5,7} = 2.8$ Hz, $J_{7,8} = 9.0$ Hz, 1H, H7), 7.93-7.91 (m, 2H, H2'), 7.73 (d, $J_{7,8} = 1.0$ Hz, 1H, H7), 7.93-7.91 (m, 2H, H2'), 7.73 (d, J_{7,8} = 1.0 Hz, 1H, H7), 7.93-7.91 (m, 2H, H2'), 7.73 (d, J_{7,8} = 1.0 Hz, 1H, H7), 7.93-7.91 (m, 2H, H2'), 7.93 (m, 2H, H2' = 9.3 Hz, 1H, H8), 7.61-7.53 (m, 3H, H3', H4'), 6.87 (s, 1H, H3); ¹³C NMR (125 MHz, CDCl₃): δ ppm 176.8 (C4), 164.2 (C2), 159.1 (C6), 144.9 (C8a), 132.5 (C4'), 130.8 (C1'), 129.4 (C2'), 128.2 (C7), 126.5 (C3'), 124.1 (C4a), 122.6 (C5), 120.0 (C8), 107.9 (C3); HRMS-ESI (m/z) calcd. for $[C_{15}H_9NO_4+H]^+$: 268.0604, obsd.: 268.0606: The data obtained for this compound were consistent with that reported in literature.³⁰³ Data for 166: $R_f = 0.46$ (toluene/EtOAc, 95/5, v/v); IR (vmax): 3068, 1658, 1645, 1493, 1387, 1177, 769, 561, 458, 442 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 9.11 (d, $J_{5,7}$ = 2.7 Hz, 1H, H7), 8.60 (dd, $J_{7,8}$ = 9.2 Hz, $J_{5,7}$ = 2.7 Hz, 1H, H7), 7.91 (d, $J_{3',4'}$ = 8.0 Hz, 2H, H3'), 7.76 (d, $J_{7,8}$ = 9.2 Hz, 1H, H8), 7.66 (d, $J_{2",3"} = 8.4$ Hz, 2H, H2"), 7.57 (t, $J_{4',5'} = 7.4$ Hz, 1H, H5'), 7.50 – 7.36 (m, 5H, H4', H3", H4"); ¹³C NMR (125 MHz, CDCl₃): δ ppm 192.4 (C1'), 175.2 (C4), 163.2 (C2), 160.0 (C6), 145.2 (C8a), 136.6 (C2'), 134.3 (C5'), 132.3 (C4"), 130.9 (C1"), 129.5 (C3'), 129.13 (C3"), 129.05 (C4'), 128.7 (C7), 126.6 (C2'), 123.6 (C4a), 123.0 (C5), 120.1 (C8); HRMS-ESI (m/z) calcd. for $[C_{22}H_{13}NO_5+H]^+$: 372.0867, obsd.: 372.0865.

General procedure for the reduction of nitroaryl groups. Nitro-chromone or nitrophenyl chromone (1 equiv.) was dissolved in AcOH (10% in H₂O, 5 mL/mmol) and stirred under argon. Fe (1/1, wt/wt) was then added into the reaction flask before the reaction was heated to reflux for 12 h, after which TLC analysis showed the disappearance of starting materials. The reaction was filtered and rinsed with hot EtOH, and the filtrate was concentrated *in vacuo* to give a brown solid, which was purified using silica gel column chromatography (petroleum ether/EtOAc, $9/1 \rightarrow 1/1$, v/v) to yield the desired aminochromones.



Ethyl-6-amino-4-oxo-4H-chromene-2-carboxylate (168). By subjecting nitrochromone 156 (962 mg, 3.65 mmol), iron powder (962 mg) and AcOH (10% in H₂O, 15 mL) to the general procedure for the reduction of nitroaryl groups, the title

compound was isolated as a white amorphous solid (621 mg, 73%); $R_f = 0.23$ (CH₂Cl₂/EtOAc, 2/1, v/v); IR (v_{max}): 3453, 3367, 3248, 1728, 1633, 1605, 1489, 1473, 1276, 1252, 1208 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 7.44 (d, $J_{7,8} = 8.8$ Hz, 1H, H8),7.34 (d, $J_{5,7} = 1.3$ Hz, 1H, H5), 7.08 (d, $J_{7,8} = 8.9$ Hz, 1H, H7), 7.04 (s, 1H, H3), 4.44 (q, $J_{CH2,CH3} = 7.1$ Hz, 2H, CH₂), 3.98 (br. s, 2H, NH₂), 1.42 (t, $J_{CH2,CH3} = 7.2$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 178.6 (C4), 160.9 (C1'), 151.9 (C2), 149.7 (C8a), 144.8 (C6), 125.5 (C4a), 123.3 (C7), 120.0 (C8), 113.7 (C3), 107.4 (C5), 63.0 (CH₂), 14.2 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₂H₁₁NO₄+H]⁺: 234.0761, obsd.: 234.0762. The data obtained for this compound matched those reported literature.²⁸⁶



2-Cyclopropyl-6-amino-*4H***-chromen-4-one** (169). By subjecting nitrochromone 158 (83.5 mg, 0.361 mmol), iron powder (83.5 mg) and AcOH (10%, 2 mL) to the general procedure for the reduction of nitroaryl groups, the title

compound was isolated as a white amorphous solid (37.0 mg, 51%); $R_f = 0.3$ (CH₂Cl₂/EtOAc, 4/1, v/v); IR (ν_{max}): 3333, 3221, 1622, 1574, 1488, 1459, 1422, 1395, 1305, 1201, 1148, 1072, 1053, 1023, 998, 927, 838, 797, 748, 731, 711, 635, 586, 533, 441 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 7.35 (d, $J_{5,7} = 2.8$ Hz, 1H, H5), 7.18 (d, $J_{7,8} = 8.9$ Hz, 1H, H8), 6.96 (dd, $J_{7,8} = 8.9$ Hz, $J_{5,7} = 2.8$ Hz, 1H, H7), 6.14 (s, 1H, H3), 1.88-1.83 (m, 1H, C1'), 1.14-1.11 (m, 2H, C2'a), 1.07-1.04 (m, 2H, C2'b); ¹³C NMR (125 MHz, CDCl₃): δ ppm 177.9 (C4), 170.0 (C2), 149.9 (C8a), 143.8 (C6), 124.7 (C4a), 121.7 (C7), 118.6 (C8), 108.3 (C5),

107.1 (C3), 14.7 (C1'), 8.6 (C2'); HRMS-ESI (m/z) calcd. for $[C_{12}H_{11}NO_2+H]^+$: 202.0863, obsd.: 202.0864.



6-Amino-3-benzoyl-2-phenyl-*4H***-chromen-4-one (171).** By subjecting nitrochromone **166** (20 mg, 0.05 mmol), iron powder (20 mg) and AcOH (10%, 0.26 mL) to the general procedure for the reduction of nitroaryl groups, the title compound was

isolated as a white amorphous solid (15.9 mg, 93%); $R_f = 0.21$ (CH₂Cl₂/EtOAc, 4/1, v/v); ¹H NMR (500 MHz, CDCl₃): δ ppm 7.93 (d, $J_{3',4'} = 7.1$ Hz, 2H, H3'), 7.63 (d, $J_{2'',3''} = 7.0$ Hz, 2H, H2"), 7.53 (t, $J_{4',5'} = 7.4$ Hz, 1H, H5'), 7.46 – 7.38 (m, 5H, H8, H4", H4', H5), 7.35 (t, $J_{2'',3''} = J_{3'',4''} = 7.5$ Hz, 2H, H3"), 7.11 (dd, J = 8.9 Hz, 2.9 Hz, 1H, H7); ¹³C NMR (125 MHz, CDCl₃): δ ppm 194.1 (C1'), 176.4 (C4), 149.8 (C6), 137.19 (C8a), 137.16 (C2') 133.6 (C5'), 132.1 (C1"), 131.2 (C4"), 129.5 (C3'), 128.7 (C4'), 128.5 (C2", C3"), 124.14 (C4a), 122.7 (C7), 119.1 (C8), 108.1 (C5); HRMS-ESI (m/z) calcd. for [C₂₂H₅NO₃+H]⁺: 342.1125, obsd.: 342.1121.



2-Phenyl-6-amino-*4H***-chromen-one (171).** By subjecting nitrochromone **165** (100.4 mg, 0.38 mmol), iron powder (100.4 mg) and AcOH (10%, 2 mL) to the general procedure for the reduction of nitroaryl groups, the title compound was isolated

as a white amorphous solid (44.2 mg, 49%); $R_f = 0.1$ (CH₂Cl₂/EtOAc, 4/1, v/v); IR (υ_{max}): 3319, 3212, 2917, 2849, 1614, 1566, 1484, 1450, 1361, 1119, 772, 687 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 7.90-7.88 (m, 2H, H2'), 7.51-7.49 (m, 3H, H2', H4'), 7.42 (d, $J_{5,7} = 2.9$ Hz, 1H, H5), 7.40 (d, $J_{7,8} = 8.7$ Hz, 1H, H8), 7.05 (dd, $J_{5,7} = 2.9$ Hz, $J_{7,8} = 8.9$ Hz, 1H, H7), 6.77 (s, 1H, H3), 3.93 (br. s, 2H, NH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 178.6 (C4), 163.1 (C2), 150.1 (C6), 144.2 (C8a), 132.2 (C1'), 131.4 (C4'), 129.0 (C2'), 126.3 (C3'), 124.8 (C4a), 122.4 (C7), 119.2 (C8), 108.0 (C5), 106.8 (C3); HRMS-ESI (m/z) calcd. for [C₁₅H₁₁NO₂+H]⁺: 238.0863, obsd.: 238.0868. The data obtained for this compound were consistent with those reported in literature.³⁰⁴



5'-Amino-2'-hydroxy-acetophenone (189). By subjecting acetophenone **163** (650 mg, 3.59 mmol), iron powder (650 mg) and AcOH (10%, 18 mL) to the general procedure for the reduction of nitroaryl groups, the title compound was isolated as a white amorphous solid (211.6 mg, 39%); $R_f =$

0.20 (EtOAc/petroleum ether, 1/1, v/v); m.p.: 104.6 °C; IR (ν_{max}): 3437, 2953, 2853, 1637, 1608, 1487, 1369, 1329, 1264, 1134, 967, 788, 725, 639, 521 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ ppm 11.72 (br. s, 1H, OH), 7.06 (d, $J_{4',6'} = 2.5$ Hz, 1H, H6'), 6.90 (dd, $J_{3',4'} = 8.8$ Hz, $J_{4',6'} = 2.5$ Hz, 1H, H4'), 6.82 (d, $J_{3',4'} = 8.6$ Hz, 1H, H3'), 2.61 (s, 3H, H2); HRMS-ESI (m/z) calcd. for [C₈H₉NO₂+H]⁺: 152.0706, obsd.: 152.0700.



2'-Hydroxy-5'-(*tert*-butyloxycarbonyl)amino-acetophenone (190). A solution of NaHCO₃ (485 mg, 5.8 mmol, 2.5 equiv.) in H₂O (8.1 mL) was added to a solution of acetophenone 189 (350 mg, 2.3 mmol) in THF (3.5 mL). Di-*tert*-butyl dicarbonate (0.72 mL, 3.5 mmol, 1.5 equiv.)

was then added to the reaction and the reaction was left to stir for 12 h, after which time TLC analysis showed the disappearance of starting materials. The solution was then concentrated *in vacuo* before it was dissolved in EtOAc and washed with H₂O. The organic layers were then dried with anhydrous MgSO₄, filtered, and the filtrate concentrated *in vacuo*. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 4/1$, v/v) gave the title compound as a white solid (514 mg, 89%). R_f = 0.24 (petroleum ether/EtOAc, 9/1, v/v); IR (v_{max}): 3354, 2920, 1710, 1635, 1589; 1437, 1347, 1301, 1213, 1025, 827, 749, 615, 508 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 12.04 (br. s, 1H, OH), 7.98 (s, 1H, H6'), 7.29 (d, $J_{3',4'} = 7.3$ Hz, 1H, H4'), 6.91 (d, $J_{3',4'} = 8.9$ Hz, 1H, H3'), 6.59 (br. s, 1H, NH), 2.64 (s, 3H, H2), 1.53 (s, 9H, 'Bu-CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 204.5 (C1), 158.4 (C2'), 153.19, 129.8 (C5'), 128.2 (C4'), 120.7 (C6'), 119.2 (1'), 118.7 (C3'), 80.8 ('Bu-C_q), 28.4 ('Bu-CH₃), 26.8 (C2); HRMS-ESI (*m*/*z*) calcd. for [C₁₃H₁₇NO₄-H]⁻: 250.1085, obsd.: 250.1085.



2-Acetyl-4-((tert-butoxycarbonyl)amino)phenyl-4-

nitrobenzoate (191). Acetophenone 190 (55 mg, 0.22 mmol) and 4-nitrobenzoic acid (73.5 mg, 0.44 mmol, 2 equiv.) were dissolved in CH_2Cl_2 (1.1 mL) under argon before EDCI (105.4 mg, 0.55 mmol, 2.5 equiv.) and DMAP

(27 mg, 0.22, 1 equiv.) were added. The mixture was stirred at room temperature for 12 h, after

which time TLC analysis showed the disappearance of the starting material. The reaction was then quenched by the addition of NaHCO₃, followed by dilution with CH₂Cl₂. The resulting solution was then stirred for 10 minutes before the product was extracted using EtOAc and washed with H₂O and brine. The organic layers were then dried with anhydrous MgSO₄, which was filtered and the filtrate concentrated *in vacuo*. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 4/1$, v/v) gave the title compound as white crystals (69 mg, 78%). R_f = 0.29 (petroleum ether/EtOAc, 4/1, v/v); m.p: 149.8 °C; IR (v_{max}): 3370, 1737, 1721, 1688, 1591, 1522, 1404, 1350, 1280, 1199, 1150, 1052, 1012, 852, 825, 775, 712, 622, 498 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.39 (s, 4H, H3", H4"), 8.04 (s, 1H, H3), 7.56 (d, $J_{5,6}$ = 8.0 Hz, 1H, H5), 7.19 (d, $J_{5,6}$ = 8.3 Hz, 1H, H6), 6.69 (br. s, 1H, NH), 2.57 (s, 3H, H2'), 1.56 (s, 9H, 'Bu-CH₃); ¹³C NMR (125 MHz, CDCl₃): δ ppm 197.2 (C1), 163.8 (C1"), 150.9 (C5"), 143.8 (C1), 137.0 (C4), 134.9 (C2"), 131.4 (C3"/C4"), 130.4 (C2), 124.3 (C6), 123.8 (C5), 120.2 (C3), 81.3 ('Bu C_q), 29.2 (C2'), 28.3 ('Bu CH₃); HRMS-ESI (*m/x*) calcd. for [C₂₀H₂₀N₂O₇+NH₄]⁺: 418.1609, obsd.: 418.1609.



6-Amino-2-(4'-nitrophenyl)-4H-chromen-4-one (192). Ester 191 (86.5 mg, 0.22 mmol) was dissolved in pyridine (0.74 mL) and KOH (18.5 mg, 0.33 mmol, 1.5 equiv.) under argon was added before the solution was warmed at 60 °C.

After two hours, the reaction was neutralised by the addition of 2 M aq. HCl. The product was then extracted with EtOAc and dried with anhydrous MgSO₄, which was filtered off and the filtrate concentrated *in vacuo*. The crude product was then dissolved in AcOH (0.74 mL) before H₂SO₄ (0.01 mL) was added and the solution warmed to reflux. After 1 h, the reaction was cooled to room temperature, diluted with EtOAc and washed with sat. aq. NaHCO₃. The organic layers were then dried with anhydrous MgSO₄, which was filtered off and the filtrate concentrated *in vacuo*. Purification with silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 1/1$, v/v) gave the title compound as white crystals (46.6 mg, 75%). R_f = 0.20 (petroleum ether/EtOAc, 1/1, v/v); m.p.: 222.4 °C; IR (v_{max}): 3338, 3230, 2918, 2849, 1620, 1606, 1571, 1540, 1518, 1494, 1485, 1466, 1413, 1372, 1341, 1321, 1297, 1256, 1209, 1137, 1107, 1078, 1041, 1012, 911, 846, 813, 768, 760, 752, 691, 651, 608, 550 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.40 (d, $J_{2,3'}$ = 8.7 Hz, 2H, H2'), 8.11 (d, $J_{2,3'}$ = 8.7 Hz, 2H, H3'), 7.46 (d, $J_{7,8}$ = 8.8 Hz, 1H, H8), 7.42 (d, $J_{5,7}$ = 2.7 Hz, 1H, H5), 7.11 (d, $J_{7,8}$ = 8.8 Hz, $J_{5,7}$ = 2.8 Hz, 1H, H7), 6.87 (s, 1H, H3), 3.95 (s, 2H, NH₂); ¹³C NMR (125 MHz, CDCl₃): δ ppm 178.1 (C4), 160.1 (C2), 149.9 (C6), 149.3 (C4'), 144.5 (C8a), 138.0 (C1'), 127.1 (C3'), 124.8 (C4a),

124.2 (C2'), 122.7 (C7), 119.2 (C8), 108.6 (C3), 107.8 (C5); HRMS-ESI (m/z) calcd. for $[C_{15}H_{10}N_2O_4+H]^+$: 283.0713, obsd.: 283.0713.

General procedure for the synthesis of chromonyl-pyrimidines. Chloropyrimidine (1 equiv.) and aminochromone (1 equiv.) were co-evaporated three times in dry toluene to remove traces of water before being dissolved in dry 1,4-dioxane or 2-ethoxyethanol (5 mL/mmol). Concentrated HCl or HBF₄ (0.5 equiv.) was then added, and the reaction was stirred under reflux for 22 hours. The precipitate was filtered and washed with Et_2O to give the title compound as a yellow solid.



Ethyl 6-((2"-amino-6"-methylpyrimidin-4"-yl)amino)-4-oxo-4H-chromene-2-carboxylate)
(172). By subjecting chloropyrimidine 150 (10 mg, 0.07 mmol) and aminochromone 168 (16 mg, 0.07

mmol) in conc. HCl (0.1 µL) and dioxane (0.7 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (20.7 mg, 87%); $R_f = 0.14$ (EtOAc/EtOH, 4/1, v/v); IR (ν_{max}): 3325, 1682, 1638, 1604, 1530, 1484, 1392, 1250, 1013, 959, 866, 805, 778, 616, 531, 450 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.39 (br. s, 1H, NH), 8.79 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 8.59 (dd, $J_{7,8} = 9.2$, $J_{5,7} = 2.7$ Hz, 1H, H7), 7.53 (d, $J_{7,8} = 9.1$ Hz, 1H, H8), 7.24 (s, 1H, H3), 6.21 (s, 1H, H5'), 4.36 (q, $J_{CH2-CH3} = 7.1$ Hz, 2H, CH₂), 2.25 (s, 3H, 1'''), 1.24 (t, $J_{CH2-CH3} = 7.1$ Hz, 3H, CH₃); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 176.3 (C4), 165.4 (C6''), 162.7 (C2''), 160.7 (C4''), 159.1 (C1'), 150.7 (C2), 149.5 (C8a), 138.5 (C6), 126.1 (C7), 123.6 (C4a), 117.6 (C8), 112.2 (C3), 112.1 (C5), 94.2 (C5''), 61.2 (CH₂), 22.4 (C1'''), 12.3 (CH₃); HRMS-ESI (*m*/*x*) calcd. for [C₁₇H₁₆N₄O₄+H]⁺: 341.1244, obsd.: 341.1242.



6-((2''-Amino-6''-methylpyrimidin-4''-yl)amino)-2-cyclopropyl-4H-chromen-4-one (173). By subjecting chloropyrimidine 150 (21.5 mg, 0.15 mmol) and aminochromone 169 (20.1 mg, 0.07 mmol) in conc.

HBF₄ (0.1 μ L) and dioxane (0.7 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (8.4

mg, 39%); $R_f = 0.10$ (EtOAc/MeOH, 4/1, v/v); IR (υ_{max}): 3316, 1567, 1481, 1435, 1365, 1205, 1057, 961, 813 cm⁻¹; ¹H NMR (500 MHz, CD₃OD): δ ppm 8.70 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 7.79 (dd, $J_{7,8} = 9.0$ Hz, $J_{5,7} = 2.8$ Hz, 1H, H7), 7.42 (d, $J_{7,8} = 9.0$ Hz, 1H, H8), 6.28 (s, 1H, H3), 5.97 (s, 1H, H5"), 2.21 (s, 3H, H1"'), 2.07-2.03 (m, 1H, C1'), 1.22-1.17 (m, 4H, C2'); ¹³C NMR (125 MHz, CD₃OD): δ ppm 178.7 (C4), 172.0 (C2), 163.0 (C6"), 161.7 (C4"), 151.7 (C8a), 137.7 (C6), 126.2 (C7), 123.1 (C4a), 117.9 (C8), 113.5 (C5), 106.3 (C3), 95.8 (C5"), 21.1 (C1"'), 14.0 (C1'), 8.12 (C2'); HRMS-ESI (m/z) calcd. for [C₁₇H₁₆N₄O₂+H]: 309.1346, obsd.: 309.1349.



6-((2''-Amino-6''-methylpyrimidin-4''yl)amino)-2-phenyl-4H-chromen-4-one (70). By subjecting chloropyrimidine 150 (13.6 mg, 0.10

NH₂ **174** mmol) and aminochromone **170** (22.5 mg, 0.10 mmol) in conc. HCl (0.2 μL) and dioxane (0.5 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (15.2 mg, 44%); $R_f = 0.79$ (1/1, CH₂Cl₂/EtOAc, v/v); IR (v_{max}): 1738, 1591, 1484, 1452, 1363, 995, 774, 601 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.35 (br. s, 1H, NH), 8.86 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 8.59 (dd, $J_{7,8} = 9.0$ Hz, $J_{5,7} = 2.7$ Hz, 1H, H7), 8.00-7.98 (m, 2H, H3'), 7.60 (d, $J_{7,8} = 9.0$ H, 1H, H8), 7.51-7.48 (m, 3H, H4', H2'), 7.15 (s, 1H, H3), 7.06 (br. s, 2H, NH₂), 6.25 (s, 1H, H5''), 2.26 (s, 3H, H1'''); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 177.6 (C4), 166.8 (C4''), 164.3 (C2''), 162.7 (C2), 162.4 (C6''), 151.5 (C6), 139.3 (C8a), 132.2 (C1'), 131.4 (C4'), 129.1 (C2'), 127.0 (C7), 126.4 (C3'), 124.7 (C4a), 118.7 (C8), 114.3 (C5), 107.2 (C3), 95.5 (C5''), 23.9 (C1'''); HRMS-ESI (*m*/*x*) calcd. for [C₂₀H₁₆N₄O₂+H]⁺: 345.1346, obsd.: 345.1378.



6-((2"-Amino-6"-methylpyrimidin-4"yl)amino)-3-benzoyl-2-phenyl-4H-chromen-4-

one (175). By subjecting chloropyrimidine 150 (7.0 mg, 0.05 mmol) and aminochromone 171 (17.3 mg,

0.05 mmol) in conc. HCl (0.2 μ L) and dioxane (0.25 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (4.9 mg, 22%); $R_f = 0.54$ (EtOAc/MeOH, 9/1, v/v); IR (ν_{max}): 3321, 1619,

1578, 1554, 1516, 1484, 1446, 1384, 1357, 1311, 1257, 1234, 1203, 1176, 892, 769, 689 cm⁻¹;¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.39 (br. s, 1H, NH), 8.80 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 8.67 (dd, $J_{7,8} = 9.2$ Hz, 2.8 Hz, 1H, H7), 8.21 (d, $J_{3',4'} = 8.1$ Hz, 2H, H3'), 7.82 (d, $J_{2'',3''} = 7.8$ Hz, 2H, H2''), 7.63 (d, $J_{7,8} = 9.0$ Hz, 1H, H8), 7.47 (d, $J_{4',5'} = 7.4$ Hz, 1H, H5'), 7.40 (t, $J_{3',4'} = J_{4',5'} = 7.4$ Hz, 2H, H4'), 7.36 – 7.29 (m, 3H, H3'', H4''), 6.24 (s, 1H, H5'''), 2.26 (s, 3H, H1''''); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 194.1 (C1'), 166.8 (C6'''), 163.0 (C2), 151.4 (C6), 139.7 (C8a), 137.8 (C2'), 133.8 (C5'), 132.5 (C1''), 131.3 (C4''), 129.6 (C3'), 129.0 (C4'), 128.9 (C3''), 128.7 (C2''), 127.4 (C7), 123.9 (C4a), 118.8 (C8), 114.1 (C5), 95.7 (C5'''), 23.8 (C1''''); HRMS-ESI (*m*/*z*) calcd. for [C₂₇H₂₀N₄O₃+H]⁺: 449.1608, obsd.: 449.1611.



Ethyl6-((2"-amino-6"-
chloromethylpyrimidin-4"-yl)-amino)-4-oxo-*4H*-chromene-2-carboxylate(176).Bysubjecting chloropyrimidine153(32.1 mg, 0.18)

mmol) and aminochromone **168** (42 mg, 0.18 mmol) in conc. HCl (0.2 μL) and dioxane (3.6 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (41.2 mg, 61%); $R_f = 0.37$ (EtOAc); IR (ν_{max}): 3334, 1734, 1638, 1597, 1485, 1390, 1303, 1231, 1100, 956, 871, 842, 777 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.65 (s, 1H, NH), 8.80 (d, $J_{5,7} = 2.6$ Hz, 1H, H5), 8.56 (dd, $J_{7,8} = 9.2$ Hz, $J_{5,7} = 2.6$ Hz, 1H, H7), 7.53 (d, $J_{7,8} = 9.2$ Hz, 1H, H8), 7.39 (br. s, 2H, NH₂), 7.25 (s, 1H, H3), 6.55 (s, 1H, H5"), 4.59 (s, 2H, H1"'), 4.36 (q, $J_{2',3'} = 7.0$ Hz, 2H, C2'), 1.24 (t, $J_{2',3'} = 7.1$ Hz, 3H, C3'); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 177.8 (C4), 164.6 (C6"), 162.6 (C4"), 160.4 (C1'), 152.2 (C2), 151.2 (C6), 139.6 (C8a), 127.7 (C7), 124.9 C4a), 119.1 (C8), 114.0 (C5), 113.7 (C3), 95.1 (C5"), 62.7 (C2'), 46.4 (C1"'), 13.6 (C3'); HRMS (ESI) calcd. for [C₁₇H₁₅ClN₄O₄+H]⁺: 375.0855, obsd.: 375.0859.



6-((2"-Amino-6"-chloromethylpyrimidin-4"yl)amino)-2-cyclopropyl-*4H*-chromen-4-one

(177). By subjecting chloropyrimidine 153 (30.7 mg, 0.17 mmol) and aminochromone 169 (23.2 mg, 0.12

mmol) in conc. HBF₄ (0.2 μ L) and dioxane (0.58 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (15.4 mg, 39%); R_f = 0.63 (EtOAc); IR (ν_{max}): 3388, 1592, 1486, 1441,

1375 cm⁻¹; ¹H NMR (500 MHz, CDCl₃/CD₃OD): δ ppm 8.42 (d, $J_{5,7} = 2.6$ Hz, 1H, H5), 7.69 (dd, $J_{7,8} = 9.0$ Hz, $J_{5,7} = 2.7$ Hz, 1H, H7), 7.23 (d, $J_{7,8} = 9.0$ Hz, 1H, H8), 6.11 (s, 1H, H3), 6.06 (s, 1H, H5"), 4.15 (s, 2H, H1"'), 1.84-1.79 (m, 1H, C1'), 1.09-1.06 (m, 2H, C2'a), 1.03-0.99 (m, 2H, C2'b); ¹³C NMR (125 MHz, CDCl₃/CD₃OD): δ ppm 178.8 (C4), 171.6 (C2), 163.0 (C6"), 151.8 (C6), 149.31 (C4"), 137.3 (C8a), 126.4 (C7), 123.4 (C4a), 118.1 (C8), 114.3 (C5), 106.8 (C3), 95.6 (C5"), 44.7 (C1""), 14.6 (C1'), 8.8 (C2'); HRMS-ESI (*m*/*x*) calcd. for [C₁₇H₁₅ClN₄O₂+H]⁺: 343.0956, obsd.: 343.0956.



6-((2"-Amino-6"-chloromethylpyrimidin-4"yl)amino)-2-phenyl-4H-chromen-4-one (178). By subjecting chloropyrimidine 153 (15.0 mg, 0.09 mmol) and aminochromone 170 (20.0 mg, 0.09

mmol) in conc. HCl (0.2 µL) and dioxane (0.5 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (22.8 mg, 71%); $R_f = 0.13$ (CH₂Cl₂/MeOH, 1/1, v/v); IR (υ_{max}): 1738, 1652, 1552, 1473, 1427, 1263, 1155, 992, 775, 686, 470, 429 cm⁻¹; ¹H NMR (500 MHz, CDCl₃/CD₃OD): δ ppm 8.48 (s, 1H, H5), 7.95 – 7.85 (m, 3H, H7, H2'), 7.57 – 7.43 (m, 4H, H8, H3', H4'), 6.80 (s, 1H, H3), 6.17 (s, 1H, H5"), 4.25 (s, 2H, H1"'); ¹³C NMR (500 MHz, CDCl₃/CD₃OD): δ ppm 179.5 (C4), 164.1 (C2), 163.4 (C4"), 152.0 (C6), 137.6 (C8a), 131.9 (C4'), 131.2 (C1'), 129.1 (C3'), 127.1 (C7), 126.4 (C2'), 123.6 (C4a), 118.7 (C8), 114.4 (C5), 106.5 (C3), 95.6 (C5"), 44.8 (C1"'); HRMS-ESI (*m*/*z*) calcd. for [C₂₀H₁₅ClN₄O₂+H]⁺:379.0956, obsd.: 379.0959.



Ethyl 6-((2"-amino-6"methoxymethylpyrimidin-4"-yl)-amino)-4oxo-4H-chromene-2-carboxylate (179). By subjecting chloropyrimidine 154 (17.2 mg, 0.10

mmol) and aminochromone **168** (23.3 mg, 0.10 mmol) in conc. HCl (0.2 μ L) and dioxane (0.5 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (20 mg, 54%); R_f = 0.26 (EtOAc/EtOH, 4/1, v/v); IR (ν_{max}): 3326, 1732, 1606, 1534, 1483, 1396, 1250, 1203, 1126, 1007, 950, 877, 826, 777, 648, 529 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.54 (br.

s, 1H, NH), 8.82 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 8.60 (dd, $J_{7,8} = 9.2$ Hz, $J_{5,7} = 2.7$ Hz, 1H, H7), 7.53 (d, $J_{7,8} = 9.2$ Hz, 1H, H8), 7.24 (s, 1H, H3), 6.60 (s, 1H, H5"), 4.46 (s, 2H, C1""), 4.36 (q, $J_{2,3'} = 7.1$ Hz, 2H, C2'), 3.31 (s, 3H, H2""), 1.24 (t, $J_{2,3'} = 7.1$ Hz, 3H, C3'); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 178.4 (C4), 168.5 (C6"), 164.8 (C2"), 163.2 (C4"), 161.3 (C1'), 152.8 (C2), 151.8 (C6), 140.5 (C8a), 128.3 (C7), 125.8 (C4a), 119.8 (C8), 114.42 (C3), 114.39 (C5), 94.0 (C5"), 75.4 (C1""), 63.4 (C2'), 23.9 (C2""), 13.8 (C3'); HRMS-ESI (*m*/*z*) calcd. for [C₁₈H₁₈N₄O₅+H]⁺: 371.1350, obsd.: 371.1346.



6-((2"-Amino-6"-methoxymethylpyrimidin-4"yl)amino)-2-cyclopropyl-4H-chromen-4-one (180). By subjecting chloropyrimidine 154 (31.3 mg,

0.18 mmol) and aminochromone 169 (24.0 mg, 0.12

mmol) in conc. HBF₄ (0.2 µL) and dioxane (0.60 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (28.4 mg, 70%); $R_f = 0.25$ (EtOAc/MeOH, 9/1, v/v); IR (ν_{max}): 1629, 1588, 1542, 1522, 1477, 1449, 1340, 1329, 1300, 1195, 1116, 1055, 958, 820 cm⁻¹; ¹H NMR (500 MHz, CDCl₃/CD₃OD): δ ppm 8.55 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 7.72 (dd, $J_{7,8} = 9.1$ Hz, $J_{5,7} = 2.7$ Hz, 1H, H7), 7.29 (d, $J_{7,8} = 9.1$ Hz, 1H, H8), 6.17 (s, 1H, H3), 6.12 (s, 1H, H5"), 4.22 (s, 2H, H1"), 3.38 (s, 3H, H2"), 1.89-1.84 (m, 1H, H1'), 1.15-1.12 (m, 2H, H2'-a), 1.10-1.05 (m, 2H, H2'-b); ¹³C NMR (125 MHz, CDCl₃/CD₃OD): δ ppm 178.7 (C4), 171.8 (C2), 161.62 (C4"), 158.3 (C6"), 152.4 (C6), 136.4 (C8a), 126.7 (C7), 123.4 (C4a), 118.4 (C8), 115.1 (C5), 107.0 (C3), 95.3 (C-5'), 71.2 (C1""), 58.9 (C2""), 14.6 (C1'), 9.1 (C2'); HRMS-ESI (m/x) calcd. for [C₁₈H₁₈N₄O₃+H]⁺: 339.1452, obsd.: 339.1452.



6-((2"-Amino-6"-methoxymethylpyrimidin-4"yl)amino)-2-phenyl-4H-chromen-4-one (181). By subjecting chloropyrimidine 154 (25.7 mg, 0.15 mmol) and aminochromone 170 (35.1 mg, 0.15

mmol) in conc. HCl (0.2 μ L) and dioxane (0.75 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (35.6 mg, 58%); $R_f = 0.31$ (EtOAc/MeOH, 4/1, v/v); IR (ν_{max}): 3323, 1638, 1568, 1519, 1479, 1452, 1356, 1340, 1242, 989, 908, 855, 799, 760, 650 cm⁻¹; ¹H NMR

(500 MHz, pyridine-d₅): δ ppm 10.50 (s, 1H, NH), 8.87 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 8.58 (dd, $J_{7,8} = 9.1$ Hz, $J_{5,7} = 2.7$ Hz, 1H, H7), 8.00 – 7.98 (m, 2H, H3'), 7.59 (m, 1H, H8), 7.51 – 7.49 (m, 3H, H2', H4'), 7.16 (s, 1H, H3), 6.63 (s, 1H, H5"), 4.48 (s, 2H, H1"'), 3.32 (s, 3H, H2"'); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 133.0 (C4'), 130.6 (C2'), 128.5 (C7), 127.9 (C3'), 120.3 (C8), 116.1 (C5), 108.8 (C3), 94.9 (C5"), 76.11 (C1"'), 59.9 (C2"'); HRMS-ESI (m/z) calcd. for [C₂₁H₁₈N₄O₃+H]⁺: 375.1452, obsd.: 375.1452.



6-((2"-Amino-6"-methylpyrimidin-4"-

yl)amino)-2-(4'-nitrophenyl)-4H-chromen-4-

one (193). By subjecting chloropyrimidine 150 (15.7 mg, 0.2 mmol) and aminochromone 192 (30.0 mg,

0.10 mmol) in conc. HCl (0.2 µL) and dioxane (0.5 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (16.7 mg, 43%); $R_f = 0.55$ (petroleum ether/EtOAc, 1/1, v/v); Fluorescence (MeOH): Ex 386 nm, Em 484 nm; IR (ν_{max}): 3323, 1634, 1567, 1519, 1479, 1454, 1343, 1300, 1202, 989, 908, 853, 799, 760, 689, 468 cm⁻¹; ¹H NMR (600 MHz, pyridine-d₃): δ ppm 11.45 (br. s, 1H, NH), 8.82 (d, $J_{5,7} = 2.6$ Hz, 1H, H5), 8.49 (dd, $J_{7,8} = 9.0$ Hz, $J_{5,7} = 3.0$ Hz, 1H, H7), 8.39 (d, $J_{2',3'} = 8.9$ Hz, 2H, H2'), 8.19 (d, $J_{2',3'} = 8.9$ Hz, 2H, H3'), 7.33 (s, 1H, H3), 6.32 (s, 1H, H5''), 2.27 (s, 3H, CH₃); ¹³C NMR (150 MHz, pyridine-d₅): δ ppm 178.8 (C4), 164.0 (C4''), 161.7 (C2), 153.6 (C6), 150.5 (C4'), 139.3 (C1'), 137.9 (C8a), 129.5 (C4a), 129.0 (C3'), 128.8 (C7), 125.6 (C2'), 120.4 (C8), 116.6 (C5), 110.8 (C3), 97.7 (C5'), 24.2 (CH₃); HRMS-ESI (*m/x*) calcd. for [C₂₀H₁₅N₅O₄+H]⁺: 390.1197, obsd.: 390.1193.



6-((2"-Amino-6"-phenylpyrimidin-4"yl)amino)-2-phenyl-4H-chromen-4-one (195). By subjecting chloropyrimidine 188 (49 mg, 0.24 mmol) and aminochromone 170 (37.8 mg, 0.16

mmol) in conc. HCl (7 µL) and dioxane (0.7 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (37.5 mg, 58%); $R_f = 0.54$ (EtOAc/MeOH, 4/1, v/v); IR (υ_{max}): 1636, 1564, 1521, 1485, 1450, 1377, 1203, 912, 822, 764, 677 cm⁻¹; Fluorescence (MeOH): Ex 384 nm, Em 485 nm; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.67 (br. s, 1H, NH), 8.88 (d, $J_{5,7} = 2.8$ Hz, 1H, H5), 8.61 (dd, $J_{7,8} = 9.1$ Hz, 2.8 Hz, 1H, H7), 8.33 – 8.24 (m, 2H, H2^{III}), 8.04 – 7.95 (m, 2H, H2^I), 7.52 – 7.47 (m,

3H, H3', H4'), 7.47 – 7.40 (m, 3H, H3", H4"'), 7.17 (s, 1H, H3), 6.89 (s, 1H, H5"); ¹³C NMR (150 MHz, pyridine-d₅): δ ppm 178.6 (C4), 165.1 (C4"), 163.7 (C2), 152.4 (C6), 139.9 (C8a), 139.3 (C1"), 133.3 (C1'), 133.16, 132.9 (C4'), 132.3 (C4"'), 130.7 (C3'), 130.68, 129.9 (C3"'), 129.8 (C7), 129.4 (C2"'), 127.8 (C2'), 127.22 (C4a), 119.5 (C8), 115.2 (C5), 107.9 (C3), 94.0 (C5"); HRMS-ESI (*m/ z*) calcd. for [C₂₅H₁₈N₄O₂+H]⁺: 407.1503, obsd.: 407.1503.



6-((2"-Amino-6"-phenylpyrimidin-4"yl)amino)-2-(4'-nitrophenyl)-*4H*-

chromen-4-one (196). By subjecting chloropyrimidine 188 (53.0 mg, 0.26 mmol) and aminochromone 192 (72.6 mg, 0.26

mmol) in conc. HCl (0.1 mL) and dioxane (1.1 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (63.4 mg, 54%); $R_f = 0.42$ (EtOAc/MeOH, 4/1, v/v); IR (ν_{max}): 1739, 1558, 1457, 1344, 1217, 773, 560, 584, 555, 502, 476, 456, 431, 416 cm⁻¹; Fluorescence (MeOH): Ex 385 nm, Em 489 nm; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.59 (br. s, 1H, NH), 8.95 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 8.66 (dd, $J_{7,8} = 9.1$ Hz, $J_{5,7} = 2.8$ Hz, 1H, H7), 8.38 (d, $J_{2,3'} = 8.9$ Hz, 2H, H3'), 8.29 – 8.23 (m, 2H, H2'''), 8.17 (d, $J_{2',3'} = 8.7$ Hz, 2H, H2'), 7.63 (d, $J_{7,8} = 9.0$ Hz, 1H, H8), 7.47 – 7.39 (m, 3H, H3''', H4'''), 7.32 (m, 3H, H3, NH₂), 6.91 (s, 1H, H5''); ¹³C NMR (150 MHz, pyridine-d₅): δ ppm 177.5 (C4), 164.63, 164.2 (C4''), 162.9 (C6''), 160.1 (C2), 151.5 (C6), 149.3 (C4'), 139.6 (C8a), 138.9 (C1'''), 137.9 (C1'), 129.9 (C4'''), 128.7 (C3'''), 127.4 (C2'), 127.2 (C6), 127.0 (C2'''), 124.7 (C4a), 124.1 (C3'), 118.8 (C8), 114.1 (C5), 109.2 (C3), 93.0 (C5''); HRMS-ESI (*m/z*) calcd. for [C₂₅H₁₇N₅O₄+H]⁺: 452.1353, obsd.: 452.1351.



6-((2"-Amino-6"-(4"'fluorophenyl)pyrimidin-4"-yl)amino)-2phenyl-4H-chromen-4-one (197). By subjecting chloropyrimidine 189 (42.5 mg, 0.19 mmol) and aminochromone 192 (44.7 mg, 0.19

mmol) in conc. HCl (9.5 μ L) and dioxane (0.955 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (50.8 mg, 63%); R_f = 0.16 [CH₂Cl₂/EtOH/ MeOH/NH₃ (aq) (25%), 25/2/2/1, v/v/v/v]; Fluorescence (MeOH): Ex 380 nm, Em 492 nm; IR (ν_{max}): 1640, 1062, 1568, 1520, 1496, 1484,

1454, 1378, 1364, 1082, 1069, 696 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.55 (br. s, 1H, NH), 8.93 (d, $J_{5,7} = 2.8$ Hz, 1H, H5), 8.61 (dd, $J_{7,8} = 9.0$ Hz, $J_{5,7} = 2.7$ Hz, 1H, H7), 8.23 (m, 2H, C2^{III}), 8.00 (dt, $J_{2',3'} = 7.6$, $J_{2',4'} = 1.7$ Hz, 2H, H2'), 7.62 (d, $J_{7,8} = 9.0$ Hz, 1H, H8), 7.53 – 7.49 (m, 3H, H3', H4'), 7.20 – 7.13 (m, 3H, H3^{III}, H3), 6.84 (s, 1H, H5^{III}); ¹³C NMR (150 MHz, pyridine-d₅): δ ppm 178.3 (C4), 164.6 (d, $J_{4",F} = 248.4$ Hz, C4^{III}), 165.3 (C4^{II}), 163.7 (C6^{II}), 163.6 (C2), 163.5 (C2^{II}), 152.4 (C6), 139.8 (C8a), 132.9 (C1'), 132.2 (C4'), 129.8 (C3'), 129.74, 129.7 (d, $J_{2",F} = 8.5$ Hz, C2^{III}), 127.7 (C7), 127.2 (C2'), 125.4 (C4a), 119.4 (C8), 116.1 (d, $J_{3",F} = 21.4$ Hz, C3^{III}), 115.2 (C5), 107.9 (C3), 93.3 (C5^{II}); ¹⁹F NMR (282 MHz, pyridine-d₅) δ ppm -111.90; HRMS-ESI (*m*/*z*) calcd. for [C₂₅H₁₇FN₄O₂+H]⁺: 425.1408, obsd.: 425.1408.



6-((2''-Amino-6''-(4'''fluorophenyl)pyrimidin-4''yl)amino)-2-(4'-nitrophenyl)-*4H*-

NO₂ chloropyrimidine **189** (14.5 mg, 0.07

chromen-4-one (198). By subjecting

mmol) and aminochromone **192** (11.0 mg, 0.05 mmol) in conc. HCl (0.2 μL) and dioxane (0.5 mL) to the general procedure for the synthesis of chromonyl-pyrimidines, the title compound was isolated as a yellow amorphous solid (17.1 mg, 73%); $R_f = 0.20$ (EtOAc); Fluorescence (MeOH): Ex 384 nm, Em 488 nm; IR (ν_{max}): 1683, 1640, 1606, 1520, 1487, 1455, 1345, 1222, 1169, 914, 852, 823, 755, 693, 562 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 11.29 (s, 1H, NH), 8.98 (t, J = 2.7 Hz, 1H), 8.66 (dt, J = 8.8, 2.8 Hz, 1H), 8.39 (dd, J = 8.9, 2.6 Hz, 2H), 8.29 (ddd, J = 8.7, 5.5, 2.6 Hz, 2H), 8.25 – 8.15 (m, 2H), 7.64 – 7.60 (m, 2H), 7.33 (d, J = 2.7 Hz, 1H), 7.20 – 7.14 (m, 1H), 7.00 (d, J = 2.7 Hz, 1H); ¹³C NMR (150 MHz, pyridine-d₅): δ ppm 178.9 (C4), 165.3 (d, $J_{4",F} = 239.8$ Hz, C4^{III}), 160.5 (C4^{III}), 158.96, 153.5 (C6), 150.9 (C2), 139.9 (C8a), 139.3 (C1^{II}), 134.0 (C1^{III}), 130.6 (d, $J_{2",F} = 8.5$ Hz, C2^{III}), 129.0 (C7), 128.8 (C2), 126.2 (C4a), 125.6 (C3^{II}), 120.3 (C8), 117.0 (d, $J_{3",F} = 21.7$ Hz, C3^{III}), 115.8 (C5), 110.8 (C3), 94.2 (C5^{III}); ¹⁹F NMR (282 MHz, pyridine-d₅): δ ppm -111.48; HRMS-ESI (*m*/*x*) calcd. for [C₂₅H₁₆FN₅O₄+H]⁺: 470.1259, obsd.: 470.1256.





2/1, v/v) before conc. HCl (0.01 mL) was added. The reaction was stirred under reflux for 1 h, after which time TLC analysis showed the disappearance of the starting materials and the appearance of carboxylic acid **182**. Purification by a short C18 reverse column chromatography $(1/0 \rightarrow 1/1, H_2O/acetone, v/v)$ gave the title compound as a yellow solid (6.2 mg, 90%). R_f = 0.02 (1/1, CH₂Cl₂/MeOH, v/v); IR (ν_{max}): 1639, 1578, 1597, 1499, 1414, 1324, 1371, 1276, 1037, 892, 860, 725, 753, 710, 623, 668, 511, 531, 561, 407 cm⁻¹; ¹H NMR (500 MHz, pyridine- d_5): δ ppm 7.89 (d, $J_{5,7}$ = 2.8 Hz, 1H, H5), 7.54 (d, $J_{7,8}$ = 9.0 Hz, 1H, H8), 7.53 (s, 1H, H3), 7.33 (dd, $J_{7,8}$ = 9.0 Hz, $J_{5,7}$ = 2.8 Hz, 1H, H5), 6.35 (s, 1H, H5"), 4.35 (s, 2H, H1""), 3.33 (s, 3H, CH₃); ¹³C NMR (125 MHz, pyridine): δ ppm 180.2 (C4), 166.9 (C4"), 165.8 (C1'), 158.9 (C2"), 156.9 (C2), 150.5 (C6 or C8a), 149.0 (C6 or C8a), 127.5 (C4a), 124.3 (C7), 121.3 (C3), 114.1 (C8), 107.7 (C5), 100.8 (C5"), 75.4 (C1""), 59.9 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₆H₁₄N₄O₅-H]⁻: 341.0891, obsd.: 341.0890.



6-((2"-Amino-6"-methylpyrimidin-4"yl)amino)-2-(4'-aminophenyl)-4*H*-chromen-4one (194). To a solution of nitrochromone 193 (11.8 mg, 0.03 mmol) in EtOH/H₂O (2/1, v/v, 0.225 mL) was added iron powder (6.7 mg, 0.12

mmol, 4 equiv.) and conc. HCl (3 µL). The reaction was warmed to reflux and stirred for 12 h, after which time TLC analysis showed complete disappearance of starting materials. The reaction mixture was then cooled and filtered through Celite before it was concentrated *in vacuo* to give the title compound as a yellow amorphous solid (3.63 mg, 33%); $R_f = 0.08$ (EtOAc/MeOH, 4/1, v/v); IR (ν_{max}): 3349, 2921, 1590, 1420, 1346, 1310, 1176, 1124, 962, 826, 798, 718, 558, 536 cm⁻¹; Fluorescence (MeOH): Ex 386 nm, Em 495 nm; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.56 (br. s, 1H, NH), 8.82 (d, $J_{5,7} = 2.7$ Hz, 1H, H5), 8.46 (dd, $J_{7,8} = 9.0$ Hz, $J_{5,7} = 2.7$ Hz, 1H, H7), 7.89 (d, $J_{2,3'} = 8.9$ Hz, 2H, H2'), 7.55 (d, $J_{7,8} = 9.0$ Hz, 1H, H8), 7.04 (s, 1H, H3), 7.02 (d, $J_{2,3'} = 8.7$ Hz, 2H, H3'), 6.23 (s, 1H, H5''), 2.24 (s, 3H, CH₃); ¹³C NMR (125 MHz, pyridine-d₅): δ ppm 177.3 (C4), 164.4 (C4''), 164.1 (C2), 163.1 (C2''), 162.5 (C6''), 159.10, 153.0 (C1'), 151.8 (C6), 138.3 (C8a), 128.3 (C2'), 126.9 (C7), 124.8 (C4a), 119.0 (C4'), 118.4 (C7), 115.3 (C5), 114.3 (C3'), 103.8 (C3), 95.6 (C5''), 23.0 (CH₃); HRMS-ESI (m/x) calcd. for [C₂₀H₁₇N₅O₂+H]⁺: 360.1455, obsd.: 360.1455.



6-((2"-Amino-6"-(4"'-

fluorophenyl)pyrimidin-4''-yl)amino)-2-(4'-aminophenyl)-4H-chromen-4one) (199). To a solution of

nitrochromone 198 (22.1 mg, 0.05 mmol)

in MeOH (2.9 mL) was added iron powder (11.17 mg, 0.2 mmol, 4 equiv.) and conc. HCl (5 μ L). The reaction was warmed to reflux and stirred for 12 h, after which time TLC analysis showed complete disappearance of starting materials. The reaction mixture was then cooled and filtered through Celite before it was concentrated *in vacuo* to vie the title compound as a yellow amorphous solid (9.2 mg, 42%); R_f = 0.63 (EtOAc/MeOH, 4/1, v/v); IR (ν_{max}): 3310, 2949, 1931, 1699, 1652, 1593, 1575, 1515, 1398, 1362, 1258, 1185, 1082, 984, 958, 802, 481, 455, 436, 423 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.82 (br. s, 1H, NH), 8.88 (s, 1H, H5), 8.52 (d, $J_{7,8}$ = 8.5 Hz, 1H, H7) 8.27 – 8.24 (m, 2H, H3''), 7.91 (d, $J_{2',3'}$ = 8.4 Hz, 2H, H3', 7.56 (m, 1H, H8), 7.18 (s, 3H), 7.07 (s, 1H, H3) 7.03 (d, $J_{2',3'}$ = 8.3 Hz, 2H, H2'), 6.84 (s, 1H, H5''); ¹³C NMR (150 MHz, pyridine-d₅): δ ppm 178.0 (C4), 165.3 (d, $J_{4'',F}$ = 195.8 Hz, 1H, H4'''), 164.8 (C1'), 163.7 (C6''), 153.7 (C2), 152.6 (C6), 138.9 (C8a), 130.7 (d, $J_{2'',F}$ = 7.9 Hz, 2H, H2'''), 129.0 (C3'), 128.2 (C4a), 127.5 (C6), 119.7 (C4'), 119.2 (C8), 117.1 (d, $J_{3'',F}$ = 21.9 Hz, 2H, H3'''), 117.0 (C5), 115.0 (C2'), 104.5 (C3), 92.5 (C5''); ¹⁹F NMR (282 MHz, pyridine-d₅) δ ppm -109.70; HRMS-ESI (*m*/x) calcd. for [C₂₅H₁₈FN₅O₂+H]⁺: 440.1517, obsd.: 440.1519.

4.4.3. Biology - testing of chromonyl-pyrimidines 193-199

Samples. Each compound was dissolved in sterile DMSO to make 10 mM stock solutions.

Obtaining MIC values. In clear-bottomed 96-well plates (Nunc), two-fold serial dilutions of each compound were added to volumes of 100 μ L of HdB minimal medium. The last column of each plate did not contain any compound and served as a negative control. Previously prepared *Mtb* mc²6230 inocula were diluted to 5% with HdB medium to achieve 0.05 OD₆₀₀. The inocula were then added to each well and the plates incubated at 37 °C for five days. After incubation, 20 μ L of resazurin was added to the wells, and the plates incubated at 37 °C for 24 h. The wells that remained blue were deemed to contain non-replicating bacteria, while those that underwent a colour change to purple or pink were deemed to contain replicating bacteria. MIC values were ascertained by visual judgment of colour.

CHAPTER FIVE

The synthesis and anti-tubercular properties of phthalazinones

5.1. Introduction

BDQ (14) is the first FDA-approved TB drug to inhibit oxidative phosphorylation in *Mtb*. To exert its inhibitory activity, BDQ (14) acts as an uncoupler by dissociating the transmembrane proton transfer from phosphorylation reactions responsible for ATP generation (Chapter 1, Section 1.2.3).³³ This uncoupling mechanism leads to the dissipation of the mycobacterial PMF, a process that has been reported to be detrimental to *Mtb*.^{33,52} The PMF is comprised of $\Delta \varphi$ and ΔpH gradients, whereby $\Delta \varphi$ measures the charge separation across the membrane (positive_{outside}) and ΔpH is the transmembrane pH gradient (acidic_{outside} : alkaline_{inside}).^{41,52} Typically, uncouplers are protonophores or ionophores that translocate

protons across proton-impermeable membranes, perturbing the $\Delta \varphi$ or ΔpH and ultimately collapsing the PMF.³⁰⁵ Examples of potent uncouplers are weak acids with ionisable protons, such as carbonyl cyanide *p*-trifluoromethoxyphenyl hydrazone (FCCP, **200**, Figure 5.1) and CCCP (**201**).³⁰⁶ When neutral, FCCP (**200**) and CCCP (**201**) are apolar and can reside in the hydrophobic environment of cell membranes. However, as FCCP (**200**) and CCCP (**201**) move through the membrane, they dissociate into their respective anions and release a proton into the aqueous environment, which may be either outside the cell or within the cytosol. This mechanism allows for uncontrolled movement of protons in and out of the cell, which leads to the loss of the transmembrane proton gradient.³⁰⁵



Figure 5.1: Potent uncouplers FCCP (200) and CCCP (201).³⁰⁶

5.1.1. Enzyme-specific uncouplers

Although FCCP (**200**) and CCCP (**200**) are strong uncouplers, they are non-site specific and exert their ionophoric activity in both eukaryotic and prokaryotic cells, which causes toxicity in humans.⁴¹ Notwithstanding, uncouplers that target specific enzymes have been reported, such as BDQ (**14**), which binds to mycobacterial ATPase, and anthraquinone derivatives emodin (**202**, Figure 5.2) and emodinanthrone (**203**) that target cytochrome *c* in *E. coli*.³⁰⁷ Of particular interest are phenothiazines that inhibit NDH-II by uncoupling oxidative phosphorylation in bacteria.³⁰⁸ Mechanistic studies have shown that thioridazine (**22**), a weak base with a pKa of 8.82,^{309,310} induced a dose-dependent collapse in membrane potentials, and consequently, ATP depletion in *Mtb*⁵² and *S. aureus*.³⁰⁸ Here, the authors postulated that when protonated, thioridazine (**22**) carries charge across the membrane by accepting a proton from the periplasm and releasing it inside the cell, thereby reducing the PMF.³⁰⁸ Unfortunately, treatment with thioridazine (**22**) exhibits significant adverse side effects and has been reported to uncouple oxidative phosphorylation in mammalian mitochondria.³¹¹

Chapter Five



Figure 5.2: Emodin (202) and emodinanthrone (203) are uncouplers of cytochrome *c* in E. *coli*,³⁰⁷ while phenothiazine 22 uncouples oxidative phosphorylation in *Mtb* and *S. aureus*.³⁰⁸

In 2015, Oldfield et al. conducted a study demonstrating the uncoupling activity of antitubercular agents.³¹² Here, a correlation was found between the degree of PMF dissipation and Mtb cell growth inhibition. Particularly potent uncouplers included lipophilic cationic species, such as SQ109 (204, Figure 5.3) and clofazimine (13), though AU1235 (205) was also active as a neutral uncoupler.³¹² SO109 (**204**) was found to inhibit cell growth in *Mtb* by acting as an uncoupler. In addition SQ109 (204) also inhibited essential enzymes, such as MenA and MenG, which are enzymes required for MK biosynthesis, and transporter MmpL3, which is involved in cell wall biosynthesis.^{34,313,314} SAR studies of SQ109 (204) analogues showed that at least one protonable amine group was essential for anti-tubercular activity, indicating that SQ109 (204) had activity as a cation.³¹⁴ Indeed, SQ109 (204) was found to be protonated at physiological pHs, allowing it to carry charge across the bacterial cell membrane and collapse the transmembrane proton gradient.³¹² Another effective uncoupler is clofazimine (13), a current third-line TB drug that produces ROS³¹⁵ by binding to and undergoing reduction by NDH-II.³⁶ In Oldfield's study, clofazimine (13) also induced PMF dissipation to the same extent as SQ109 (204) and BDQ (14).³¹² Finally, urea 205 is a neutral uncoupler of tubercular PMF that targets the MmpL3 enzyme.³¹⁶ Unlike BDQ (14), which exerts its uncoupling activity by binding to its target enzyme ATPase, TB drugs 204, 205 and 13 are uncouplers of respiration that also target essential Mtb enzymes. Compounds with multiple modes of action are promising TB drug candidates as they are less susceptible to the development of bacterial resistance. Indeed, the rise in mycobacterial resistance to BDQ (14) has been reported,³¹⁷ while SQ109 (204) has a strikingly low frequency of persister Mtb populations.³¹⁸



Figure 5.3: Anti-tubercular drugs 204, 205, and 13 induce PMF dissipation in bacteria.

5.1.2. The phthalazinone scaffold in drug discovery

Phthalazinones are becoming increasingly important in the field of drug discovery due to their diverse range of pharmaceutical properties, such as anti-cancer,³¹⁹⁻³²¹ anti-inflammatory,³²²⁻³²⁴ anti-bacterial,^{319,325} antioxidant,³¹⁹ and anti-neurodegenerative³²⁶ properties. In particular, anti-bacterial phthalazinones include inosine-5'-monophosphate dehydrogenase inhibitor **206** (Figure 5.4), which has an MBC of 0.94 µM against *Francisella tularensis*,³²⁷ as well as oxadiazole **207**, which inhibit the growth of E. *coli* and *Salmonella typhi*.³²⁸ In addition, many clinically available phthalazinone-containing drugs are known, all with specific mechanisms of action. For example, oliparib (**208**) inhibits the poly(ADP-ribose)polymerase, an enzyme family responsible for repairing DNA damage, in tumour cells,³²⁹ while azelastine (**209**) is an effective histamine inhibitor that is preferentially taken up by the lung and alveolar macrophages.³³⁰ Others are known phosphodiesterase inhibitors (*i.e.* EG626, **210**)³³¹ and aldose reductase inhibitors in tumour cells (*i.e.* zopolrestate, **211**).³³²


Figure 5.4: Anti-bacterial phthalazinones 206 and 207,^{327,328} and FDA-approved phthalazinone-containing drugs oliparib (208), azelastine (209), EG626 (210), and zopolrestat (211).

5.1.3. The phthalazinone scaffold as potential uncouplers

Effective uncouplers are commonly characterised as weak acids³³³ or bases,³¹² such as thioridazine (**22**) and BDQ (**14**), both of which have a pKa of 8.89.^{334,312} Electron-withdrawing and lipophilic groups have also been reported to enhance the uncoupling capabilities of weakly acidic or basic compounds.³⁰⁵ In this chapter, the phthalazinone scaffold (**31**, Figure 5.4) will be investigated for their anti-tubercular activity, as well as their capacity to uncouple oxidative phosphorylation in *Mtb*. The capability of phthalazinones to act as an uncoupler has yet to be investigated, however phthalazinones are weak bases that can be functionalised with lipophilic and electron-withdrawing groups. The basic pKa of unfunctionalised phthalazinones is calculated to be 8.88,³³⁵ while functionalised phthalazinones, *i.e.* azelastine (**209**) has a pKa of 9.5.³³⁶ Here, unfunctionalised phthalazinone **31** has an ionisable proton akin to FCCP (**200**) and CCCP (**201**), which can assist in charge transport across cell membranes,³⁰⁵ while the hydrazone moiety in *N*-substituted phthalazinones can be protonated, thereby enabling the cationic species to act as a charge carrier in a comparable manner to phenothiazines.³⁰⁸



Figure 5.5: Phthalazinones (31) are weakly basic and could act as an uncoupler.

5.1.4. Project aims and retrosynthesis

In light of the uncoupling mechanisms of effective anti-tubercular drugs BDQ (**14**), SQ109 (**204**) and clofazimine (**13**), it was proposed that phthalazinones could also act as an uncoupler. In addition, it was envisioned that the ketone-containing bicyclic phthalazinone scaffold would fulfill the structural requirements for the NDH-II Q-site. Specifically, the planar heterocyclic moiety could be accommodated between hydrophobic residues Q317 and I379, while the ketone oxygen could participate in hydrogen bonding interactions with the ring nitrogen of the FAD isoalloxazine ring, as observed with menadione (**18**) and HQNO (**19**) in the NDH-II crystal structure (Chapter 1, Section 1.3.1).^{58,62} Given the ability of quinolinyl pyrimidines to inhibit NDH-II, ⁷⁹ it was envisaged that the addition of a pyrimidine to the phthalazinone scaffold could enhance their specificity for NDH-II. Moreover, docking studies of chromonyl-pyrimidines (Chapter 4) have shown possible hydrogen bonds between the pyrimidine amine protons and a glutamic acid residue (E324) in the NDH-II Q-site.

To this end, a retrosynthetic route was devised, whereby pyrimidinyl-phthalazinones **XXV** functionalised at the 2- and 6"-positions could be assembled from functionalised aminophthalazinones **XXVI** (where $R^3 = NH_2$) and chloropyrimidines **XXVII** (Scheme 5.1). Here, the synthesis of phthalazinones bearing apolar aryl and alkyl groups was proposed in order to increase the lipophilicity of the phthalazinone scaffold and assist with binding to the hydrophobic NDH-II Q-site.^{58,62} Moreover, the addition of electron-withdrawing groups, such as fluorophenyl and sulfonamide, was envisioned to enhance the ability of the phthalazinones to disrupt the mycobacterial ETC.³⁰⁵ For this series of compounds, previously synthesised methyl-, phenyl- and fluorophenyl-substituted chloropyrimidines were to be used (Chapter 4). These pyrimidines **194-199**. Functionalised phthalazinones **XXVI** could be prepared from the condensation of 3-bromo-6-nitro-isobenzofuranone (**XXVIII**, $R^3 = NO_2$) with various hydrazines, followed by reduction of the nitro group, while the chloropyrimidines **XXVII** were

to be available from the condensation of functionalised beta-ketoesters (**XXIX**) with guanidine, as previously described in Chapter 4. Furanone **XXVIII** could in turn be prepared from the reduction of phthalic anhydride, followed by nitration and subsequent benzylic bromination. Using this same synthetic route, a library of phthalazinones **XXVI** (where $R^3 = H$) could also be synthesised from phthalic anhydride.



Scheme 5.1: Retrosynthetic analysis of pyrimidinyl-phthalazinones **XXV** and phthalazinones **XXVI**.

5.2. Results and Discussion

5.2.1. Docking studies of phthalazinones and pyrimidinyl phthalazinones

To investigate whether phthalazinones could be accommodated in the NDH-II Q-site, molecular docking of 2-methylphthalazin-1(2*H*)-one **212** (Figure 5.6A) was undertaken using USCF Chimera/DOCK6.²⁸² Here, different molecular orientations with similar binding scores were adopted by the phthalazinone scaffold (Figure 5.6B). In all instances, the docked phthalazinone molecules were placed between the hydrophobic residues Q317 and I379, providing a similar binding orientation reported of menadione (**18**) and HQNO (**19**).^{58,62}

Chapter Five

Moreover, hydrogen bonding was also evident between phthalazinone **212** and R382 side chains. A similar interaction was also observed for the docked structure of menadione (**18**) in the NDH-II Q-site,⁵⁸ whereby R382 interacts with one of the ketone oxygen atoms. That said, the authors queried the plausibility of this interaction, as crystal structures have shown this fragment of NDH-II to be embedded in the cell membrane and R382 was likely to interact with phosopholipids in the cell wall.⁵⁸ Notwithstanding, a hydrogen bond interaction between phthalazinone **212** and the ring nitrogen in FAD was observed for certain binding modes (Figure 5.6C).



Figure 5.6: Docking studies of phthalazinone **212** in *C. thermarum* NDH-II (PDB: 6BDO),⁶² calculated using USCF Chimera/DOCK 6. A). Structure of 2-methylphthalazin-1(2*H*)-one (**212**). B). Phthalazinone **212** (light blue) can adopt many different conformations in the binding tunnel, sandwiched between Q317 and I379. C). Positioning of a high ranked conformer of **212** with a hydrogen bond to FAD (gold).

Next, docking studies of 7-((2-amino-6-methylpyrimidin-4-yl)-2-methylphthalazin-1(2*H*)-one (**213**, Figure 5.7A) in NDH-II were also conducted. Again, many different orientations of the pyrimidinyl-phthalazinone **213** were placed into the putative binding tunnel between hydrophobic residues Q317 and I379 (Figure 5.7B-D). Here, hydrogen bonds involving the pyrimidine amine group and Q317, Q321, E324, and R382 (Figure 5.7B), as well as that between the hydrazone nitrogen and the FAD isoalloxazine ring (Figure 5.7C) were observed.

A well-positioned pyrimidinyl-phthalazinone **213** is shown in Figure 5.7D, which shows phthalazinone **213** occupying the putative binding tunnel, while the bridging and primary amine protons form a hydrogen bond with R382 and Q321, respectively. As previously noted however, the binding of R382 is physiologically unlikely as this portion of the enzyme is hypothesised to be well within the cell membrane. Taken together, these interactions suggest that compared to the phthalazinone ring on its own, pyrimidinyl-phthalazinones could bind the NDH-II Q-site more specifically. Further analysis of the NDH-II Q-site also indicated that the binding pocket could accommodate substituents at the 2- and 6"-positions.



Figure 5.7: Docking studies of pyrimidinyl phthalazinone **213** in *C. thermarum* NDH-II (PDB: 6BDO).⁶² A). Structure of 7-((2-amino-6-methylpyrimidin-4-yl)amino)-2-methylphthalazin-1(2*H*)-one (**213**). B). Possible binding modes of pyrimidinyl-phthalazinone **213** within the putative Q-site of NDH-II. C). Hydrogen bond interactions between phthalazinone **213** and the FAD isoalloxazine ring. D). Pyrimidinyl phthalazinone **213** is bound between Q317 and I379, while forming hydrogen bonds with surrounding amino acids R382 and Q321. Molecular graphics and analyses were performed with USCF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Fransisco

5.2.2. The synthesis of phthalazinones

The synthesis of N-substituted phthalazinones commenced with the reduction of phthalic anhydride with sodium borohydride to give isobenzofuranone 214 in good yield (Scheme

5.2).³³⁷ A Wohl-Ziegler reaction was then performed on isobenzofuranone **214**³³⁸ to give bromo-ester **215**,³³⁷ which was then treated with various hydrazines to afford phthalazinones **31**, **216-223** in good yields (35-92%).



Scheme 5.2: Synthesis of phthalazinones 31, 216-223.

The successful formation of phthalazinones **31** and **216-223** were confirmed by ¹H and ¹³C NMR spectroscopy, which showed the loss of resonances corresponding to H3 and C3 of bromide **215** (7.41 ppm and 74.8 ppm, respectively, in CDCl₃) and the appearance of resonances corresponding to the 4-position of the phthalazinones (8.00 - 8.30 ppm, 136.0 - 139.0 ppm, respectively, in CDCl₃). In addition, IR spectra of phthalazinones showed bands between 1102 - 1120 cm⁻¹, typical of N-N stretches,³³⁹ while spectral data of phthalazinones **31**,³⁴⁰ **216**,³⁴¹ **217**,³⁴¹ **218**,³⁴² **220**,³⁴³ and **221**³⁴² matched those reported in literature. In addition to these compounds, phthalazinone **31** was alkylated using heptylbromide and

propargylbromide under basic conditions to give alkyl phthalazinones **224** and **225**, respectively (Scheme 5.3). Here, the connectivity of the alkyl group to the ring nitrogen was confirmed by HMBC, in which correlations between the N-CH₂ and the carbonyl carbon were observed (*i.e.* Figure 5.8 for phthalazinone **224**).



Scheme 5.3: The synthesis of heptylphthalazinone 224 and propargylphthalazinone 225.





Having completed the synthesis of phthalazinones **31** and **216-225**, 7-substituted phthalazinones were prepared (Scheme 5.4). Initially, it was envisaged that nitro-phthalide **226** could be synthesised by subjecting bromo-benzofuranone **215** to nitric acid. Unfortunately however, benzofuranone **215** was unstable under highly acidic conditions, due to the lability of the bromide group. Accordingly, nitration of isobenzofuran-1(3*H*)-one (**214**) was first undertaken to give nitro-phthalide **226**, which was then subjected to Wohl Ziegler conditions³³⁸ to yield the desired phthalide **226**.

Chapter Five



Scheme 5.4: Synthesis of nitro phthalide 226.344

Next, bromo-phthalide **226** was reacted with phenylhydrazinium chloride to give phenylphthalazinone **228** (Scheme 5.5),³⁴⁵ the structure of which was unequivocally confirmed by XRD data (Figure 5.9). Next, an iron-mediated reduction of nitro-phthalazinone **228** was then undertaken to afford 7-amino-2-phenyl phthalazinone (**229**) in 99% yield.³⁴⁵ Similarly, treatment of nitrophthalide **226** with hydrazine hydrate gave nitro-phthalazinone **230**, which was alkylated with propargylbromide and bromoheptane to give 7-nitro-2-propargyl-phthalazinone **231** and 7-nitro-2-heptyl-phthalazinone **233**, respectively. Finally, nitro-phthalazinone **231** and **233** were reduced using iron powder to give amino-propargyl phthalazinone **232** and amino-heptyl-phthalazinone **234**, respectively, in excellent yields from their respective nitro-functionalised precursors. Confirmation of successful synthesis of amino-phthalazinones **229**, **232**, and **234** was observed by ¹H NMR spectroscopy, whereby a broad singlet at approximately 7 ppm in CDCl₃ corresponded to primary amine protons and IR spectroscopy revealed stretching frequencies between 3400 – 3300 cm⁻¹, typical of N-H stretches.¹³⁰

Chapter Five



Scheme 5.5: Synthesis of amino- and nitro-phthalazinones 228-234.



Figure 5.9: Crystal structure of nitrophthalazinone 228.

5.2.3. The synthesis of pyrimidinyl-phthalazinones

With amino phthalazinones 229, 232, and 234 in hand, the assembly of pyrimidinyl phthalazinones was undertaken. Accordingly, the condensation of amino-phthalazinones 229, 232, and 234 and chloropyrimidines 150, 187, and 188 under acidic conditions gave pyrimidinyl-phthalazinones 235-243 in moderate to good (24%-83%) yields (Scheme 5.6). Successful formation of pyrimidinyl-phthalazinones 235-243 was confirmed by NMR spectroscopy, which included an HMBC between the bridging amine and protons at the 5"-, 8-, and 6- positions, as illustrated in Figure 5.10 for phthalazinone 242.



Scheme 5.6: The synthesis of pyrimidinyl phthalazinones 235-243.

Chapter Five



Figure 5.10: HMBC (500 MHz, pyridine-d₅) of pyrimidinyl phthalazinone 242.

5.2.4. The anti-tubercular activity of phthalazinones and pyrimidinyl-phthalazinones

Having completed the synthesis of phthalazinones and pyrimidinyl-phthalazinones, the compounds were then screened for their ability to inhibit the growth of *Mth* (Table 5.1). The biological testing was conducted at the University of Otago under the supervision of Professor Gregory Cook. First, the anti-tubercular activity of unfunctionalised phthalazinone **31** (MIC = 50μ M, Entry 1) was compared with phthalazinones **212-225**, which bear various lipophilic and electron-withdrawing substituents at the 2-position (Entries 2-11). Here, the incorporation of an alkyl chain at the 2-position led to an increase in inhibitory activity of the phthalazinones, with *tert*-butyl- (**216**), heptyl- (**224**) and propargyl- (**225**) phthalazinones all exhibiting low micromolar MIC values (3 μ M, 6 μ M, 12.5 μ M, respectively, Entries 2-4). However, phenyl-substituted phthalazinone **217** was a weaker inhibitor (MIC = 100 μ M, Entry 5) compared to phthalazinone **31**, though when an electron-withdrawing group was incorporated onto the phenyl ring (*i.e.* phenylphthalazinones **218-223**, Entries 6-11), lower MIC values were obtained (MIC = 50 μ M for **218**, **219**, **221**, **222**, **223**, MIC = 12.5 μ M for **220**). These results supported the hypothesis that increasing lipophilicity and electron-withdrawing nature of the phthalazinones can increase the inhibitory activity of the compounds against *Mth*.

Chapter Five

Entry	Compound	MIC (µM)
1	7 0 2 NH N	50
2	31	3
	216	
3		6
	224	
4	O N N	12.5
	225	
5		100
	217	
6	O N N N	50
	218	
7		50
	219	

Table 5.1: Inhibition of *Mtb* by phthalazinones and pyrimidinyl-phthalazinones.

















12.5

























Chapter Five



Next, the effects of including electron-withdrawing and electron-donating groups at the 7position of the phthalazinones on their anti-tubercular activity were analysed. Here, the incorporation of a nitro group at the 6-position led to a remarkable increase in anti-tubercular activity for phthalazinone **230** (MIC = 3 μ M, Entry 12) as compared to the unfunctionalised phthalazinone **31** (MIC = 50 μ M, Entry 1) and a two-fold improvement in activity for nitrophthalazinone **231** (MIC = 6 μ M, Entry 13) when compared to the corresponding propargyl **225** (MIC = 12.5 μ M, Entry 4). For heptylphthalazinone **233** however, the 6-nitro group led to a loss in anti-tubercular activity (MIC = 100 μ M, Entry 14 vs. MIC = 6 μ M for **224**, Entry 3), while no change in inhibitory activity was observed between phenyl-phthalazinones **228** and **217** (Entries 15 and 5, respectively). The addition of electron-donating amine substituents at the 7-position (*i.e.* phthalazinones 234, 232 and 229, Entries 16-18) resulted in a loss of *Mtb* growth inhibition when compared to phthalazinones 224, 225, and 217, respectively (Entries 3-5). These results demonstrated that the instalment of an electron-donating group at the 7-position appears to reduce the inhibitory action of the drugs, while the incorporation of an electron-withdrawing group led to variable results with respect to their ability to inhibit mycobacterial growth. The decreased inhibition exhibited by aminophthalazinones 229, 232 and 234 could be attributed to the ability of amine groups to form hydrogen bonds with residues away from the putative NDH-II Q-site, *i.e.* E324. Moreover, the relatively high polarity of aminophthalazinones 229, 232 and 234 could also lower their binding affinity to the hydrophobic NDH Q-site.

Finally, the ability of pyrimidinyl-phthalazinones **235-243** to inhibit *Mtb* growth were determined. In general, compounds bearing a 6-methyl-pyrimidine moiety were poor *Mtb* inhibitors, with phthalazinones **235-237** having high MIC values ($50 - 100 \mu$ M, Entries 19-21). Similarly, 6-phenyl-pyrimidines **239** and **228** had low potency against *Mtb* with an MIC value of 100 μ M (Entries 22 and 23), while phenyl-pyrimidinyl-alkyne **240** elicited good anti-tubercular activity (MIC = 12.5 μ M, Entry 24). Aside from propargyl phthalazinone **243** (Entry 25), the incorporation of a fluoro-phenyl pyrimidine led to an increase of anti-tubercular activity of the pyrimidinyl-phthalazinones. Evidence for this trend include the low MIC values of fluorophenyl phthalazinones **241** (MIC = 12.5 μ M, Entry 26) and **242** (MIC = 1.6 μ M, Entry 27), with phthalazinone **242** exhibiting the highest anti-tubercular activity of the series. Thus, while incoporating a pyrimidine group did not significantly increase the anti-tubercular activity of all phthalazinones, the lead *Mtb* inhibitor did contain this functional group, with fluorophenyl-pyrimidines.

Taken together, these studies demonstrated that the inclusion of lipophilic and electronwithdrawing groups of the phthalazinones increased the anti-tubercular activity of the compounds. That said, the size and position of such functionalities also influence the inhibitory activity of the phthalazinones. To better explain the anti-tubercular activity of the compounds, investigations into the ability of the phthalazinones to affect NADH oxidation were undertaken.

5.2.5. The effect of NADH oxidation exerted by phthalazinones

To investigate whether phthalazinones could affect mycobacterial respiration, the rates of NADH oxidation in the presence and absence of phthalazinones were measured using mycobacterial IMVs at the University of Otago under the supervision of Prof. Gregory Cook. Here, the results suggested that the addition of several phthalazinones to IMVs led to higher rates of NADH oxidation as compared to the basal rate (Figure 5.11). In particular, pyrimidinyl phthalazinones 238, 241 and 243 caused a higher rate of oxidation, suggesting that these compounds activate NDH-II, possibly via a redox-cycling mechanism. In contrast, many phthalazinones induced a lower rate of NADH oxidation, notably phenyl phthalazinone 217, heptyl phthalazinone 224, and nitrophthalazinone 233. The lower rates of NADH oxidation promoted by phthalazinones 217, 224, and 233 could be a result of NDH-II inhibition or uncoupling of oxidative phosphorylation, as observed with thioridazine (22).^{52,308} In the latter, NADH oxidation could slow down or halt when the $\Delta \varphi$ has collapsed, due to the release of charged species as a result of NADH oxidation. Taken together, it is likely that phthalazinones and pyrimidinyl phthalazinones could inhibit Mtb growth through different modes of action, whereby representative pyrimidinyl phthalazinones activate NDH-II, which could lead to the formation of lethal levels of ROS.³⁷ On the other hand, several phthalazinones may exert their anti-tubercular activity through the inhibition of NDH-II and/or acting as an uncoupler of oxidative phosphorylation in mycobacteria.⁶⁴ Notwithstanding, the mode of action of lead phthalazinones 216 and 230 and pyrimidinyl-phthalazinone 242 appears to be independent of NDH-II.



Figure 5.11: Rates of NADH oxidation when IMVs are treated with phthalazinones 31, 216-225, 228-243, and pyrimidinyl phthalazinones 237-245. Negative control is the vehicle control, whereby IMV was not treated with any compound, nor was NADH added. The basal rate is the rate of NADH oxidation by IMVs without the addition of any drug. Data is shown as the average \pm standard deviation of three independent replicates.

5.3. Conclusion

In summary, a new class of anti-tubercular heterocyclic compounds, phthalazinones, was investigated. The bicyclic ketone-containing structure of phthalazinones make them a potential NDH-II substrate. As a weakly basic and apolar scaffold, phthalazinones also showed promise as an uncoupler. In the present study, a library of phthalazinones functionalised at the 2- and 7-positions, including pyrimidinyl-phthalazinones, were synthesised and tested against *Mth*. Docking studies of phthalazinones and pyrimidinyl-phthalazinones undertaken using the *C. thermarum* NDH-II protein showed that the phthalazinone scaffold could be accomodated in the putative NDH-II Q-site. To this end, a library of phthalazinones functionalised at the 2- and 6'-positions were synthesised and screened for their ability to inhibit the growth of *Mtb*.

In general, phthalazinones bearing alkyl chains (phthalazinones 216, 224, 225) and electronwithdrawing substituents (i.e. phthalazinones 218-223) elicited good anti-tubercular activity. Moreover, the inclusion of amine groups at the 7-position led to reduced inhibitory activity of the phthalazinones, while the effect of a nitro group at this position gave varying inhibitory results. The pyrimidinyl-phthalazinones also exerted good inhibitory activity against Mtb, identifying a lead compound, fluorophenyl-pyrimidinyl-heptyl-phthalazinone 244, with an MIC of 1.6 µM. The compounds were then screened for their ability to affect NADH oxidation IMVs. Here, increased rates of NADH oxidation were induced by pyrimidinyl phthalazinones 238, 241, and 243, while decreased rates were observed when the IMVs were treated with phthalazinones 217, 224, and 233. Other anti-tubercular phthalazinones, such as heptylphthalazinone 242, did not greatly affect NADH oxidation, suggesting that the mechanism by which these compounds inhibit Mtb growth is independent of mycobacterial respiration. Taken together, the work presented in this chapter is the first to demonstrate the potential for phthalazinones to act as anti-tubercular agents. Further studies into optimising the antitubercular activity of these compounds and to better understand their mode of action are underway.

5.4. Experimental

5.4.1. Docking studies

Phthalazinone **212** and pyrimidinyl-phthalazinone **213** were prepared for docking using the *DockPrep* tool in USCF Chimera (version 13.1).²⁸² The quinone binding site of chain B of the *C. thermarum* NDH-II crystal structure (PDB: 6BDO)⁶² was used for docking. The NDH-II crystal structure was prepared by removing the co-crystallised ligand HQNO (**19**) and applying the *DockPrep* tool in USCF Chimera (version 13.1). A 5Å grid was generated whereby the centre was defined as residues 46, 47, 316, 317, 318, 347, 348, 349, 376, 379, 380, and 383. Ligands **212** and **213** were then modelled into the NDH-II quinone binding site using the *anchor and grow* algorithm in DOCK 6 (version 6.9).²⁹⁸ The conformers with the top 50 binding scores were analysed.

5.4.2. Chemistry

General procedure. Unless otherwise stated, all reactions were performed under atmospheric air. Prior to use, DMF (Acros) was distilled over BaO, THF (Panreac) was distilled over sodium wire and benzophenone, CH₂Cl₂ (Fisher) was distilled from P₂O₅, pyridine (BDH) was distilled over CaH₂, and EtOAc (drum), petroleum ether (drum), acetone (drum), MeOH (Pure Science) and H₂O were distilled. 12% AIBN in acetone (Aldrich), ammonium formate (AnalaR), CCl₄ (AnalaR), diethyl ether (Aldrich), 2-ethoxyethanol (Unilab), 4-fluorophenyl hydrazine hydrochloride (Alfa Aesar), Fe (Scientific supplies), 37% HCl (Merck), 4-hydrazine benzene sulfonic acid (Alfa Aesar), hydrazine hydrate (BDH), MgSO4 (Pure Science), NBS (Unilab), nitric acid (Aldrich), pentafluorophenyl hydrazine (Alfa Aesar), phenylhydrazinium chloride (BDH), phthalic anhydride (Aldrich), potassium carbonate (Panreac), propargyl bromide (Acros), sodium (Aldrich), sodium borohydride (Aldrich), 4-sulfonamide hydrazine hydrochloride (Alfa Aesar), sulfuric acid (Panreac), tert-butyl hydrazine hydrochloride (Alfa 4-trifluoromethoxyphenyl hydrazine hydrochloride (Alfa Aesar), Aesar), 4-(trifluoromethyl)phenyl hydrazine (Alfa Aesar), were used as received.

All solvents were removed by evaporation under reduced pressure. Reactions were monitored by TLC-analysis on Macherey-Nagel silica gel coated plastic sheets (0.20 mm, with fluorescent indicator UV_{254}) with detection by UV-absorption (short wave UV - 254 nm; long wave UV - 366 nm) by dipping in KMnO₄ in H₂O. Column chromatography was performed on Pure Science silica gel (40 – 63 micron). Infrared spectra were recorded as thin films using a Bruker Alpha II FTIR spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling accessory and are reported in wavenumbers (cm⁻¹). Melting points (m.p.) were obtained on a DigiMelt MPA160 melting point apparatus. Fluorescence data were obtained on a Shimadzu RF-5301PC spectrophotometer. Nuclear magnetic resonance spectra were recorded at 20 °C in D₂O, CDCl₃, pyridine-d₅, or DMSO-d₆ using either a Varian INOVA operating at 500 MHz (500 MHz for ¹H nuclei and 125 MHz for ¹³C nuclei) or Varian Direct Drive operating at 600 MHz (600 MHz for ¹H nuclei, 150 MHz for ¹³C nuclei). Chemical shifts are given in ppm (δ) relative to solvent residues. NMR peak assignments were made using COSY, HSQC, and HMBC 2D experiments. High-resolution (ESI) mass spectrometric data were obtained with an Agilent 6530 Accurate-Mass Q-TOF LC-MS equipped with a 1260 Infinity binary pump.



Isobenzofuran-1(3*H***)-one (214).** To a solution of phthalic anhydride (13 g, 87 mmol) in freshly distilled THF (152 mL) at 0 °C was added NaBH₄ (3.8 g, 87 mmol, 1 equiv.) portionwise. The thick white suspension was then stirred for 12 h at room temperature, after which time the reaction was acidified with 2 M aq.

HCl until pH 1 was reached. The resulting mixture was again stirred for 12 h at room temperature, after which time the reaction was concentrated *in vacuo* to give a brown solid. The crude product was then extracted with ethyl acetate (50 mL x 3) and washed with sat. aq. NaHCO₃ (50 mL x 2), followed by brine (50 mL), dried with anhydrous MgSO₄, filtered, and concentrated *in vacuo*. Recrystallisation from Et₂O gave the title compound as white crystals (9.2 g, 79%). $R_f = 0.31$ (petroleum ether/EtOAc, 2/1, v/v); m.p.: 79.8 °C (lit.³³⁷ 72-73 °C); IR (v_{max}): 1745, 1712, 1615, 1595, 1466, 1438, 1367, 1318, 1286, 1217, 1199, 1110, 1048, 1017, 999, 959, 737, 700, 680, 563, 473 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 7.91 (d, *J*_{6,7} = 7.2 Hz, 1H, H7), 7.68 (t, *J*_{4,5} = *J*_{5,6} = 7.3 Hz, 1H, H5), 7.54 – 7.51 (m, 2H, H4, H6), 5.33 (s, 2H, H3); ¹³C NMR (125 MHz, CDCl₃): δ ppm 171.24 (C1), 146.6 (C7a), 134.3 (C5), 129.2 (C6), 125.8 (C7), 125.7 (C3a), 122.2 (C4), 69.7 (C3); HRMS-ESI (*m*/*x*) calcd. for [C₈H₆O₂+H]⁺: 135.0441, obsd.: 135.0444 The data obtained for this compound matched those reported in literature.³³⁷



3-Bromoisobenzofuran-1(3*H***)-one (215).³³⁷** To a solution of phthalide **214** (2.6 g, 19.3 mmol) in CCl₄ (77 mL) was added NBS (10.3 g, 58 mmol, 3 equiv.) and AIBN (12% in acetone, 2.2 mL, 0.97 mmol, 0.1 equiv.). The reaction was stirred at 75 °C for 12 h, after which time TLC analysis showed the disappearance

of starting materials and the appearance of bromide 213. The precipitate was filtered and

discarded, and the filtrate concentrated *in vacuo*. Purification via silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 3/1$, v/v) gave the title compound as colourless crystals (2.6 g, 63%). R_f = 0.44 (petroleum ether/EtOAc, 1/1, v/v); m.p.: 87.3 °C (lit.³³⁷ 79-82 °C); IR (ν_{max}): 1774, 1601, 1463, 1341, 1297, 1277, 1214, 1172, 1095, 1034, 959, 772, 691, 650, 598, 459 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 7.93 (d, $J_{6,7}$ = 7.5 Hz, 1H, H7), 7.79 (t, $J_{5,6} = J_{4,5} = 7.6$, 1.0 Hz, 1H, H5), 7.64 – 7.61 (m, 2H, H4, H6), 7.41 (s, H3); ¹³C NMR (125 MHz, CDCl₃) δ ppm 167.5 (C1), 149.0 (C3a), 135.4 (C5), 131.1 (C6), 126.1 (C7), 124.2 (C7a), 123.4 (C4), 74.7 (C3); HRMS-ESI (*m*/z) calcd. for [C₈H₅⁷⁹BrO₂+NH₄]⁺: 229.9811, obsd.: 229.9812.



3-Bromo-6-nitro-benzofuran-1(3*H***)-one (226).³⁴⁴** To a suspension of phthalide **227** (469 mg, 2.62 mmol) in CCl₄ (13 mL) was added NBS (513 mg, 2.88 mmol, 1.1 equiv.) and AIBN (12% in acetone, 0.5 mL, 0.262 mmol, 0.1 equiv.). The reaction was warmed to 75 °C and stirred for 12 h,

after which time TLC analysis showed the disappearance of starting materials and the appearance of bromide **226**. The precipitate was filtered and discarded, and the filtrate concentrated *in vacuo*. Purification via silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 3/1$, v/v) then gave the title compound as a yellow solid (554 mg, 82%). R_f = 0.6 (petroleum ether/EtOAc, 4/1, v/v); IR (v_{max}): 1648, 1589, 1483, 1454, 1344, 1304, 1236, 1181, 1084, 948, 895, 890, 796, 761, 687, 602, 568, 487 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.78 (s, 1H, H7), 8.67 (d, $J_{4,5}$ = 8.4, 1H H5), 7.88 (d, $J_{4,5}$ = 8.4 Hz, 1H, H4), 7.51 (s, 1H, H3); ¹³C NMR (125 MHz, CDCl₃): δ ppm 165.0 (C1), 153.6 (C7a), 149.8 (C6), 130.2 (C5), 125.8 (C3a), 125.1 (C4), 121.6 (C7), 73.1 (C3).



6-Nitrobenzofuran-1(3*H***)-one (227).³⁴⁴** Benzofuranone **214** (878 mg, 6.5 mmol) was dissolved in nitric acid (0.91 mL) and sulfuric acid (1.1 mL) at 0 °C. The ice bath was then removed, allowing it to warm to room temperature, and stirred for 12 h, after which time TLC analysis showed

the disappearance of starting materials and the appearance of phthalide **229**. The reaction was then poured into an ice-H₂O bath and collected via filtration to give the crude product as a white solid. Recrystallisation from Et₂O then gave the title compound as white crystals (919 mg, 79%); m.p.: 176.2 °C; $R_f = 0.21$ (petroleum ether/EtOAc, 2/1, v/v); IR (ν_{max}): 3056, 1654, 1560, 1522, 1457, 1309, 1143, 927, 848, 826, 782, 744, 681, 618, 571, 497, 418 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ ppm 8.76 (d, $J_{5,7} = 1.8$ Hz, 1H, H7), 8.58 (dd, $J_{4,5} = 8.3$ Hz, $J_{5,7} = 2.0$ Hz,

1H, H5), 7.72 (d, $J_{4,5}$ = 8.4 Hz, 1H, H4), 5.46 (s, 2H, H3); ¹³C NMR (125 MHz, CDCl₃) δ ppm 168.7 (C1), 151.9 (C3a), 149.2 (C6), 129.0 (C5), 127.7 (C7a), 123.7 (C4), 121.6 (C7), 69.7 (C3).

General procedure for the formation of phthalazinones. Bromophthalide 215 or 226 (1 equiv.) was dissolved in 5% HCl in H₂O (5 mL/mmol) and stirred at reflux for 2 h, after which time the reaction was allowed to cool to room temperature. Once cooled, a hydrazinium chloride (1.2 equiv.) was added to the solution and the reaction stirred at room temperature for a further 2 h. The resulting precipitate was then collected and recrystallised from hot ethanol to afford the title compounds.

Phthalazin-1(2*H*)-one (31).³⁴⁰ By subjecting bromophthalide 215 (125.7 mg, 0.59 mmol) and hydrazine hydrate (0.03 mL, 0.71 mmol) to the general procedure for the formation of phthalazinones to obtain the title compound as a white amorphous solid (40.5 mg, 47%); $R_f = 0.27$ (petroleum ether/EtOAc, 1/1, v/v); IR (ν_{max}): 2922, 1651, 1348, 1152, 1102, 1053, 877, 797, 769, 681, 591, 592, 490 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 10.87 (br. s, 1H, NH), 8.46 (d, $J_{7,8} = 7.8$ Hz, 1H, H8), 8.20 (s, 1H, H4), 7.92 – 7.79 (m, 2H, H6, H7), 7.76 (d, $J_{5,6} = 7.9$ Hz, 1H, H5); ¹³C NMR (125 MHz, CDCl₃) δ ppm 160.8 (C1), 139.2 (C4), 133.9 (C6), 132.0 (C7), 130.4 (C4a), 128.2 (C8a), 126.6 (C8), 126.4 (C5); HRMS-ESI (m/z) calcd. for [C₈H₆N₂O+H]⁺: 147.0553, obsd.: 147.0549.



2-*Tert*-butylphthalazin-1(2*H*)-one (216). By subjecting bromophthalide 215 (52 mg, 0.24 mmol) and *tert*-butylhydrazinium hydrochloride (35.9 mg, 0.29 mmol) to the general procedure for the formation of phthalazinones

to obtain the title compound as a white amorphous solid (44.7 mg, 92%); $R_f = 0.74$ (EtOAc/petroleum ether, 1/1, v/v); IR (v_{max}): 1650, 1594, 1365, 1198, 1151, 1103, 1086, 761, 690, 602 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.44 (d, $J_{7,8} = 7.8$ Hz, 1H, H8), 8.13 (s, 1H, H4), 7.81 – 7.71 (m, 2H, H6, H7), 7.67 (d, $J_{6,7} = 7.6$ Hz, 1H, H5), 1.74 (s, 9H, H2'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 160.0 (C1); 135.6 (C4), 132.7 (C7), 131.1 (C6), 129.4 (C4a), 129.3 (C8a), 126.6 (C8), 125.3 (C5), 64.2 (C1'), 28.3 (C2'); HRMS-ESI (m/x) calcd. for [C₁₂H₁₄N₂O+H]⁺: 203.1179, obsd.: 203.1178. The data obtained for this compound matched those reported in literature.³⁴¹



2-Phenylphthalazin-1(2H)-one (217). By subjecting bromophthalide **215** (50.2 mg, 0.24 mmol) and phenylhydrazinium hydrochloride (41.6 mg, 0.29 mmol) to the general procedure for the formation of phthalazinones to obtain the title compound as a colourless crystals (32.5

mg, 61%); $R_f = 0.45$ (EtOAc/petroleum ether, 1/1, v/v); m.p.: 106.4 °C (lit.³⁴¹ 104-106 °C); IR (ν_{max}): 1654, 1584, 1488, 1452, 1330, 1136, 1060, 904, 862, 798, 764, 735, 706, 685, 617, 599, 582, 538, 483 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.52 (d, $J_{7,8} = 7.7$ Hz, 1H, H8), 8.30 (s, 1H, H4), 7.87 – 7.80 (m, 2H, H6, H7), 7.76 (d, $J_{5,6} = 7.8$ Hz, 1H, H5), 7.66 (d, $J_{2,3'} = 8.0$ Hz, 2H, H2'), 7.50 (t, $J_{2,3'} = J_{3,4'} = 7.9$ Hz, 2H, H3'), 7.39 (t, $J_{3',4'} = 7.7$ Hz, 1H, H4'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 159.2 (C1), 141.9 (C1'), 138.5 (C4), 133.5 (C6), 132.0 (C7), 129.5 (C4a), 128.8 (C8), 128.6 (C8a), 127.8 (C3'), 127.3 (C4'), 126.2 (C5), 125.8 (C2'); HRMS-ESI (m/z) calcd. for [C₁₄H₁N₂O+H]⁺: 223.0866, obsd.: 223.0864. The data obtained for this compound matched those reported in literature.³⁴¹



2-(4-Fluorophenyl)phthalazin-1(2*H***)-one (218).** By subjecting bromophthalide **215** (28.0 mg, 0.13 mmol) and 4-fluorophenyl hydrazine hydrochloride (25.4 mg, 0.16 mmol) to the general procedure for the formation of phthalazinones to obtain the title

compound as white crystals (25.0 mg, 80%); $R_f = 0.57$ (EtOAc/petroleum ether, 1/1, v/v); m.p.: 134.5 °C; IR (ν_{max}): 1651, 1592, 1504, 1335, 1225, 1140, 913, 871, 836, 807, 754, 728, 682, 611, 596, 451, 518, 477 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.53 (d, $J_{7,8} = 7.5$ Hz, 1H, H8), 8.31 (s, 1H, H4), 7.93 – 7.81 (m, 2H, H6, H7), 7.78 (d, $J_{5,6} = 7.4$ Hz, 1H, H5), 7.70 – 7.63 (m, 2H, H2'), 7.23 – 7.15 (m, 2H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 161.6 (d, $J_{4,F} =$ 245.4 Hz, C4'), 159.2 (C1), 137.9 (C1'), 138.6 (C4), 133.6 (C6), 132.1 (C7), 129.5 (C8a), 128.5 (C4a), 127.6 (C2'), 127.5 (C8), 126.2 (C5), 115.6 (d, $J_{3',F} = 23.0$ Hz, C3'); ¹⁹F NMR (282 MHz, CDCl₃) δ ppm -113.90; HRMS-ESI (m/z) calcd. for [C₁₄H₉FN₂O+H]⁺: 241.0772, obsd.: 241.0769. The data for this compound matched that in literature.³⁴²



2-(Pentafluorophenyl)phthalazin-1(2*H***)-one (219).** By subjecting bromophthalide **215** (51.0 mg, 0.24 mmol) and pentafluorophenyl hydrazine (57.0 mg, 0.29 mmol) to the general procedure for the formation of phthalazinones to obtain the title compound as white crystals (25.5 mg, 34%); $R_f = 0.23$ (petroleum ether/EtOAc, 4/1,

v/v); m.p.: 136.8 °C; IR (u_{max}): 1678, 1509, 1301, 1136, 1070, 992, 958, 899, 801, 764, 734, 682,

616, 598, 489 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.51 (d, $J_{7,8} = 7.8$ Hz, 1H, H8), 8.32 (s, 1H, H4), 7.95 (td, $J_{6,7} = J_{5,6} = 7.6$ Hz, $J_{6,8} = 1.4$ Hz, 1H, H6), 7.89 (dd, $J_{7,8} = 8.6$ Hz, $J_{5,7}$ 1.3 Hz, 1H, H7), 7.82 (dd, $J_{4,5} = 7.8$ Hz, $J_{5,7} = 1.3$ Hz, 1H, H5); ¹³C NMR (125 MHz, CDCl₃) δ ppm 162.3 (C1'), 158.9 (C1), 145.2 (CF), 143.1 (CF), 140.9 (CF), 140.4 (C4), 139.2 (CF), 137.0 (CF), 134.6 (C6), 132.8 (C7), 129.8 (C8a), 127.8 (C4a), 127.5 (C8), 126.9 (C5); ¹⁹F NMR (282 MHz, CDCl₃) δ ppm -144.49 (d, $J_{0,m} = 17.8$ Hz, 2F, *o*-F), -152.85 (t, $J_{m,p} = 21.1$ Hz, 1F, *p*-F), -161.74 (t, $J_{0,m} = J_{m,p} = 21.89$ Hz, 2F, *m*-F); HRMS-ESI (*m*/*z*) calcd. for [C₁₄H₅F₅N₂O +H]⁺: 313.0395, obsd.: 313.0398.



2-(4-Trifluoromethyl)phenyl)phthalazin-1(2*H***)-one (220). By subjecting bromophthalide 215** (45.9 mg, 0.22 mmol) and 4- (trifluoromethyl)phenyl hydrazine (46.5 mg, 0.26 mmol) to the general procedure for the formation of phthalazinones to obtain

the title compound as white crystals (37.0 mg, 58%); $R_f = 0.52$ (EtOAc/petroleum ether, 1/1, v/v); m.p.: 164.9 °C; IR (ν_{max}): 2173, 1671, 1327, 1105, 1073, 1057, 870, 834, 7674, 682, 626, 602, 536, 503, 435, 424, 407 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.51 (d, $J_{7,8} = 7.9$ Hz, 1H, H8), 8.31 (s, 1H, H4), 7.91 – 7.80 (m, 4H, H6, H7, H2'), 7.80 – 7.71 (m, 3H, H5, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 159.3 (C1), 144.8 (C1'), 139.2 (C4), 134.0 (C6), 132.4 (C7), 129.5 (q, $J_{4',F} = 32.6$ Hz, C4'), 129.4 (C8a), 128.5 (C4a), 127.3 (C8), 126.4 (C5), 125.9 (q, $J_{3',F} = 3.7$ Hz, C3'), 125.9 (C2'), 124.0 (q, $J_{CF3,F} = 272.9$ Hz, CF₃); ¹⁹F NMR (282 MHz, CDCl₃) δ ppm -62.46; HRMS-ESI (m/r_{2}) calcd. for [C₁₅H₉F₃N₂O+H]⁺: 291.0740, obsd.: 291.0740. The data obtained for this compound matched those reported in literature.³⁴³



2-(4-(Trifluoromethoxy)phenyl)phthalazin-1(2*H***)-one (221). By subjecting bromophthalide 215 (21.4 mg, 0.10 mmol) and 4-(trifluoromethoxy)phenyl hydrazine (27.4 mg, 0.12 mmol) to the general procedure for the formation of phthalazinones to**

obtain the title compound as white crystals (19.9 mg, 65%); $R_f = 0.6$ (EtOAc/petroleum ether, 1/1, v/v); m.p.: 115 °C; IR (ν_{max}): 1660. 1590. 1504. 1137. 902. 842. 766. 685. 592. 504. 481 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 8.51 (d, $J_{7,8} = 7.8$ Hz, 1H, H8), 8.30 (s, 1H, H4), 7.90 – 7.80 (m, 2H, H6, H7), 7.79 – 7.71 (m, 3H, H5, H3'), 7.34 (d, $J_{2',3'} = 8.8$ Hz, 2H, H2'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 159.3 (C1), 148.2 (C4'), 140.4 (C1'), 139.0 (C4), 133.9 (C6), 132.4 (C7), 129.6 (C8a), 128.6 (C4a), 127.5 (C8), 127.2 (C3'), 126.4 (C5), 121.4 (C2'), 120.6 (q,

 $J_{CF3,F} = 269.7 \text{ Hz}, CF_3$; ¹⁹F NMR (282 MHz, CDCl₃) δ ppm -57.85; HRMS-ESI (*m*/*z*) calcd. for $[C_{15}H_9F_3N_2O_2+H]^+$: 207.0689, obsd.: 307.0691.



2-(1-Oxophthalazin-1(2*H*)-yl)benzenesulfonic acid (222). By subjecting bromophthalide 215 (49.3 mg, 0.23 mmol) and 4hydrazine benzene sulfonic acid (51.9 mg, 0.28 mmol) to the general procedure for the formation of phthalazinones to obtain the title compound as colourless crystals (52.8 mg, 76%); $R_f =$

0.19 (EtOAc/MeOH, 4/1, v/v); m.p.: 214.8 °C; IR (ν_{max}): 3032, 1645, 1591, 1428, 1332, 1225, 1177, 1120, 1029, 987, 912, 8334, 762, 684, 666, 618, 593, 572 cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆) δ ppm 8.58 (s, 1H, H4), 8.32 (dd, $J_{7,8} = 7.9$ Hz, $J_{4,6} = 1.1$ Hz, 1H, H8), 8.04 – 7.95 (m, 2H, H5, H7), 7.91 (t, $J_{5,6} = 7.3$ Hz, 1H, H6), 7.78 – 7.72 (m, 2H, H2'), 7.63 – 7.57 (m, 2H, H3'); ¹³C NMR (125 MHz, dmso-d₆) δ ppm 158.8 (C1), 142.2 (C4'), 139.4 (C1'), 134.5 (C7), 133.0 (C6), 129.7 (C4a), 128.1 (C8a), 127.6 (C5), 126.7 (C8), 126.3 (C2'), 125.8 (C3'); HRMS-ESI (m/z) calcd. for [C₁₄H₁₀N₂O₄S+H]⁺: 303.0434, obsd.: 303.0434.



2-(1-Oxophthalazin-1(2*H***)-yl)benzenesulfonamide (223).** By subjecting bromophthalide **215** (35.1 mg, 0.17 mmol) and 4sulfonamide phenyl hydrazine hydrochloride (44.3 mg, 0.20 mmol) to the general procedure for the formation of phthalazinones to obtain the title compound as white crystals

(19.5 mg, 38%); $R_f = 0.52$ (EtOAc); IR (v_{max}): 3290, 1643, 1580, 1491, 1331, 1156, 1091, 903, 831, 758, 685, 612, 584, 549, 524 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.19 (s, 2H, NH₂), 8.56 (d, $J_{7,8} = 7.9$ Hz, 1H, H8), 8.45 – 8.38 (m, 3H, H4, H2'), 8.18 – 8.07 (m, 2H, H3'), 7.81 – 7.69 (m, 3H, H6, H7, H7); ¹³C NMR (125 MHz, pyridine-d₅) δ ppm 160.39 (C1), 146.5 (C4'), 145.3 (C1'), 140.7 (C4), 135.3 (C6), 133.7 (C7), 131.1 (C4a), 130.0 (C8a), 128.5 (C8), 128.26 (C2'), 128.23 (C5), 127.7 (C3'); HRMS-ESI (*m/z*) calcd. for [C₁₄H₁₁N₃O₃S+H]⁺: 302.0594, obsd.: 302.0592.



7-Nitro-2-phenylphthalazin-1(2*H*)-one (228). By subjecting bromophthalide 226 (326 mg, 1.26 mmol) and phenylhydrazinium chloride (219 mg, 1.51 mmol) to the general procedure for the formation of phthalazinones to obtain the title compound as

yellow amorphous solid (252.5 mg, 75%); $R_f = 0.21$ (petroleum ether/EtOAc, 1/1, v/v); m.p.: 149 °C; IR (ν_{max}): 1656, 1591, 1518, 1348, 1142, 924, 847, 823, 753, 680, 618, 588 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.34 (d, $J_{6,8} = 2.2$ Hz, 1H, H8), 8.65 (dd, $J_{5,6} = 8.5$, $J_{6,8} = 2.3$ Hz, 1H, H6), 8.41 (s, 1H, H4), 7.95 (d, $J_{5,6} = 8.7$ Hz, 1H, H5), 7.66 (d, $J_{2',3'} = 7.4$ Hz, 2H, H2'), 7.53 (t, $J_{2',3'} = J_{3',4'} = 7.9$ Hz, 2H, H3'), 7.44 (t, $J_{3',4'} = 7.4$ Hz, 1H, H4'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 157.9 (C1), 149.5 (C7), 141.2 (C1'), 136.8 (C4), 133.0 (C8a), 129.4 (C4a), 129.0 (C3'), 128.4 (C4'), 128.0 (C5), 127.7 (C6), 125.5 (C2'), 123.5 (C8); HRMS-ESI (m/x) calcd. for [C₁₄H₉N₃O₃+H]⁺: 268.0717, obsd.: 268.0716. The data obtained for this compound were consistent with those reported in literature.³⁴⁵



7-Nitro-phthalazin-1(2*H*)-one (230). By subjecting bromophthalide 226 (184 mg, 0.71 mmol) and hydrazine hydrate (0.05 mL, 1.07 mmol) to the general procedure for the formation of phthalazinones to obtain the title compound as yellow amorphous solid (99.1 mg, 73%); $R_f = 0.35$

(EtOAc/petroleum ether, 1/1, v/v); IR (ν_{max}): 3036, 2919, 2870, 1685, 1670, 1617, 1513, 1334, 1225, 1154, 1091, 926, 897, 800, 745, 677, 622, 562, 529 cm⁻¹; ¹H NMR (500 MHz, pyridined₅) δ ppm 9.33 (d, $J_{6,8} = 2.3$ Hz, 1H, H8), 8.57 (dd, $J_{5,6} = 8.6$ Hz, $J_{6,8} = 2.4$ Hz, 1H, H6), 8.48 (s, 1H, H4), 7.95 (d, $J_{5,6} = 8.6$ Hz, 1H, H5); ¹³C NMR (125 MHz, pyridine-d₅) δ ppm 161.1 (C1), 150.5 (C7), 138.5 (C4), 135.6 (C4a), 130.6 (C8a), 130.0 (C5), 128.8 (C6), 123.5 (C8); HRMS-ESI (m/z) calcd. for [C₈H₅N₃O₃+H]⁺: 192.0404, obsd.: 192.0408.



2-Heptylphthalazin-1(2*H***)-one (224).** Phthalazinone **31** (34.4 mg, 0.24 mmol) was dissolved in DMF (1.18 mL) before potassium carbonate (132.7 mg, 0.96 mmol) and bromoheptane (0.11 mL, 0.72 mmol) were added. The

reaction was warmed to 50 °C and stirred for 12 h, after which time TLC analysis showed complete disappearance of the starting material. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 4/1$, v/v) gave the title compound as a white amorphous solid (19.9 mg, 34%); R_f = 0.47 (EtOAc/petroleum ether, 1/1, v/v); ¹H NMR (500 MHz, CDCl₃) δ ppm 8.43 (d, $J_{7,8}$ = 7.7 Hz, 1H, H8), 8.16 (s, 1H, H4), 7.82 – 7.72 (m, 2H, H7, H6), 7.68 (d, $J_{6,7}$ = 7.6 Hz, 1H, H5), 4.22 (t, $J_{1',2'}$ = 7.5 Hz, 2H, H1'), 1.89 – 1.80 (m, 2H, H2'), 1.42 – 1.31 (m, 4H, H3', H5'), 1.30 – 1.22 (m, 4H, H4', H6'), 0.86 (t, $J_{6,7'}$ = 6.9 Hz, 3H, H7'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 159.4 (C1), 137.7 (C4), 133.0 (C6), 131.7 (C7), 129.7 (C8a), 128.1 (C4a), 126.8 (C8), 126.0 (C5), 51.4 (C1'), 31.9 (C6'), 29.1 (C3'), 28.7 (C2'), 26.8 (C5'), 22.7 (C4'), 14.2 (C7'); HRMS-ESI (*m*/*z*) calcd. for [C₁₅H₂₀N₂O+H]⁺: 245.1648, obsd.: 245.1646.



2-propargylphthalazin-1(2*H*)-one (225). Phthalazinone 31 (5.1 mg, 0.04 mmol) was dissolved in DMF (0.18 mL) before a solution of NaOEt (21% in EtOH, 0.05 mL) and propargyl bromide (80% in toluene, 0.02 mL) were added. The reaction was stirred at room

temperature for 2 d, after which time TLC analysis showed complete disappearance of the starting material. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 4/1$, v/v) gave the title compound as colourless crystals (4.3 mg, 58%); R_f = 0.24 (petroleum/EtOAc, 4/1, v/v); m.p.: 104.8 °C; IR (ν_{max}): 2925, 1639, 1590, 1338, 1102, 905, 767, 683, 583 cm^{-1, 1}H NMR (500 MHz, CDCl₃) δ ppm 8.45 (d, $J_{6,8}$ = 7.5 Hz, 1H, H8), 8.21 (s, 1H, H4), 7.87 – 7.76 (m, 2H, H6, H7), 7.71 (d, $J_{5,6}$ = 7.4 Hz, 1H, H5), 5.03 (d, $J_{1',3'}$ = 2.5 Hz, 2H, H1'), 2.34 (t, $J_{1',3'}$ = 2.5 Hz, 1H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 138.7 (C4), 133.6 (C6), 132.1 (C7), 129.9 (C8a), 128.0 (C4a), 127.0 (C8), 126.4 (C5), 78.2 (C2'), 72.6 (C3'), 40.7 (C1'); HRMS-ESI (m/z) calcd. for [C₁₁H₈N₂O+H]⁺: 185.0709, obsd.: 185.0707.

7-Nitro-2-propargylphthalazin-1(2H)-one



Phthalazinone **31** (72.5 mg, 0.38 mmol) was dissolved in DMF (1.89 mL) before a solution of NaOEt (21% in EtOH, 0.5 mL) and propargyl bromide (80% in toluene, 0.15 mL) were added. The

(231).

reaction was stirred at room temperature for 2 d, after which time TLC analysis showed complete disappearance of the starting material. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 4/1$, v/v) gave the title compound as yellow crystals (80.1 mg, 92%); $R_f = 0.37$ (EtOAc/petroleum ether, 1/1, v/v); m.p.: 151.4 °C; IR (v_{max}): 3295, 1654, 1593, 1565, 1518, 1351, 1128, 920, 841, 786, 772, 745, 685, 642, 622, 593, 540 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.27 (d, $J_{6,8} = 2.2$ Hz, 1H, H8), 8.62 (dd, $J_{5,6} = 8.6$ Hz, $J_{6,8} = 2.3$ Hz, 1H, H6), 8.31 (s, 1H, H4), 7.91 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 5.05 (d, $J_{1',3'} = 2.5$ Hz, 2H, H1'), 2.38 (t, $J_{1',3'} = 2.5$ Hz, 1H, H3'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 157.6

(C1), 149.4 (C7), 136.8 (C4), 133.2 (C4a), 128.6 (C8a), 128.1 (C5), 127.6 (C6), 123.1 (C8), 77.3 (C2'), 73.1 (C3'), 41.02 (C1'); HRMS-ESI (*m/z*) calcd. for [C₁₁H₇N₃O₃+H]⁺: 230.0560, obsd.: 230.0558.



2-Heptyl-7-nitro-phthalazin-1(2*H*)-one (233). Phthalazinone 230 (95.1 mg, 0.49 mmol) was dissolved in DMF (2.5 mL) before potassium carbonate (270.9 mg, 1.96 mmol) and bromoheptane (0.23 mL, 1.47

mmol) were added. The reaction was warmed to 50 °C and stirred for 12 h, after which time TLC analysis showed complete disappearance of the starting material. Purification by silica gel flash column chromatography (petroleum ether/EtOAc, $1/0 \rightarrow 4/1$, v/v) gave the title compound as yellow crystals (83.6 mg, 59%); $R_f = 0.56$ (EtOAc/petroleum ether, 1/1, v/v); m.p.: 152.8 °C; IR (v_{max}): 2918, 1853, 1651, 1617, 1561, 1528, 1465, 1341, 1165, 1086, 1063, 911, 541, 769, 758, 725, 684, 620, 595, 492 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ ppm 9.29 (d, $J_{4,6} = 2.3$ Hz, 1H, H8), 8.60 (dd, $J_{5,6} = 8.6$ Hz, $J_{6,8} = 2.3$ Hz, 1H, H6), 8.28 (s, 1H, H4), 7.90 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 4.28 (t, $J_{1',2'} = 7.5$ Hz, 2H, H1'), 1.87 (pent., $J_{1',2'} = J_{2',3'} = 7.4$ Hz, 2H, H2'), 1.43 – 1.25 (m, 8H, H3', H4', H5', H6'), 0.89 (t, $J_{6,7'} = 6.9$ Hz, 3H, H7'); ¹³C NMR (125 MHz, CDCl₃) δ ppm 158.2 (C1), 149.3 (C7), 136.0 (C4), 133.2 (C4a), 128.7 (C8a), 127.8 (C5), 127.2 (C6), 123.2 (C8), 51.8 (C1'), 31.8 (C4'), 29.1 (C5'), 28.6 (C2'), 26.8 (C3'), 22.7 (C6'), 14.21 (C7'); HRMS-ESI (m/z) calcd. for [C₁₅H₁₉N₃O₃+H]⁺: 290.1499, obsd.: 290.1498.

General procedure for the reduction of nitroaryl groups. Nitro-chromone or nitrophenyl chromone (1 equiv.) was dissolved in EtOH/H₂O (2/1, v/v, 5 mL/mmol) and stirred under argon. Fe (10 equiv.) and ammonium formate (8 equiv.) were then added into the reaction flask, and the reaction heated to reflux for 12 h, after which time TLC analysis showed the disappearance of starting materials. The reaction was filtered and rinsed with hot EtOH, and the filtrate was concentrated *in vacuo* to give a brown solid, which was purified using silica gel column chromatography (petroleum ether/EtOAc, $9/1 \rightarrow 1/1$, v/v) to yield the desired aminochromones.



7-Nitro-2-phenylphthalazin-1(2*H*)-one (229). By subjecting nitro-phthalazinone 228 (100 mg, 0.37 mmol), iron (208.9 mg, 3.74 mmol), and ammonium formate (356.5 mg, 2.99 mmol) in EtOH/H₂O (2/1, v/v, 2.1 mL) to the general procedure for the

reduction of nitroaryl groups, the title compound was isolated as a white amorphous solid (86.9 mg, 99%); $R_f = 0.38$ (EtOAc/petroleum ether, 2/1, v/v); IR (ν_{max}): 2977, 2797, 1648, 1577, 1570, 1510, 1491, 1452, 1425, 1371, 1342, 1293, 1129, 1051, 1027, 773, 758 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.25 (s, 1H, H4), 8.12 (d, $J_{6,8} = 2.4$ Hz, 1H, H8), 7.99 (d, $J_{2;3'} = 7.5$ Hz, 2H, H2'), 7.61 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 7.47 (t, $J_{2;3'} = J_{3',4'} = 7.9$ Hz, 2H, H3'), 7.38 (dd, $J_{5,6} = 8.5$, $J_{6,8} = 2.4$ Hz, 1H, H6), 7.32 (t, $J_{3',4'} = 7.5$ Hz, 1H, H4'), 7.00 (br. s, 2H, NH₂); ¹³C NMR (125 MHz, pyridine-d₅) δ ppm 160.0 (C1), 154.0 (C7), 144.0 (C1'), 139.4 (C4), 131.6 (C8a), 129.2 (C5), 129.2 (C3'), 127.8 (C4'), 127.0 (C2'), 121.6 (C6), 120.8 (C4a), 108.8 (C8); HRMS-ESI (m/s) calcd. for [C₁₄H₁₁N₃O+H]⁺: 238.0975, obsd.: 238.0973. The data obtained for this compound were consistent with those reported in literature.³⁴⁵



7-Amino-2-propargyl-phthalazin-1(2*H*)-one (232). By subjecting nitro-phthalazinone 233 (76.8 mg, 0.34 mmol), iron (187.1 mg, 3.35 mmol), and ammonium formate (319.4 mg, 2.68 mmol) in EtOH/H₂O (2/1, v/v, 1.68 mL) to the general

procedure for the reduction of nitroaryl groups, the title compound was isolated as colourless crystals (59.6 mg, 88%); $R_f = 0.17$ (petroleum ether/EtOAc, 1/1, v/v); m.p.: 216 °C; IR (υ_{max}): 3206, 1636, 1592, 1500, 1450, 1363, 1317, 1250, 1138, 1097, 8728, 706, 604, 587, 511, 461 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.14 (s, 1H, H4), 8.03 (d, $J_{6,8} = 2.3$ Hz, 1H, H8), 7.52 (d, $J_{5,6} = 8.5$ Hz, 1H, H5), 7.32 (dd, $J_{5,6} = 8.5$, $J_{6,8} = 2.3$ Hz, 1H, H6), 6.97 (br. s, 1H, NH₂), 5.23 (d, $J_{1',3'} = 2.6$ Hz, 1H, H1'), 3.28 (m, 1H, H3'); ¹³C NMR (125 MHz, pyridine-d₅) δ ppm 160.5 (C1), 154.8 (C7), 140.0 (C4), 131.8 (C8a), 130.1 (C5), 122.4 (C6), 122.0 (C4a), 109.1 (C8), 81.5 (C2'), 74.8 (C3'), 42.0 (C1'); HRMS-ESI (m/z) calcd. for [C₁₁H₉N₃O+H]⁺: 200.0818, obsd.: 200.0816.



7-Amino-2-heptylphthalazin-1(2H)-one (234). By

subjecting nitro-phthalazinone **233** (84 mg, 0.29 mmol), iron (52 mg, 2.9 mmol), and ammonium formate (276.5 mg, 2.32 mmol) in EtOH/H₂O (2/1, v/v, 2.1 mL) to

the general procedure for the reduction of nitroaryl groups, the title compound was isolated

as colourless crystals (73.7 mg, 98%); $R_f = 0.3$ (EtOAc/petroleum ether, 1/1, v/v); m.p.: 116.8 °C; IR (v_{max}): 2967, 2792, 2710, 1557, 1454, 1420, 1342, 1107, 1096, 773 cm⁻¹; ¹H NMR (500 MHz, pyridine- d_5/CD_3OD) δ ppm 8.19 (s, 1H, H4), 8.12 (d, $J_{6,8} = 2.4$ Hz, 1H, H8), 7.57 (m, 1H, H5), 7.37 (dd, $J_{5,6} = 8.5$ Hz, $J_{6,8} = 2.4$ Hz, 1H, H6), 6.93 (br. s, 2H, NH₂), 4.38 (t, $J_{1',2'} = 7.3$ Hz, 2H, H1'), 1.93 (pent., $J_{1',2'} = J_{2',3'} = 7.4$ Hz, 2H, H2'), 1.37 – 1.29 (m, 2H, H3'), 1.28 – 1.20 (m, 2H, H4'), 1.20 – 1.10 (m, 4H, H5', H6'), 0.79 (t, $J_{6',7'} = 7.0$ Hz, 3H, H7'); ¹³C NMR (150 MHz, pyridine- d_5/CD_3OD) δ ppm 160.0 (C1), 153.7 (C7), 138.4 (C4), 131.2 (C8a), 129.0 (C5), 121.4 (C6), 108.3 (C8), 51.5 (C1'), 32.4 (C6'), 29.7 (C4'), 29.5 (C2'), 27.5 (C3'), 23.3 (C5'), 14.7 (C7'); HRMS-ESI (m/z) calcd. for [C₁₅H₂₁N₃O+H]⁺: 260.1757, obsd.: 260.1761.

General procedure for the synthesis of pyrimidinyl-phthalazinone. Chloropyrimidine (1.5 equiv.) and aminophthalazinone (1 equiv.) were co-evaporated three times in dry toluene to remove traces of water before being dissolved in 2-ethoxyethanol (5 mL/mmol). Concentrated HCl (0.5 equiv.) was then added, and the reaction was stirred under reflux for 22 h. The precipitate was filtered and washed with Et₂O to give the title compound as yellow solids.



7-((2-Amino-6-methylpyrimidin-4-yl)amino)-2phenylphthalazin-1(2*H*)-one (235). By subjecting methyl-chloropyrimidine 150 (18.1 mg, 0.13 mmol) and amino-phthalazinone 229 (20 mg, 0.08 mmol) in conc. HCl (0.04 mL) and 2-ethoxyethanol (0.425 mL) to the

general procedure for the synthesis of pyrimidinyl-phthalazinones, the title compound was isolated as a white amorphous solid (17.4 mg, 60%); $R_f = 0.19$ (EtOAc/MeOH, 4/1, v/v); Fluorescence (MeOH): Ex 380 nm, Em 480 nm; IR (ν_{max}): 1640, 1582, 1518, 1496, 1456, 1356, 1341, 1151, 1061, 973 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 10.85 (br. s, 1H, NH), 9.05 (d, $J_{6,8} = 2.2$ Hz, 1H, H8), 8.73 – 8.71 (m, 1H, H6), 8.35 (s, 1H, H4), 7.98 (d, $J_{2',3'} = 7.8$ Hz, 2H, H2'), 7.67 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 7.50 (t, $J_{2',3'} = J_{3',4'} = 7.8$ Hz, 2H, H3'), 7.34 (t, $J_{3',4'} = 7.4$ Hz, 1H, H4'), 6.29 (s, 1H, H5''), 2.27 (s, 3H, CH₃); ¹³C NMR (125 MHz, pyridine-d₅) δ ppm 168.1 (C2''), 164.0 (C6''), 162.9 (C4''), 160.3 (C1), 144.5 (C7), 144.3 (C1'), 139.7 (C4), 131.0 (C8a), 130.1 (C4'), 129.03 (C5), 128.97 (C3'), 128.5 (C6), 127.7 (C2'), 126.9 (C4a), 119.2 (C8), 98.9 (C5''), 23.3 (CH₃); HRMS-ESI (m/z) calcd. for [C₁₉H₁₆N₆O₁+H]⁺: 345.1458, obsd.: 345.1456.



7-((2-Amino-6-methylpyrimidin-4-yl)amino)-2-heptylphthalazin-1(2H)-one (236). By subjecting methyl-chloropyrimidine 150 (16.6 mg, 0.12 mmol) and amino-

phthalazinone **232** (20 mg, 0.08 mmol) in conc. HCl (0.04 mL) and 2-ethoxyethanol (0.425 mL) to the general procedure for the synthesis of pyrimidinyl-phthalazinones, the title compound was isolated as a white amorphous solid (23.2 mg, 79%); $R_f = 0.47$ (EtOAc/MeOH, 4/1, v/v); Fluorescence: Ex 387 nm, 481nm; IR (ν_{max}): 2954, 2841, 1654, 1636, 1588, 1522, 1518, 1452, 1420, 1104, 599, 578, 541, 516, 472, 462, 455 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 11.91 (br. s, 1H, NH), 9.05 (d, $J_{6,8} = 2.0$ Hz, 1H, H8), 8.55 (dd, $J_{5,6} = 8.6, J_{6,8} = 2.1$ Hz, 1H, H6), 8.31 (s, 1H, H4), 7.66 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 6.42 (s, 1H, H5"), 4.35 (t, $J_{1,2} = 7.3$ Hz, 2H, H1'), 2.26 (s, 3H, CH₃), 1.91 (q, $J_{1',2'} = 7.4$ Hz, $J_{2',3'} = 2$ H, H2'), 1.40 – 1.09 (m, 8H, H3', H4', H5', H6'), 0.80 (t, $J_{7,8'} = 7.0$ Hz, 3H, H7'); ¹³C NMR (125 MHz, pyridine-d₅) δ ppm 163.2 (C6"), 159.8 (C2'), 159.5 (C1), 157.8 (C4"), 143.5 (C7), 137.8 (C4), 129.7 (8a), 128.0 (C5), 127.3 (C6), 126.4 (C4a), 117.7 (C8), 97.9 (C5"), 51.6 (C1'), 32.3 (C2'), 29.7 (C3'), 29.4 (C4'), 27.4 (C5'), 23.3 (CH₃), 20.3 (C6'), 14.7 (C7'); HRMS-ESI (m/z) calcd. for [C₂₀H₂₆N₃O+H]⁺: 367.2241, obsd.: 367.2239.



7-(2-Amino-6-methylpyrimidin-4-yl)amino)-2propargylphthalazin-1(2*H*)-one (237). By subjecting methyl-chloropyrimidine 150 (22.2 mg, 0.15 mmol) and amino-phthalazinone 232 (20.6 mg, 0.10 mmol) in conc.

HCl (0.05 mL) and 2-ethoxyethanol (0.52 mL) to the general procedure for the synthesis of pyrimidinyl-phthalazinones, the title compound was isolated as a white amorphous solid (9.2 mg, 29%); $R_f = 0.31$ (EtOAc/MeOH, 4/1, v/v); Fluorescence (MeOH): Ex 387 nm, Em 484 nm; IR (ν_{max}): 2179, 2061, 1983, 1969, 1578, 1558, 1543, 1534, 1523, 1509, 1435, 1165, 1153, 1076, 894, 877, 650, 637, 451, 426, 417 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 10.70 (br. s, 1H, NH), 9.06 (d, $J_{6,8} = 2.2$ Hz, 1H, H8), 8.62 (dd, $J_{5,6} = 8.7$, $J_{6,8} = 2.3$ Hz, 1H, H6), 8.23 (s, 1H, H4), 7.60 (d, $J_{5,6} = 8.8$ Hz, 1H, H5), 6.25 (s, 1H, H5"), 5.25 (d, $J_{1',3'} = 2.5$ Hz, 2H, H1'), 3.35 (d, $J_{1',3'} = 2.4$ Hz, 1H, H3'), 2.25 (s, 3H, CH₃); ¹³C NMR (150 MHz, pyridine-d₅) δ ppm 168.4 (C4"), 165.5 (C2"), 163.5 (C6"), 160.2 (C1), 146.8 (C7), 139.6 (C4), 130.6 (C8a), 129.1

(C5), 126.8 (C6), 125.5 (C4a), 116.0 (C8), 97.8 (C5"), 75.0 (C3'), 42.1 (C1'), 81.2 (C2'), 31.77, 25.2 (CH₃); HRMS-ESI calcd. for [C₁₆H₁₄N₆O+H]⁺: 307.1302, obsd.: 307.1304.



7-((2-Amino-6-phenylpyrimidin-4-yl)amino)-2-phenylphthalazin-1(2*H*)-one (238). By subjecting chloropyrimidine 187 (43.2 mg, 0.21 mmol) and amino-phthalazinone 229 (33.5 mg,

0.14 mmol) in conc. HCl (0.07 mL) and 2-ethoxyethanol (0.7mL) to the general procedure for the synthesis of pyrimidinyl-phthalazinones, the title compound was isolated as a white amorphous solid (13.1 mg, 23%); $R_f = 0.57$ (EtOAc); Fluorescence (MeOH): Ex 384 nm, Em 432 nm; IR (v_{mas}): 2961, 2851, 1637, 1570, 1518, 1494, 1453, 1260, 1095, 1024, 798, 692, 625, 599, 591, 581, 569, 549, 538, 486, 472, 458, 438, 431 cm⁻¹; ¹H NMR (600 MHz, pyridine-d₅) δ ppm 10.82 (br. s, 1H, NH), 9.13 (d, $J_{6.8} = 2.0$ Hz, 1H, H8), 8.76 (dd, $J_{5.6} = 8.6, J_{6.8} = 2.1$ Hz, 1H, H6), 8.35 (s, 1H, H4), 8.27 (d, $J_{2^m,3^m} = 7.5$ Hz, 2H, H2^{''}), 7.99 (d, $J_{2',3'} = 7.5$ Hz, 2H, H2[']), 7.69 (d, $J_{5.6} = 8.7$ Hz, 1H, H5), 7.51 (t, $J_{2',3'} = J_{3',4'} = 7.8$ Hz, 2H, H3[']), 7.46 – 7.43 (m, 3H, H3^{'''}, H4^{'''}), 7.40 (br. s, 2H, NH₂), 7.35 (t, $J_{3',4'} = 7.5$ Hz, 1H, H4[']), 6.94 (s, 1H, H5^{''}); ¹³C NMR (150 MHz, pyridine-d₅) δ ppm 166.1 (C6^{''}), 164.2 (C4^{''}), 160.6 (C1), 146.9 (C7), 144.6 (C1[']), 140.2 (C1^{'''}), 139.9 (C3), 131.5 (C4^{'''}), 131.4 (C8a), 130.2 (C3^{'''}), 130.1 (C3'), 129.1 (C5), 128.8 (C4'), 128.5 (C2^{'''}), 127.7 (C2'), 126.9 (C6), 125.3 (C4a), 116.6 (C8), 95.1 (C5^{''}); HRMS-ESI (m/x) calcd. for [C₂₄H₁₈N₆O+H]⁺: 407.1615, obsd.: 407.1613.



7-((2-Amino-6-phenylpyrimidin-4yl)amino)-2-heptylphthalazin1(2*H*)-one (239). By subjecting chloropyrimidine 187 (56.0 mg, 0.27)

mmol) and amino-phthalazinone **234** (47.0 mg, 0.18 mmol) in conc. HCl (0.09 mL) and 2ethoxyethanol (0.91 mL) to the general procedure for the synthesis of pyrimidinylphthalazinones, the title compound was isolated as a white amorphous solid (34.9 mg, 45%); $R_f = 0.53$ (EtOAc); Fluorescence (MeOH): Ex 385 nm, Em 449 nm; IR (ν_{max}): 1643, 1590, 1520, 1497, 1456, 1429, 1357, 1247, 1077, 971 cm⁻¹; ¹H NMR (600 MHz, pyridine-d₅): δ ppm 11.07 (s, 1H, NH), 9.19 (d, $J_{6,8} = 2.2$ Hz, 1H, H8), 8.69 (dd, $J_{5,6} = 9.0$ Hz, $J_{6,8} = 1.7$ Hz, 1H, H6), 8.31 – 8.19 (m, 3H, H2''', H8), 7.67 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 7.47 – 7.38 (m, 3H, H3''', H4'''), 6.98 (s, 1H, H5''), 4.38 (t, $J_{1,2'} = 7.3$ Hz, 2H, H1'), 1.94 (pent., $J_{1,2'} = J_{2,3'} = 7.5$ Hz, 2H, H2'), 1.34 – 1.18 (m, 8H, H3', H4', H5', H6'), 0.81 (t, $J_{6,7'}$ = 6.9 Hz, 3H, H7'); ¹³C NMR (150 MHz, pyridine-d₅): δ ppm 163.6 (C4"), 162.7 (C6"), 159.0 (C1), 144.6 (C7), 137.4 (C1"'), 137.2 (C4), 130.3 (C4"'), 129.3 (C8a) 128.8 (C3"'), 127.3 (C5), 127.0 (C2"'), 125.4 (C6), 124.4 (C4a), 115.0 (C8), 93.9 (C5"), 50.9 (C1'), 31.7 (C6'), 30.3 (C2'), 29.0 (C4'), 28.8 (C3'), 26.7 (C6'), 14.04 (C7'); HRMS-ESI (*m*/*z*) calcd. for [C₂₅H₂₈N₆O+H]⁺: 429.2397, obsd.: 429.2398.



7-((2-Amino-phenylpyrimidin-4-yl)amino)-2-

propargylphthalazin-1(2*H*)-one (240). By subjecting chloropyrimidine 187 (7.7 mg, 0.04 mmol) and amino-phthalazinone 232 (12 mg, 0.06 mmol) in

conc. HCl (0.02 mL) and 2-ethoxyethanol (0.2 mL) to the general procedure for the synthesis of pyrimidinyl-phthalazinones, the title compound was isolated as a white amorphous solid (11.8 mg, 83%); $R_f = 0.63$ (EtOAc); Fluorescence (MeOH): Ex 385 nm, Em 436 nm; IR (ν_{max}): 2921, 1645, 1596, 1523, 1453, 1428, 1365, 1180, 1133, 911, 832, 799, 758, 719 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 10.81 (s, 1H, NH), 9.07 (d, $J_{6,8} = 2.4$ Hz, 1H, H8), 8.67 (dd, $J_{5,6} = 8.7$ Hz, $J_{6,8} = 2.4$ Hz, 1H, H6), 8.26 – 8.24 (m, 3H, H4, H2"), 7.62 (d, $J_{5,6} = 8.8$ Hz, 1H, H5), 7.45 – 7.42 (m, 3H, H3", H4"), 6.88 (s, 1H, H5"), 5.26 (d, $J_{1',3'} = 2.1$ Hz, 2H, H1'), 3.36 (m, 1H, H3'); ¹³C NMR (150 MHz, pyridine-d₅) δ ppm 165.3 (C4"), 163.3 (C6"), 159.4 (C1), 145.9 (C7), 139.4 (C1"), 138.8 (C4), 130.7 (C4"'), 129.9 (C8a), 129.4 (C3"'), 128.6 (C5), 127.7 (C2"'), 126.0 (C6), 124.8 (C4a), 115.2 (C8), 94.2 (C5"), 80.4 (C2'), 74.2 (C3'), 41.3 (C1'); HRMS-ESI (m/z) calcd. for [$C_{21}H_{16}N_6O+H$]⁺: 369.1458, obsd.: 369.1453.



7-((2-Amino-6-(4-fluorophenyl)pyrimidin4-yl)amino)-2-phenylphthalazin-1(2*H*)one (241). By subjecting chloropyrimidine 188

mmol)

and

amino-

0.15

mg,

phthalazinone **229** (24 mg, 0.1 mmol) in conc. HCl (0.05 mL) and 2-ethoxyethanol (0.5 mL) to the general procedure for the synthesis of pyrimidinyl-phthalazinones, the title compound was isolated as a white amorphous solid (16.1 mg, 38%); $R_f = 0.42$ (EtOAc/petroleum ether, 2/1, v/v); Fluorescence (MeOH): Ex 385 nm, Em 436 nm; IR (ν_{max}): 3071, 1647, 1598, 1493, 1440, 1240, 1158, 1129, 1059, 902, 813, 759, 736, 703, 684, 567, 582, 507 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅) δ ppm 10.88 (br. s, 1H, NH), 9.14 (s, 1H, H8), 8.78 (m, 1H, H6), 8.36 (s, 1H, H4), 8.27 – 8.19 (m, 2H, H3'''), 7.99 (d, $J_{2,3'} = 8.2$

(33.5)
Hz, 2H, H2'), 7.70 (d, $J_{5,6}$ = 8.7 Hz, 1H, H5), 7.51 (t, $J_{2',3'}$ = $J_{3',4'}$ = 7.8 Hz, 2H, H3'), 7.36 (t, $J_{3',4'}$ = 7.2 Hz, 1H, H4'), 7.19 – 7.17 (m, 2H, H2"), 6.90 (s, 1H, H5");¹³C NMR (125 MHz, pyridine-d₅) δ ppm 164.06 (d, $J_{4'',F}$ = 247.8 Hz, C4"'), 164.02 (C6"), 162.7 (C4"'), 162.3 (C4"), 159.1 (C1), 145.2 (C7), 143.0 (C1'), 138.4 (C4), 134.3 (C1"'), 129.8 (C8a), 129.2 (d, $J_{2'',F}$ = 8.3 Hz, C2"'), 128.6 (C3'), 127.6 (C5), 127.4 (C4'), 126.2 (C2'), 125.6 (C6), 123.9 (C4a), 115.6 (d, $J_{3'',F}$ = 21.6 Hz, C3"'), 115.4 (C8), 93.6 (C5"); ¹⁹F NMR (282 MHz, pyridine) δ ppm -110.14; HRMS-ESI (*m*/*z*) calcd. for [C₂₄H₁₇FN₆O+H]⁺: 425.1521, obsd.: 425.1519.



7-((2-Amino-6-(4fluorophenyl)pyrimidin-4yl)amino)-2-heptylphthalazin-1(2*H*)-one (242). By subjecting chloropyrimidine 188 (29.0 mg, 0.13

mmol) and amino-phthalazinone **234** (22.4 mg, 0.09 mmol) in conc. HCl (0.04 mL) and 2ethoxyethanol (0.43 mL) to the general procedure for the synthesis of pyrimidinylphthalazinones, the title compound was isolated as a white amorphous solid (10.4 mg, 27%); $R_f = 0.36$ (EtOAc/petroleum ether, 2/1, v/v); Fluorescence (MeOH): Ex 283 nm, Em 438 nm; IR (ν_{max}): 1638, 1599, 1571, 1510, 1499, 1440, 1378, 1356, 1229, 1204, 1156, 1075, 882, 839, 601 cm⁻¹; ¹H NMR (500 MHz, pyridine-d₅): δ ppm 10.83 (br. s, 1H, NH), 9.16 (d, $J_{6,8} =$ 2.3 Hz, 1H, H8), 8.71 (dd, $J_{5,6} = 8.7$ Hz, $J_{6,8} = 2.3$ Hz, 1H, H6), 8.29 (s, 1H, H4), 8.23 – 8.15 (m, 2H, H2^{III}), 7.68 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 7.43 (s, 2H, NH₂), 7.20 – 7.12 (m, 2H, H3^{III}), 6.86 (s, 1H, H5^{II}), 4.38 (t, $J_{1',2} = 7.3$ Hz, 2H, H1'), 1.94 (pent., $J_{1',2} = J_{2',3} = 7.4$ Hz, 2H, H2'), 1.37 – 1.12 (m, 8H, H3', H4', H5', H6'), 0.80 (t, $J_{6',7} = 6.9$ Hz, 3H, H7'); ¹³C NMR (150 MHz, pyridined₅): δ ppm 165.4 (d, $J_{4^*,F} = 247.9$ Hz, C4^{III}), 166.0 (C4^{II}), 164.2 (C6^{II}), 160.6 (C1), 146.5 (C7), 138.8 (C4), 136.4 (C1^{III}), 130.9 (C8a), 130.5 (d, $J_{2^*,F} = 8.4$ Hz, C2^{III}), 128.2 (C4a), 125.05 (C5), 126.0 (C6), 116.9 (d, $J_{3^*,F} = 22.1$ Hz, C3^{III}), 116.1 (C8), 94.7 (C5^{II}), 52.4 (C1), 33.2 (C6'), 30.5 (C2'), 30.3 (C4'), 28.3 (C3'), 24.1 (C5), 15.5 (C7'); ¹⁹F NMR (282 MHz, pyridine-d₅) δ ppm -111.71; HRMS-ESI ($m/_{3'}$) calcd. for [C₂₅H₂₄FN₆O+H]⁺: 447.2303, obsd.: 447.2305.



7-((2-Amino-(4-fluorophenyl)pyrimidin-4yl)amino-2-propargylphthalazin-1(2*H*)-one

(243). By subjecting chloropyrimidine 188 (6.4 mg, 0.03 mmol) and amino-phthalazinone 232 (10.7 mg, 0.05 mmol) in conc. HCl (0.02 mL) and

2-ethoxyethanol (0.2 mL) to the general procedure for the synthesis of pyrimidinyl-

phthalazinones, the title compound was isolated as a white amorphous solid (6.1 mg, 53%); $R_f = 0.44$ (EtOAc); IR (ν_{max}): 2925, 1648, 1595, 1501, 1360, 1108, 1034, 928, 847, 798, 754, 719 cm⁻¹; ¹H NMR (600 MHz, pyridine-d₅) δ ppm 10.77 (br. s, 1H, NH), 9.08 (d, $J_{6,8} = 2.2$ Hz, 1H, H8), 8.62 (dd, $J_{5,6} = 8.5$ Hz, $J_{6,8} = 2.2$ Hz, 1H, H6), 8.18 – 8.13 (m, 3H, H4, H2"), 7.60 (d, $J_{5,6} = 8.6$ Hz, 1H, H5), 7.39 (s, 2H, NH₂), 7.16 – 7.13 (m, 2H, H3"), 6.81 (s, 1H, H5"), 5.23 (d, $J_{1',3'} = 2.5$ Hz, 2H), 3.31 (m, 1H, H3'); ¹³C NMR (150 MHz, pyridine-d₅) δ ppm 164.7 (d, $J_{4",F} = 247.9$ Hz, C4"), 165.2 (C4"), 164.0 (C6"), 163.3 (C2"), 159.4 (C1), 145.9 (C7), 138.8 (C4), 135.6 (C1"'), 129.8 (C8a), 129.7 (d, $J_{2",F} = 8.4$ Hz, C2"'), 128.3 (C5), 126.0 (C6), 124.9 (C4a), 116.2 (C8), 116.2 (d, $J_{3",F} = 21.5$ Hz, C3"), 94.0 (C5"), 80.4 (C2'), 74.2 (C3'), 41.3 (C1'); ¹⁹F NMR (282 MHz, pyridine-d₅) δ ppm -111.64; HRMS-ESI (m/s) calcd. for [C₂₁H₁₅FN₆O+H]⁺: 387.1364, obsd.: 387.1365.

5.4.3. Biology

Samples. Each compound was dissolved in sterile DMSO to make 10 mM stock solutions.

Obtaining MIC values. In clear-bottomed 96-well plates, two-fold serial dilutions of each compound were added to volumes of 100 μ L of HEPES-NaOH buffer (pH 7.5). The buffer consisted of 10 mM HEPES-NaOH, 5 mM MgCl₂, and 100 mM KCl. The last column of each plate did not contain any compound and served as a negative control. Previously prepared *Mtb* mc²6230 inocula were diluted to 5% with HEPES-NaOH buffer to achieve OD₆₀₀. The inocula were then added to each well and the plates incubated at 37 °C for four days. After incubation, 20 μ L of resazurin was added to the wells, and the plates incubated at 37 °C for 24 hours. The wells that remained blue were deemed to contain non-replicating bacteria, while those that underwent a colour change to purple or pink were deemed to contain replicating bacteria. MIC values were ascertained by visual judgment of colour.

Measuring rates of NADH oxidation. To make a stock solution of *M. smegmatis* IMVs, 1 μ L of IMV solution (20 mg/mL protein) was added to 1 mL of HEPES-NaOH buffer (pH 7.5). The HEPES-NaOH buffer is composed of 10 mM HEPES-NaOH, 5 mM MgCl₂, 100 mM KCl. In clear-bottomed 96-well plates, 20 μ L of the IMV/buffer solution was added to each well, followed by 2 μ L of 10 mM (in DMSO) solutions of each compound. NADH (10 μ L, 400 μ M) was then added to each well. The solution in the well was mixed with a pipette and put into the UV spectrometer. Each plate had two wells without any drug, to serve as negative controls. The vehicle control contained IMV/buffer solution (20 μ L) and DMSO (2 μ L) while the second negative control consisted of IMV/buffer solution (20 μ L) and NADH (10 μ L) to

obtain the basal rate of NADH oxidation. Absorbance values were recorded every minute for twenty minutes at 340 nm to allow for calculations of the NADH consumption rate. The experiments were undertaken three times, and the average rate of reaction was taken for each compound.

CHAPTER SIX Conclusion and future prospects

The overall objective of the research in this thesis was to develop new classes of heterocyclic compounds as anti-tuberculosis agents using NDH-II as the drug target. NDH-II is an attractive therapeutic target against *Mtb* as it is essential for the viability of *Mtb*, yet it is absent in mammalian mitochondria. To date, the crystal structures of NDH-II in several organisms have been solved, providing insight into the binding sites of known substrates NADH, FAD and menaquinone, as highlighted in **Chapter 1**. Accordingly, considerations of potential binding interactions with NDH-II were taken during the exploration of the four classes of heterocyclic compounds discussed in this dissertation

Ascidiathiazone A and ascidiathiazone B are tricyclic natural products that have been shown to possess potent anti-inflammatory activity.¹⁰⁴ It has been proposed that ascidiathiazones A and B could also exhibit anti-tubercular activity as they contain the QQ scaffold which, as previously described, is a promising backbone used in TB drugs. Here, QQs are thought to exert their biological properties through the activation of NDH-II and consequent overproduction of ROS in *Mth*.^{64,65} Accordingly, **Chapter 2** described a divergent synthetic strategy to access ascidiathiazone A and ascidiathiazone B. Here, the first total synthesis of ascidiathiazone B was achieved in 2.5% yield over six steps from the same starting reagent used for the synthesis of ascidiathiazone A (6% over 5 steps). In addition, the crystal structure of ascidiathiazone B. The two synthetic procedures presented also allowed for the preparation of a library of related analogues of the natural products.

The biological screening of ascidiathiazones A and B, and derivatives thereof, led to the identification of ascidiathiazone A as a promising anti-tuberculosis agent with an MIC of 1.6 μ M, as well as previously noted low cytotoxicity in mammalian cells.¹⁰⁵ Insight into the mode of action of the ascidiathiazone analogues demonstrated the ability of 7-chloro-6-chloroethylamino-2-methyl-QQ to increase NADH oxidation rates in mycobacteria, while ascidiathiazone A did not affect NADH oxidation. This finding indicated that ascidiathiazone A exhibited a respiration-independent mode of inhibition. With this in mind, investigations to determine the mechanism(s) by which ascidiathiazone A inhibits mycobacterial growth are required. Here, genetic target-identification methods could be applied, whereby the DNA of ascidiathiazone A-resistant *Mtb* mutants could be sequenced and analysed to identify the protein affected by the drug.³⁴⁶

Given the anti-tubercular activity of QQs,^{64,65} **Chapter 3** discussed the preparation of a library of amine-substituted QQs, whereby the synthesised compounds were screened for their ability to inhibit *Mtb* growth. Along with the identification of a new lead compound, 7-chloro-6-propargylamino-QQ (MIC = 8 μ M), SAR data of QQ library was extrapolated. Here, it was observed that a short C3 alkyl chain on the QQ scaffold was insufficient to effectively inhibit *Mtb* growth, though installing a tetradecylamine on the QQ also led to a loss of inhibitory activity. Notwithstanding, QQs bearing moderate chain lengths, such as octylamino-QQs and heptylanilino-QQs exhibited high anti-tubercular activity. Moreover, the redox activity of QQs were measured and while no correlation was found between tuberculostatic activity and redox potentials in CVs conducted in acetonitrile, a near linear relationship was observed for those

QQs that were able to be measured in a microemulsion system. Here, QQs with redox potentials between -0.5 and -0.6 V typically exhibited high anti-tubercular activity.

In addition to the redox activity of QQs, it was proposed that electrophilic substituents on the QQ scaffold, *i.e.* acetylene and chloroethylamine, could enhance the anti-tubercular activity of QQs by participating in covalent inhibition with nucleophilic amino acids within NDH-II. To explore this hypothesis, other electrophiles such as α , β -unsaturated ketone and thiocyanide could be incorporated into the QQ scaffold at the 6-position (*i.e.* QQ **244** and QQ **245**, Figure 6.1) and the effect of these drugs on the anti-tubercular activity explored.



Figure 6.1: Proposed QQs bearing electrophilic substituents to be synthesised.

In **Chapter 4**, the anti-tubercular activity of two libraries of chromonyl-pyrimidines, which have a structural resemblance to *Mtb* NDH-II inhibitors quinolinyl pyrimidines, was investigated. The synthesis of chromonyl-pyrimidines involved a convergent synthesis, whereby functionalised pyrimidines and chromones were condensed to give di-substituted chromonyl-pyrimidines in good (20%-87%) yields. Docking studies demonstrated that chromonyl-pyrimidines could occupy the quinone binding tunnel surrounded by the hydrophobic residues, Q317 and I379. Moreover, a hydrogen bond between the primary amine protons of the pyrimidine scaffold with a glutamic acid side chain in the NDH-II Q-site was observed. Accordingly, an eleven-member set of chromonyl-pyrimidines was synthesised and screened against *Mtb*. SAR data for this library showed that the instalment of aromatic substituents led to enhanced inhibitory activity. Subsequently, a second generation library of chromonyl-pyrimidines bearing aromatic substituents was prepared and found to exhibit improved anti-tubercular activity.

When compared to quinolinyl pyrimidines, chromonyl-pyrimidines exhibited poor *Mtb* growth inhibition, despite both showing similar binding modes within the NDH-II Q-site, as was observed via docking studies. The marked difference in anti-tubercular activity between the

two scaffolds suggests that they may target different proteins. Notwithstanding, future work in this area should focus on the quinolinyl pyrimidine scaffold due to its high efficacy against *Mtb*. SAR analysis of aryl-substituted quinolinyl pyrimidines found that when different phenyl substituents were installed on the quinolinyl pyrimidine scaffold, *i.e.* fluorophenyl and methoxyphenyl, the same degree of growth inhibition was achieved. While altering the electronic properties of the aromatic substituents on the quinolinyl pyrimidine scaffold does not affect the compounds' anti-tubercular activity, it is postulated that increasing the π conjugation of the substituents may improve the ability of the quinolinyl pyrimidines to bind. To explore this hypothesis, a second generation library of quinolinyl pyrimidines bearing functional groups with various degrees of conjugation such as naphthalene, heptatriene, biphenyl, or styrylbenzene, at the 6'- and 2-positions (*i.e.* quinolinyl pyrimidines **246**, Figure 6.2) could be synthesised. In addition, analysis of how lead quinolinyl pyrimidines affect NADH oxidation in IMVs that overexpress NDH-II could further support the speculation that NDH-II is the target protein of quinolinyl pyrimidines.



Figure 6.2: Proposed structures of quinolinyl pyrimidines bearing highly aromatic substituents to be prepared.

Finally, **Chapter 5** concerned the synthesis and evaluation of phthalazinones and pyrimidinylphthalazinones as anti-tubercular agents. Functionalised phthalazinones were readily synthesised in 3-4 steps in good overall (7%-38%) yields from phthalic anhydride, while pyrimidinyl-phthalazinones were prepared via the condensation of functionalised phthalazinones and pyrimidines (24%-83% yield). Here, the biological screening of phthalazinones identified *N-tert*-butyl- and nitro-phthalazinones as lead compounds (MIC = 3 μ M), while 4-fluorophenyl-pyrimidinyl-*N*-heptylphthalazinone displayed the highest potency of the library against *Mtb* (MIC = 1.6 μ M). Investigations into the effect of phthalazinones on NADH oxidation rates showed that several phthalazinones decreased the rate of NADH oxidation in IMVs, which could be due to redox cycling or uncoupling activity,³⁷ while a number of pyrimidinyl-phthalazinones increased the oxidation rate, which could result in the generation of lethal levels of ROS.⁶⁴ These findings suggest that the two classes of compounds have different modes of inhibition, though the mechanism of action of the lead inhibitors appeared to be independent of mycobacterial respiration.

To investigate the respiration-independent inhibition mechanism of the lead tuberculostatic phthalazinone, phthalazinone-resistant populations of *Mtb* could be generated and their genetic material examined to determine the mycobacterial proteins affected.^{346,347} Moreover, a second generation library of functionalised phthalazinones could be prepared. From the SAR data of the phthalazinone library, it was noted that the instalment of hydrocarbons on the hydrazone nitrogen, as well as a nitro-group on the 7-position generally increased the compounds' ability to inhibit *Mtb* growth. To this end, investigations into how the instalment of different hydrocarbons, *i.e.* allyl, cyclopropyl, dodecyl, on the hydrazone nitrogen (*i.e.* phthalazinones **247**, **248**, **249**, Figure 6.3) and modifying the position of the electron-withdrawing nitro substituent affect the anti-tubercular activity of phthalazinones are required.



Figure 6.3: Proposed phthalazinones to synthesise

Overall, the ascidiathiazone analogues and phthalazinones showed promise as future antituberculosis agents, with lead compounds ascidiathiazone A and 7-((2-amino-6-(4fluorophenyl)pyrimidin-4-yl)amino)2-heptylphthalazin-1(2*H*)-one, both exhibiting an MIC of 1.6 μ M. Here, tuberculostatic drugs have a place in the ongoing search for new TB drugs as they can be included in combination therapies with other more cytotoxic drugs. This drug synergism has been demonstrated with the bacteriostatic agent linezolid (**250**, Figure 6.4).³⁴⁸⁻³⁵⁰ While linezolid (**250**) has low MIC values against *Mtb* (\leq 0.125 mg/L),³⁵¹ it has limited cidal activity during the exponential growth phase of the bacteria.³⁵² Notwithstanding, the WHO has listed linezolid (**250**) as a second-line TB drug³⁵⁰ as linezolid (**250**) has been reported to enhance the sterilizing ability of bedaquiline and pretomanid in a three-drug regimen.³⁵³ Accordingly, effort should be focused on the mode of inhibition exerted by lead compounds ascidiathiazone A and 7-((2-amino-6-(4-fluorophenyl)pyrimidin-4-yl)amino)2-heptylphthalazin-1(2*H*)-one as their potent inhibitory activity could lead to the discovery of new *Mtb* drug targets and new TB drug regimens.



Figure 6.4: Linezolid (250), a bacteriostatic TB drug.

References

- 1. I. G. Sia and M. L. Wieland, *Mayo Clin. Proc.*, 2011, **86**, 348-361.
- 2. A. Zumla, P. Nahid and S. T. Cole, Nat. Rev. Drug Discov., 2013, 12, 388-404.
- 3. WHO, *Global tuberculosis report 2018*, World Health Organisation, 2018.
- 4. S. E. Weis, P. C. Slocum, F. X. Blais, B. King, M. Nunn, G. B. Matney, E. Gomez and B. H. Foresman, *New Engl. J. Med.*, 1994, **330**, 1179-1184.
- 5. Y. L. Janin, Bioorg. Med. Chem., 2007, 15, 2479-2513.
- 6. S. Ahmad, *Clin. Dev. Immunol.*, 2011, DOI: 10.1155/2011/814943, 17.
- 7. E. M. Dangerfield, A. L. Win-Mason, M. S. M. Timmer and B. L. Stocker, *Chemistry in Australia*, 2010, **May**, 17-21.
- 8. S. Schwander and K. Dheda, Am. J. Respir. Cell Mol. Biol., 2011, 183, 696-707.
- 9. M. J. Marakalala, L. M. Graham and G. D. Brown, *Clin. Dev. Immunol.*, 2010, DOI: 10.1155/2010/567571.
- 10. P. Constantoulakis, E. Filiou, N. Rovina, G. Chras, A. Hamhougia, S. Karabela, A. Sotiriou, C. Roussos and N. Poulakis, *BMC Infect. Dis.*, 2010, **10**, 243.
- J. Zuñiga, D. Torres-García, T. Santos-Mendoza, T. S. Rodriguez-Reyna, J. Granados and E. J. Yunis, *Clin. Dev. Immunol.*, 2012, 18.
- 12. D. G. Russell, Nat. Rev. Mol. Cell Biol., 2001, 2, 569-586.
- 13. B. M. Saunders and W. J. Britton, Immunol. Cell Biol., 2007, 85, 103-111.
- 14. D. G. Russell, P.-J. Cardona, M.-J. Kim, S. Allain and F. Altare, *Nat. Immunol.*, 2009, **10**, 943-948.
- 15. M. I. Sadek, E. Sada, Z. Toossi, S. K. Schwander and E. A. Rich, *Am. J. Respir. Cell Mol. Biol.*, 1998, **19**, 513-521.
- 16. P. Peyron, J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. Daffé, J.-F. Emile, B. Marchou, P.-J. Cardona, C. de Chastellier and F. Altare, *PLoS Path.*, 2008, 4, e1000204.
- 17. J. E. Gomez and J. D. McKinney, *Tuberculosis*, 2004, 84, 29-44.
- 18. A. Koch, V. Mizrahi and D. F. Warner, *Emerg. Microbes Infect.*, 2014, **3**, e17.
- 19. S. H. Gillespie, Antimicrob. Agents Chemother., 2002, 46, 267-274.
- 20. T. Smith, K. A. Wolff and L. Nguyen, Curr. Top. Microbiol. Immunol., 2013, 374, 53-80.
- 21. L. Schrager, O. Oleson, J. Vekemans, D. Lewisnsohn, J. Shea, W. Hanekom and N. Drager, *Global report on tuberculosis vaccines*, 2018.
- 22. A. Schatz and S. A. Waksman, *Exp. Biol. Med.*, 1944, **57**, 244-248.
- 23. J. Lehmann, The Lancet, 1946, 247, 15-16.
- 24. S. Füresz and M. T. Timbal, *Chemotherapia*, 1963, 7, 200-208.
- 25. P. Klee, Br. Med. J., 1952, 2, 764-765.
- 26. K. D. Mc, L. Malone and et al., J. Lab. Clin. Med., 1948, 33, 1249-1253.
- 27. S. H. Ferebee, B. E. Doster and F. J. Murray, Ann. N. Y. Acad. Sci., 1966, 135, 910-920.
- 28. G. L. Hobby and T. F. Lenert, Am. Rev. Tuberc., 1952, 65, 771-774.
- 29. S.-J. Cheng, L. Thibert, T. Sanchez, L. Heifets and Y. Zhang, *Antimicrob. Agents Chemother.*, 2000, 44, 528-532.
- 30. R. Johnson, E. M. Streicher, G. E. Louw, R. M. Warren, P. D. van Helden and T. C. Victor, *Curr. Issues Mol. Biol.*, 2006, **8**, 97-111.
- 31. A. Scorpio and Y. Zhang, Nat. Med., 1996, 2, 662-667.
- 32. K. Hirano, M. Takahashi, Y. Kazumi, Y. Fukasawa and C. Abe, *Tuberc. Lung Dis.*, 1997, 78, 117-122.
- 33. K. Hards, J. R. Robson, M. Berney, L. Shaw, D. Bald, A. Koul, K. Andries and G. M. Cook, *J. Antimicrob. Chemother.*, 2015, DOI: 10.1093/jac/dkv054.
- 34. J. Debnath, S. Siricilla, B. Wan, D. C. Crick, A. J. Lenaerts, S. G. Franzblau and M. Kurosu, *J. Med. Chem.*, 2012, **55**, 3739-3755.
- 35. E. A. Weinstein, T. Yano, L.-S. Li, D. Avarbock, A. Avarbock, D. Helm, A. A. McColm, K. Duncan, J. T. Lonsdale and H. Rubin, *Proc. Natl. Acad. Sci. U.S.A.*, 2005, **102**, 4548-4553.

- 36. B. Lechartier and S. T. Cole, *Antimicrob. Agents Chemother.*, 2015, **59**, 4457-4463.
- 37. T. Yano, S. Kassovska-Bratinova, J. S. Teh, J. Winkler, K. Sullivan, A. Isaacs, N. M. Schechter and H. Rubin, *J. Biol. Chem.*, 2011, **286**, 10276-10287.
- 38. T. Yano, L.-S. Li, E. Weinstein, J.-S. Teh and H. Rubin, J. Biol. Chem., 2006, 281, 11456-11463.
- 39. R. H. Garrett and C. M. Grisham, *Biochemistry*, Mary Finch, Boston, USA, 2010.
- 40. B. A. Haddock and C. W. Jones, *Bacteriol. Rev.*, 1977, Mar., 47-99.
- 41. G. M. Cook, C. Greening, K. Hards and M. Berney, in *Adv. Microb. Physiol.*, ed. K. P. Robert, Academic Press, 2014, vol. Volume 65, pp. 1-62.
- 42. D. L. Piddington, A. Kashkouli and N. A. Buchmeier, Infect. Immun., 2000, 68, 4518-4522.
- 43. P. R. Jensen and O. Michelsen, J. Bacteriol., 1992, 174, 7635-7641.
- 44. M. Santana, M. S. Ionescu, A. Vertes, R. Longin, F. Kunst, A. Danchin and P. Glaser, J. Bacteriol., 1994, 176, 6802-6811.
- 45. S. L. Tran, M. Rao, C. Simmers, S. Gebhard, K. Olsson and G. M. Cook, *Microbiology*, 2005, **151**, 665-672.
- 46. M. Rao, T. L. Streur, F. E. Aldwell and G. M. Cook, *Microbiology*, 2001, 147, 1017-1024.
- 47. S. L. Tran and G. M. Cook, J. Bacteriol., 2005, 187, 5023-5028.
- 48. D. Jones, Nat. Rev. Drug Discov., 2013, 12, 175-176.
- K. Andries, P. Verhasselt, J. Guillemont, H. W. H. Göhlmann, J.-M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. d. Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis and V. Jarlier, *Science*, 2005, **307**, 223-227.
- A. Koul, N. Dendouga, K. Vergauwen, B. Molenberghs, L. Vranckx, R. Willebrords, Z. Ristic, H. Lill, I. Dorange, J. Guillemont, D. Bald and K. Andries, *Nat. Chem. Biol.*, 2007, 3, 323-324.
- 51. L. Formentini, M. Sánchez-Aragó, L. Sánchez-Cenizo and José M. Cuezva, *Mol. Cell*, 2012, **45**, 731-742.
- 52. S. P. S. Rao, S. Alonso, L. Rand, T. Dick and K. Pethe, *Proc. Natl. Acad. Sci. U.S.A.*, 2008, **105**, 11945-11950.
- 53. A. Heikal, Y. Nakatani, E. Dunn, M. R. Weimar, C. L. Day, E. N. Baker, J. S. Lott, L. A. Sazanov and G. M. Cook, *Mol. Microbiol.*, 2014, **91**, 950-964.
- 54. A. M. P. Melo, T. M. Bandeiras and M. Teixeira, *Microbiol. Mol. Biol. Rev.*, 2004, 68, 603-616.
- 55. D. Awasthy, A. Ambady, A. Narayana, S. Morayya and U. Sharma, *Gene*, 2014, 550, 110-116.
- 56. A. J. Warman, T. S. Rito, N. E. Fisher, D. M. Moss, N. G. Berry, P. M. O'Neill, S. A. Ward and G. A. Biagini, *J. Antimicrob. Chemother.*, 2013, **68**, 869-880.
- 57. J. Knuuti, G. Belevich, V. Sharma, D. A. Bloch and M. Verkhovskaya, *Mol. Microbiol.*, 2013, **90**, 1190-1200.
- 58. Y. Nakatani, W. Jiao, D. Aragao, Y. Shimaki, J. Petri, E. J. Parker and G. M. Cook, *Acta Crystallogr. Sect. F*, 2017, **73**, 541-549.
- 59. M. Iwata, Y. Lee, T. Yamashita, T. Yagi, S. Iwata, A. D. Cameron and M. J. Maher, *Proc. Natl. Acad. Sci. U.S.A.*, 2012, **109**, 15247-15252.
- 60. F. V. Sena, A. P. Batista, T. Catarino, J. A. Brito, M. Archer, M. Viertler, T. Madl, E. J. Cabrita and M. M. Pereira, *Mol. Microbiol.*, 2015, **98**, 272-288.
- 61. Y. Yang, Y. Yu, X. Li, J. Li, Y. Wu, J. Yu, J. Ge, Z. Huang, L. Jiang, Y. Rao and M. Yang, *J. Med. Chem.*, 2017, **60**, 1994-2005.
- 62. J. Petri, Y. Shimaki, W. Jiao, H. R. Bridges, E. R. Russell, E. J. Parker, D. Aragão, G. M. Cook and Y. Nakatani, *Biochim. Biophys. Acta*, 2018, **1859**, 482-490.
- 63. Y. Feng, W. Li, J. Li, J. Wang, J. Ge, D. Xu, Y. Liu, K. Wu, Q. Zeng, J. W. Wu, C. Tian, B. Zhou and M. Yang, *Nature*, 2012, **491**, 478-482.
- 64. A. Heikal, K. Hards, C.-Y. Cheung, A. Menorca, M. S. M. Timmer, B. L. Stocker and G. M. Cook, *J. Antimicrob. Chemother.*, 2016, **71**, 2840-2847.
- B. J. Mulchin, C. G. Newton, J. W. Baty, C. H. Grasso, W. J. Martin, M. C. Walton, E. M. Dangerfield, C. H. Plunkett, M. V. Berridge, J. L. Harper, M. S. M. Timmer and B. L. Stocker, *Bioorg. Med. Chem.*, 2010, 18, 3238-3251.
- 66. C.-X. He, H. Meng, X. Zhang, H.-Q. Cui and D.-L. Yin, Chin. Chem. Lett., 2015, 26, 951-954.
- L. Amaral, A. Martins, J. Molnar, J. E. Kristiansen, M. Martins, M. Viveiros, L. Rodrigues, G. Spengler, I. Couto, J. Ramos, S. Dastidar, S. Fanning, M. McCusker and J.-M. Pages, *In Vivo*, 2010, 24, 409-424.

- 68. D. V. Gadre, V. Talwar, H. C. Gupta and R. Murthy, *Int. Clin. Pyschopharmacol.*, 1998, **13**, 129-132.
- 69. L. Amaral, J. E. Kristiansen, M. Viveiros and J. Atouguia, J. Antimicrob. Chemother., 2001, 47, 505-511.
- 70. S. Sellamuthu, M. Singh, A. Kumar and S. K. Singh, *Expert Opin. Ther. Targets*, 2017, **21**, 559-570.
- 71. L. Amaral and M. Viveiros, Int. J. Antimicrob. Agents, 2012, 39, 376-380.
- 72. L. Amaral and M. Viveiros, *Antibiotics*, 2017, 6, 3.
- 73. D. van Soolingen, R. Hernandez-Pando, H. Orozco, D. Aguilar, C. Magis-Escurra, L. Amaral, J. van Ingen and M. J. Boeree, *PLoS ONE*, 2010, **5**.
- 74. L. Amaral, J. E. Kristiansen, L. S. Abebe and W. Millett, *J. Antimicrob. Chemother.*, 1996, **38**, 1049-1053.
- 75. D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, M. Martins, J. E. Kristiansen, J. Molnar and L. Amaral, *Antimicrob. Agents Chemother.*, 2003, **47**, 917-922.
- 76. L. Amaral and J. Molnar, In Vivo, 2014, 28, 267-271.
- 77. L. Amaral, M. Martins and M. Viveiros, J. Antimicrob. Chemother., 2007, 59, 1237-1246.
- 78. A. J. Crowle, G. S. Douvas and M. H. May, *Chemother.*, 1992, **38**, 410-419.
- 79. P. S. Shirude, B. Paul, N. Roy Choudhury, C. Kedari, B. Bandodkar and B. G. Ugarkar, ACS Med. Chem. Lett., 2012, **3**, 736-740.
- T. R. Ioerger, T. O'Malley, R. Liao, K. M. Guinn, M. J. Hickey, N. Mohaideen, K. C. Murphy, H. I. M. Boshoff, V. Mizrahi, E. J. Rubin, C. M. Sassetti, C. E. Barry, III, D. R. Sherman, T. Parish and J. C. Sacchettini, *PLoS ONE*, 2013, 8, e75245.
- M. B. Harbut, B. Yang, R. Liu, T. Yano, C. Vilchèze, B. Cheng, J. Lockner, H. Guo, C. Yu, S. G. Franzblau, H. M. Petrassi, W. R. Jacobs, H. Rubin, A. K. Chatterjee and F. Wang, *Angew. Chem. Int. Ed.*, 2018, 57, 3478-3482.
- D. Murugesan, P. C. Ray, T. Bayliss, G. A. Prosser, J. R. Harrison, K. Green, C. Soares de Melo, T.-S. Feng, L. J. Street, K. Chibale, D. F. Warner, V. Mizrahi, O. Epemolu, P. Scullion, L. Ellis, J. Riley, Y. Shishikura, L. Ferguson, M. Osuna-Cabello, K. D. Read, S. R. Green, D. A. Lamprecht, P. M. Finin, A. J. C. Steyn, T. R. Ioerger, J. Sacchettini, K. Y. Rhee, K. Arora, C. E. Barry, P. G. Wyatt and H. I. M. Boshoff, *ACS Infect. Dis.*, 2018, 4, 954-969.
- 83. A. S. Ginsburg, J. H. Grosset and W. R. Bishai, The Lancet Infect. Dis., 2003, 3, 432-442.
- 84. K. J. Aldred, R. J. Kerns and N. Osheroff, *Biochem.*, 2014, 53, 1565-1574.
- S. C. Leung, P. Gibbons, R. Amewu, G. L. Nixon, C. Pidathala, W. D. Hong, B. Pacorel, N. G. Berry, R. Sharma, P. A. Stocks, A. Srivastava, A. E. Shone, S. Charoensutthivarakul, L. Taylor, O. Berger, A. Mbekeani, A. Hill, N. E. Fisher, A. J. Warman, G. A. Biagini, S. A. Ward and P. M. O'Neill, *J. Med. Chem.*, 2012, 55, 1844-1857.
- C. Pidathala, R. Amewu, B. Pacorel, G. L. Nixon, P. Gibbons, W. D. Hong, S. C. Leung, N. G. Berry, R. Sharma, P. A. Stocks, A. Srivastava, A. E. Shone, S. Charoensutthivarakul, L. Taylor, O. Berger, A. Mbekeani, A. Hill, N. E. Fisher, A. J. Warman, G. A. Biagini, S. A. Ward and P. M. O'Neill, *J. Med. Chem.*, 2012, 55, 1831-1843.
- W. D. Hong, P. D. Gibbons, S. C. Leung, R. Amewu, P. A. Stocks, A. Stachulski, P. Horta, M. L. S. Cristiano, A. E. Shone, D. Moss, A. Ardrey, R. Sharma, A. J. Warman, P. T. P. Bedingfield, N. E. Fisher, G. Aljayyoussi, S. Mead, M. Caws, N. G. Berry, S. A. Ward, G. A. Biagini, P. M. O'Neill and G. L. Nixon, *J. Med. Chem.*, 2017, 60, 3703-3726.
- 88. L. Z. Holland, Curr. Biol., 2016, 26, R146-R152.
- 89. C. Bertanha, A. Januário, T. Alvarenga, L. Pimenta, M. Silva, W. Cunha and P. Pauletti, *Mar. Drugs*, 2014, **12**, 3608.
- A. Aiello, E. Fattorusso, P. Luciano, A. Macho, M. Menna and E. Muñoz, *J. Med. Chem.*, 2005, 48, 3410-3416.
- 91. A. Aiello, E. Fattorusso, P. Luciano, A. Mangoni and M. Menna, *Eur. J. Org. Chem.*, 2005, 2005, 5024-5030.
- 92. M. Broggini, S. V. Marchini, E. Galliera, P. Borsotti, G. Taraboletti, E. Erba, M. Sironi, J. Jimeno, G. T. Faircloth, R. Giavazzi and M. d'Incalci, *Leukemia*, 2003, **17**, 52.
- 93. D. J. Newman and G. M. Cragg, J. Nat. Prod., 2004, 67, 1216-1238.
- 94. M. Gompel, M. Leost, E. B. De Kier Joffe, L. Puricelli, L. H. Franco, J. Palermo and L. Meijer, *Bioorg. Med. Chem. Lett.*, 2004, 14, 1703-1707.

- 95. L. Núñez-Pons, R. M. Nieto, C. Avila, C. Jiménez and J. Rodríguez, J. Mass Spectrom., 2015, 50, 103-111.
- 96. S. Yin, G. M. Boyle, A. R. Carroll, M. Kotiw, J. Dearnaley, R. J. Quinn and R. A. Davis, *J. Nat. Prod.*, 2010, **73**, 1586-1589.
- 97. D. R. Appleton, C. S. Chuen, M. V. Berridge, V. L. Webb and B. R. Copp, *J. Org. Chem.*, 2009, **74**, 9195-9198.
- 98. M. Menna, C. Imperatore, F. Aniello and A. Aiello, Mar. Drugs, 2013, 11, 1602.
- 99. B. S. Davidson, Chem. Rev., 1993, 93, 1771-1791.
- 100. C. S. Bertanha, A. H. Januário, T. A. Alvarenga, L. P. Pimenta, M. L. A. E. Silva, W. R. Cunha and P. M. Pauletti, *Mar. Drugs*, 2014, **12**, 3608-3633.
- 101. A. Aiello, E. Fattorusso, P. Luciano, M. Menna, M. A. Calzado, E. Muñoz, F. Bonadies, M. Guiso, M. F. Sanasi, G. Cocco and R. Nicoletti, *Bioorg. Med. Chem.*, 2010, **18**, 719-727.
- 102. A. Aiello, E. Fattorusso, P. Luciano, M. Menna, G. Esposito, T. Iuvone and D. Pala, *Eur. J. Org. Chem.*, 2003, **2003**, 898-900.
- 103. M. Menna, A. Aiello, F. D'Aniello, C. Imperatore, P. Luciano, R. Vitalone, C. Irace and R. Santamaria, *Eur. J. Org. Chem.*, 2013, **2013**, 3241-3246.
- 104. A. N. Pearce, E. W. Chia, M. V. Berridge, G. R. Clark, J. L. Harper, L. Larsen, E. W. Maas, M. J. Page, N. B. Perry, V. L. Webb and B. R. Copp, *J. Nat. Prod.*, 2007, **70**, 936-940.
- 105. E. W. Chia, A. N. Pearce, M. V. Berridge, L. Larsen, N. B. Perry, C. E. Sansom, C. A. Godfrey, L. R. Hanton, G.-L. Lu, M. Walton, W. A. Denny, V. L. Webb, B. R. Copp and J. L. Harper, *Bioorg. Med. Chem.*, 2008, 16, 9432-9442.
- 106. J. E. Nycz and G. J. Malecki, J. Mol. Struct., 2013, 1032, 159-168.
- 107. W.-H. Sun, P. Hao, S. Zhang, Q. Shi, W. Zuo, X. Tang and X. Lu, Organometallics, 2007, 26, 2720-2734.
- 108. V. Chandrasekhar, S. Hossain, S. Das, S. Biswas and J.-P. Sutter, *Inorg. Chem.*, 2013, **52**, 6346-6353.
- 109. G. Black, E. Depp and B. B. Corson, J. Org. Chem., 1949, 14, 14-21.
- 110. T. M. Ali Shaikh, L. Emmanuvel and A. Sudalai, J. Org. Chem., 2006, 71, 5043-5046.
- 111. F. Z. Basha, S. Hibino, D. Kim, W. E. Pye, T.-T. Wu and S. M. Weinreb, J. Am. Chem. Soc., 1980, **102**, 3962-3964.
- 112. S. M. Weinreb, F. Z. Basha, S. Hibino, N. A. Khatri, D. Kim, W. E. Pye and T. T. Wu, *J. Am. Chem. Soc.*, 1982, **104**, 536-544.
- 113. A. S. Kende, D. P. Lorah and R. J. Boatman, J. Am. Chem. Soc., 1981, 103, 1271-1273.
- 114. S. Mukhopadhyay and S. B. Chandalia, Org. Process Res. Dev., 1999, 3, 455-459.
- 115. V. Verones, N. Flouquet, M. Lecoeur, A. Lemoine, A. Farce, B. Baldeyrou, C. Mahieu, N. Wattez, A. Lansiaux, J.-F. Goossens, P. Berthelot and N. Lebegue, *Eur. J. Med. Chem.*, 2013, 59, 39-47.
- 116. N. Sharma, R. Gupta, M. Kumar and R. R. Gupta, J. Fluorine Chem., 1999, 98, 153-157.
- 117. D. V. Kalinin, S. Wagner, B. Riemann, S. Hermann, F. Schmidt, C. Becker-Pauly, S. Rose-John, M. Schäfers and R. Holl, *J. Med. Chem.*, 2016, **59**, 9541-9559.
- 118. K. S. Battula, S. Narsimha, R. K. Thatipamula, Y. N. Reddy and V. R. Nagavelli, *ChemistrySelect*, 2017, **2**, 4001-4005.
- 119. X. Huang, D. Chen, N. Wu, A. Zhang, Z. Jia and X. Li, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 4130-4133.
- 120. E. Badetti, A. Bonetto, F. Romano, L. Marchiò, C. Zonta and G. Licini, *Catal. Lett.*, 2017, **147**, 2313-2318.
- 121. M. T. Gallego, E. Brunet, J. L. Garcia Ruano and E. L. Eliel, J. Org. Chem., 1993, 58, 3905-3911.
- 122. R. A. Henry and W. M. Dehn, J. Am. Chem. Soc., 1950, 72, 2280-2281.
- 123. S. Dhanju and D. Crich, Org. Lett., 2016, 18, 1820-1823.
- 124. J. B. Lambert and R. G. Keske, J. Org. Chem., 1966, 31, 3429-3431.
- 125. H. P. Yennawar, Z. Yang and L. J. Silverberg, Acta Crystallogr. Sect. E, 2016, 72, 1541-1543.
- 126. E. Hough, E. Wold and S. G. Dahl, Acta Crystallogr. Sect. C, 1985, 41, 386-389.
- 127. Q. Wang, Z. Xu and Y. Sun, Acta Crystallogr. Sect. E, 2010, 66, 01422.
- 128. M. R. Johnson, M. J. Fazio, D. L. Ward and L. R. Sousa, J. Org. Chem., 1983, 48, 494-499.

- 129. H. P. Yennawar, J. Tierney, P. D. Hullihen and L. J. Silverberg, *Acta Crystallogr. Sect. E*, 2015, **71**, 264-267.
- 130. R. M. Silverstein, F. X. Webster and D. J. Kiemle, *Spectrometric identification of organic compounds*, John Wiley & Sons, Inc., New Jersey, USA, 2005.
- 131. R. H. Pouwer, S. M. Deydier, P. V. Le, B. D. Schwartz, N. C. Franken, R. A. Davis, M. J. Coster, S. A. Charman, M. D. Edstein, T. S. Skinner-Adams, K. T. Andrews, I. D. Jenkins and R. J. Quinn, ACS Med. Chem. Lett., 2014, 5, 178-182.
- 132. C. Vilchèze, B. Weinrick, L. W. Leung and W. R. Jacobs, *Proc. Natl. Acad. Sci. U.S.A.*, 2018, 115, 1599-1604.
- 133. R. O. Akinola, G. K. Mazandu and N. J. Mulder, J. Bacteriol. Parasitol., 2013, 4, 173.
- 134. Z. He and J. De Buck, *BMC Microbiol.*, 2010, **10**, 121.
- 135. T. Lu and K. Drlica, J. Antimicrob. Chemother., 2003, 52, 1025-1028.
- 136. V. Chaturvedi, N. Dwivedi, R. P. Tripathi and S. Sinha, *The Journal of General and Applied Microbiology*, 2007, **53**, 333-337.
- 137. K. Andries, P. Verhasselt, J. Guillemont, H. W. H. Göhlmann, J.-M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis and V. Jarlier, *Science*, 2005, **307**, 223-227.
- 138. C. Lam, A. Pearce, S. Tan, M. Kaiser and B. Copp, Mar. Drugs, 2013, 11, 3472.
- 139. T. Fryatt, H. I. Pettersson, W. T. Gardipee, K. C. Bray, S. J. Green, A. M. Z. Slawin, H. D. Beall and C. J. Moody, *Bioorg. Med. Chem.*, 2004, **12**, 1667-1687.
- 140. Y. Wang, D. Oxer and S. Hekimi, Nat. Comm., 2015, 6, 6393.
- 141. B. Nowicka and J. Kruk, Biochim. Biophys. Acta, 2010, 1797, 1587-1605.
- 142. T. Hasegawa, A. Bando, K. Tsuchiya, S. Abe, M. Okamoto, K. Kirima, S. Ueno, M. Yoshizumi, H. Houchi and T. Tamaki, *Biochim. Biophys. Acta*, 2004, **1670**, 19-27.
- 143. Y. Zu, R. J. Shannon and J. Hirst, J. Am. Chem. Soc., 2003, 125, 6020-6021.
- 144. J. W. Lown and S.-K. Sim, Can. J. Chem., 1976, 54, 2563-2572.
- 145. L. Kussmaul and J. Hirst, Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 7607-7612.
- 146. M. P. Murphy, Biochem. J., 2009, 417, 1-13.
- 147. J. Imlay and S. Linn, Science, 1988, 240, 1302-1309.
- A. Alfadhli, A. Mack, L. Harper, S. Berk, C. Ritchie and E. Barklis, *Bioorg. Med. Chem.*, 2016, 24, 5618-5625.
- 149. A. Chakraborty, P. R. Gangadharam, P. Damle, P. Pratt, P. Wright and P. T. Davidson, *Tubercle*, 1981, **62**, 37-41.
- 150. S. A. Egu, A. Ibezim, E. A. Onoabedje and U. C. Okoro, *ChemistrySelect*, 2017, 2, 9222-9226.
- 151. R. Cone, S. K. Hasan, J. W. Lown and A. R. Morgan, Can. J. Biochem., 1976, 54, 219-223.
- 152. K. V. Rao, K. Biemann and R. B. Woodward, J. Am. Chem. Soc., 1963, 85, 2532-2533.
- 153. D. L. Boger, M. Yasuda, L. A. Mitscher, S. D. Drake, P. A. Kitos and S. C. Thompson, *J. Med. Chem.*, 1987, **30**, 1918-1928.
- 154. H. D. Beall, Y. Liu, D. Siegel, E. M. Bolton, N. W. Gibson and D. Ross, *Biochem. Pharmacol.*, 1996, **51**, 645-652.
- 155. C.-K. Ryu, H.-J. Jeong, S. K. Lee, H.-J. You, K. U. Choi, J.-Y. Shim, Y. H. Heo and C.-O. Lee, *Arch. Pharmacal Res.*, 2001, **24**, 390.
- 156. H. A. Kontos and E. P. Wei, Stroke, 1993, 24, 427-434.
- 157. A. Mülsch, R. Busse, S. Liebau and U. Förstermann, J. Pharmacol. Exp. Ther., 1988, 247, 283-288.
- 158. P. R. Gangadharam, P. F. Pratt, P. B. Damle, P. T. Davidson, T. H. Porter and K. Folkers, *Am. Rev. Res. Dis.*, 1978, **118**, 467-473.
- 159. P. Claes, D. Cappoen, C. Uythethofken, J. Jacobs, B. Mertens, V. Mathys, L. Verschaeve, K. Huygen and N. De Kimpe, *Eur. J. Med. Chem.*, 2014, **77**, 409-421.
- 160. B. R. Copp, H. C. Christiansen, B. S. Lindsay and S. G. Franzblau, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 4097-4099.
- 161. X. Wei, W. Xu, J. Huang, L. Zhang, E. Walter, C. Lawrence, M. Vijayakumar, W. A. Henderson, T. Liu, L. Cosimbescu, B. Li, V. Sprenkle and W. Wang, *Angew. Chem. Int. Ed.*, 2015, **54**, 8684-8687.

- 162. J. Huang, B. Pan, W. Duan, X. Wei, R. S. Assary, L. Su, F. R. Brushett, L. Cheng, C. Liao, M. S. Ferrandon, W. Wang, Z. Zhang, A. K. Burrell, L. A. Curtiss, I. A. Shkrob, J. S. Moore and L. Zhang, *Sci. Rep.*, 2016, 6, 32102.
- 163. Y. Song and G. R. Buettner, Free Radical Biol. Med., 2010, 49, 919-962.
- 164. F. C. de Abreu, P. A. de L. Ferraz and M. O. F. Goulart, J. Braz. Chem. Soc., 2002, 13, 19-35.
- 165. S. Er, C. Suh, M. P. Marshak and A. Aspuru-Guzik, Chem. Sci., 2015, 6, 885-893.
- 166. S. Ergun, C. F. Elliott, A. P. Kaur, S. R. Parkin and S. A. Odom, *Chem. Comm.*, 2014, **50**, 5339-5341.
- 167. M.-H. Livertoux, P. Lagrange and A. Minn, Brain Res., 1996, 725, 207-216.
- 168. P. S. Guin, S. Das and P. C. Mandal, Int. J. Electrochem., 2011, DOI: 10.4061/2011/816202, 22.
- 169. M. G. Evans and J. De Heer, *Q. Rev. Chem. Soc.*, 1950, **4**, 94-114.
- 170. C. J. O'Connor, D. J. McLennan, B. M. Sutton, W. A. Denny and W. R. Wilson, *J. Chem. Soc.*, 1991, DOI: 10.1039/P29910000951, 951-954.
- 171. P. Gopinath, A. Mahammed, S. Ohayon, Z. Gross and A. Brik, Chem. Sci., 2016, 7, 7079-7086.
- 172. S. Ohayon, M. Refua, A. Hendler, A. Aharoni and A. Brik, *Angew. Chem. Int. Ed.*, 2015, 54, 599-603.
- 173. T. Yano, M. Rahimian, K. K. Aneja, N. M. Schechter, H. Rubin and C. P. Scott, *Biochem.*, 2014, 53, 1179-1190.
- 174. H. Zimmer, D. C. Lankin and S. W. Horgan, Chem. Rev., 1971, 71, 229-246.
- 175. C. M. Keyari, A. K. Kearns, N. S. Duncan, E. A. Eickholt, G. Abbott, H. D. Beall and P. Diaz, *J. Med. Chem.*, 2013, **56**, 3806-3819.
- 176. K. Nepali, S. Kumar, H.-L. Huang, F.-C. Kuo, C.-H. Lee, C.-C. Kuo, T.-K. Yeh, Y.-H. Li, J.-Y. Chang, J.-P. Liou and H.-Y. Lee, *Org. Biomol. Chem.*, 2016, **14**, 716-723.
- 177. R. H. J. Hargreaves, C. L. David, L. J. Whitesell, D. V. LaBarbera, A. Jamil, J. C. Chapuis and E. B. Skibo, *J. Med. Chem.*, 2008, **51**, 2492-2501.
- 178. Y. Wada, Y. Harayama, D. Kamimura, M. Yoshida, T. Shibata, K. Fujiwara, K. Morimoto, H. Fujioka and Y. Kita, *Org. Biomol. Chem.*, 2011, **9**, 4959-4976.
- 179. K. Majerz-Maniecka, R. Musiol, A. Skórska-Stania, D. Tabak, P. Mazur, B. J. Oleksyn and J. Polanski, *Bioorg. Med. Chem.*, 2011, **19**, 1606-1612.
- 180. K. Yoshida, M. Yamamoto and M. Ishiguro, Chem. Lett., 1986, 1059-1062.
- 181. A. Orzeł, R. Podsiadły, K. Podemska, R. Strzelczyk, J. Kolińska and J. Sokołowska, *Color. Technol.*, 2014, **130**, 185-190.
- 182. E. Y. Yoon, H. Y. Choi, K. J. Shin, K. H. Yoo, D. Y. Chi* and D. J. Kim, *Tetrahedron Lett.*, 2000, **41**, 7475-7480.
- 183. X. Xiao and B. Chen, *Environ. Sci. Technol.*, 2017, **51**, 5473-5482.
- 184. F. H. Allen, O. Kennard, D. G. Watson, L. Brammer, A. G. Orpen and R. Taylor, *J. Chem. Soc.*, 1987, DOI: 10.1039/P298700000S1, S1-S19.
- 185. M. Fatollahpour and H. Tahermansouri, C. R. Chim., 2017, 20, 942-951.
- M. Kadela-Tomanek, M. Jastrzębska, E. Bębenek, E. Chrobak, M. T. Latocha, J. Kusz and D. Tarnawska, *Crystals*, 2017.
- M. Jastrzebska, S. Boryczka, M. Kadela, R. Wrzalik, J. Kusz and M. Nowak, *J. Mol. Struct.*, 2014, 1067, 160-168.
- 188. S. S. Jhamb, A. Goyal and P. P. Singh, Braz. J. Infect. Dis., 2014, 18, 336-340.
- S. S. Lin, S. Kerscher, A. Saleh, U. Brandt, U. Groß and W. Bohne, *Biochim. Biophys. Acta*, 2008, 1777, 1455-1462.
- 190. L. Jeftić and G. Manning, J. Electroanal. Chem. Interfacial Electrochem., 1970, 26, 195-200.
- 191. M. W. Lehmann and D. H. Evans, J. Electroanal. Chem., 2001, 500, 12-20.
- 192. S. G. Bratsch, J. Chem. Educ., 1985, 62, 101.
- 193. J. Mullay, J. Am. Chem. Soc., 1985, 107, 7271-7275.
- 194. D. W. Smith, J. Chem. Soc., Faraday Trans., 1998, 94, 201-205.
- 195. 2018.
- 196. S. Kishi, K. Saito, Y. Kato and H. Ishikita, *Photosynthesis Res.*, 2017, 134, 193-200.
- 197. E. Bębenek, E. Chrobak, J. Wietrzyk, M. Kadela, A. Chrobak, J. Kusz, M. Książek, M. Jastrzębska and S. Boryczka, *J. Mol. Struct.*, 2016, **1106**, 210-219.
- 198. W. Mól, M. Matyja, B. Filip, J. Wietrzyk and S. Boryczka, *Bioorg. Med. Chem.*, 2008, **16**, 8136-8141.

- 199. S. J. Senior, P. A. Illarionov, S. S. Gurcha, I. B. Campbell, M. L. Schaeffer, D. E. Minnikin and G. S. Besra, *Bioorg. Med. Chem. Lett.*, 2004, 14, 373-376.
- 200. M. Kögler, B. Vanderhoydonck, S. De Jonghe, J. Rozenski, K. Van Belle, J. Herman, T. Louat, A. Parchina, C. Sibley, E. Lescrinier and P. Herdewijn, *J. Med. Chem.*, 2011, **54**, 4847-4862.
- R. Ekkebus, S. I. van Kasteren, Y. Kulathu, A. Scholten, I. Berlin, P. P. Geurink, A. de Jong, S. Goerdayal, J. Neefjes, A. J. R. Heck, D. Komander and H. Ovaa, *J. Am. Chem. Soc.*, 2013, 135, 2867-2870.
- 202. F. Brotzel and H. Mayr, Org. Biomol. Chem., 2007, 5, 3814-3820.
- 203. D. Tull, S. G. Withers, N. R. Gilkes, D. G. Kilburn, R. A. Warren and R. Aebersold, J. Biol. Chem., 1991, 266, 15621-15625.
- 204. S. Miao, L. Ziser, R. Aebersold and S. G. Withers, Biochem., 1994, 33, 7027-7032.
- 205. A. Heikal, Y. Nakatani, W. Jiao, C. Wilson, D. Rennison, M. R. Weimar, E. J. Parker, M. A. Brimble and G. M. Cook, *Bioorg. Med. Chem. Lett.*, 2018, 28, 2239-2243.
- 206. I. Smith, Clin. Microbiol. Rev., 2003, 16, 463-496.
- 207. A. Gaspar, M. J. Matos, J. Garrido, E. Uriarte and F. Borges, Chem. Rev., 2014, 114, 4960-4992.
- 208. J. R. Mays, S. A. Hill, J. T. Moyers and B. S. J. Blagg, *Bioorg. Med. Chem.*, 2010, 18, 249-266.
- 209. W. Huang, M.-Z. Liu, Y. Li, Y. Tan and G.-F. Yang, Bioorg. Med. Chem., 2007, 15, 5191-5197.
- 210. M. Isaka, M. Sappan, P. Auncharoen and P. Srikitikulchai, Phytochem. Lett., 2010, 3, 152-155.
- 211. D. H. Nam, K. Y. Lee, C. S. Moon and Y. S. Lee, Eur. J. Med. Chem., 2010, 45, 4288-4292.
- 212. P. Singh, M. Kaur and W. Holzer, Eur. J. Med. Chem., 2010, 45, 4968-4982.
- 213. S. Zhang, J. Ma, Y. Bao, P. Yang, L. Zou, K. Li and X. Sun, *Bioorg. Med. Chem.*, 2008, **16**, 7127-7132.
- 214. A. Gaspar, J. Reis, A. Fonseca, N. Milhazes, D. Viña, E. Uriarte and F. Borges, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 707-709.
- 215. C. A. V., G. D. S., S. S. Bhagat and G. C. H., J. Heterocyclic Chem., 2013, 50, 149-154.
- P. Cano, A. Islas-Jácome, Á. Rangel-Serrano, F. Anaya-Velázquez, F. Padilla-Vaca, E. Trujillo-Esquivel, P. Ponce-Noyola, A. Martínez-Richa and R. Gámez-Montaño, *Molecules*, 2015, 20, 12436.
- 217. L. Feng, M. M. Maddox, M. Z. Alam, L. S. Tsutsumi, G. Narula, D. F. Bruhn, X. Wu, S. Sandhaus, R. B. Lee, C. J. Simmons, Y.-C. Tse-Dinh, J. G. Hurdle, R. E. Lee and D. Sun, *J. Med. Chem.*, 2014, **57**, 8398-8420.
- 218. D. R. Ferry, A. Smith, J. Malkhandi, D. W. Fyfe, P. G. deTakats, D. Anderson, J. Baker and D. J. Kerr, *Clin. Cancer. Res.*, 1996, **2**, 659-668.
- 219. R. B. Weiss, R. F. Greene, R. D. Knight, J. M. Collins, J. J. Pelosi, A. Sulkes and G. A. Curt, *Cancer Res.*, 1988, **48**, 5878-5882.
- 220. A. M. Senderowicz, Inves. New Drugs, 1999, 17, 313-320.
- 221. S. Dianqing, H. J. G., L. Robin, L. Richard, C. Mark and P. J. M., *ChemMedChem*, 2012, 7, 1541-1545.
- 222. D. D. Haveliwala, N. R. Kamdar, P. T. Mistry and S. K. Patel, J. Sulfur Chem., 2011, 32, 451-462.
- 223. D. Sriram, P. Yogeeswari, M. Dinakaran, D. Banerjee, P. Bhat and S. Gadhwal, *Eur. J. Med. Chem.*, 2010, **45**, 120-123.
- 224. D. E. Stevenson and R. D. Hurst, Cell. Mol. Life Sci., 2007, 64, 2900-2916.
- 225. C. Proença, H. M. T. Albuquerque, D. Ribeiro, M. Freitas, C. M. M. Santos, A. M. S. Silva and E. Fernandes, *Eur. J. Med. Chem.*, 2016, **115**, 381-392.
- 226. S. de Vries and L. A. Grivell, Eur. J. Biochem., 1988, 176, 377-384.
- 227. A. M. O. Amoussa, M. Bourjot, L. Lagnika, C. Vonthron-Sénécheau and A. Sanni, BMC Complement. Altern. Med., 2016, 16, 506.
- 228. K. M. Hatzade, V. S. Taile, P. K. Gaidhane, V. D. Umare, A. G. M. Haldar and V. N. Ingle, *Indian J. Chem.*, 2009, **48B**, 1548-1557.
- 229. H. Liu, C. Jiang, C. Xiong and J. Ruan, Toxicol. In Vitro, 2012, 26, 16-23.
- 230. Y. M. Ahn, L. Vogeti, C.-J. Liu, H. K. R. Santhapuram, J. M. White, V. Vasandani, L. A. Mitscher, G. H. Lushington, P. R. Hanson, D. R. Powell, R. H. Himes, K. F. Roby, Q. Ye and G. I. Georg, *Bioorg. Med. Chem.*, 2007, **15**, 702-713.
- 231. J. Xi, X. Zhu, Y. Feng, N. Huang, G. Luo, Y. Mao, X. Han, W. Tian, G. Wang, X. Han, R. Luo, Z. Huang and J. An, *Mol. Cancer Res.*, 2013, **11**, 856-864.

- 232. V. J. Watts, Neuropsychopharmacology, 2017, 43, 215.
- 233. L. Huang, X. Yuan, D. Yu, K. H. Lee and C. Ho Chen, *Virology*, 2005, **332**, 623-628.
- 234. C. F. M. Silva, D. C. G. A. Pinto and A. M. S. Silva, ChemMedChem, 2016, 11, 2252-2260.
- 235. R. S. Keri, S. Budagumpi, R. K. Pai and R. G. Balakrishna, *Eur. J. Med. Chem.*, 2014, **78**, 340-374.
- 236. K. Pia, N. Olivia, K. Olga, S. Gregor and W. S. R., *Eur. J. Org. Chem.*, 2010, DOI: doi:10.1002/ejoc.201000957, 6417-6422.
- 237. W. Baker, J. Chem. Soc., 1933, DOI: 10.1039/JR9330001381, 1381-1389.
- 238. L. Costantino, G. Rastelli, M. C. Gamberini, J. A. Vinson, P. Bose, A. Iannone, M. Staffieri, L. Antolini, A. Del Corso, U. Mura and A. Albasini, *J. Med. Chem.*, 1999, **42**, 1881-1893.
- 239. A. Gomes, O. Neuwirth, M. Freitas, D. Couto, D. Ribeiro, A. G. P. R. Figueiredo, A. M. S. Silva, R. S. G. R. Seixas, D. C. G. A. Pinto, A. C. Tomé, J. A. S. Cavaleiro, E. Fernandes and J. L. F. C. Lima, *Bioorg. Med. Chem.*, 2009, **17**, 7218-7226.
- 240. A. Y. Shaw, C.-Y. Chang, H.-H. Liau, P.-J. Lu, H.-L. Chen, C.-N. Yang and H.-Y. Li, *Eur. J. Med. Chem.*, 2009, **44**, 2552-2562.
- 241. I. Goodall and A. Robertson, J. Chem. Soc., 1936, 426-428.
- 242. A. Robertson, Nature, 1931, 128, 908.
- 243. M. Hadjeri, M. Barbier, X. Ronot, A.-M. Mariotte, A. Boumendjel and J. Boutonnat, J. Med. Chem., 2003, 46, 2125-2131.
- 244. R. A. Appleton, J. R. Bantick, T. R. Chamberlain, D. N. Hardern, T. B. Lee and A. D. Pratt, *J. Med. Chem.*, 1977, **20**, 371-379.
- 245. P. Kumar and M. S. Bodas, Org. Lett., 2000, 2, 3821-3823.
- 246. L. Yet, Privileged structures in drug discovery: Medicinal chemistry and synthesis, John Wiley & Sons, 2018.
- 247. E. Vitaku, D. T. Smith and J. T. Njardarson, J. Med. Chem., 2014, 57, 10257-10274.
- 248. P. A. Harris, A. Boloor, M. Cheung, R. Kumar, R. M. Crosby, R. G. Davis-Ward, A. H. Epperly, K. W. Hinkle, R. N. Hunter, J. H. Johnson, V. B. Knick, C. P. Laudeman, D. K. Luttrell, R. A. Mook, R. T. Nolte, S. K. Rudolph, J. R. Szewczyk, A. T. Truesdale, J. M. Veal, L. Wang and J. A. Stafford, *J. Med. Chem.*, 2008, **51**, 4632-4640.
- 249. B. J. Druker, M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones and C. L. Sawyers, *New Engl. J. Med.*, 2001, 344, 1031-1037.
- 250. G. L. Plosker and D. M. Robinson, Drugs, 2008, 68, 449-459.
- 251. K. M. Amin, F. M. Awadalla, A. A. M. Eissa, S. M. Abou-Seri and G. S. Hassan, *Bioorg. Med. Chem.*, 2011, **19**, 6087-6097.
- 252. N. A. Powell, J. K. Hoffman, F. L. Ciske, J. T. Kohrt, S. M. Baxi, Y.-W. Peng, M. Zhong, C. Catana, J. Ohren, L. A. Perrin and J. J. Edmunds, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 1051-1055.
- 253. S. Yang, C. Pannecouque, D. Daelemans, X.-D. Ma, Y. Liu, F.-E. Chen and E. De Clercq, *Eur. J. Med. Chem.*, 2013, **65**, 134-143.
- 254. Q. Choo, G. Kuo, A. Weiner, L. Overby, D. Bradley and M. Houghton, *Science*, 1989, **244**, 359-362.
- 255. A. Arasappan, F. Bennett, V. Girijavallabhan, Y. Huang, R. Huelgas, C. Alvarez, L. Chen, S. Gavalas, S.-H. Kim, A. Kosinski, P. Pinto, R. Rizvi, R. Rossman, B. Shankar, L. Tong, F. Velazquez, S. Venkatraman, V. A. Verma, J. Kozlowski, N.-Y. Shih, J. J. Piwinski, M. MacCoss, C. D. Kwong, J. L. Clark, A. T. Fowler, F. Geng, H. S. Kezar, A. Roychowdhury, R. C. Reynolds, J. A. Maddry, S. Ananthan, J. A. Secrist, C. Li, R. Chase, S. Curry, H.-C. Huang, X. Tong and F. G. Njoroge, *Bioorg. Med. Chem. Lett.*, 2012, 22, 3229-3234.
- 256. N. Ingarsal, G. Saravanan, P. Amutha and S. Nagarajan, Eur. J. Med. Chem., 2007, 42, 517-520.
- 257. J. Morgan, R. Haritakul and P. A. Keller, Bioorg. Med. Chem. Lett., 2003, 13, 1755-1757.
- 258. A. R. Trivedi, D. K. Dodiya, N. R. Ravat and V. H. Shah, Arch. Org. Chem., 2008, 131-141.
- E. V. Verbitskiy, E. M. Cheprakova, P. A. Slepukhin, M. A. Kravchenko, S. N. Skornyakov,
 G. L. Rusinov, O. N. Chupakhin and V. N. Charushin, *Eur. J. Med. Chem.*, 2015, 97, 225-234.
- 260. H. Sohn, K.-S. Lee, Y.-K. Ko, J.-W. Ryu, J.-C. Woo, D.-W. Koo, S.-J. Shin, S.-J. Ahn, A. R. Shin, C.-H. Song, E.-K. Jo, J.-K. Park and H.-J. Kim, *Int. J. Antimicrob. Agents*, 2008, **31**, 567-571.

- 261. M. L. Read, M. Brændvang, P. O. Miranda and L.-L. Gundersen, *Bioorg. Med. Chem.*, 2010, **18**, 3885-3897.
- 262. V. Virsodia, R. R. S. Pissurlenkar, D. Manvar, C. Dholakia, P. Adlakha, A. Shah and E. C. Coutinho, *Eur. J. Med. Chem.*, 2008, **43**, 2103-2115.
- 263. A. A. Siddiqui, R. Rajesh, M. Ul-Islam, V. Alagarsamy and E. de Clercq, *Arch. pharm.*, 2007, **340**, 95-102.
- 264. N. C. Srivastav, D. Rai, C. Tse, B. Agrawal, D. Y. Kunimoto and R. Kumar, J. Med. Chem., 2010, 53, 6180-6187.
- 265. M. Johar, T. Manning, C. Tse, N. Desroches, B. Agrawal, D. Y. Kunimoto and R. Kumar, J. Med. Chem., 2007, 50, 3696-3705.
- 266. N. C. Srivastav, T. Manning, D. Y. Kunimoto and R. Kumar, *Bioorg. Med. Chem.*, 2007, 15, 2045-2053.
- 267. A. L. B. Gerum, J. E. Ulmer, D. P. Jacobus, N. P. Jensen, D. R. Sherman and C. H. Sibley, *Antimicrob. Agents Chemother.*, 2002, **46**, 3362-3369.
- 268. A. M. Dhople, Int. J. Antimicrob. Agents, 2002, 19, 71-74.
- 269. W. J. Suling and J. A. Maddry, J. Antimicrob. Chemother., 2001, 47, 451-454.
- 270. A. K. Debnath, J. Med. Chem., 2002, 45, 41-53.
- 271. A. A. Joshi, S. S. Narkhede and C. L. Viswanathan, Bioorg. Med. Chem. Lett., 2005, 15, 73-76.
- 272. K. M. Khan, S. Iqbal, M. A. Bashir, N. Ambreen, S. Perveen and W. Voelter, *Tetrahedron Lett.*, 2015, **56**, 1179-1182.
- 273. P. R. Patel, C. Ramalingan and Y.-T. Park, Bioorg. Med. Chem. Lett., 2007, 17, 6610-6614.
- 274. P. G. Baraldi, A. Bovero, F. Fruttarolo, R. Romagnoli, M. A. Tabrizi, D. Preti, K. Varani, P. A. Borea and A. R. Moorman, *Bioorg. Med. Chem.*, 2003, **11**, 4161-4169.
- 275. R. Goldschmidt, P. M. Arce, O. M. Khdour, V. C. Collin, S. Dey, J. Jaruvangsanti, D. M. Fash and S. M. Hecht, *Bioorg. Med. Chem.*, 2013, **21**, 969-978.
- 276. H. Chen, J. Bai, L. Jiao, Z. Guo, Q. Yin and X. Li, Bioorg. Med. Chem., 2009, 17, 3980-3986.
- 277. R. K. Rawal, R. Tripathi, S. B. Katti, C. Pannecouque and E. De Clercq, *Bioorg. Med. Chem.*, 2007, **15**, 3134-3142.
- 278. A. S. Komendantova, A. V. Komkov, Y. A. Volkova and I. V. Zavarzin, *Eur. J. Org. Chem.*, 2017, DOI: doi:10.1002/ejoc.201700737, 4260-4264.
- 279. A. V. Erkin, V. V. Gurzhii and V. I. Krutikov, Russ. J. Gen. Chem., 2015, 85, 79-87.
- 280. F. Wakita, Y. Ando, K. Ohmori and K. Suzuki, Org. Lett., 2018, 20, 3928-3932.
- 281. X.-Y. Meng, H.-X. Zhang, M. Mezei and M. Cui, Curr. Comput.-Aided Drug Des., 2011, 7, 146-157.
- 282. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng and T. E. Ferrin, *J. Comput. Chem.*, 2004, **25**, 1605-1612.
- 283. W. J. Allen, T. E. Balius, S. Mukherjee, S. R. Brozell, D. T. Moustakas, P. T. Lang, D. A. Case, I. D. Kuntz and R. C. Rizzo, *J. Comput. Chem.*, 2015, **36**, 1132-1156.
- 284. A. V. Erkin and V. I. Krutikov, Russ. J. Gen. Chem., 2011, 81, 1699.
- 285. B. M. Savall, S. P. Meduna, J. Venable, J. Wei, R. C. Smith, M. D. Hack, R. L. Thurmond, P. McGovern and J. P. Edwards, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 5489-5492.
- 286. W. A. Velema, M. van der Toorn, W. Szymanski and B. L. Feringa, J. Med. Chem., 2013, 56, 4456-4464.
- 287. Z. Dongbing, B. Bernhard and G. Frank, Angew. Chem. Int. Ed., 2013, 52, 8454-8458.
- 288. J. Rocha-Pereira, R. Cunha, D. C. G. A. Pinto, A. M. S. Silva and M. S. J. Nascimento, *Bioorg. Med. Chem.*, 2010, **18**, 4195-4201.
- E. Venkateswararao, M. Manickam, P. Boggu, Y. Kim and S.-H. Jung, *Bioorg. Med. Chem.*, 2015, 23, 2498-2504.
- 290. P. Pérez, L. R. Domingo, M. Duque-Noreña and E. Chamorro, J. Mol. Struct., 2009, 895, 86-91.
- 291. M. Cárdenas, M. Marder, V. C. Blank and L. P. Roguin, *Bioorg. Med. Chem.*, 2006, 14, 2966-2971.
- 292. A. O. Fitton and B. T. Hatton, J. Chem. Soc. C: Org., 1970, DOI: 10.1039/J39700002518, 2518-2522.
- 293. A. Patel, W. Lewis, M. S. Searle, M. F. G. Stevens and C. J. Moody, *Tetrahedron*, 2015, **71**, 7339-7343.

- 294. V. Kolman, F. Kalčic, P. Jansa, Z. Zídek and Z. Janeba, Eur. J. Med. Chem., 2018, 156, 295-301.
- 295. N. Thasana and S. Ruchirawat, Tetrahedron Lett., 2002, 43, 4515-4517.
- 296. P. Kahnberg, E. Lager, C. Rosenberg, J. Schougaard, L. Camet, O. Sterner, E. Ø. Nielsen, M. Nielsen and T. Liljefors, *J. Med. Chem.*, 2002, **45**, 4188-4201.
- 297. S. S. Roy, P. Chakraborty and S. Bhattacharya, Eur. J. Med. Chem., 2014, 73, 195-209.
- 298. U. Uciechowska-Kaczmarzyk, I. Chauvot de Beauchene and S. A. Samsonov, J. Mol. Graphics Model., 2019, **90**, 42-50.
- 299. B. Zhu, Z. Feng, Z. Zheng and X. Wang, J. Appl. Polym. Sci., 2012, 123, 1755-1763.
- 300. K. Radhakrishnan, N. Sharma and L. M. Kundu, RSC Adv., 2014, 4, 15087-15090.
- 301. P. Ghosh, A. K. Nandi and S. Das, *Tetrahedron Lett.*, 2018, **59**, 2025-2029.
- 302. R. A. Joshi, M. K. Gurjar, N. K. Tripathy and M. S. Chorghade, Org. Process Res. Dev., 2001, 5, 176-178.
- 303. V. K. Rai, F. Verma, G. P. Sahu, M. Singh and A. Rai, *Eur. J. Org. Chem.*, 2018, DOI: doi:10.1002/ejoc.201701435, 537-544.
- 304. G. Casano, M. Robin, P. Barbier, V. Peyrot and R. Faure, Magn. Reson. Chem., 2010, 48, 738-744.
- 305. H. Terada, Environ. Health Perspect., 1990, 87, 213-218.
- 306. V. P. Skulachev, A. A. Sharaf and E. A. Liberman, *Nature*, 1967, **216**, 718.
- 307. T. Ubbink-Kok, J. A. Anderson and W. N. Konings, Antimicrob. Agents Chemother., 1986, 30, 147-151.
- 308. L. A. Schurig-Briccio, T. Yano, H. Rubin and R. B. Gennis, *Biochim. Biophys. Acta*, 2014, 1837, 954-963.
- 309. P. Skrobecki, A. Chmielińska, P. Bonarek, P. Stepien, A. Wisniewska-Becker, M. Dziedzicka-Wasylewska and A. Polit, *ACS Chem. Neurosci.*, 2017, **8**, 1543-1553.
- 310. U. Domańska, A. Pelczarska and A. Pobudkowska, Int. J. Pharm., 2011, 421, 135-144.
- 311. J. S. Modica-Napolitano, C. J. Lagace, W. A. Brennan and J. R. Aprille, *Arch. Pharmacal Res.*, 2003, 26, 951-959.
- 312. X. Feng, W. Zhu, L. A. Schurig-Briccio, S. Lindert, C. Shoen, R. Hitchings, J. Li, Y. Wang, N. Baig, T. Zhou, B. K. Kim, D. C. Crick, M. Cynamon, J. A. McCammon, R. B. Gennis and E. Oldfield, *Proc. Natl. Acad. Sci. U.S.A.*, 2015, **112**, E7073-E7082.
- 313. M. Kurosu, P. Narayanasamy, K. Biswas, R. Dhiman and D. C. Crick, *J. Med. Chem.*, 2007, **50**, 3973-3975.
- 314. K. Li, L. A. Schurig-Briccio, X. Feng, A. Upadhyay, V. Pujari, B. Lechartier, F. L. Fontes, H. Yang, G. Rao, W. Zhu, A. Gulati, J. H. No, G. Cintra, S. Bogue, Y.-L. Liu, K. Molohon, P. Orlean, D. A. Mitchell, L. Freitas-Junior, F. Ren, H. Sun, T. Jiang, Y. Li, R.-T. Guo, S. T. Cole, R. B. Gennis, D. C. Crick and E. Oldfield, *J. Med. Chem.*, 2014, **57**, 3126-3139.
- 315. S. S. Grant, B. B. Kaufmann, N. S. Chand, N. Haseley and D. T. Hung, *Proc. Natl. Acad. Sci.* U.S.A., 2012, **109**, 12147-12152.
- 316. W. Li, A. Sanchez-Hidalgo, V. Jones, V. C. N. de Moura, E. J. North and M. Jackson, *Antimicrob. Agents Chemother.*, 2017, **61**, e02399-02316.
- 317. T. V. A. Nguyen, R. M. Anthony, A.-L. Bañuls, T. V. A. Nguyen, D. H. Vu and J.-W. C. Alffenaar, *Clin. Infect. Dis.*, 2018, **66**, 1625-1630.
- 318. K. A. Sacksteder, M. Protopopova, C. E. Barry, K. Andries and C. A. Nacy, *Future Microbiology*, 2012, **7**, 823-837.
- M. I. Marzouk, S. A. Shaker, A. A. Abdel Hafiz and K. Z. El-Baghdady, *Biol. Pharm. Bull.*, 2016, 39, 239-251.
- 320. L. Yang, W. Wang, Q. Sun, F. Xu, Y. Niu, C. Wang, L. Liang and P. Xu, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 2801-2805.
- 321. A. D. Hameed, S. Ovais, R. Yaseen, P. Rathore, M. Samim, S. Singh, K. Sharma, M. Akhtar and K. Javed, *Arch. pharm.*, 2016, **349**, 150-159.
- 322. P. A. Procopiou, A. J. Ford, P. M. Gore, B. E. Looker, S. T. Hodgson, D. S. Holmes, S. Vile, K. L. Clark, K. A. Saunders, R. J. Slack, J. E. Rowedder and C. J. Watts, *ACS Med. Chem. Lett.*, 2017, **8**, 577-581.
- 323. P. A. Procopiou, C. Browning, P. M. Gore, S. M. Lynn, S. A. Richards, R. J. Slack and S. L. Sollis, *Bioorg. Med. Chem.*, 2012, **20**, 6097-6108.

- 324. P. A. Procopiou, C. Browning, J. M. Buckley, K. L. Clark, L. Fechner, P. M. Gore, A. P. Hancock, S. T. Hodgson, D. S. Holmes, M. Kranz, B. E. Looker, K. M. L. Morriss, D. L. Parton, L. J. Russell, R. J. Slack, S. L. Sollis, S. Vile and C. J. Watts, *J. Med. Chem.*, 2011, 54, 2183-2195.
- 325. T. Önkol, D. S. Doğruer, L. Uzun, S. Adak, S. Özkan and M. Fethi Şahin, *J. Enzyme Inhib. Med. Chem.*, 2008, **23**, 277-284.
- 326. N. Vila, P. Besada, D. Viña, M. Sturlese, S. Moro and C. Terán, RSC Adv., 2016, 6, 46170-46185.
- 327. S. K. Gorla, Y. Zhang, M. M. Rabideau, A. Qin, S. Chacko, A. L. House, C. R. Johnson, K. Mandapati, H. M. Bernstein, E. S. McKenney, H. Boshoff, M. Zhang, I. J. Glomski, J. B. Goldberg, G. D. Cuny, B. J. Mann and L. Hedstrom, *Antimicrob. Agents Chemother.*, 2017, 61.
- 328. A. M. Sridhara, K. R. Venugopala Reddy, J. Keshavayya, P. S. Kumar Goud, B. C. Somashekar, P. Bose, S. K. Peethambar and S. K. Gaddam, *Eur. J. Med. Chem.*, 2010, **45**, 4983-4989.
- 329. C. C. Gunderson and K. N. Moore, Future Oncology, 2015, 11, 747-757.
- 330. N. Chand and R. D. Sofia, J. Asthma, 1995, 32, 227-234.
- 331. T. Tomita, I. Yonekura, Y. Shirasaki, E. Hayashi and F. Numano, *Jpn. J. Pharmacol.*, 1980, **30**, 65-73.
- 332. A. Melikian, G. Schlewer, J. P. Chambon and C. G. Wermuth, *J. Med. Chem.*, 1992, **35**, 4092-4097.
- 333. S. Nath, Biophys. Chem., 2018, 242, 15-21.
- 334. U. Domańska, A. Pobudkowska and A. Pelczarska, J. Phys. Chem. B, 2011, 115, 2547-2554.
- 335. ChemAxon, Chemicalize).
- 336. Tokyo Pat., EP0580074B1, 1995.
- 337. X. Qiang, Y. Li, X. Yang, L. Luo, R. Xu, Y. Zheng, Z. Cao, Z. Tan and Y. Deng, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 718-722.
- 338. C. Walling, A. L. Rieger and D. D. Tanner, J. Am. Chem. Soc., 1963, 85, 3129-3134.
- 339. D. Sroczyński and Z. Malinowski, J. Mol. Struct., 2017, 1150, 614-628.
- 340. H. Gökce and S. Bahçeli, J. Mol. Struct., 2010, 967, 42-46.
- 341. V. M. Outerbridge, S. M. Landge, H. Tamaki and B. Török, Synthesis, 2009, 2009, 1801-1806.
- 342. H. Wang, J. Cai, H. Huang and G.-J. Deng, Org. Lett., 2014, 16, 5324-5327.
- 343. X.-F. Wu, H. Neumann, S. Neumann and M. Beller, Chem. Eur. J., 2012, 18, 8596-8599.
- 344. D. E. Beck, K. Agama, C. Marchand, A. Chergui, Y. Pommier and M. Cushman, *J. Med. Chem.*, 2014, **57**, 1495-1512.
- 345. A. Sugimoto, K. Sakamoto, Y. Fujino, Y. Takashima and M. Ishikawa, *Chem. Pharm. Bull.* (*Tokyo*), 1985, **33**, 2809-2820.
- 346. M. Schenone, V. Dančík, B. K. Wagner and P. A. Clemons, Nat. Chem. Biol., 2013, 9, 232-240.
- 347. S. A. Wacker, B. R. Houghtaling, O. Elemento and T. M. Kapoor, *Nat. Chem. Biol.*, 2012, **8**, 235-237.
- 348. G. Corti, R. Cinelli and F. Paradisi, Int. J. Antimicrob. Agents, 2000, 16, 527-530.
- 349. G. E. Zurenko, B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn and S. J. Brickner, *Antimicrob. Agents Chemother.*, 1996, 40, 839-845.
- 350. S. Wasserman, G. Meintjes and G. Maartens, Expert Rev. Anti-infect. Ther., 2016, 14, 901-915.
- 351. L. Alcalá, M. J. Ruiz-Serrano, C. Pérez-Fernández Turégano, D. García de Viedma, M. Díaz-Infantes, M. Marín-Arriaza and E. Bouza, *Antimicrob. Agents Chemother.*, 2003, **47**, 416-417.
- 352. R. Cremades, J. C. Rodriguez, E. Garcia-Pachon, A. Galiana, M. Ruiz-Garcia, P. Lopez and G. Royo, *APMIS*, 2011, **119**, 304-308.
- 353. X. Zhang, M. E. Falagas, K. Z. Vardakas, R. Wang, R. Qin, J. Wang and Y. Liu, *J. Thoracic Dis.*, 2015, **7**, 603-615.

APPENDIX: CHAPTER TWO

















A9
































230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)





















APPENDIX: CHAPTER THREE

Table A.3.1. Selected bond lenths of QQ 104b.	A35
Table A.3.2. Intermolecular hydrogen bonds in QQ 104	A35
Table A.3.3. Redox potentials of selected QQs in DMF	A35-A37
Figure A.3.1. Redox potentials (in DMF) vs. MIC of selected QQs	.A37
NMR spectra:	
QQs 92-111	A38-A95

Entry	Atom 1	Atom 2	Bond length (Å)
1	C2	С3	1.404(2)
2	C3	C4	1.373(2)
3	C4	C4a	1.396(2)
4	C4a	C8a	1.3908(18)
5	N1	C8a	1.3387(18)
6	N1	C2	1.3423(18)
7	C6	C7	1.3756(18)
8	C4a	C5	1.4752(19)
9	C5	C6	1.5085(19)
10	C7	C8	1.4613(19)
11	C8	C8a	1.5070(19)

Table A.3.2: Selected bond lengths of 6-anilino-2-methylquinolinequinone (104b).

Table A.3.3: Intermolecular hydrogen bonds in 6-anilino-2-methylquinolinequinone (104b).

Entry	H-bond donor	d(H…A) (Å)	H-bond acceptor
1	N2–H2n	2.539	O1
2	N2-H2n	2.223	N1

Table A.3.3: Redox potentials of selected QQs in DMF.



98b

-0.57 -1.10

-1.12

0 .CI `N´ H \int_{0} 99a

5

4



-0.56 -1.11

-0.59

6

7



-1.10 -0.45



-0.56 -1.09

8



-0.56 -1.09

9

0 || CI N H) O l Ph 107a





Redox potential (determined by CV in DMF) vs. MIC of selected QQs



Figure A.3.1.: Lack of correlation between redox potentials obtained for a selection of QQs via CV experiments in DMF and their anti-tubercular activity.




















































































¹H NMR (500 MHz, CDCl₃)

ار کر ک

 $\underset{\scriptstyle < 8.53}{\scriptstyle < 9.00}$












































APPENDIX: CHAPTER FOUR

Figure A.4.1. Additional docking studies	A97
NMR spectra:	. A98-A153



Figure A.4.18: Docking studies of 6-((2-amino-6-phenylpyrimidin-4-yl)amino)-2-phenyl-4*H*-chromen-4-one (**196**) (A) and *N*-(2-amino-6-phenylpyrimidin-4-yl)-2-phenylquinoline-4,6-diamine (**A.1**.) (B) in *C. thermarum* NDH-II (PDB: 6BDO), calculated using USCF Chimera/DOCK6. In both cases, chromonyl-pyrimidine **196** and quinolinyl pyrimidine **A.1**. are well-placed in the quinone binding site between Q317 and I317. Here, distant edge-to-face π - π interactions are possible between the phenyl substituents on the chromone and quinoline scaffolds in diphenyls **196** and **A.1**., respectively and the FAD isoalloxazine ring..




























































































A139

















¹⁹F NMR (282 MHz, pyridine-d₅)









¹⁹F NMR (282 MHz, pyridine-d₅)









¹⁹F NMR (282 MHz, pyridine-d₅)



APPENDIX: CHAPTER FIVE
























¹H NMR (500 MHz, CDCl₃)













¹⁹F NMR (282 MHz, CDCl₃)

















1.



¹H NMR (500 MHz, CDCl₃)







¹³C NMR (125 MHz, CDCl₃)


























































r ,

Т

:00













¹⁹F NMR (282 MHz, pyridine-d₅)









¹⁹F NMR (282 MHz, pyridine-d₅)

